0001802768-22-000035.txt : 20220804 0001802768-22-000035.hdr.sgml : 20220804 20220804091046 ACCESSION NUMBER: 0001802768-22-000035 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Royalty Pharma plc CENTRAL INDEX KEY: 0001802768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39329 FILM NUMBER: 221134967 BUSINESS ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 883-0200 MAIL ADDRESS: STREET 1: 110 EAST 59TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 10-Q 1 rprx-20220630.htm 10-Q rprx-20220630
0001802768December 312022Q2FALSE00018027682022-01-012022-06-300001802768us-gaap:CommonClassAMember2022-08-01xbrli:shares0001802768us-gaap:CommonClassBMember2022-08-0100018027682022-06-30iso4217:USD00018027682021-12-310001802768us-gaap:CommonClassAMember2021-12-31iso4217:USDxbrli:shares0001802768us-gaap:CommonClassAMember2022-06-300001802768us-gaap:CommonClassBMember2021-12-310001802768us-gaap:CommonClassBMember2022-06-300001802768rprx:ClassRRedeemableStockMember2021-12-31iso4217:GBPxbrli:shares0001802768rprx:ClassRRedeemableStockMember2022-06-300001802768rprx:FinancialRoyaltyAssetsMember2022-04-012022-06-300001802768rprx:FinancialRoyaltyAssetsMember2021-04-012021-06-300001802768rprx:FinancialRoyaltyAssetsMember2022-01-012022-06-300001802768rprx:FinancialRoyaltyAssetsMember2021-01-012021-06-300001802768rprx:IntangibleRoyaltyAssetsMember2022-04-012022-06-300001802768rprx:IntangibleRoyaltyAssetsMember2021-04-012021-06-300001802768rprx:IntangibleRoyaltyAssetsMember2022-01-012022-06-300001802768rprx:IntangibleRoyaltyAssetsMember2021-01-012021-06-300001802768rprx:RoyaltyIncomeOtherMember2022-04-012022-06-300001802768rprx:RoyaltyIncomeOtherMember2021-04-012021-06-300001802768rprx:RoyaltyIncomeOtherMember2022-01-012022-06-300001802768rprx:RoyaltyIncomeOtherMember2021-01-012021-06-3000018027682022-04-012022-06-3000018027682021-04-012021-06-3000018027682021-01-012021-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-03-310001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-03-310001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2022-03-310001802768rprx:DeferredSharesMember2022-03-310001802768us-gaap:AdditionalPaidInCapitalMember2022-03-310001802768us-gaap:RetainedEarningsMember2022-03-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310001802768us-gaap:NoncontrollingInterestMember2022-03-310001802768us-gaap:TreasuryStockMember2022-03-3100018027682022-03-310001802768us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001802768us-gaap:CommonClassAMember2022-04-012022-06-300001802768us-gaap:RetainedEarningsMember2022-04-012022-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-04-012022-06-300001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-04-012022-06-300001802768rprx:DeferredSharesMember2022-04-012022-06-300001802768us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300001802768us-gaap:TreasuryStockMember2022-04-012022-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-06-300001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-06-300001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2022-06-300001802768rprx:DeferredSharesMember2022-06-300001802768us-gaap:AdditionalPaidInCapitalMember2022-06-300001802768us-gaap:RetainedEarningsMember2022-06-300001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001802768us-gaap:NoncontrollingInterestMember2022-06-300001802768us-gaap:TreasuryStockMember2022-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-03-310001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-03-310001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2021-03-310001802768rprx:DeferredSharesMember2021-03-310001802768us-gaap:AdditionalPaidInCapitalMember2021-03-310001802768us-gaap:RetainedEarningsMember2021-03-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-03-310001802768us-gaap:NoncontrollingInterestMember2021-03-310001802768us-gaap:TreasuryStockMember2021-03-3100018027682021-03-310001802768us-gaap:NoncontrollingInterestMember2021-04-012021-06-300001802768us-gaap:CommonClassAMember2021-04-012021-06-300001802768us-gaap:RetainedEarningsMember2021-04-012021-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-04-012021-06-300001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-04-012021-06-300001802768rprx:DeferredSharesMember2021-04-012021-06-300001802768us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-04-012021-06-300001802768us-gaap:TreasuryStockMember2021-04-012021-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-06-300001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-06-300001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2021-06-300001802768rprx:DeferredSharesMember2021-06-300001802768us-gaap:AdditionalPaidInCapitalMember2021-06-300001802768us-gaap:RetainedEarningsMember2021-06-300001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-06-300001802768us-gaap:NoncontrollingInterestMember2021-06-300001802768us-gaap:TreasuryStockMember2021-06-3000018027682021-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-12-310001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-12-310001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2021-12-310001802768rprx:DeferredSharesMember2021-12-310001802768us-gaap:AdditionalPaidInCapitalMember2021-12-310001802768us-gaap:RetainedEarningsMember2021-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001802768us-gaap:NoncontrollingInterestMember2021-12-310001802768us-gaap:TreasuryStockMember2021-12-310001802768us-gaap:NoncontrollingInterestMember2022-01-012022-06-300001802768us-gaap:CommonClassAMember2022-01-012022-06-300001802768us-gaap:RetainedEarningsMember2022-01-012022-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-01-012022-06-300001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-01-012022-06-300001802768rprx:DeferredSharesMember2022-01-012022-06-300001802768us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-06-300001802768us-gaap:TreasuryStockMember2022-01-012022-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-12-310001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001802768us-gaap:CommonStockMemberrprx:ClassRRedeemableStockMember2020-12-310001802768rprx:DeferredSharesMember2020-12-310001802768us-gaap:AdditionalPaidInCapitalMember2020-12-310001802768us-gaap:RetainedEarningsMember2020-12-310001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001802768us-gaap:NoncontrollingInterestMember2020-12-310001802768us-gaap:TreasuryStockMember2020-12-3100018027682020-12-310001802768us-gaap:NoncontrollingInterestMember2021-01-012021-06-300001802768us-gaap:RetainedEarningsMember2021-01-012021-06-300001802768us-gaap:CommonClassAMember2021-01-012021-06-300001802768us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-01-012021-06-300001802768us-gaap:CommonClassBMemberus-gaap:CommonStockMember2021-01-012021-06-300001802768rprx:DeferredSharesMember2021-01-012021-06-300001802768us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001802768us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-06-300001802768us-gaap:TreasuryStockMember2021-01-012021-06-300001802768rprx:LegacyInvestorsPartnershipsMemberrprx:ExchangeOfferTransactionMember2020-02-112020-02-11xbrli:pure0001802768rprx:RoyaltyPharmaInvestmentsOldRPIMemberrprx:ExchangeOfferTransactionMember2020-02-110001802768rprx:RoyaltyPharmaCollectionTrustMember2020-02-110001802768rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMemberrprx:RoyaltyPharmaCollectionTrustMember2020-02-110001802768rprx:LegacyInvestorsPartnershipsMemberrprx:RoyaltyPharmaInvestmentsOldRPIMember2020-02-290001802768rprx:VertexMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:FinanceReceivablesMember2021-01-012021-12-310001802768rprx:VertexMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:FinanceReceivablesMember2022-01-012022-06-3000018027682022-01-072022-01-07rprx:tranche0001802768rprx:MorphoSysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-06-300001802768rprx:MorphoSysMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-04-012022-06-300001802768rprx:MorphoSysMember2022-04-012022-06-300001802768rprx:MorphoSysMember2022-01-012022-06-300001802768rprx:MorphoSysMemberus-gaap:SubsequentEventMember2022-07-012022-07-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2019-04-052019-04-050001802768us-gaap:SeriesAPreferredStockMember2019-04-052019-04-050001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember2022-01-012022-03-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMemberrprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember2022-01-012022-06-300001802768us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300001802768us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-06-300001802768us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-04-012021-06-300001802768us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-06-300001802768us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2020-08-072020-08-070001802768rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMemberus-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2022-01-012022-06-300001802768us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2022-01-012022-06-300001802768us-gaap:PreferredStockMember2022-06-300001802768us-gaap:ForwardContractsMember2022-06-300001802768rprx:FundingCommitmentsMember2022-06-300001802768us-gaap:PreferredStockMember2021-12-310001802768us-gaap:ForwardContractsMember2021-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-06-300001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2022-06-300001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-06-300001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-06-300001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2022-06-300001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-06-300001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2021-12-310001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:DebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2022-06-300001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForwardContractsMember2022-06-300001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2022-06-300001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForwardContractsMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2021-12-310001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768rprx:MilestoneAccelerationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberrprx:RoyaltyInvestmentsMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberrprx:RoyaltyInvestmentsMember2022-06-300001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberrprx:RoyaltyInvestmentsMember2022-06-300001802768us-gaap:FairValueMeasurementsRecurringMemberrprx:RoyaltyInvestmentsMember2022-06-300001802768us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberrprx:RoyaltyInvestmentsMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberrprx:RoyaltyInvestmentsMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberrprx:RoyaltyInvestmentsMember2021-12-310001802768us-gaap:FairValueMeasurementsRecurringMemberrprx:RoyaltyInvestmentsMember2021-12-310001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberrprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:FairValueInputsLevel2Memberrprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768rprx:CytokineticsFundingCommitmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001802768us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-03-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2022-03-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2022-03-310001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2022-03-310001802768rprx:DerivativeAssetMemberus-gaap:FairValueInputsLevel3Member2022-03-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:RoyaltyMember2022-03-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2021-03-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2021-03-310001802768us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-04-012022-06-300001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2022-04-012022-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:RoyaltyMember2022-04-012022-06-300001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2021-04-012021-06-300001802768rprx:DerivativeAssetMemberus-gaap:FairValueInputsLevel3Member2022-04-012022-06-300001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2022-04-012022-06-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2022-04-012022-06-300001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2021-04-012021-06-300001802768us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2022-06-300001802768rprx:DerivativeAssetMemberus-gaap:FairValueInputsLevel3Member2022-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:RoyaltyMember2022-06-300001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2021-06-300001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2021-06-300001802768us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2021-12-310001802768rprx:DerivativeAssetMemberus-gaap:FairValueInputsLevel3Member2021-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:RoyaltyMember2021-12-310001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001802768us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-06-300001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:RoyaltyMember2022-01-012022-06-300001802768us-gaap:SeriesAPreferredStockMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-06-300001802768us-gaap:FairValueInputsLevel3Memberrprx:FundingCommitmentsMember2022-01-012022-06-300001802768rprx:DerivativeAssetMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-06-300001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-06-300001802768us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-06-300001802768rprx:CytokineticsCommercialLaunchFundingMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-06-300001802768us-gaap:FairValueInputsLevel3Memberrprx:BioCrystPharmaceuticalsIncMember2021-11-012021-11-3000018027682021-11-012021-11-300001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2022-01-012022-06-300001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-02-012020-02-290001802768us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2021-01-012021-12-310001802768rprx:MilestoneAccelerationMemberus-gaap:PreferredStockMember2022-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-06-300001802768us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001802768us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001802768rprx:CysticFibrosisFranchiseMember2022-06-300001802768rprx:TysabriMember2022-06-300001802768rprx:ImbruvicaMember2022-06-300001802768rprx:XtandiMember2022-06-300001802768rprx:TremfyaMember2022-06-300001802768rprx:EvrysdiMember2022-06-300001802768rprx:OtherFinancialRoyaltyAssetMember2022-06-300001802768rprx:CysticFibrosisFranchiseMember2021-12-310001802768rprx:TysabriMember2021-12-310001802768rprx:ImbruvicaMember2021-12-310001802768rprx:XtandiMember2021-12-310001802768rprx:TremfyaMember2021-12-310001802768rprx:EvrysdiMember2021-12-310001802768rprx:OtherFinancialRoyaltyAssetMember2021-12-310001802768rprx:DPPIVInhibitorsMember2022-06-300001802768rprx:DPPIVInhibitorsMember2021-12-310001802768rprx:DPPIVInhibitorsMemberrprx:IndividualLicenseesConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-04-012021-06-300001802768rprx:DPPIVInhibitorsMemberrprx:IndividualLicenseesConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-06-300001802768rprx:DPPIVInhibitorsMemberrprx:IndividualLicenseesConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-06-300001802768rprx:LegacyInvestorsPartnershipsMember2020-02-110001802768rprx:LegacyInvestorsPartnershipsMember2022-04-012022-06-300001802768rprx:LegacyInvestorsPartnershipsMember2022-01-012022-06-300001802768rprx:LegacyInvestorsPartnershipsMember2021-04-012021-06-300001802768rprx:LegacyInvestorsPartnershipsMember2021-01-012021-06-300001802768rprx:AvillionEntitiesMember2022-04-012022-06-300001802768rprx:AvillionEntitiesMember2022-01-012022-06-300001802768rprx:AvillionEntitiesMember2021-04-012021-06-300001802768rprx:AvillionEntitiesMember2021-01-012021-06-300001802768rprx:AvillionIMember2021-01-012021-06-300001802768rprx:AvillionIMember2022-01-012022-06-300001802768rprx:AvillionIIMemberrprx:MerckAssetPhaseIIClinicalTrialMember2022-06-300001802768rprx:AvillionEntitiesMember2022-06-300001802768rprx:AvillionEntitiesMember2021-12-310001802768rprx:CytokineticsMember2022-01-012022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:PointSevenFivePercentSeniorNotesDue2023Member2022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:PointSevenFivePercentSeniorNotesDue2023Member2022-01-012022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:PointSevenFivePercentSeniorNotesDue2023Member2021-12-310001802768rprx:OnePointTwoZeroPercentSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2022-06-300001802768rprx:OnePointTwoZeroPercentSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2022-01-012022-06-300001802768rprx:OnePointTwoZeroPercentSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2022-01-012022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:OnePointSevenFivePercentSeniorNotesDue2027Member2021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member2022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member2022-01-012022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member2021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member2022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member2022-01-012022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member2021-12-310001802768rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Memberus-gaap:UnsecuredDebtMember2022-06-300001802768rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Memberus-gaap:UnsecuredDebtMember2022-01-012022-06-300001802768rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Memberus-gaap:UnsecuredDebtMember2021-12-310001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointFiveFivePercentSeniorNotesDue2050Member2022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointFiveFivePercentSeniorNotesDue2050Member2022-01-012022-06-300001802768us-gaap:UnsecuredDebtMemberrprx:ThreePointFiveFivePercentSeniorNotesDue2050Member2021-12-310001802768rprx:ThreePointThreeFiveZeroPercentDue2051Memberus-gaap:UnsecuredDebtMember2022-06-300001802768rprx:ThreePointThreeFiveZeroPercentDue2051Memberus-gaap:UnsecuredDebtMember2022-01-012022-06-300001802768rprx:ThreePointThreeFiveZeroPercentDue2051Memberus-gaap:UnsecuredDebtMember2021-12-310001802768us-gaap:SeniorNotesMember2021-07-260001802768rprx:SeniorNotesDue2031Memberus-gaap:SeniorNotesMember2021-07-260001802768rprx:SeniorNotesDue2051Memberus-gaap:SeniorNotesMember2021-07-260001802768rprx:SeniorNotesDue2051Memberus-gaap:SeniorNotesMember2022-06-300001802768rprx:TheNotesMemberus-gaap:UnsecuredDebtMember2020-09-020001802768rprx:TheNotesMemberus-gaap:UnsecuredDebtMember2022-06-300001802768rprx:TheNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:UnsecuredDebtMember2020-09-022020-09-020001802768rprx:TheNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:UnsecuredDebtMember2020-09-022020-09-020001802768us-gaap:FairValueInputsLevel2Memberrprx:TheNotesMemberus-gaap:UnsecuredDebtMember2022-06-300001802768us-gaap:FairValueInputsLevel2Memberrprx:TheNotesMemberus-gaap:UnsecuredDebtMember2021-12-310001802768us-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2020-09-182020-09-180001802768us-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2020-09-180001802768us-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2022-06-300001802768us-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2021-12-310001802768rprx:OvernightBankFundingRateMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2020-09-182020-09-180001802768us-gaap:FederalFundsPurchasedMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2020-09-182020-09-180001802768us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMemberrprx:SeniorUnsecuredRevolvingCreditFacilityMember2020-09-182020-09-18rprx:classrprx:vote0001802768rprx:ClassRRedeemableStockMember2022-01-012022-06-30rprx:noncontrolling_interest0001802768us-gaap:NoncontrollingInterestMemberrprx:RoyalPharmacySelectFinanceTrustMember2022-03-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2022-03-310001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2022-03-310001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2022-03-310001802768us-gaap:NoncontrollingInterestMemberrprx:RoyalPharmacySelectFinanceTrustMember2022-04-012022-06-300001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2022-04-012022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2022-04-012022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2022-04-012022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:RoyalPharmacySelectFinanceTrustMember2022-06-300001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:RoyalPharmacySelectFinanceTrustMember2021-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2021-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2021-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2021-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:RoyalPharmacySelectFinanceTrustMember2022-01-012022-06-300001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2022-01-012022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2022-01-012022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2022-01-012022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:RoyalPharmacySelectFinanceTrustMember2021-03-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2021-03-310001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2021-03-310001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2021-03-310001802768us-gaap:NoncontrollingInterestMemberrprx:RoyalPharmacySelectFinanceTrustMember2021-04-012021-06-300001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2021-04-012021-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2021-04-012021-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2021-04-012021-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:RoyalPharmacySelectFinanceTrustMember2021-06-300001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2021-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2021-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2021-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:RoyalPharmacySelectFinanceTrustMember2020-12-310001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2020-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2020-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2020-12-310001802768us-gaap:NoncontrollingInterestMemberrprx:RoyalPharmacySelectFinanceTrustMember2021-01-012021-06-300001802768rprx:LegacyInvestorsPartnershipsMemberus-gaap:NoncontrollingInterestMember2021-01-012021-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:ContinuingInvestorsPartnershipMember2021-01-012021-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:EPAHoldingsMember2021-01-012021-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:RPHoldingsMemberrprx:ContinuingInvestorsPartnershipMember2022-06-300001802768us-gaap:NoncontrollingInterestMemberrprx:RPHoldingsMember2022-06-300001802768rprx:A2020EquityIncentivePlanMemberus-gaap:CommonClassAMember2020-06-150001802768rprx:ClassBHoldersMember2022-04-012022-06-300001802768rprx:ClassBHoldersMember2021-04-012021-06-300001802768rprx:ClassBHoldersMember2022-01-012022-06-300001802768rprx:ClassBHoldersMember2021-01-012021-06-300001802768rprx:LegacyInvestorsPartnershipsAndRPSFTMember2022-04-012022-06-300001802768rprx:LegacyInvestorsPartnershipsAndRPSFTMember2021-04-012021-06-300001802768rprx:LegacyInvestorsPartnershipsAndRPSFTMember2022-01-012022-06-300001802768rprx:LegacyInvestorsPartnershipsAndRPSFTMember2021-01-012021-06-300001802768rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember2022-06-300001802768rprx:OperatingAndPersonnelPaymentsMembersrt:ManagementMember2022-06-300001802768rprx:OperatingAndPersonnelPaymentsMembersrt:ManagementMember2022-01-012022-06-300001802768rprx:OperatingAndPersonnelPaymentsMembersrt:ManagementMember2022-04-012022-06-300001802768rprx:FormerOperatingAndPersonnelPaymentsMembersrt:ManagementMember2021-04-012021-06-300001802768rprx:FormerOperatingAndPersonnelPaymentsMembersrt:ManagementMember2021-01-012021-06-300001802768rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMembersrt:AffiliatedEntityMember2022-06-300001802768rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMembersrt:AffiliatedEntityMember2021-12-310001802768rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMembersrt:AffiliatedEntityMember2022-06-300001802768rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMembersrt:AffiliatedEntityMember2021-12-310001802768rprx:AssignmentAgreementBenefitOfPaymentStreamMembersrt:AffiliatedEntityMemberrprx:BristolMyersSquibbMember2017-12-082017-12-080001802768rprx:AssignmentAgreementFundingObligationsMembersrt:AffiliatedEntityMemberrprx:BristolMyersSquibbMember2017-12-082017-12-080001802768rprx:AssignmentAgreementFundingObligationsMembersrt:AffiliatedEntityMemberrprx:BristolMyersSquibbMember2022-06-300001802768rprx:AssignmentAgreementFundingObligationsMembersrt:AffiliatedEntityMemberrprx:BristolMyersSquibbMember2021-12-310001802768rprx:AgreementWithMSCIMember2021-04-162021-04-160001802768rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMembersrt:AffiliatedEntityMember2022-01-012022-06-300001802768rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMemberus-gaap:TreasuryStockMembersrt:AffiliatedEntityMember2022-06-300001802768rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMemberus-gaap:NoncontrollingInterestMembersrt:AffiliatedEntityMember2022-06-300001802768rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMemberus-gaap:NoncontrollingInterestMembersrt:AffiliatedEntityMember2021-12-310001802768us-gaap:SubsequentEventMember2022-07-012022-07-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 001-39329
Royalty Pharma plc
(Exact name of registrant as specified in its charter)
England and Wales
98-1535773
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
110 East 59th Street
New York, New York 10022
(Address of principal executive offices and zip code)

(212) 883-0200
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Class A ordinary shares, par value $0.0001RPRXThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐ 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes  ☒   No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer  
☐
Smaller reporting company
☐
Emerging growth company
☐
                
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes  ☐     No  ☒




As of August 1, 2022, Royalty Pharma plc had 437,139,178 Class A ordinary shares outstanding and 170,080,791 Class B ordinary shares outstanding.

ROYALTY PHARMA PLC

INDEX

PART I.FINANCIAL INFORMATION
Item 1.Condensed Consolidated Financial Statements
Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 (unaudited)
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 (unaudited)
Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2022 and 2021 (unaudited)
Condensed Consolidated Statements of Shareholders’ Equity for the Three and Six Months Ended June 30, 2022 and 2021 (unaudited)
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 (unaudited)
Notes to Condensed Consolidated Financial Statements (unaudited)
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 3.Quantitative and Qualitative Disclosures About Market Risk
Item 4.Controls and Procedures
PART II.OTHER INFORMATION
Item 1.Legal Proceedings
Item 1A.Risk Factors
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.Defaults Upon Senior Securities
Item 4.Mine Safety Disclosures
Item 5.Other Information
Item 6.Exhibits



















Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains statements reflecting our views about our future performance that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective assets, our industry, our beliefs and our assumptions. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of the numerous risks outlined in Part I under Item 1A. under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

These risks and uncertainties include factors related to:
•sales risks of biopharmaceutical products on which we receive royalties;
•our ability to locate suitable assets to acquire;
•uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;
•the assumptions underlying our business model;
•our ability to successfully execute our royalty acquisition strategy;
•our ability to leverage our competitive strengths;
•actual and potential conflicts of interest with the Manager and its affiliates;
•the ability of RP Management, LLC (the “Manager”) to attract and retain highly talented professionals;
•the effect of changes to tax legislation and our tax position; and
•the risks, uncertainties and other factors we identify elsewhere in this Quarterly Report on Form 10-Q and in our other filings with the U.S. Securities and Exchange Commission.

Although we believe the expectations reflected in the forward-looking statements are reasonable, any of those expectations could prove to be inaccurate, and as a result, the forward-looking statements based on those expectations also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this Quarterly Report on Form 10-Q should not be regarded as a representation by us that our plans and business objectives will be achieved. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We are under no duty to update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform our prior statements to actual results or revised expectations.





PART 1.     FINANCIAL INFORMATION
Item 1.         CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
(Unaudited)
 As of June 30, As of December 31,
20222021
Assets
Current assets
Cash and cash equivalents$2,108,037 $1,541,048 
Marketable securities290,402 581,872 
Financial royalty assets639,244 614,351 
Accrued royalty receivable18,032 53,286 
Available for sale debt securities363,700 66,000 
Other royalty income receivable17,315 15,023 
Other current assets67,119 6,631 
Total current assets3,503,849 2,878,211 
Financial royalty assets, net13,423,629 13,718,245 
Intangible royalty assets, net— 5,670 
Equity securities304,447 269,800 
Available for sale debt securities63,000 204,400 
Equity method investments412,076 435,394 
Other assets33,412 4,145 
Total assets$17,740,413 $17,515,865 
Liabilities and shareholders’ equity
Current liabilities
Distributions payable to non-controlling interests$115,990 $107,934 
Accounts payable and accrued expenses12,175 5,620 
Interest payable54,162 57,696 
Total current liabilities182,327 171,250 
Long-term debt7,106,199 7,096,070 
Other liabilities43,700 — 
Total liabilities7,332,226 7,267,320 
Commitments and contingencies
Shareholders’ equity
Class A ordinary shares, $0.0001 par value; 437,139 and 432,963 issued and outstanding, respectively
44 43 
Class B ordinary shares, $0.000001 par value; 170,081 and 174,213 issued and outstanding, respectively
— — 
Class R redeemable shares, £1 par value; 50 and 50 issued and outstanding, respectively
63 63 
Deferred shares, $0.000001 par value; 365,302 and 361,170 issued and outstanding, respectively
— — 
Additional paid-in capital3,570,585 3,507,533 
Retained earnings2,446,132 2,255,179 
Non-controlling interests4,380,938 4,471,951 
Accumulated other comprehensive income13,177 16,491 
Treasury interests(2,752)(2,715)
Total shareholders’ equity10,408,187 10,248,545 
Total liabilities and shareholders’ equity$17,740,413 $17,515,865 

See accompanying notes to these unaudited condensed consolidated financial statements.
1



ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

For the Three Months Ended June 30,For the Six Months Ended June 30,
2022202120222021
Income and other revenues:
Income from financial royalty assets$515,350 $503,414 $1,026,873 $1,033,039 
Revenue from intangible royalty assets2,537 40,127 36,123 76,188 
Other royalty income18,068 11,422 35,008 18,763 
Total income and other revenues535,955 554,963 1,098,004 1,127,990 
Operating expenses
Provision for changes in expected cash flows from financial royalty assets105,714 (243,762)290,335 48,499 
Research and development funding expense606 3,122 101,106 5,763 
Amortization of intangible assets— 5,733 5,670 11,404 
General and administrative expenses51,843 44,921 103,383 88,077 
Total operating expenses/(income), net158,163 (189,986)500,494 153,743 
Operating income377,792 744,949 597,510 974,247 
Other (income)/expense
Equity in earnings of equity method investees(737)(17,701)(1,134)(15,783)
Interest expense46,966 37,426 94,029 74,841 
(Gains)/losses on derivative financial instruments(71,805)1,909 (71,805)4,464 
(Gains)/losses on equity securities(8,024)(55,495)28,138 (1,309)
Unrealized gains on available for sale debt securities(70,321)(14,015)(53,742)(23,130)
Interest income(10,919)(14,037)(20,448)(30,635)
Other non-operating expense, net1,035 107 2,792 65 
Total other (income)/expenses, net(113,805)(61,806)(22,170)8,513 
Consolidated net income before tax491,597 806,755 619,680 965,734 
Income tax expense— — — — 
Consolidated net income491,597 806,755 619,680 965,734 
Net income attributable to non-controlling interests187,093 365,979 263,415 455,839 
Net income attributable to Royalty Pharma plc$304,504 $440,776 $356,265 $509,895 
Earnings per Class A ordinary share:
     Basic$0.70 $1.08 $0.82 $1.28 
     Diluted$0.70 $1.08 $0.82 $1.25 
Weighted average Class A ordinary shares outstanding:
     Basic436,318 409,344 435,144 399,606 
     Diluted607,214 607,163 607,207 607,151 
See accompanying notes to these unaudited condensed consolidated financial statements.
2



ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
(Unaudited)

For the Three Months Ended June 30,For the Six Months Ended June 30,
2022202120222021
Consolidated net income$491,597 $806,755 $619,680 $965,734 
Changes in other comprehensive income/(loss):
Unrealized gains on available for sale debt securities9,325 6,025 10,950 11,150 
Reclassification of unrealized gains on available for sale debt securities(7,988)(13,299)(16,942)(28,790)
Other comprehensive income/(loss)$1,337 $(7,274)$(5,992)$(17,640)
Comprehensive income$492,934 $799,481 $613,688 $948,094 
Comprehensive income attributable to non-controlling interests187,638 362,748 260,948 447,727 
Comprehensive income attributable to Royalty Pharma plc$305,296 $436,733 $352,740 $500,367 

See accompanying notes to these unaudited condensed consolidated financial statements.

3



ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(In thousands, except per share amounts)
(Unaudited)

Class A
Ordinary Shares		Class B
Ordinary Shares		Class R
Redeemable Shares		Deferred SharesAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive IncomeNon-Controlling InterestsTreasury InterestsTotal Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at March 31, 2022435,316$43 171,862$— 50$63 363,521$— $3,543,204 $2,224,677 $12,304 $4,364,324 $(2,736)$10,141,879 
Contributions— — — — — — — — — — — 2,881 — 2,881 
Distributions— — — — — — — — — — — (146,967)— (146,967)
Dividends ($0.19 per Class A ordinary share)
— — — — — — — — — (83,049)— — — (83,049)
Other exchanges1,781 1 (1,781)— — — 1,781 — 26,872 — 81 (26,938)(16)— 
Share-based compensation and related issuances of Class A ordinary shares42 — — — — — — — 509 — — — — 509 
Net income— — — — — — — — — 304,504 — 187,093 — 491,597 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— — — — — — — — — — 5,523 3,802 — 9,325 
Reclassification of unrealized gains on available for sale debt securities— — — — — — — — — — (4,731)(3,257)— (7,988)
Balance at June 30, 2022437,139$44 170,081$— 50$63 365,302$— $3,570,585 $2,446,132 $13,177 $4,380,938 $(2,752)$10,408,187 

Class A
Ordinary Shares		Class B
Ordinary Shares		Class R Redeemable SharesDeferred SharesAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive IncomeNon-Controlling InterestsTreasury InterestsTotal Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at March 31, 2021392,857 $39 214,255 $— 50 $63 321,128 $— $2,931,249 $1,923,771 $29,452 $4,954,818 $(2,359)$9,837,033 
Contributions— — — — — — — — — — — 11,519 — 11,519 
Distributions— — — — — — — — — — — (170,808)— (170,808)
Dividends ($0.17 per Class A ordinary share)
— — — — — — — — — (72,581)— — — (72,581)
Other exchanges34,089 3 (34,089)— — — 34,089 — 483,628 — 3,263 (486,591)(303)— 
Share-based compensation and related issuances of Class A ordinary shares60 — — — — — — — 721 — — — — 721 
Net income— — — — — — — — — 440,776 — 365,979 — 806,755 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— — — — — — — — — — 3,348 2,677 — 6,025 
Reclassification of unrealized gains on available for sale debt securities— — — — — — — — — — (7,391)(5,908)— (13,299)
Balance at June 30, 2021427,006$42 180,166$— 50$63 355,217$— $3,415,598 $2,291,966 $28,672 $4,671,686 $(2,662)$10,405,365 

See accompanying notes to these unaudited condensed consolidated financial statements.

4



ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(In thousands, except per share amounts)
(Unaudited)

Class A
Ordinary Shares		Class B
Ordinary Shares		Class R
Redeemable Shares		Deferred SharesAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive IncomeNon-Controlling InterestsTreasury InterestsTotal Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at December 31, 2021432,963 $43 174,213 $— 50 $63 361,170 $— $3,507,533 $2,255,179 $16,491 $4,471,951 $(2,715)$10,248,545 
Contributions— — — — — — — — — — — 6,203 — 6,203 
Distributions— — — — — — — — — — — (295,942)— (295,942)
Dividends ($0.38 per Class A ordinary share)
— — — — — — — — — (165,312)— — — (165,312)
Other exchanges4,132 1 (4,132)— — — 4,132 — 62,047 — 211 (62,222)(37)— 
Share based compensation and related issuances of Class A ordinary shares44 — — — — — — — 1,005 — — — — 1,005 
Net income— — — — — — — — — 356,265 — 263,415 — 619,680 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— — — — — — — — — — 6,480 4,470 — 10,950 
Reclassification of unrealized gains on available for sale debt securities— — — — — — — — — — (10,005)(6,937)— (16,942)
Balance at June 30, 2022437,139$44 170,081$— 50$63 365,302$— $3,570,585 $2,446,132 $13,177 $4,380,938 $(2,752)$10,408,187 

Class A
Ordinary Shares		Class B
Ordinary Shares		Class R
Redeemable Shares		Deferred SharesAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive IncomeNon-Controlling InterestsTreasury InterestsTotal Equity
SharesAmountSharesAmountSharesAmountSharesAmount
Balance at December 31, 2020388,135 $39 218,976 $— 50 $63 316,407 $— $2,865,964 $1,920,635 $34,395 $5,077,036 $(2,317)$9,895,815 
Contributions— — — — — — — — — — — 14,772 — 14,772 
Distributions— — — — — — — — — — — (316,186)— (316,186)
Dividends ($0.34 per Class A ordinary share)
— — — — — — — — — (138,564)— — — (138,564)
Other exchanges38,810 3 (38,810)— — — 38,810 — 548,200 — 3,805 (551,663)(345)— 
Share-based compensation and related issuances of Class A ordinary shares61 — — — — — — — 1,434 — — — — 1,434 
Net income— — — — — — — — — 509,895 — 455,839 — 965,734 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— — — — — — — — — — 6,060 5,090 — 11,150 
Reclassification of unrealized gains on available for sale debt securities— — — — — — — — — — (15,588)(13,202)— (28,790)
Balance at June 30, 2021427,006$42 180,166$— 50$63 355,217$— $3,415,598 $2,291,966 $28,672 $4,671,686 $(2,662)$10,405,365 

See accompanying notes to these unaudited condensed consolidated financial statements.
5



ROYALTY PHARMA PLC
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
For the Six Months Ended June 30,
20222021
Cash flows from operating activities:
Cash collections from financial royalty assets$1,181,354 $1,094,094 
Cash collections from intangible royalty assets71,377 75,200 
Other royalty cash collections32,716 14,088 
Distributions from equity method investees27,502 22,003 
Interest received3,262 2,332 
Derivative collateral received— 11,470 
Derivative collateral posted— (9,340)
Development-stage funding payments - ongoing(1,106)(5,763)
Development-stage funding payments - upfront and milestone(100,000)— 
Payments for operating and professional costs(93,003)(81,764)
Interest paid(86,880)(64,500)
Net cash provided by operating activities1,035,222 1,057,820 
Cash flows from investing activities:
Distributions from equity method investees— 523 
Investments in equity method investees(3,050)(17,427)
Purchases of equity securities(62,785)— 
Proceeds from equity securities— 109,367 
Purchases of available for sale debt securities(79,158)(35,170)
Proceeds from available for sale debt securities31,250 31,250 
Purchases of marketable securities(234,869)(728,025)
Proceeds from sales and maturities of marketable securities525,907 868,689 
Acquisitions of financial royalty assets(175,093)(683,741)
Acquisitions of other financial assets(21,215)— 
Milestone payments— (18,600)
Net cash used in investing activities(19,013)(473,134)
Cash flows from financing activities:
Distributions to non-controlling interests(215,543)(238,197)
Distributions to non-controlling interests- other(72,343)(86,978)
Dividends to shareholders(165,312)(138,564)
Contributions from non-controlling interests- R&D731 4,080 
Contributions from non-controlling interests- other3,247 8,574 
Net cash used in financing activities(449,220)(451,085)
Net change in cash and cash equivalents566,989 133,601 
Cash and cash equivalents, beginning of period1,541,048 1,008,680 
Cash and cash equivalents, end of period$2,108,037 $1,142,281 

See accompanying notes to these unaudited condensed consolidated financial statements.

6
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

1. Organization and Purpose

Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (“IPO”) of our Class A ordinary shares. “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

We control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings’ Class A ordinary shares and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). The Continuing Investors Partnerships (defined below) have a non-controlling interest in RP Holdings through their ownership of RP Holdings Class B Interests. We conduct our business through RP Holdings and its subsidiaries.

RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”). RP Holdings is directly or indirectly owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”) and Royalty Pharma plc. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

RP Management, LLC (the “Manager”), a Delaware limited liability company, is responsible for our management, including our day-to-day operations, pursuant to advisory and management agreements (collectively, the “Management Agreement”).

Exchange Offer Transactions

We consummated an exchange offer on February 11, 2020 to facilitate the IPO. Through the exchange offer, investors which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under senior secured credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”

As a result of the Exchange Offer Transactions, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”). We are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust.

2. Summary of Significant Accounting Policies

Basis of Preparation and Use of Estimates

The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

7
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K.

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.

We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.

Basis of Consolidation

The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record Net income attributable to non-controlling interests on our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI, (2) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain conditions are met.

All intercompany transactions and balances have been eliminated in consolidation.

Concentrations of Credit Risk

Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.

The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson & Johnson, Merck & Co., Pfizer, Astellas, Novartis, and Gilead. As of June 30, 2022 and December 31, 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% of our current portion of financial royalty assets and represented the largest individual marketer and payor of our royalties.

8
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.

Significant Accounting Policies

There have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2021.

3. Available for Sale Debt Securities

Cytokinetics Commercial Launch Funding

On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (“Cytokinetics”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. As part of the funding agreement, we agreed to provide capital (“Cytokinetics Commercial Launch Funding”) of up to $300 million, which is comprised of five tranches, including an initial tranche of $50 million that was funded upon closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”). As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022. Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn.

We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within Available for sale debt securities on the condensed consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within Other liabilities as of June 30, 2022 and within Available for sale debt securities as of December 31, 2021 on the condensed consolidated balance sheets. The unrealized change in fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations.

MorphoSys Development Funding Bonds

On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support its acquisition of Constellation Pharmaceuticals, Inc. that closed on July 15, 2021. As part of the funding agreement, which was amended in the three months ended June 30, 2022 to extend the initial funding date, we agreed to provide MorphoSys up to $350 million of capital (the “Development Funding Bonds”) to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $150 million. Our commitment to fund at least $150 million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding is drawn. As of June 30, 2022, MorphoSys had not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $300 million under the Development Funding Bonds to be funded in September 2022.

We elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within Other liabilities as of June 30, 2022 and within Available for sale debt securities as of December 31, 2021 on our condensed consolidated balance sheets. The unrealized change in fair value of the Development Funding Bond Forward is recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations.

9
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Series A Biohaven Preferred Shares

On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) at a price of $50,100 per preferred share for a total of $125 million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (“FDA”) in February 2020 resulted in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price.

The Series A Biohaven Preferred Shares are classified as Available for sale debt securities on our condensed consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of comprehensive income. In the three and six months ended June 30, 2022, $8.0 million and $16.9 million, respectively, of the unrealized gains were reclassified from other comprehensive income to Interest income in the condensed consolidated statements of operations. In the three and six months ended June 30, 2021, $13.3 million and $28.8 million, respectively, of the unrealized gains were reclassified from other comprehensive income to Interest income in the condensed consolidated statements of operations.

Series B Biohaven Preferred Shares

On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”) for a total of $200 million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between the three months ended March 31, 2025 and the three months ended December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the original issue price of the Series B Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares.

As of June 30, 2022, we have acquired 1,988 shares of Series B Biohaven Preferred Shares. We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which are recorded in aggregate as Available for sale debt securities on the condensed consolidated balance sheets. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations.
10
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)


The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):

CostUnrealized GainsFair Value Current AssetsNon-Current AssetsCurrent LiabilitiesNon-Current Liabilities (3)Total
As of June 30, 2022
Debt securities (1)$278,759 $84,241 $363,000 $300,000 $63,000 $— $— $363,000 
Forwards (2)— 28,100 28,100 63,700 — — (35,600)28,100 
Funding commitments (2)(9,400)1,300 (8,100)— — — (8,100)(8,100)
Total available for sale debt securities$269,359 $113,641 $383,000 $363,700 $63,000 $— $(43,700)$383,000 
As of December 31, 2021
Debt securities (1)$204,509 $49,191 $253,700 $66,000 $187,700 $— $— $253,700 
Forwards (2)— 16,700 16,700 — 16,700 — — 16,700 
Total available for sale debt securities$204,509 $65,891 $270,400 $66,000 $204,400 $— $— $270,400 
(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date.
(2)There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date.
(3)Reflected within Other liabilities on the condensed consolidated balance sheet.

4. Fair Value Measurements and Financial Instruments

Fair Value Hierarchy

We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

•Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.

•Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.

11
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):
As of June 30, 2022As of December 31, 2021
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents
Money market funds$307,797 $— $— $307,797 $598,253 $— $— $598,253 
Commercial paper— 181,681 — 181,681 — 13,997 — 13,997 
Certificates of deposit— 36,001 — 36,001 — 40,954 — 40,954 
Marketable securities
Commercial paper— 87,622 — 87,622 — 207,457 — 207,457 
Certificates of deposit— 178,766 — 178,766 — 374,415 — 374,415 
U.S. government securities— 24,014 — 24,014 — — — — 
Available for sale debt securities
Debt securities (1)— — 300,000 300,000 — — 66,000 66,000 
Forwards (2)— — 63,700 63,700 — — — — 
Derivative instrument (3)— — 63,200 63,200 — — — — 
Total current assets$307,797 $508,084 $426,900 $1,242,781 $598,253 $636,823 $66,000 $1,301,076 
Equity securities275,662 — 28,785 304,447 226,787 — 43,013 269,800 
Available for sale debt securities
Debt securities (1)— — 63,000 63,000 — — 187,700 187,700 
Forwards (2)— — — — — — 16,700 16,700 
Derivative instrument (3)— — 8,600 8,600 — — — — 
Royalty at fair value (4)— — 21,215 21,215 — — — — 
Total non-current assets$275,662 $— $121,600 $397,262 $226,787 $— $247,413 $474,200 
Liabilities:
Available for sale debt securities
Forwards (2)— — (35,600)(35,600)— — — — 
Funding commitments (5)— — (8,100)(8,100)— — — — 
Total non-current liabilities$— $— $(43,700)$(43,700)$— $— $— $— 
(1)Reflects the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. As of June 30, 2022, amounts also include the fair value of the funded portion of the Cytokinetics Commercial Launch Funding.
(2)Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within Other liabilities on the condensed consolidated balance sheet.
(3)Related to the Milestone Acceleration Option (defined below) recorded within Other current assets and Other assets on the condensed consolidated balance sheet.
(4)Recorded within Other assets on the condensed consolidated balance sheet. See Note 8–Non-Consolidated Affiliates for additional discussion.
(5)Related to the fair value of the Cytokinetics Funding Commitments as reflected within Other liabilities on the condensed consolidated balance sheet as of June 30, 2022.

For the three and six months ended June 30, 2022, we recognized gains of $8.0 million and losses of $28.1 million, respectively, on equity securities still held as of June 30, 2022. For the three and six months ended June 30, 2021, we recognized gains of $28.3 million and losses of $10.7 million, respectively, on equity securities still held as of June 30, 2022.

12
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities, a royalty interest, a derivative instrument and available for sale debt securities, including the underlying debt securities, related forwards and funding commitments (in thousands):

For the Three Months Ended June 30, 2022For the Three Months Ended June 30, 2021
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentRoyalty at Fair ValueDebt SecuritiesForwards
Balance at the beginning of the period$62,538 $314,000 $(1,200)$(8,400)$— $— $226,800 $22,400 
Purchases28,785 14,579 — — — 21,215 17,585 — 
Losses on equity securities(21,846)— — — — — — — 
Gains on derivative financial instrument— — — — 71,800 — — — 
Unrealized gains included in other comprehensive losses (1) — 9,325 — — — — 6,025 — 
Unrealized gains included in earnings (2)— 31,800 38,221 300 — — 500 13,515 
Settlement of forwards (3)— 8,921 (8,921)— — — 5,115 (5,115)
Transfer to Level 1 (4)(40,692)— — — — — — — 
Redemption of debt securities— (15,625)— — — — (15,625)— 
Balance at the end of the period$28,785 $363,000 $28,100 $(8,100)$71,800 $21,215 $240,400 $30,800 
(1)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.
(2)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.
(3)Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.
(4)Related to transfer restriction expiration of BioCryst common stock.

For the Six Months Ended June 30, 2022For the Six Months Ended June 30, 2021
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentRoyalty at Fair ValueDebt SecuritiesForwards
Balance at the beginning of the period$43,013 $253,700 $16,700 $— $— $— $214,400 $18,600 
Purchases28,785 79,158 — — — 21,215 35,170 — 
Gains/(losses) on initial recognition (1)— 9,400 — (9,400)— — — — 
Losses on equity securities(2,321)— — — — — — — 
Gains on derivative financial instrument— — — — 71,800 — — — 
Unrealized gains included in other comprehensive losses (2) — 10,950 — — — — 11,150 — 
Unrealized gains included in earnings (3)— 30,200 22,242 1,300 — — 500 22,630 
Settlement of forwards (4)— 10,842 (10,842)— — — 10,430 (10,430)
Transfer to Level 1 (5) (40,692)— — — — — — — 
Redemption of debt securities— (31,250)— — — — (31,250)— 
Balance at the end of the period$28,785 $363,000 $28,100 $(8,100)$71,800 $21,215 $240,400 $30,800 
13
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

(1)Represents purchase price allocation to arrive at the appropriate fair value on initial recognition.
(2)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.
(3)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.
(4)Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.
(5)Related to transfer restriction expiration of BioCryst common stock.

Valuation Inputs for Recurring Fair Value Measurements

Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.

ApiJect Investment

We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value of equity securities and the revenue participation right that we acquired from ApiJect Holdings, Inc. (“ApiJect”) in April 2022. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant in the event of a sale of the instruments, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 8–Non-Consolidated Affiliates for additional discussion.

Cytokinetics Commercial Launch Funding

We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of June 30, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding requires significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.

We estimated the fair value of the Cytokinetics Funding Commitments as of June 30, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty’s assumed cost of debt, which would impact Cytokinetics’ decision to exercise its option to draw on each respective tranche. This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of 30% and an assumed risk-adjusted discount rate of 15.2%. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.
14
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)


BioCryst Common Stock

In November 2021, we purchased 3,846 thousand shares of common stock of BioCryst Pharmaceuticals, Inc. (“BioCryst”), calculated based on the volume-weighted average price of BioCryst’s common stock over a period preceding the closing of the transaction. As part of the transaction, we were restricted from selling the BioCryst common stock for six months following the close of the transaction. We determined the fair value of the BioCryst common stock as of December 31, 2021 based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the BioCryst common stock to match the duration of the transfer restriction. This methodology incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which required the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility of BioCryst’s common stock, which would mean that the estimated fair value for the BioCryst common stock could be significantly higher or lower than the fair value determined by management at any particular date. During the three months ended June 30, 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset.

MorphoSys Development Funding Bonds

The fair value of the Development Funding Bond Forward as of June 30, 2022 and December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. As of June 30, 2022, the Development Funding Bonds remain undrawn.

Series A Biohaven Preferred Shares

The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following the FDA approval and starting one-year after FDA approval through the three months ended December 31, 2024. When the FDA approved Nurtec ODT in February 2020, we became entitled to receive a fixed payment amount of $250 million payable in equal quarterly payments between the three months ended March 31, 2021 and the three months ended December 31, 2024.

The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated that there is a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate of 13.7% and 9.5% as of June 30, 2022 and December 31, 2021, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.

Series B Biohaven Preferred Shares

The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of June 30, 2022 and December 31, 2021 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.

15
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Milestone Acceleration Option

On August 7, 2020, we entered into an expanded funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to accelerate the payment of any outstanding zavegepant milestone payments in a lump sum amount (“Milestone Acceleration Option”). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material in prior periods. As of June 30, 2022, the fair value of the Milestone Acceleration Option was $71.8 million, of which $63.2 million was recorded within Other current assets and $8.6 million was recorded within Other assets on the condensed consolidated balance sheet. For the three months ended June 30, 2022, we recorded $71.8 million of unrealized gain related to the change in the fair value of the Milestone Acceleration Option within (Gains)/losses on derivative financial instruments in the condensed consolidated statements of operations.

We estimated the fair value of the Milestone Acceleration Option as of June 30, 2022 using the “with-and-without” methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates, estimated probabilities of achieving the success-based milestones, and the probability that there will be a change of control event in different periods of time, which would result in accelerated milestone payments. Assessing the probability that there will be a change of control event, the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate, probabilities of achieving marketing approval, and our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.

Other Financial Instruments

Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that either provide quoted market prices in active markets for identical or similar securities or observable inputs for their pricing without applying significant adjustments.

Financial Assets Not Measured at Fair Value

Financial royalty assets are measured and carried on the condensed consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts. Where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are presented below (in thousands):

As of June 30, 2022As of December 31, 2021
Fair ValueCarrying Value, netFair ValueCarrying Value, net
Financial royalty assets, net$18,254,440 $13,423,629 $19,047,183 $13,718,245 

16
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

5. Financial Royalty Assets

Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.

The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):
As of June 30, 2022
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,347,911 $(54,609)$5,293,302 
Tysabri
(3)
1,759,427 — 1,759,427 
Imbruvica2027-20321,439,443 (417,165)1,022,278 
Xtandi2027-20281,053,621 (153,154)900,467 
Tremfya2031-2032876,834 — 876,834 
Evrysdi
2030-2035 (4)
746,524 (1,992)744,532 
Other2020-20404,824,393 (1,110,515)3,713,878 
Total$16,048,153 $(1,737,435)$14,310,718 
Less: Cumulative allowance for credit losses (Note 6)(247,845)
Total financial royalty assets, net$14,062,873 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

As of December 31, 2021
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,335,641 $(48,636)$5,287,005 
Tysabri
(3)
1,846,069 (16,617)1,829,452 
Imbruvica2027-20321,438,730 (236,871)1,201,859 
Xtandi2027-20281,100,065 (172,101)927,964 
Tremfya2031-2032881,671 — 881,671 
Evrysdi
2030-2035 (4)
727,774 — 727,774 
Other2020-20404,697,591 (909,916)3,787,675 
Total$16,027,541 $(1,384,141)$14,643,400 
Less: Cumulative allowance for credit losses (Note 6)(310,804)
Total financial royalty assets, net$14,332,596 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.
17
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)


6. Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets

The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets on the condensed consolidated balance sheets and includes the following activities:

•the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts, and
•the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights.

The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):
Activity for the Period
Balance at December 31, 2021 (1)$(1,694,945)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(556,020)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets202,726 
Current period provision for credit losses, net (2)62,959 
Balance at June 30, 2022$(1,985,280)
(1)Includes $310.8 million related to cumulative allowance for credit losses.
(2)In the six months ended June 30, 2022, the provision income for credit losses was primarily related to a significant decline in the value of the Tazverik financial royalty asset.

7. Intangible Royalty Assets, Net

The following tables summarize the cost, accumulated amortization and net carrying value of our intangible royalty assets as of June 30, 2022 and December 31, 2021 (in thousands):
As of June 30, 2022CostAccumulated AmortizationNet Carrying Value
DPP-IV patents$606,216 $606,216 $— 
Total intangible royalty assets$606,216 $606,216 $— 
As of December 31, 2021CostAccumulated AmortizationNet Carrying Value
DPP-IV patents$606,216 $600,546 $5,670 
Total intangible royalty assets$606,216 $600,546 $5,670 

As of June 30, 2022, the intangible royalty assets were fully amortized as our royalties on Januvia and Janumet expired in the three months ended March 31, 2022. Our royalties on the other DPP-IV products have also substantially ended.

Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate such revenue from licensees based on the geography of the underlying sales as this information may not be provided to us by marketers. For the three months ended June 30, 2022, revenue from intangible royalty assets was not material. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 90% of revenues from intangible royalty assets in the three months ended June 30, 2021. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 93% and 94% of revenues from intangible royalty assets in the six months ended June 30, 2022 and 2021, respectively.

18
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

8. Non-Consolidated Affiliates

We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities for which we have elected the fair value option.

ApiJect

During the three months ended June 30, 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for our investments in ApiJect. We are also required to acquire additional common stock in ApiJect if certain milestones are achieved. The fair value of our equity investment was recorded within Equity securities and the fair value of the revenue participation right was recorded within Other assets on the condensed consolidated balance sheet as of June 30, 2022. No amounts were due from ApiJect as of June 30, 2022.

The Legacy SLP Interest

In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI.

The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this quarterly report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the three and six months ended June 30, 2022, we recorded income allocations of $4.7 million and $9.3 million, respectively, within Equity in earnings of equity method investees. During the three and six months ended June 30, 2021, we recorded income allocations of $25.6 million and $30.8 million, respectively, within Equity in earnings of equity method investees. We received cash distributions from the Legacy SLP Interest of $6.8 million and $14.1 million in the three and six months ended June 30, 2022, respectively. We received cash distributions from the Legacy SLP Interest of $4.7 million and $8.6 million in the three and six months ended June 30, 2021, respectively.

The Avillion Entities

We account for our partnership interests in Avillion Financing I, LP and its related entities (“Avillion I”), BAv Financing II, LP and its related entities (“Avillion II,” together with Avillion I, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. During the three and six months ended June 30, 2022, we recorded a loss allocation from the Avillion Entities of $4.0 million and $8.2 million, respectively, within Equity in earnings of equity method investees. During the three and six months ended June 30, 2021, we recorded a loss allocation from the Avillion Entities of $7.9 million and $15.0 million, respectively, within Equity in earnings of equity method investees.

On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4 million during each of the six months ended June 30, 2022 and 2021, respectively.

19
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

In May 2018, RPIFT entered into an agreement, which was amended in July 2021 and was further amended in June 2022 to increase the funding amount by $27.5 million, which totaled $150.0 million over multiple years in Avillion II, which is a party to a co-development agreement with AstraZeneca, to fund a portion of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.

Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments. As of June 30, 2022 and December 31, 2021, RPIFT had $35.7 million and $11.2 million, respectively, of unfunded commitments related to the Avillion Entities.

9. Research & Development (“R&D”) Funding Expense

R&D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. R&D funding expense includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. During the six months ended June 30, 2022 and 2021, we did not enter into any new ongoing R&D funding arrangements.

We recognized R&D funding expense of $0.6 million and $101.1 million for the three and six months ended June 30, 2022, respectively. We recognized R&D funding expense of $3.1 million and $5.8 million for the three and six months ended June 30, 2021, respectively. During the six months ended June 30, 2022, R&D funding expense primarily related to upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product candidate.

10. Borrowings

Our borrowings as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):

Type of BorrowingDate of IssuanceMaturityAs of June 30, 2022As of December 31, 2021
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)
9/20209/2023$1,000,000 $1,000,000 
$1,000,000, 1.20% (issued at 98.875% of par)
9/20209/20251,000,000 1,000,000 
$1,000,000, 1.75% (issued at 98.284% of par)
9/20209/20271,000,000 1,000,000 
$1,000,000, 2.20% (issued at 97.760% of par)
9/20209/20301,000,000 1,000,000 
$600,000, 2.15% (issued at 98.263% of par)
7/20219/2031600,000 600,000 
$1,000,000, 3.30% (issued at 95.556% of par)
9/20209/20401,000,000 1,000,000 
$1,000,000, 3.55% (issued at 95.306% of par)
9/20209/20501,000,000 1,000,000 
$700,000, 3.35% (issued at 97.565% of par)
7/20219/2051700,000 700,000 
Unamortized debt discount and issuance costs(193,801)(203,930)
Total debt carrying value7,106,199 7,096,070 
Less: Current portion of long-term debt— —
Total long-term debt$7,106,199 $7,096,070 

20
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Senior Unsecured Notes

On July 26, 2021, we issued $1.3 billion of senior unsecured notes (the “2021 Notes”) comprised of $600.0 million principal amount of notes due September 2031 and $700.0 million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5 million and we capitalized approximately $12.3 million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.

On September 2, 2020, we issued $6.0 billion of senior unsecured notes (the “2020 Notes” and, together with the 2021 Notes, the “Notes”). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0 million and we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively.

On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933.

The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.

Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and as of June 30, 2022, we were in compliance with all applicable covenants.

As of June 30, 2022 and December 31, 2021, the fair value of our outstanding Notes using Level 2 inputs was approximately $5.9 billion and $7.2 billion, respectively.

Senior Unsecured Revolving Credit Facility

On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”). The Credit Agreement amended and restated the prior credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement extended the maturity of the Revolving Credit Facility to September 15, 2026. As of June 30, 2022 and December 31, 2021, there were no outstanding borrowings under the Revolving Credit Facility.

The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.

21
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. If these financial covenants are not satisfied, the Credit Agreement prohibits us from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of June 30, 2022, RP Holdings was in compliance with these covenants.

Principal Payments on the Notes

The future principal payments for our borrowings as of June 30, 2022 over the next five years and thereafter are as follows (in thousands):

YearPrincipal Payments
Remainder of 2022$— 
20231,000,000 
2024— 
20251,000,000 
2026— 
Thereafter5,300,000 
Total (1)$7,300,000 
(1)Excludes unamortized debt discount and issuance costs of $193.8 million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.

11. Shareholders’ Equity

Capital Structure

We have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. As of June 30, 2022, we had 437,139 thousand Class A ordinary shares and 170,081 thousand Class B ordinary shares outstanding.

An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of June 30, 2022, we had outstanding deferred shares of 365,302 thousand.

In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of £1 each.

22
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Non-Controlling Interests

The net change in the balance of our four non-controlling interests for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands):

RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
March 31, 2022$8,409 $1,756,269 $2,599,646 $— $4,364,324 
Contributions— 1,425 1,456 — 2,881 
Distributions(5,754)(103,385)(37,828)— (146,967)
Other exchanges— — (26,938)— (26,938)
Net Income6,227 61,642 119,224 — 187,093 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,639 2,163 — 3,802 
Reclassification of unrealized gains on available for sale debt securities— (1,404)(1,853)— (3,257)
June 30, 2022$8,882 $1,716,186 $2,655,870 $— $4,380,938 

RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2021$13,528 $1,809,269 $2,649,154 $— $4,471,951 
Contributions— 3,395 2,808 — 6,203 
Distributions(16,013)(207,586)(72,343)— (295,942)
Other exchanges— — (62,222)— (62,222)
Net Income11,367 112,162 139,886 — 263,415 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,925 2,545 — 4,470 
Reclassification of unrealized gains on available for sale debt securities— (2,979)(3,958)— (6,937)
June 30, 2022$8,882 $1,716,186 $2,655,870 $— $4,380,938 

RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
March 31, 2021$13,841 $1,882,655 $3,058,322 $— $4,954,818 
Contributions— 6,654 4,865 — 11,519 
Distributions(12,476)(127,747)(30,585)— (170,808)
Other exchanges— — (486,591)— (486,591)
Net income19,275 133,743 212,961 — 365,979 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,059 1,618 — 2,677 
Reclassification of unrealized gains on available for sale debt securities— (2,337)(3,571)— (5,908)
June 30, 2021$20,640 $1,894,027 $2,757,019 $— $4,671,686 


23
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
Contributions— 9,907 4,865 — 14,772 
Distributions(26,129)(222,289)(67,768)— (316,186)
Other exchanges— — (551,663)— (551,663)
Net income34,333 170,000 251,506 — 455,839 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,960 3,130 — 5,090 
Reclassification of unrealized gains on available for sale debt securities— (5,060)(8,142)— (13,202)
June 30, 2021$20,640 $1,894,027 $2,757,019 $— $4,671,686 

The Continuing Investors Partnerships’ ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of June 30, 2022, the Continuing Investors Partnerships owned approximately 28% of RP Holdings with the remaining 72% owned by Royalty Pharma plc.

RP Holdings Class C Special Interest Held by EPA Holdings

EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met.

Dividends

The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. In the six months ended June 30, 2022, we declared and paid two quarterly cash dividends of $0.19 per Class A ordinary share for an aggregate amount of $165.3 million to holders of our Class A ordinary shares. In the six months ended June 30, 2021, we declared and paid two quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $138.6 million to holders of our Class A ordinary shares.

2020 Independent Directors Equity Incentive Plan

On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors.

RSU Activity and Share-based Compensation

We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized on a straight-line basis over the requisite service period of generally one year as part of General and administrative expenses in the condensed consolidated statements of operations. In the three and six months ended June 30, 2022 and 2021, respectively, we did not recognize material share-based compensation expenses.

24
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

12. Earnings per Share

Basic earnings per share (“EPS”) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares and deferred shares under the two-class method has not been presented.

Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs. For the three and six months ended June 30, 2022 and 2021, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact.

The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share amounts):
For the Three Months Ended June 30,For the Six Months Ended June 30,
2022202120222021
Numerator
Consolidated net income$491,597 $806,755 $619,680 $965,734 
Less: Net income attributable to Continuing Investors Partnerships119,224 212,961 139,886 251,506 
Less: Net income attributable to Legacy Investors Partnerships and RPSFT67,869 153,018 123,529 204,333 
Net income attributable to Royalty Pharma plc - basic304,504 440,776 356,265 509,895 
Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares 119,224 212,961 139,886 251,506 
Net income attributable to Royalty Pharma plc - diluted$423,728 $653,737 $496,151 $761,401 
Denominator
Weighted average Class A ordinary shares outstanding - basic436,318 409,344 435,144 399,606 
Add: Dilutive effects as shown separately below
Class B ordinary shares exchangeable for Class A ordinary shares170,864 197,773 172,035 207,508 
Unvested RSUs32 46 28 37 
Weighted average Class A ordinary shares outstanding - diluted607,214 607,163 607,207 607,151 
Earnings per Class A ordinary share - basic$0.70 $1.08 $0.82 $1.28 
Earnings per Class A ordinary share - diluted$0.70 $1.08 $0.82 $1.25 







25
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

13. Indirect Cash Flow

Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):
For the Six Months Ended June 30,
20222021
Cash flow from operating activities:
Consolidated net income$619,680 $965,734 
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Income from financial royalty assets(1,026,873)(1,033,039)
Provision for changes in expected cash flows from financial royalty assets290,335 48,499 
Amortization of intangible assets5,670 11,404 
Amortization of debt discount and issuance costs10,683 9,583 
(Gains)/losses on derivative financial instruments(71,805)4,464 
Losses/(gains) on equity securities28,138 (1,309)
Equity in earnings of equity method investees(1,134)(15,783)
Distributions from equity method investees27,502 22,003 
Share-based compensation1,005 1,434 
Interest income accretion(16,942)(28,790)
Unrealized gains on available for sale debt securities(53,742)(23,130)
Other2,657 2,049 
Decrease/(increase) in operating assets:
Cash collected on financial royalty assets1,181,354 1,094,094 
Accrued royalty receivable35,254 (988)
Other royalty income receivable(2,292)(4,683)
Other current assets and other assets2,711 3,703 
Increase/(decrease) in operating liabilities:
Accounts payable and accrued expenses6,555 (913)
Interest payable(3,534)758 
Other current liabilities— 2,730 
Net cash provided by operating activities$1,035,222 $1,057,820 

14. Commitments and Contingencies

Funding Commitments

We have various funding commitments as of June 30, 2022 as described below. See Note 3–Available for Sale Debt Securities for additional discussion of the respective arrangements.

Cytokinetics Commercial Launch Funding

As of June 30, 2022, $250 million of the Cytokinetics Commercial Launch Funding remained unfunded. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones. As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022.

MorphoSys Development Funding Bonds

As of June 30, 2022, $350 million of the MorphoSys Development Funding Bonds remained unfunded. In July 2022, MorphoSys notified us of its intention to draw $300 million under the Development Funding Bonds to be funded in September 2022.

26
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Series B Biohaven Preferred Shares

As of June 30, 2022, we have a remaining commitment of $100.4 million under the Commercial Launch Preferred Equity to purchase 2,004 shares of Series B Biohaven Preferred Shares on a quarterly basis through the three months ended December 31, 2024.

Other Commitments

We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 8–Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the Management Agreement as described in Note 15–Related Party Transactions, which are variable and primarily based on cash receipts.

Indemnifications

In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such occurrences taking place in the future is remote.

Legal Proceedings

We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.

15. Related Party Transactions

The Manager

The Manager is the investment manager of Royalty Pharma and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.

Pursuant to the Management Agreement, we pay quarterly operating and personnel expenses to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months.

During the three and six months ended June 30, 2022, total operating and personnel payments incurred were $36.0 million and $77.2 million, respectively, including the amounts attributable to Old RPI, and were recognized within General and administrative expenses in the condensed consolidated statements of operations. During the three and six months ended June 30, 2021, total operating and personnel payments incurred were $32.4 million and $68.1 million, respectively, including the amounts attributable to Old RPI, and were recognized within General and administrative expenses in the condensed consolidated statements of operations.

27
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Distributions Payable to Non-Controlling Interests

The distributions payable to non-controlling interests represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The distributions payable to non-controlling interests as of June 30, 2022 and December 31, 2021 include the following (in thousands):
As of June 30, 2022As of December 31, 2021
Due to Legacy Investors Partnerships$107,886 $92,608 
Due to RPSFT8,104 15,326 
Total distributions payable to non-controlling interests$115,990 $107,934 

Acquisition from Bristol Myers Squibb

In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement.

As of June 30, 2022 and December 31, 2021, the financial royalty asset of $118.1 million and $130.9 million, respectively, on the condensed consolidated balance sheets represents only our right to the future payment streams acquired from BMS.

Other Transactions

Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI Inc. (“MSCI”). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI’s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI’s revenues from those indexes. No amounts were due from MSCI as of both June 30, 2022 and December 31, 2021. The financial impact associated with this transaction has not been material to date.

In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 8–Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.

RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million is recorded as treasury interests, of which $1.5 million and $1.6 million were held by non-controlling interests as of June 30, 2022 and December 31, 2021, respectively.

Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.

28
ROYALTY PHARMA PLC
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)



16. Subsequent Events

In July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance Biopharma, Inc. (“Theravance”) and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy. We made an upfront payment of $1.31 billion in July 2022 and committed up to $300 million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25 million in upfront funding and a potential $15 million regulatory milestone payment to support the clinical development of ampreloxetine.
29

Item 2.         MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand our results of operations and financial condition, cash flows and other changes in financial condition. MD&A is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements and the accompanying notes to our consolidated financial statements included in our Annual Report on Form 10-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Special Note Regarding Forward-Looking Statements included elsewhere in this Quarterly Report on Form 10-Q and in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K.

Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (“IPO”) of our Class A ordinary shares. “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.

Business Overview

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, which includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Biohaven and Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 11 development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Our capital-efficient business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, including long product life cycles, significant barriers to entry and noncyclical revenues, but with substantially reduced exposure to many common industry challenges such as early stage development risk, therapeutic area constraints, high research and development costs, and high fixed manufacturing and marketing costs. We have a highly flexible approach that is agnostic to both therapeutic area and treatment modality, allowing us to acquire royalties on the most attractive therapies across the biopharmaceutical industry.

We classify our royalty acquisitions by the approval status of the therapy at the time of acquisition:

•Approved Products – We acquire royalties in approved products that generate predictable cash flows and may offer upside potential from unapproved indications. Since inception in 1996 through 2021, we have deployed $15.0 billion of cash to acquire royalties on approved products. From 2012 through 2021, we have acquired $10.2 billion of royalties on approved products.

•Development-Stage Product Candidates – We acquire royalties on development-stage product candidates that have demonstrated strong clinical proof of concept. From 2012, when we began acquiring royalties on development-stage product candidates, through 2021, we have deployed $7.8 billion to acquire royalties on development-stage product candidates.

While we classify our acquisitions in these two broad categories, several of our acquisitions of royalties on approved products were driven by the long-term potential of these products in other, unapproved indications. Similarly, some of our royalty acquisitions in development-stage product candidates are for products that are approved in other indications.

30

We acquire product royalties in ways that can be tailored to the needs of our partners through a variety of structures:

•Third-party Royalties – Existing royalties on approved or late-stage development therapies with high commercial potential. A royalty is the contractual right to a percentage of top-line sales from a licensee’s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.

•Synthetic Royalties/R&D Funding – Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments. We also fund ongoing research and development (“R&D”), typically for large biopharmaceutical companies, in exchange for future royalties and/or milestones if the product or indication we are funding is approved.

•Launch and Development Capital – Tailored supplemental funding solutions, generally included as a component within a transaction, increasing the scale of our capital. Launch and development capital is generally provided in exchange for a long-term stream of fixed payments with a predetermined schedule around the launch of a drug. Launch and development capital may also include a direct investment in the public equity of a company.

•Mergers and Acquisitions (“M&A”) Related – We acquire royalties in connection with M&A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.

Additionally, we may identify additional opportunities, platforms or technologies that leverage our capabilities. One example is our strategic alliance with MSCI Inc. (“MSCI”) to develop thematic life sciences indices.

Background and Format of Presentation

We consummated an exchange offer on February 11, 2020 to facilitate our IPO. Through the exchange offer, investors which represented 82% of the aggregate limited partnership in the various partnerships (the “Legacy Investors Partnerships”) that owned Royalty Pharma Investments, an Irish unit trust (“Old RPI”), exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in RPI US Partners 2019, LP, a Delaware limited partnership or RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”). The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under senior credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”

We control Royalty Pharma Holdings Ltd (“RP Holdings”) through our ownership of RP Holdings’ Class A ordinary shares and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). RP Holdings is the sole owner of RPI 2019 ICAV, which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions, and is the successor to Old RPI.

As a result of the Exchange Offer Transactions, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”). We are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”).

The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust.

31

Understanding Our Financial Reporting

Most of the royalties we acquire are treated as investments in cash flow streams and are classified as financial assets measured under the effective interest method in accordance with generally accepted accounting principles in the United States (“GAAP”). Under this accounting methodology, we calculate the effective interest rate on each financial royalty asset using a forecast of the expected cash flows to be received over the life of the financial royalty asset relative to the initial acquisition price. The yield, which is calculated at the end of each reporting period and applied prospectively, is then recognized via accretion into our income at the effective rate of return over the expected life of the financial royalty asset.

The measurement of income from our financial royalty assets requires significant judgments and estimates, including management’s judgment in forecasting the expected future cash flows of the underlying royalties and the expected duration of the financial royalty asset. Our cash flow forecasts are generated and updated each reporting period by manually compiling sell-side equity research analysts’ consensus sales estimates for each of the products in which we own royalties. We then calculate our expected royalty cash flows using these consensus sales forecasts. In any given reporting period, any decline or increase in the expected future cash flows associated with a financial royalty asset is recognized in our income statement as non-cash provision expense or provision income, respectively.

As a result of the non-cash charges associated with applying the effective interest method accounting methodology, our income statement activity can be volatile and unpredictable. Small declines in sell-side equity research analysts’ consensus sales forecasts over a long term horizon can result in an immediate non-cash income statement expense recognition which generates a corresponding cumulative allowance that reduces the gross asset balance, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014 we acquired the cystic fibrosis franchise royalty and beginning in the second quarter of 2015, declines in near-term sales forecasts of sell-side equity research analysts caused us to recognize non-cash provision expense. Over the course of 10 quarters, we recognized non-cash provision expense as a result of these changes in forecasts including non-cash provision expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017 related to this financial royalty asset. With the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts’ consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty. While small reductions in the cumulative allowance for the cystic fibrosis franchise were recognized as provision income over the course of 2017 and 2018, there remained a $1.10 billion cumulative allowance that was fully reduced by recognizing provision income of $1.10 billion in 2019 as a result of an increase in sell-side equity research analysts’ consensus sales forecasts associated with the Trikafta approval. This example illustrates the volatility caused by our accounting model.

In addition, due to the nature of our effective interest methodology, there is no direct correlation between our income from financial royalty assets and our royalty receipts. Therefore, management believes investors should not look to income from royalties and the associated provision for changes in future cash flows as a measure of our near-term financial performance or as a source for predicting future income or growth trends. Our operations have historically been financed primarily with cash flows generated by our royalties. Given the importance of cash flows and their predictability to management’s operation of the business, management uses royalty receipts as the primary measure of our operating performance. Royalty receipts refer to the summation of the following line items from our GAAP consolidated statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees.

In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. The closest comparable GAAP measure to each of the non-GAAP measures that management review is Net cash provided by operating activities. The key non-GAAP metrics we focus on are Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow, each of which is further discussed in the section titled “Non-GAAP Financial Results.”

Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of our strength and the performance of the business. Management uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, which is derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants.

Refer to the section titled “Non-GAAP Reconciliations” for additional discussion of management’s use of non-GAAP measures as supplemental financial measures.

32


Portfolio Overview

Our portfolio consists of royalties on more than 35 marketed therapies and 11 development-stage product candidates. The therapies in our portfolio address therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology and diabetes, and are delivered to patients across both primary and specialty care settings. The table below includes royalty receipts for the three and six months ended June 30, 2022 and 2021 by product in order of contribution to royalty receipts for the six months ended June 30, 2022 (in thousands).
RoyaltiesMarketer(s)Therapeutic AreaFor the Three Months Ended June 30,For the Six Months Ended June 30,
2022202120222021
Cystic fibrosis franchise (1)VertexRare disease$181,968 $156,023 $383,851 $322,832 
TysabriBiogenNeurology93,128 92,070 190,567 178,991 
ImbruvicaAbbVie, Johnson & JohnsonCancer80,381 87,289 167,552 176,424 
XtandiPfizer, AstellasCancer51,988 35,767 95,383 76,812 
PromactaNovartisHematology34,715 32,341 82,612 76,466 
Januvia, Janumet, Other DPP-IVs (2)Merck & Co., othersDiabetes35,695 39,438 71,377 75,200 
TremfyaJohnson & JohnsonImmunology18,428 — 46,653 — 
Nurtec ODT/Biohaven payment (3)Biohaven, PfizerNeurology18,715 16,721 39,090 33,222 
Cabometyx/CometriqExelixis, Ipsen, TakedaCancer13,055 10,129 25,911 10,129 
Farxiga/Onglyza AstraZenecaDiabetes11,346 9,113 20,815 17,675 
EvrysdiRocheRare disease8,134 2,971 17,331 4,648 
PrevymisMerck & Co.Infectious disease9,997 8,772 14,123 17,402 
TrodelvyGileadCancer6,040 2,992 10,932 5,597 
ErleadaJohnson & JohnsonCancer4,834 3,116 9,720 6,220 
CrysvitaUltragenyx, Kyowa KirinRare disease4,933 3,929 9,645 7,516 
OrladeyoBioCrystRare disease4,765 957 9,191 969 
EmgalityLillyNeurology4,425 3,550 9,188 6,814 
OxlumoAlnylamRare disease583 — 1,349 — 
Other products (4)50,038 82,502 138,909 220,241 
Total royalty receipts$633,168 $587,680 $1,344,199 $1,237,158 
(1)The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.
(2)Januvia, Janumet, Other DPP-IVs include the following approved products: Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by AstraZeneca, Novartis and Takeda.
(3)We have received quarterly redemption payments of $15.6 million beginning in the first quarter of 2021 related to the Series A Biohaven Preferred Shares (presented as Proceeds from available for sale debt securities on the statements of cash flows). The remaining cash receipts related to royalty receipts from Nurtec ODT.
(4)Other products primarily include royalty receipts on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion I, for which receipts are presented as Distributions from equity method investees on the statements of cash flows), Cimzia, Entyvio, HIV franchise, IDHIFA, Letairis, Lexiscan, Mircera, Myozyme, Nesina, Soliqua, Tazverik and contributions from the Legacy SLP Interest (defined below).

33

Financial Overview

Financial Highlights

•Net cash provided by operating activities totaled $1.0 billion and $1.1 billion for the six months ended June 30, 2022 and 2021, respectively. Net cash provided by operating activities is the closest comparable GAAP financial measure to the supplemental non-GAAP liquidity measures that follow.
•Adjusted Cash Receipts (a non-GAAP metric) totaled $1.1 billion and $999.0 million for the six months ended June 30, 2022 and 2021, respectively.
•Adjusted EBITDA (a non-GAAP metric) totaled $1.0 billion and $917.2 million for the six months ended June 30, 2022 and 2021, respectively.
•Adjusted Cash Flow (a non-GAAP metric) totaled $848.6 million and $838.0 million for the six months ended June 30, 2022 and 2021, respectively.

Understanding Our Results of Operations

We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to:

1.     The Legacy Investors Partnerships’ 18% ownership interest in Old RPI. The value of this non-controlling interest will decline over time as the assets in Old RPI expire.

2.     The RP Holdings Class B Interests held indirectly by the Continuing Investors Partnerships, which represent an approximate 28% ownership interest in RP Holdings as of June 30, 2022 and are exchangeable for our Class A ordinary shares. The value of this non-controlling interest will decline over time if the investors who indirectly own the RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares.

3.     A de minimis interest in RPCT held by RPSFT as a result of a 2011 reorganization transaction. The value of this non-controlling interest will decline over time as the royalty assets owned by RPCT expire and is expected to be substantially eliminated by the end of 2022.

4.     The RP Holdings Class C ordinary share (the “RP Holdings Class C Special Interest”) held by RPI EPA Holdings, LP (“EPA Holdings”), an affiliate of RP Management, LLC (the “Manager”). Income will not be allocated to this non-controlling interest until certain conditions are met.

All of the results of operations of RP Holdings, Old RPI and RPCT are consolidated into our financial statements.

EPA Holdings is entitled to receive Equity Performance Awards through its RP Holdings Class C Special Interest. Equity Performance Awards owed to EPA Holdings will be recognized as an equity transaction when the obligation becomes due and will impact the income allocated to non-controlling interest related to the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions are met, which we do not expect to occur until the mid-2020s.

Total income and other revenues

Total income and other revenues is primarily comprised of income from our financial royalty assets, royalty revenue from our intangible royalty assets, and royalty income generally arising from successful commercialization of products developed through R&D funding arrangements. Most of our royalties on both approved products and development-stage product candidates that are not accounted for as R&D funding expense are classified as financial assets as our ownership rights are generally passive in nature. In instances in which we acquire a royalty that does include more substantial rights or ownership of the underlying intellectual property, we classify such royalties as intangible assets.

34

We recognize interest income related to our financial royalty assets. Royalty revenue relates solely to revenue from our DPP-IV products for which the patent rights have been licensed to various counterparties. For the three and six months ended June 30, 2022 and 2021, the royalty payors accounting for greater than 10% of our total income and other revenues in any one period are shown in the table below:

For the Three Months Ended June 30,For the Six Months Ended June 30,
Royalty PayorRoyalties2022202120222021
VertexCystic fibrosis franchise38 %33 %36 %33 %
AbbVieImbruvica15 %17 %15 %17 %
Income from financial royalty assets

Our financial royalty assets represent investments in cash flow streams with yield components that most closely resemble loans measured at amortized cost under the effective interest method. We calculate the effective interest rate using forecasted expected cash flows to be received over the life of the royalty asset relative to the initial acquisition price. Interest income is recognized at the effective rate of return over the expected life of the asset, which is calculated at the end of each reporting period and applied prospectively. As changes in sell-side equity research analysts’ consensus sales estimates are updated on a quarterly basis, the effective rate of return changes. For example, if sell-side equity research analysts’ consensus sales forecasts increase, the yield to derive income on a financial royalty asset will increase and result in higher income for subsequent periods.

Variables affecting the recognition of interest income from financial royalty assets on individual products under the prospective effective interest method include any one of the following: (1) additional acquisitions, (2) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts’ consensus sales forecasts, (3) regulatory approval of additional indications which leads to new cash flow streams, (4) changes to the estimated duration of the royalty (i.e., patent expiration date) and (5) changes in amounts and timing of projected royalty receipts and milestone payments. Our financial royalty assets are directly linked to sales of underlying pharmaceutical products whose life cycle typically peaks at a point in time, followed frequently by declining sales trends due to the entry of generic competition, resulting in natural declines in the asset balance and periodic interest income over the life of our royalties. The recognition of interest income from royalties requires management to make estimates and assumptions around many factors, including those impacting the variables noted above.

Revenue from intangible royalty assets

Revenue from intangible royalty assets is derived from sales of Januvia, Janumet and other DPP-IV products by our licensees. Our royalties on Januvia and Janumet expired in the three months ended March 31, 2022. Our royalties on other DPP-IVs have also substantially ended and we do not expect any material revenue from our DPP-IV in the future periods.

Other royalty income

Other royalty income primarily includes income from financial royalty assets that have been fully amortized by the expected expiration date and royalty income from synthetic royalties arising out of R&D funding arrangements. Occasionally, a royalty asset may be amortized on an accelerated basis due to collectability concerns, which, if resolved, may result in future cash collections when no financial royalty asset remains. Similarly, we may continue to collect royalties on a financial royalty asset beyond the estimated duration by which the financial asset was fully amortized. In each scenario where a financial royalty asset has been fully amortized, income from such royalty is recognized as Other royalty income. Other royalty income also includes income from royalties that are recorded at fair value on our condensed consolidated balance sheets.

35

Provision for changes in expected cash flows from financial royalty assets

The Provision for changes in expected future cash flows from financial royalty assets includes the following:

•expense or income related to the current period activity resulting from adjustments to the cumulative allowance for changes in expected cash flows; and
•expense or income related to the provision for current expected credit losses, which reflects the activity for the period, primarily due to new financial royalty assets with limited protective rights and changes to cash flow estimates for financial royalty assets with limited protective rights.

As discussed above, income is accreted on our financial royalty assets using the effective interest method. As we update our forecasted cash flows on a periodic basis and recalculate the present value of the remaining future cash flows, any shortfall when compared to the carrying value of the financial royalty asset is recorded directly to the income statement through the line item Provision for changes in expected cash flows from financial royalty assets. If, in a subsequent period, there is an increase in expected cash flows or if actual cash flows are greater than cash flows previously expected, we reduce the cumulative allowance previously established for a financial royalty asset for the incremental increase in the present value of cash flows expected to be collected. This results in provision income (i.e., a credit to the provision).

Most of the same variables and management’s estimates affecting the recognition of interest income on our financial royalty assets also impact the provision. In any period, we will recognize provision income or expense as a result of the following factors: (1) changes in expected cash flows of the underlying pharmaceutical products, derived primarily from sell-side equity research analysts’ consensus sales forecasts, (2) regulatory approval of additional indications which leads to new cash flow streams, (3) changes to the estimated duration of the royalty (i.e., patent expiration date) and (4) changes in amounts and timing of projected royalty receipts and milestone payments.

R&D funding expense

R&D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates, and includes development-stage funding payments that are made upfront or upon pre-approval milestones, and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties.

General and administrative expenses

General and administrative (“G&A”) expenses include primarily Operating and Personnel Payments (defined below), legal expenses, other expenses for professional services and share-based compensation. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&A expenses on an ongoing basis.

Under the management agreements (collectively, the “Management Agreement”), we pay quarterly operating and personnel expenses to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter.

The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in G&A expenses, are calculated as the greater of $1 million per quarter and 0.3125% of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investors Partnerships) during the previous twelve calendar months.

36

Equity in earnings of equity method investees

Equity in earnings of equity method investees primarily includes the results of our share of income or loss from the following non-consolidated affiliates:

1. Legacy SLP Interest. In connection with the Exchange Offer Transactions, we acquired an equity method investment from the Continuing Investors Partnerships in the form of a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) in exchange for issuing shares in our subsidiary. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and a performance income allocation on a similar basis. As the Legacy Investors Partnerships no longer participate in investment opportunities, the value of the Legacy SLP Interest is expected to decline over time.

2. The Avillion Entities. The Avillion Entities (as defined below) partner with global biopharmaceutical companies to perform R&D in exchange for success-based milestones and royalties if products are commercialized. Our investments in Avillion Financing I, LP (“Avillion I”) and BAv Financing II, LP (“Avillion II”, or, together with Avillion I, the “Avillion Entities”) are accounted for using the equity method.

Other income, net

Other income, net primarily includes the change in fair market value of our equity securities, the unrealized gains or losses on derivative instruments and available for sale debt securities, including related forwards and funding commitments, and interest income.

Net income attributable to non-controlling interests

The net income attributable to non-controlling interests includes the Legacy Investors Partnerships’ approximately 18% share of earnings in Old RPI. As the Legacy Investors Partnerships no longer participate in investment opportunities, the related net income attributable to this non-controlling interest is expected to decline over time.

Net income attributable to non-controlling interests includes the RP Holdings Class B Interests held by the Continuing Investors Partnerships and will include net income attributable to the RP Holdings Class C Special Interest held by EPA Holdings once certain conditions have been met. Future net income attributable to the non-controlling interest related to the RP Holdings Class B Interests held by the Continuing Investors Partnerships will decline over time if the investors who indirectly own the RP Holdings Class B Interests conduct exchanges for our Class A ordinary shares.

Net income attributable to non-controlling interests also includes RPSFT’s 20% share of earnings in RPCT, which is a consolidated subsidiary of Old RPI. We expect net income attributable to this non-controlling interest to decline over time as the royalty assets owned by RPCT expire and to be substantially eliminated by the end of 2022.

Net income attributable to non-controlling interests above can fluctuate significantly from period to period, primarily driven by volatility in the income statement activity of the respective underlying entity as a result of the non-cash charges associated with applying the effective interest accounting methodology as described in section titled “Understanding Our Financial Reporting.”


37

Results of Operations

For the Three and Six Months Ended June 30, 2022 and 2021

The comparison of our historical results of operations for the three and six months ended June 30, 2022 and 2021 is as follows:

(in thousands)For the Three Months Ended June 30,ChangeFor the Six Months Ended June 30,Change
20222021$ % 20222021$ %
Income and other revenues:
Income from financial royalty assets$515,350 $503,414 $11,936 2.4 %$1,026,873 $1,033,039 $(6,166)(0.6)%
Revenue from intangible royalty assets2,537 40,127 (37,590)(93.7)%36,123 76,188 (40,065)(52.6)%
Other royalty income18,068 11,422 6,646 58.2 %35,008 18,763 16,245 86.6 %
Total income and other revenues535,955 554,963 (19,008)(3.4)%1,098,004 1,127,990 (29,986)(2.7)%
Operating expenses:
Provision for changes in expected cash flows from financial royalty assets105,714 (243,762)349,476 (143.4)%290,335 48,499 241,836 *
Research and development funding expense606 3,122 (2,516)(80.6)%101,106 5,763 95,343 *
Amortization of intangible assets— 5,733 (5,733)(100.0)%5,670 11,404 (5,734)(50.3)%
General and administrative expenses51,843 44,921 6,922 15.4 %103,383 88,077 15,306 17.4 %
Total operating expenses/(income), net158,163 (189,986)348,149 (183.2)%500,494 153,743 346,751 225.5 %
Operating income377,792 744,949 (367,157)(49.3)%597,510 974,247 (376,737)(38.7)%
Other (income)/expense:
Equity in earnings of equity method investees(737)(17,701)16,964 (95.8)%(1,134)(15,783)14,649 (92.8)%
Interest expense46,966 37,426 9,540 25.5 %94,029 74,841 19,188 25.6 %
Other income, net(160,034)(81,531)(78,503)96.3 %(115,065)(50,545)(64,520)127.6 %
Total other (income)/expenses, net(113,805)(61,806)(51,999)84.1 %(22,170)8,513 (30,683)(360.4)%
Consolidated net income491,597 806,755 (315,158)(39.1)%619,680 965,734 (346,054)(35.8)%
Net income attributable to non-controlling interests187,093 365,979 (178,886)(48.9)%263,415 455,839 (192,424)(42.2)%
Net income attributable to Royalty Pharma plc$304,504 $440,776 $(136,272)(30.9)%$356,265 $509,895 $(153,630)(30.1)%
*Percentage change is not meaningful.

38

Total income and other revenues

Income from financial royalty assets

Income from financial royalty assets by top products for the three and six months ended June 30, 2022 and 2021 is as follows, in order of contribution to income for the six months ended June 30, 2022:

(in thousands)For the Three Months Ended June 30,ChangeFor the Six Months Ended June 30,Change
20222021$ % 20222021$ %
Cystic fibrosis franchise$201,664 $185,597 $16,067 8.7 %$396,121 $370,413 $25,708 6.9 %
Imbruvica80,638 96,315 (15,677)(16.3)%168,265 195,430 (27,165)(13.9)%
Tysabri51,403 50,650 753 1.5 %103,924 101,749 2,175 2.1 %
Xtandi24,021 25,738 (1,717)(6.7)%48,939 52,718 (3,779)(7.2)%
Promacta23,786 19,680 4,106 20.9 %44,590 35,964 8,626 24.0 %
Tremfya25,666 — 25,666 — %41,816 — 41,816 — %
Other108,172 125,434 (17,262)(13.8)%223,218 276,765 (53,547)(19.3)%
Total income from financial royalty assets$515,350 $503,414 $11,936 2.4 %$1,026,873 $1,033,039 $(6,166)(0.6)%

Three months ended June 30, 2022 and 2021

Income from financial royalty assets increased by $11.9 million, or 2.4%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily driven by income related to newly acquired assets, primarily Tremfya, for which there was no comparable activity in the three months ended June 30, 2021, and the performance of the cystic fibrosis franchise. The increase was partially offset by the maturity of our royalties from the HIV franchise and declines in sell-side equity research analysts’ consensus sales forecasts for Imbruvica.

Six Months Ended June 30, 2022 and 2021

Income from financial royalty assets decreased by $6.2 million, or 0.6%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by the maturity of our royalties from the HIV franchise and declines in sell-side equity research analysts’ consensus sales forecasts for Imbruvica. The decrease in income was partially offset by income from newly acquired assets, primarily Tremfya, for which there was no comparable activity in the six months ended June 30, 2021, and the performance of the cystic fibrosis franchise and Promacta.

Revenue from intangible royalty assets

Three months ended June 30, 2022 and 2021

Revenue from intangible royalty assets decreased by $37.6 million, or 93.7%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily driven by the maturity of our royalties on Januvia and Janumet in the three months ended March 31, 2022.

Six Months Ended June 30, 2022 and 2021

Revenue from intangible royalty assets decreased by $40.1 million, or 52.6%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by the maturity of our royalties on Januvia and Janumet in the three months ended March 31, 2022.

39

Other royalty income

Three months ended June 30, 2022 and 2021

Other royalty income increased by $6.6 million, or 58.2%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily related to growth in the ongoing product launches of Trodelvy and Nurtec ODT that arose from our R&D funding agreements with Immunomedics and Biohaven, respectively.

Six Months Ended June 30, 2022 and 2021

Other royalty income increased by $16.2 million, or 86.6%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily related to income from Trodelvy and Nurtec ODT.

Provision for changes in expected cash flows from financial royalty assets

The breakdown of our provision for changes in expected future cash flows includes the following:
•expense or income related to the current period activity resulting from adjustments to the cumulative allowance for changes in expected cash flows; and
•expense or income related to the provision for current expected credit losses.

As the provision activity is a combination of income and expense items, the provision breakdown by royalty, exclusive of the provision for current expected credit losses, is as follows, based on the largest contributors to each period’s provision income or expense:

(in thousands)For the Three Months Ended June 30, 2022For the Three Months Ended June 30, 2021
RoyaltyRoyalty
Imbruvica$71,385 Tysabri$(114,354)
Cystic fibrosis franchise54,609 Xtandi(101,172)
Promacta29,295 Cystic fibrosis franchise(53,092)
Tysabri(30,613)Lexiscan(34,286)
Xtandi(43,804)Imbruvica46,378 
Other38,220 Other13,473 
Total provision, exclusive of provision for credit losses119,092 Total provision, exclusive of provision for credit losses(243,053)
Provision for current expected credit losses(13,378)Provision for current expected credit losses(709)
Total provision$105,714 Total provision$(243,762)

(in thousands)For the Six Months Ended June 30, 2022For the Six Months Ended June 30, 2021
ProductProduct
Imbruvica$180,294 Imbruvica$109,792 
Tazverik78,171 Tazverik61,391 
IDHIFA38,112 Emgality55,253 
Promacta29,295 Xtandi(58,320)
Emgality27,843 Tysabri(112,720)
Other(421)Other(42,129)
Total provision, exclusive of provision for credit losses353,294 Total provision, exclusive of provision for credit losses13,267 
Provision for current expected credit losses(62,959)Provision for current expected credit losses35,232 
Total provision expense$290,335 Total provision$48,499 
40

Three months ended June 30, 2022 and 2021

In the three months ended June 30, 2022, we recorded provision expense of $105.7 million, comprised of $119.1 million in provision expense for changes in expected cash flows and $13.4 million in provision income for current expected credit losses. We recorded provision expense for changes in expected cash flows for Imbruvica and the cystic fibrosis franchise primarily due to significant declines in sell-side equity research analysts’ consensus sales forecasts, which was partially offset by provision income for Xtandi and Tysabri due to a significant increase in sell-side equity research analysts’ consensus sales forecasts. The provision income for credit losses was primarily driven by a decrease in current expected credit losses related to Tazverik as a result of the corresponding decline in the financial asset value.

In the three months ended June 30, 2021, we recorded provision income of $243.8 million, of which $243.1 million and $0.7 million related to provision income for changes in expected cash flows and current expected credit losses, respectively. We recorded provision income primarily due to increases in sell-side equity research analysts’ consensus sales forecasts for Tysabri, Xtandi and the cystic fibrosis franchise. Offsetting the provision income was provision expense related to Imbruvica, primarily due to declines in sell-side equity research analysts’ consensus forecasts.

Six Months Ended June 30, 2022 and 2021

In the six months ended June 30, 2022, we recorded provision expense of $290.3 million, comprised of $353.3 million in provision expense for changes in expected cash flows and $63.0 million in provision income for current expected credit losses. We recorded provision expense for changes in expected cash flows for Imbruvica and Tazverik, primarily due to declines in sell-side equity research analysts’ consensus sales forecasts. The provision income for credit losses was primarily driven by a significant decrease in current expected credit losses related to Tazverik as a result of the corresponding significant decline in the financial asset value.

In the six months ended June 30, 2021, we recorded provision expense of $48.5 million, of which $13.3 million and $35.2 million related to provision expense for changes in expected cash flows and current expected credit losses, respectively. We recorded provision expense for Imbruvica, primarily due to declines in sell-side equity research analysts’ consensus sales forecasts, and for Tazverik as a result of a slower than expected product launch. Offsetting the provision expense was provision income from a significant increase in sell-side equity research analysts’ consensus forecasts for Tysabri and Xtandi. During the six months ended June 30, 2021, the provision expense for current expected credit losses was primarily driven by certain additions to our portfolio of financial royalty assets, including the incremental $100.0 million financial royalty asset related to the start of the oral zavegepant Phase 3 program and a new royalty interest in Cabometyx/Cometriq.

R&D funding expense

Three months ended June 30, 2022 and 2021

R&D funding expense was relatively flat in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021.

Six Months Ended June 30, 2022 and 2021

R&D funding expense increased by $95.3 million, for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021, primarily driven by upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product in the three months ended March 31, 2022.

G&A expenses

Three months ended June 30, 2022 and 2021

G&A expenses increased by $6.9 million, or 15.4%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily driven by higher Operating and Personnel Payments due to increased cash receipts from royalty investments.

41

Six Months Ended June 30, 2022 and 2021

G&A expenses increased by $15.3 million, or 17.4%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by higher Operating and Personnel Payments due to increased cash receipts from royalty investments.

Equity in earnings of equity method investees

Three months ended June 30, 2022 and 2021

Equity in earnings of equity method investees decreased by $17.0 million, or 95.8%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily driven by a $20.9 million decrease in equity in earnings from the Legacy SLP Interest.

Six Months Ended June 30, 2022 and 2021

Equity in earnings of equity method investees decreased by $14.6 million, or 92.8%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by a $21.5 million decrease in equity in earnings from the Legacy SLP Interest.

Interest expense

Three months ended June 30, 2022 and 2021

Interest expense increased by $9.5 million, or 25.5%, in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021, primarily driven by the issuance of $1.3 billion senior unsecured notes in July 2021 (“2021 Notes”). The weighted average coupon rate was 2.245% and 2.125% in the three months ended June 30, 2022 and 2021, respectively.

Six Months Ended June 30, 2022 and 2021

Interest expense increased by $19.2 million, or 25.6% in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by the issuance of the 2021 Notes. The weighted average coupon rate was 2.245% and 2.125% in the six months ended June 30, 2022 and 2021, respectively.

Refer to the “Liquidity and Capital Resources” section for additional discussion of the Notes.

Other income, net

Three months ended June 30, 2022 and 2021

Other income, net increased by $78.5 million, or 96.3%, in the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily driven by gains on derivative instruments of $71.8 million and higher gains on available for sale debt securities in the three months ended June 30, 2022 partially offset by lower gains on equity securities. The gains on derivative instruments and higher gains on available for sale debt securities are primarily driven by an estimated high probability of a change of control event for Biohaven within the next year.

Six Months Ended June 30, 2022 and 2021

Other income, net increased by $64.5 million, or 127.6%, in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by gains on derivative instruments of $71.8 million and higher gains on available for sale debt securities partially offset by losses on equity securities of $28.1 million and lower interest income in the six months ended June 30, 2022. The gains on derivative instruments and higher gains on available for sale debt securities are primarily driven by an estimated high probability of a change of control event for Biohaven within the next year.
42

Net income attributable to non-controlling interests

Three months ended June 30, 2022 and 2021

Net income attributable to the Legacy Investors Partnerships decreased by $72.1 million in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021, primarily driven by lower net income attributable to Old RPI.

Net income attributable to the Continuing Investors Partnerships decreased by $93.7 million in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021, primarily driven by lower net income attributable to RP Holdings in the three months ended June 30, 2022. Exchanges by investors in the Continuing Investors Partnerships who indirectly own the RP Holdings Class B Interests for our Class A ordinary shares resulted in a decline in the Continuing Investors Partnerships’ ownership of RP Holdings.

Net income attributable to RPSFT decreased by $13.0 million in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021. We expect net income attributable to RPSFT to continue to decline as the assets held by RPCT mature.

Six Months Ended June 30, 2022 and 2021

Net income attributable to the Legacy Investors Partnerships decreased by $57.8 million in the six months ended June 30, 2022 as compared to the six months ended June 30, 2021, primarily driven by lower net income attributable to Old RPI.

Net income attributable to the Continuing Investors Partnerships decreased by $111.6 million in the six months ended June 30, 2022 as compared to the six months ended June 30, 2021, primarily driven by lower net income attributable to RP Holdings in the six months ended June 30, 2022. Exchanges by investors in the Continuing Investors Partnerships who indirectly own the RP Holdings Class B Interests for our Class A ordinary shares resulted in a decline in the Continuing Investors Partnerships’ ownership of RP Holdings.

Net income attributable to RPSFT decreased by $23.0 million in the six months ended June 30, 2022 as compared to the six months ended June 30, 2021. We expect net income attributable to RPSFT to continue to decline as the assets held by RPCT mature.

Key Developments and Upcoming Events Relating to Our Portfolio

The key developments impacting our cash receipts and income and revenue from our royalty interests are discussed below:

Commercial Products

•Cystic fibrosis franchise. In April 2021, Vertex announced European Commission (“EC”) approval for Kaftrio in combination with ivacaftor for the treatment of patients with cystic fibrosis ages 12 and older who have at least one F508del mutation.

In June 2021, Vertex announced that U.S. Food and Drug Administration (“FDA”) approved Trikafta for the treatment of children with cystic fibrosis ages 6 through 11 who have at least one F508del mutation or have certain mutations that are responsive to Trikafta based on in vitro data.

In January 2022, Vertex announced that the EC granted approval for the label expansion of Kaftrio in combination with ivacaftor for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

•Tysabri. In April 2021, Biogen announced that the EC granted marketing authorization for a subcutaneous injection of Tysabri to treat relapsing-remitting multiple sclerosis. Biogen also announced that it had received a complete response letter from the FDA for its supplemental biologics license application for subcutaneous Tysabri. The complete response letter indicated that the FDA was unable to approve Biogen’s filing as submitted.
43

In August 2021, Biogen announced results from Phase 3b NOVA study evaluation every six-week dosing with Tysabri intravenous administration in relapsing-remitting multiple sclerosis. Results show that every six-week Tysabri intravenous administration provides a high level of efficacy in controlling multiple sclerosis disease activity in patients who switched from the approved every four-week dosing regimen.

•Imbruvica. In June 2021, Johnson and Johnson announced Phase 3 GLOW study results for Imbruvica in combination with Venetoclax for the treatment of first-line chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrated superior progression-free survival versus chlorambucil plus obinutuzumab as a first-line treatment of chronic lymphocytic leukemia. The study also showed improved duration of remission and significantly improved depth of remission. Johnson & Johnson had indicated that approval could occur in 2022.

In August 2021, AbbVie announced that the U.S. District Court for the District of Delaware had issued a decision holding patent rights relating to Imbruvica were valid and infringed by a generic product from Alvogen and Natco. The decision, which is subject to appeal, prohibits regulatory approval of that generic product until the last AbbVie patent expires. Previously, AbbVie entered into several settlement and license agreements with other generic companies. Consequently, AbbVie does not expect any generic product entry prior to March 30, 2032, assuming pediatric exclusivity is granted.

In June 2022, Johnson & Johnson announced primary results from the Phase 3 SHINE study, which demonstrated that the combination of once-daily oral Imbruvica plus bendamustine-rituximab (BR) and rituximab maintenance significantly reduced the risk of disease progression or death by 25% compared to patients who received placebo plus BR and rituximab maintenance in patients aged 65 years or older with newly diagnosed mantle cell lymphoma. With a median follow-up of 84.7 months, the Imbruvica plus BR and rituximab maintenance combination showed a statistically significant and clinically meaningful 2.3 year improvement in median progression-free survival (6.7 years) vs. BR (4.4 years). The safety profile of the Imbruvica plus BR regimen was consistent with the known safety profiles of Imbruvica as well as BR.

•Xtandi. In May 2021, Astellas and Pfizer announced that the EC approved Xtandi for the treatment of patients with metastatic hormone-sensitive prostate cancer.

In September 2021, Astellas and Pfizer announced that Xtandi plus androgen deprivation therapy reduced the risk of death by 34% compared to placebo plus androgen deprivation therapy in the Phase 3 ARCHES study in men with metastatic hormone-sensitive prostate cancer. The primary results from the ARCHES trial were published in 2019.

In July 2022, Pfizer indicated that there could be a potential readout of the Phase 3 EMBARK trial for high-risk non-metastatic prostate cancer in the second half of 2022.

•Nurtec ODT. In May 2021, Biohaven announced that the FDA approved Nurtec ODT for the preventative treatment of migraine, indicated for adult patients with episodic migraine who experience less than 15 headache days per month.

In April 2022, Pfizer and Biohaven announced that the EC has granted marketing authorization for Vydura (rimegepant) for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month.

In May 2022, Pfizer and Biohaven announced that they entered into a definitive agreement under which Pfizer will acquire Biohaven. Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash for a total of approximately $11.6 billion. Pfizer will also make payments at closing to settle Biohaven’s third-party debt and for the redemption of all outstanding shares of Biohaven’s redeemable preferred stock. The transaction is expected to close by early 2023.

•Trodelvy. In April 2021, Gilead announced the FDA granted full approval to Trodelvy for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The approval is supported by data from the Phase 3 ASCENT study.
44


In April 2021, Gilead announced that the FDA granted an accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor. The accelerated approval was based on data from the international Phase 2, single-arm TROPHY study.

In June 2021, Gilead announced superior outcomes to standard of care in second-line treatment of metastatic TNBC in the Phase 3 ASCENT study. Trodelvy more than doubled overall survival as a second-line treatment in the new ASCENT subgroup analysis.

In October 2021, Gilead announced a collaboration with Merck & Co. to investigate Trodelvy in combination with Keytruda as a first-line treatment for people with locally advanced or metastatic TNBC.

In November 2021, Gilead announced that the EC granted marketing authorization for Trodelvy as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for advanced disease. The EC’s decision is supported by results from the Phase 3 ASCENT study where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with physician’s choice of chemotherapy.

In January 2022, Gilead announced it has entered into two clinical trial collaboration and supply agreements with Merck & Co. to evaluate the combination of Trodelvy and Merck & Co.’s anti-PD-1 therapy Keytruda in first-line metastatic non-small cell lung cancer (NSCLC). As part of the collaboration, Merck & Co. will sponsor a global Phase 3 clinical trial of Trodelvy in combination with Keytruda as a first-line treatment of patients with metastatic NSCLC.

Additionally, Gilead and Merck & Co. established an agreement where Gilead will sponsor a Phase 2 signal-seeking study evaluating combinations that include pembrolizumab in first-line NSCLC.

In June 2022, Gilead announced results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy versus physicians’ choice of chemotherapy in heavily pre-treated HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. The study met its primary endpoint of progression-free survival with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death. The first interim analysis of the key secondary endpoint of overall survival demonstrated a trend in improvement. Patients will be followed for a subsequent overall survival analysis. The safety profile for Trodelvy was consistent with prior studies.

•Cabometyx. In January 2021, Exelixis announced that the FDA approved Cabometyx for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in combination with Bristol Myers Squibb’s Opdivo. The approval was based on the Phase 3 CheckMate 9ER trial, in which the combination of Cabometyx and Opdivo significantly improved overall survival while doubling progression-free survival and objective response rate versus sunitinib as a first-line treatment for patients with advanced RCC.

In March 2021, Ipsen announced that the EC approved the combination of Cabometyx and Opdivo for the first-line treatment of advanced RCC.

In August 2021, Exelixis announced that their partners Takeda and Ono received approval in Japan for Cabometyx in combination with Opdivo for the treatment of unresectable or metastatic RCC.

In September 2021, Exelixis announced detailed results from the expanded Cohort 6 of the Phase 1b COSMIC-021 trial of Cabometyx in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer, which included patients with metastatic castration-resistant prostate cancer who had been previously treated with novel hormone therapies enzalutamide or abiraterone acetate used along with prednisone. Following discussions with FDA, Exelixis announced that it will not pursue a regulatory submission for the combination regimen based on cohort 6 of COSMIC-021. Exelixis believes that CONTACT-02, a global Phase 3 pivotal trial that initiated enrollment in June 2020 may serve as a basis for future regulatory applications.

45

In September 2021, Exelixis announced FDA approved Cabometyx for patients with previously treated radioactive iodine-refractory differentiated thyroid cancer. The approval was based on the Phase 3 COSMIC-311 pivotal trial.

In March 2022, Exelixis announced results from the final analysis of the second primary endpoint of overall survival from the Phase 3 COSMIC-312 trial, which evaluated cabozantinib in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma. The final analysis showed neither improvement nor detriment in overall survival for cabozantinib in combination with atezolizumab versus sorafenib.

In May 2022, Ipsen announced that it received approval from the EC for Cabometyx as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.

In July 2022, Exelixis announced that COSMIC-313, an ongoing Phase 3 trial evaluating Cabometyx, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC, met its primary endpoint, demonstrating significant improvement in progression-free survival at the primary analysis. At a prespecified interim analysis for the secondary endpoint of overall survival, the combination of Cabometyx, nivolumab and ipilimumab did not demonstrate a significant benefit. The trial will continue to the next analysis of overall survival. Exelixis intends to discuss the results with the FDA to determine next steps toward a potential regulatory submission.

Exelixis has indicated it expects initial Phase 3 data in the second half of 2022 from CONTACT-01 in metastatic NSCLC and CONTACT-03 in advanced or metastatic RCC.

•Evrysdi. In March 2021, Roche announced that the EC approved Evrysdi for the treatment of spinal muscular atrophy (SMA) in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four splicing modifier of motor neuron 2 copies.

In June 2021, Evrysdi was approved in Japan for the treatment of SMA.

In May 2022, Roche announced that the FDA has approved a label extension for Evrysdi to include infants under two months old with SMA. The approval is based on the interim efficacy and safety data from the RAINBOWFISH study in newborns, which showed that the majority of pre-symptomatic infants treated with Evrysdi achieved key milestones such as sitting and standing with half walking after 12 months of treatment.

•Orladeyo. In January 2021, Orladeyo was approved in Japan, becoming the first and only prophylactic hereditary angioedema (HAE) medication approved in the region.

In April 2021, BioCryst announced that the EC approved Orladeyo for the prevention of recurrent HAE attacks in patients 12 years and older.

In April 2021, BioCryst announced approval of Japanese National Health Insurance System price listing of Orladeyo for prophylactic treatment of HAE.

•Oxlumo. In July 2021, Alnylam announced results from ILLUMINATE-C, a Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 associated with progressive decline in renal function. Results from the primary analysis at six months demonstrated a substantial reduction in plasma oxalate from baseline in patients with advanced disease, including those on hemodialysis. The safety and tolerability profile of lumasiran following six months of treatment was encouraging across all ages, with no drug related serious adverse events and injection site reactions as the most common adverse event.

46

In March 2022, the FDA accepted Alnylam’s supplemental New Drug Application (“NDA”) for lumasiran for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1. The FDA has set an action date for October 6, 2022. Additionally, a Type II Variation for lumasiran to amend the label in patients with advanced primary hyperoxaluria Type 1 was submitted and validated by the European Medicines Agency (“EMA”) in December 2021.

•Tremfya. In February 2022, Johnson & Johnson announced results from the Phase 2a VEGA proof-of-concept study. Results showed that the combination of Tremfya and golimumab, a tumor necrosis factor-alpha antagonist, induced higher rates of clinical response, clinical remission, endoscopic improvement and a composite histologic-endoscopic endpoint at 12 weeks than either treatment alone in adults with moderately to severely active ulcerative colitis. Rates of adverse events were comparable among treatment groups.

In February 2022, Johnson & Johnson announced results from the Phase 2b QUASAR Induction Study 1. Results showed that a significantly greater proportion of adults with moderately to severely active ulcerative colitis who previously had an inadequate response or intolerance to conventional therapies or selected advanced therapies and were treated with Tremfya achieved clinical response at week 12 (Tremfya 200 mg: 61.4% and Tremfya 400 mg: 60.7%), the study’s primary endpoint compared with placebo (27.6%). Safety data at week 12 was consistent with the safety profile for Tremfya in approved indications.

•Tazverik: In June 2022, Ipsen and Epizyme announced that they had entered into a definitive merger agreement under which Ipsen will acquire Epizyme. Ipsen intends to initiate a tender offer to acquire all outstanding shares of Epizyme at a price of $1.45 per share in cash at the closing of the transaction for an initial estimated aggregate consideration of $247 million plus a contingent value right of $1 per share. The transaction is anticipated to close by the end of the third quarter of 2022.

Development-Stage Product Candidates

•Aficamten. In December 2021, Cytokinetics announced the FDA granted breakthrough therapy designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) based on results from REDWOOD-HCM.

In February 2022, Cytokinetics announced positive topline results from Cohort 3 of the REDWOOD-HCM Phase 2 trial. Results from Cohort 3 showed that substantial reductions in the average resting left ventricular outflow tract pressure gradient (LVOT-G) as well as the post-Valsalva LVOT-G were achieved for patients with oHCM and a resting or post-Valsalva LVOT-G of greater than 50 mmHg whose background therapy included disopyramide and in the majority a beta-adrenergic blocker. The safety and tolerability of aficamten were consistent with prior experience in REDWOOD-HCM with no treatment interruptions and no serious adverse events attributed to treatment reported by the investigators.

•BCX9930. In April 2022, BioCryst announced that it is pausing enrollment in clinical trials with BCX9930, while BioCryst investigates elevated serum creatinine levels seen in some patients. BioCryst will not enroll new patients in the REDEEM-1, REDEEM-2 or RENEW clinical trials during the investigation. Patients currently enrolled in the trials are expected to continue on the study drug.

In May 2022, BioCryst announced that it plans to discuss with regulators whether clinical trials with amended protocols could resume using stepped dosing to 400 milligrams twice-daily of BCX9930 by the end of the third quarter of 2022.

•Gantenerumab. In October 2021, Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted breakthrough therapy designation by the FDA for the treatment of people living with Alzheimer’s disease. This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of Alzheimer’s disease, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies.

47

In March 2022, Roche announced a new Phase 3 Alzheimer’s disease prevention trial (SKYLINE). Roche has stated that it intends to enter into a collaboration agreement with Banner Alzheimer’s Institute’s Alzheimer’s Prevention Initiative, Massachusetts General Hospital and the University of Southern California Alzheimer’s Therapeutic Research Institute to further exchange scientific insights and advance the trial goals. SKYLINE aims to evaluate the potential of gantenerumab to slow disease progression in people with the earliest biologic signs of Alzheimer’s disease and who show no signs of cognitive impairment.

Roche has indicated it expects Phase 3 data from the GRADUATE 1/2 trial in Alzheimer’s disease in the fourth quarter of 2022.

•Omecamtiv mecarbil. In February 2022, Cytokinetics announced that FDA has accepted and filed its NDA for omecamtiv mecarbil. The FDA assigned the NDA a standard review with a PDUFA date of November 30, 2022. The FDA also indicated that it is currently not planning to hold an advisory committee meeting to discuss the application. The submission is supported by GALACTIC-HF, which demonstrated a positive effect on the primary composite endpoint of cardiovascular death or heart failure events in patients with heart failure and reduced ejection fraction who were receiving standard of care plus omecamtiv mecarbil.

In February 2022, Cytokinetics announced results from METEORIC-HF, a Phase 3 trial evaluating the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity in patients with heart failure with reduced ejection fraction. After 20 weeks of treatment, there was no change in peak oxygen uptake in patients treated with omecamtiv mecarbil versus placebo.

In June 2022, Cytokinetics announced that the FDA had informed the company that the Cardiovascular and Renal Drugs Advisory Committee will review its NDA on December 13, 2022. Additionally, the FDA has assigned the NDA a PDUFA date of February 28, 2023.

•Otilimab. GlaxoSmithKline has indicated it expects Phase 3 data from the contRast trials in rheumatoid arthritis in the second half of 2022.

•Pelabresib. In December 2021, MorphoSys presented the latest data from the Phase 2 MANIFEST study evaluating pelabresib in the treatment of myelofibrosis. As of September 10, 2021, the data cut-off, a total of 84 JAK inhibitor-naive patients were enrolled and received the first-line combination of pelabresib and ruxolitinib. The data showed 68% (n=57) of patients treated with the combination achieved a greater than or equal to 35% reduction in spleen volume from baseline at week 24 and 60% (n=47) maintained a greater than or equal to 35% reduction in spleen volume at week 48. Most patients also saw their symptoms reduced with 56% (n=46) achieving greater than or equal to 50% reduction in total symptom score from baseline at week 24.

•PT027. In September 2021, AstraZeneca and Avillion announced positive results from MANDALA and DENALI, two Phase 3 trials evaluating PT027 (albuterol/budesonide) in patients with asthma. PT027 is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. In MANDALA, PT027 demonstrated a statistically significant and clinically meaningful reduction in the risk of severe exacerbations compared to albuterol, when used as a rescue medicine in response to symptoms. In DENALI, PT027 showed a statistically significant improvement in lung function measured by forced expiratory volume in one second, compared to the individual components albuterol and budesonide, and compared to placebo. The safety and tolerability of PT027 in both trials was consistent with the known profiles of the components.

In May 2022, Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, announced that FDA accepted for filing the NDA for AstraZeneca’s PT027. The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbation of asthma. The co-development partnership between AstraZeneca and Avillion also recently expanded to include the BATURA study, a randomized Phase 3b decentralized trial to further assess the role of PT027 in preventing asthma exacerbations.

48

•Zavegepant. In March 2021, Biohaven announced that it enrolled the first patient in a Phase 2/3 clinical trial of oral zavegepant for the preventive treatment of migraine. Accordingly, per the agreement with Biohaven announced in August 2020, Royalty Pharma paid $100 million to Biohaven for the achievement of this milestone, bringing total zavegepant funding to $250 million.

In December 2021, Biohaven announced positive topline results from the second pivotal clinical trial evaluating the safety and efficacy of intranasal zavegepant for the acute treatment of migraine in adults. The Phase 3 study achieved its co-primary regulatory endpoints of pain freedom and freedom of most bothersome symptom at two hours and showed broad efficacy by demonstrating statistically significant superiority to placebo across a total of 15 prespecified primary and secondary outcome measures.

In May 2022, Biohaven announced that the FDA accepted for review a NDA for zavegepant nasal spray for the acute treatment of migraine in adults. The PDUFA date is in the first quarter of 2023.

Non-GAAP Financial Results

In addition to analyzing our results on a GAAP basis, management also reviews our results on a non-GAAP basis. There is no direct correlation between income from financial royalty assets and royalty receipts due to the nature of the accounting methodology applied for financial royalty assets. Further, income from financial royalty assets and the provision for changes in expected cash flows related to these financial royalty assets can be volatile and unpredictable. As a result, management places importance on royalty receipts as they are predictable and we use them as a measure of our operating performance. Refer to section titled “Non-GAAP Reconciliations” for additional discussion of management’s use of non-GAAP measures as supplemental financial measures and reconciliations from the most directly GAAP comparable measures of Net cash provided by operating activities.

Adjusted Cash Receipts is a measure calculated with inputs directly from the statements of cash flows and includes (1) royalty receipts by product: (i) Cash collections from royalty assets (financial assets and intangible assets), (ii) Other royalty cash collections, (iii) Distributions from equity method investees, plus (2) Proceeds from available for sale debt securities; less (1) Distributions to non-controlling interests, which represent contractual distributions of royalty receipts and proceeds from available for sale debt securities to our historical non-controlling interests related to the Legacy Investors Partnerships and RPSFT. Adjusted Cash Receipts is most directly comparable to the GAAP measure of Net cash provided by operating activities.

Adjusted EBITDA and Adjusted Cash Flow are similar non-GAAP liquidity measures that are both most closely comparable to the GAAP measure, Net cash provided by operating activities. Adjusted EBITDA is important to our lenders and is defined under the Credit Agreement as Adjusted Cash Receipts less Payments for operating and professional costs. Payments for operating and professional costs are comprised of Payments for operating and professional costs and Payments for rebates from the statements of cash flows.

Adjusted Cash Flow is defined as Adjusted EBITDA less (1) Development-stage funding payments - ongoing, (2) Development-stage funding payments - upfront and milestone, (3) Interest paid, net of Interest received, (4) Investments in equity method investees and (5) Other (including Derivative collateral posted, net of Derivative collateral received, and Termination payments on derivative instruments) plus (1) Contributions from non-controlling interests- R&D, all directly reconcilable to the statements of cash flows.

Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of the strength of the Company and the performance of the business. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income used by companies in the biopharmaceutical industry. Adjusted EBITDA, as derived from Adjusted Cash Receipts, is used by our lenders to assess our ability to meet our financial covenants.

49

The table below includes the royalty receipts and non-GAAP financial results for the six months ended June 30, 2022 and 2021 by product in order of contribution to royalty receipts for the six months ended June 30, 2022 (in thousands).

Royalties For the Three Months Ended June 30,For the Six Months Ended June 30,Six Months Year-to-Date Change
2022202120222021$ %
Cystic fibrosis franchise (1)$181,968 $156,023 $383,851 $322,832 $61,019 18.9 %
Tysabri93,128 92,070 190,567 178,991 11,576 6.5 %
Imbruvica80,381 87,289 167,552 176,424 (8,872)(5.0)%
Xtandi51,988 35,767 95,383 76,812 18,571 24.2 %
Promacta34,715 32,341 82,612 76,466 6,146 8.0 %
Januvia, Janumet, Other DPP-IVs (2)35,695 39,438 71,377 75,200 (3,823)(5.1)%
Tremfya18,428 — 46,653 — 46,653 — %
Nurtec ODT/Biohaven payment (3)18,715 16,721 39,090 33,222 5,868 17.7 %
Cabometyx/Cometriq13,055 10,129 25,911 10,129 15,782 155.8 %
Farxiga/Onglyza 11,346 9,113 20,815 17,675 3,140 17.8 %
Evrysdi8,134 2,971 17,331 4,648 12,683 272.9 %
Prevymis9,997 8,772 14,123 17,402 (3,279)(18.8)%
Trodelvy6,040 2,992 10,932 5,597 5,335 95.3 %
Erleada4,834 3,116 9,720 6,220 3,500 56.3 %
Crysvita4,933 3,929 9,645 7,516 2,129 28.3 %
Orladeyo4,765 957 9,191 969 8,222 *
Emgality4,425 3,550 9,188 6,814 2,374 34.8 %
Oxlumo583 — 1,349 — 1,349 — %
Other products (4)50,038 82,502 138,909 220,241 (81,332)(36.9)%
Total royalty receipts$633,168 $587,680 $1,344,199 $1,237,158 $107,041 8.7 %
Distributions to non-controlling interests(109,158)(112,476)(215,543)(238,197)22,654 (9.5)%
Adjusted Cash Receipts (non-GAAP)$524,010 $475,204 $1,128,656 $998,961 $129,695 13.0 %
Payments for operating and professional costs(44,101)(39,604)(93,003)(81,764)(11,239)13.7 %
Adjusted EBITDA (non-GAAP)$479,909 $435,600 $1,035,653 $917,197 $118,456 12.9 %
Development-stage funding payments - ongoing(606)(3,122)(1,106)(5,763)4,657 (80.8)%
Development-stage funding payments - upfront and milestone— — (100,000)— (100,000)— %
Interest received/(paid), net2,116 784 (83,618)(62,168)(21,450)34.5 %
Investments in equity method investees— (8,713)(3,050)(17,427)14,377 (82.5)%
Contributions from non-controlling interests- R&D107 2,083 731 4,080 (3,349)(82.1)%
Other— 2,130 — 2,130 (2,130)(100.0)%
Adjusted Cash Flow (non-GAAP)$481,526 $428,762 $848,610 $838,049 $10,561 1.3 %
Weighted average Class A ordinary shares outstanding - diluted607,214607,163607,207607,151
*Percentage change is not meaningful.

(1)The cystic fibrosis franchise includes the following approved products: Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio.
(2)Januvia, Janumet, Other DPP-IVs include the following approved products: Onglyza, Kombiglyze, Galvus, Eucreas and Nesina. The Other DPP-IVs are marketed by AstraZeneca, Novartis and Takeda.
(3)We have received quarterly redemption payments of $15.6 million beginning in the first quarter of 2021 related to the Series A Biohaven Preferred Shares (presented as Proceeds from available for sale debt securities on the statements of cash flows). The remaining cash receipts related to royalty receipts from Nurtec ODT.
(4)Other products primarily include royalty receipts on the following products: Bosulif (a product co-developed by our joint venture investee, Avillion I, for which receipts are presented as Distributions from equity method investees on the statements of cash flows), Cimzia, Entyvio, HIV franchise, IDHIFA, Letairis, Lexiscan, Mircera, Myozyme, Nesina, Soliqua, Tazverik and contributions from the Legacy SLP Interest.




50


Adjusted Cash Receipts (non-GAAP)

Six Months Ended June 30, 2022 and 2021

Adjusted Cash Receipts increased by $129.7 million to $1.1 billion in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by an increase in royalty receipts from the cystic fibrosis franchise and newly acquired royalties, which was partially offset by a decline in royalty receipts from matured royalties, primarily the HIV franchise, and unfavorable foreign exchange movements. The increase in Adjusted Cash Receipts also reflects a decline in distributions to non-controlling interests due to maturing royalties jointly owned by the Legacy Investors Partnerships and RPSFT.

Below we discuss the key drivers of royalty receipts.

Royalty Receipts

•Cystic fibrosis franchise – Royalty receipts from the cystic fibrosis franchise, which includes Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio, which are marketed by Vertex for patients with certain mutations causing cystic fibrosis, increased by $61.0 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021. The increase was primarily driven by the launch of Kaftrio in additional countries outside the United States and the performance of Trikafta in the United States, including its uptake in children 6 through 11 years old.

•Tysabri – Royalty receipts from Tysabri, which is marketed by Biogen for the treatment of multiple sclerosis, increased by $11.6 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by continued global patient growth and positive channel dynamics in the United States.

•Imbruvica – Royalty receipts from Imbruvica, which is marketed by AbbVie and Johnson & Johnson for the treatment of blood cancers and chronic graft versus host disease, decreased by $8.9 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021. The decrease was largely due to a slower-than-anticipated recovery of the chronic lymphocytic leukemia market from COVID-19 and increased competition from newer therapies in the United States.

•Xtandi – Royalty receipts from Xtandi, which is marketed by Pfizer and Astellas for the treatment of prostate cancer, increased by $18.6 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily due to a true-up of royalties from prior periods.

•Promacta – Royalty receipts from Promacta, which is marketed by Novartis for the treatment of chronic immune thrombocytopenia purpura (ITP) and aplastic anemia, increased by $6.1 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021. This growth was primarily driven by increased use in ITP and further uptake as first-line treatment for severe aplastic anemia in the United States.

•Januvia, Janumet, Other DPP-IVs – Royalty receipts from the DPP-IVs for type 2 diabetes, which includes Januvia and Janumet, both marketed by Merck & Co., decreased by $3.8 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021.

•Tremfya – Royalty receipts from Tremfya, which is marketed by Johnson & Johnson for the treatment of plaque psoriasis and active psoriatic arthritis, were $46.7 million in the six months ended June 30, 2022 primarily driven by continued market share gains. We acquired the Tremfya royalty in July 2021.

•Nurtec ODT/Biohaven payment – Royalty receipts from Nurtec ODT, marketed by Biohaven and Pfizer for the acute and preventative treatment of migraine, increased by $5.9 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by prescription volume growth. In addition, we received $31.3 million in fixed payments from Biohaven related to the Series A Biohaven Preferred Shares during each of the six months ended June 30, 2022 and 2021.

51

•Cabometyx/Cometriq – Royalty receipts from Cabometyx/Cometriq, which is marketed by Exelixis, Ipsen and Takeda, were $25.9 million in the six months ended June 30, 2022, primarily driven by uptake of Cabometyx in combination with Opdivo as a first-line treatment for patients with advanced renal cell carcinoma. We acquired the Cabometyx/Cometriq royalty in March 2021.

Distributions to Non-Controlling Interests

Distributions to non-controlling interests decreased by $22.7 million to $215.5 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, which positively impacted Adjusted Cash Receipts. The decrease in distributions to non-controlling interests is primarily due to maturing royalties jointly owned by the Legacy Investors Partnerships and RPSFT.

Adjusted EBITDA (non-GAAP)

Six Months Ended June 30, 2022 and 2021

Adjusted EBITDA increased by $118.5 million to $1.0 billion in the six months ended June 30, 2022 compared to the six months ended June 30, 2021 as a result of the factors noted above in “Adjusted Cash Receipts (Non-GAAP).” Payments for operating and professional costs, the only adjustment between Adjusted Cash Receipts and Adjusted EBITDA, increased in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by higher Operating and Personnel Payments from increased cash receipts from royalty investments.

Adjusted Cash Flow (non-GAAP)

Six Months Ended June 30, 2022 and 2021

Adjusted Cash Flow increased by $10.6 million to $848.6 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by the factors noted above in “Adjusted Cash Receipts (non-GAAP)” and “Adjusted EBITDA (non-GAAP).” The increase was partially offset by upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product candidate and a $21.5 million increase in net interest paid in the six months ended June 30, 2022 due to the first interest payment on the 2021 Notes.

Non-GAAP Reconciliations

Adjusted Cash Receipts, Adjusted EBITDA and Adjusted Cash Flow are non-GAAP measures presented as supplemental measures to our GAAP financial performance. These non-GAAP financial measures exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. In each case, because our operating performance is a function of our liquidity, the non-GAAP measures used by management are presented and defined as supplemental liquidity measures. We caution readers that amounts presented in accordance with our definitions of Adjusted Cash Receipts, Adjusted EBITDA, and Adjusted Cash Flow may not be the same as similar measures used by other companies. Not all companies and analysts calculate the non-GAAP measures we use in the same manner. We compensate for these limitations by using non-GAAP financial measures as supplements to GAAP financial measures and by presenting the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures, in each case being Net cash provided by operating activities.

We believe that Adjusted Cash Receipts and Adjusted Cash Flow provide meaningful information about our operating performance because the business is heavily reliant on its ability to generate consistent cash flows and these measures reflect the core cash collections and cash charges comprising our operating results. Management strongly believes that our significant operating cash flow is one of the attributes that attracts potential investors to our business.

52

In addition, we believe that Adjusted Cash Receipts and Adjusted Cash Flow help identify underlying trends in the business and permit investors to more fully understand how management assesses our performance, including planning and forecasting for future periods. Adjusted Cash Receipts and Adjusted Cash Flow are used by management as key liquidity measures in the evaluation of our ability to generate cash from operations. Both measures are an indication of our strength and the performance of the business. Management uses Adjusted Cash Receipts and Adjusted Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, voluntary debt repayments, dividends and other discretionary investments. Further, these non-GAAP financial measures help management, the audit committee and investors evaluate our ability to generate liquidity from operating activities.

Management believes that Adjusted EBITDA is an important non-GAAP measure in analyzing our liquidity and is a key component of certain material covenants contained within our credit agreement. Noncompliance with the interest coverage ratio and leverage ratio covenants under the credit agreement could result in our lenders requiring us to immediately repay all amounts borrowed. If we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the assessment of our liquidity.

Management uses Adjusted Cash Flow to evaluate its ability to generate cash and performance of the business and to evaluate our performance as compared to its peer group. Management also uses Adjusted Cash Flow to compare its performance against non-GAAP adjusted net income measures used by many companies in the biopharmaceutical industry, even though each company may customize its own calculation and therefore one company’s metric may not be directly comparable to another’s. We believe that non-GAAP financial measures, including Adjusted Cash Flow, are frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry.

The non-GAAP financial measures used in this Quarterly Report on Form 10-Q have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of our results as reported under GAAP. We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, in each case being Net cash provided by operating activities below.

To arrive at Adjusted Cash Receipts, we start with the GAAP line item, Net cash provided by operating activities, and adjust for the following items from the statements of cash flows: to add back (1) Proceeds from available for sale debt securities (redemption of Biohaven Preferred Shares), which are cash inflows that management believes are derived from royalties and form part of our core business strategy, (2) Distributions from equity method investees which are classified as cash inflows from investing activities, (3) Interest paid, net of Interest received, (4) Development-stage funding payments, (5) Payments for operating and professional costs, (6) Payments for rebates and (7) Termination payments on derivative instruments, and to deduct (1) Distributions to non-controlling interests, which represents distributions to our historical non-controlling interests related to the Legacy Investors Partnerships and RPSFT, and (2) Derivative collateral posted or (received), net, both of which are excluded when management assesses its operating performance through cash collections, or Adjusted Cash Receipts.

To arrive at Adjusted EBITDA, we start with Net cash provided by operating activities and adjust for the following items from the statements of cash flows: to add back (1) Proceeds from available for sale debt securities (redemption of Biohaven Preferred Shares), (2) Distributions from equity method investees which are classified as cash inflows from investing activities, (3) Interest paid, net of Interest received, (4) Development-stage funding payments and (5) Termination payments on derivative instruments, and to deduct (1) Distributions to non-controlling interests and (2) Derivative collateral posted or (received), net.

To arrive at Adjusted Cash Flow, we start with Net cash provided by operating activities and adjust for the following items from the statements of cash flows: to add back (1) Proceeds from available for sale debt securities (redemption of Biohaven Preferred Shares), (2) Distributions from equity method investees classified as cash inflows from investing activities and (3) Contributions from non-controlling interests-R&D, and to deduct (1) Distributions to non-controlling interests and (2) Investments in equity method investees. This is intended to present an Adjusted Cash Flow measure that is representative of cash generated from the broader business strategy of acquiring royalty-generating assets that are available for reinvestment and for discretionary purposes.

53

(in thousands)For the Three Months Ended June 30,For the Six Months Ended June 30,
2022202120222021
Net cash provided by operating activities (GAAP)$574,952 $531,720 $1,035,222 $1,057,820 
Adjustments:
Proceeds from available for sale debt securities (1), (2)15,625 15,625 31,250 31,250 
Distributions from equity method investees – investing (2)— 523 — 523 
Interest (received)/paid, net (2)(2,116)(784)83,618 62,168 
Development-stage funding payments - ongoing (3)606 3,122 1,106 5,763 
Development-stage funding payments - upfront and milestone (3)— — 100,000 — 
Payments for operating and professional costs44,101 39,604 93,003 81,764 
Distributions to non-controlling interests (2)(109,158)(112,476)(215,543)(238,197)
Derivative collateral received, net (2)— (2,130)— (2,130)
Adjusted Cash Receipts (non-GAAP)$524,010 $475,204 $1,128,656 $998,961 
Net cash provided by operating activities (GAAP)$574,952 $531,720 $1,035,222 $1,057,820 
Adjustments:
Proceeds from available for sale debt securities (1), (2)15,625 15,625 31,250 31,250 
Distributions from equity method investees – investing (2)— 523 — 523 
Interest (received)/paid, net (2)(2,116)(784)83,618 62,168 
Development-stage funding payments - ongoing (3)606 3,122 1,106 5,763 
Development-stage funding payments - upfront and milestone (3)— — 100,000 — 
Distributions to non-controlling interests (2)(109,158)(112,476)(215,543)(238,197)
Derivative collateral received, net (2)— (2,130)— (2,130)
Adjusted EBITDA (non-GAAP)$479,909 $435,600 $1,035,653 $917,197 
Net cash provided by operating activities (GAAP)$574,952 $531,720 $1,035,222 $1,057,820 
Adjustments:
Proceeds from available for sale debt securities (1), (2)15,625 15,625 31,250 31,250 
Distributions from equity method investees – investing (2)— 523 — 523 
Contributions from non-controlling interests-R&D (2)107 2,083 731 4,080 
Distributions to non-controlling interests (2)(109,158)(112,476)(215,543)(238,197)
Investments in equity method investees (2), (4)— (8,713)(3,050)(17,427)
Adjusted Cash Flow (non-GAAP)$481,526 $428,762 $848,610 $838,049 
(1)Receipts from the quarterly redemption of the Series A Biohaven Preferred Shares are presented as Proceeds from available for sale debt securities on the statements of cash flows.
(2)The table below shows the line item for each adjustment and the direct location for such line item on the statements of cash flows.
Reconciling AdjustmentStatements of Cash Flows Classification
Proceeds from available for sale debt securitiesInvesting activities
Investments in equity method investeesInvesting activities
Distributions to non-controlling interestsFinancing activities
Interest (received)/paid, net
Operating activities (Interest paid less Interest received)
Derivative collateral received, net
Operating activities (Derivative collateral received less Derivative collateral posted)
Contributions from non-controlling interests- R&DFinancing activities
Distributions from equity method investees - investingInvesting activities
(3)Our lenders consider all payments made to support R&D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. All ongoing development-stage funding payments and upfront and milestone development-stage funding payments are reported in R&D funding expense in net income and are added back in aggregate to Net cash provided by operating activities to arrive at Adjusted EBITDA. As a result, Adjusted EBITDA captures the full add-back for development-stage funding payments.
(4)We consider all payments to fund our operating joint ventures that are performing R&D activities for development-stage product candidates similar to asset acquisitions as these funds are expected to generate operational returns in the future. As a result, amounts funded through capital calls by our equity method investees, the Avillion Entities, are deducted to arrive at Adjusted Cash Flow, but are not deducted in Adjusted EBITDA.
54

Investments Overview

Ongoing investment in new royalties is fundamental to the long-term prospects of our business. New investments provide a source of growth for our royalty receipts, supplementing growth within our existing portfolio and offsetting declines for royalties on products that have lost market exclusivity. We evaluate an array of royalty acquisition opportunities on a continuous basis and expect to continue to make acquisitions in the ordinary course of our business. We have established a strong track record of identifying, evaluating and investing in royalties tied to leading products across therapeutic areas and treatment modalities. We invest in approved products and development-stage product candidates that have generated robust proof of concept data. We invest in these therapies through the purchase of royalties, by making hybrid investments and by acquiring businesses with significant existing royalty assets or the potential for the creation of such assets.

For the six months ended June 30, 2022, we invested $442.4 million in royalties and related assets. While volatility exists in the total amount of our new acquisitions on a year-to-year basis due to the unpredictable timing of new investment opportunities, we have consistently deployed significant amounts of cash when measured over multi-year periods. Our approach is rooted in a highly disciplined evaluation process that is not dictated by a minimum annual investment threshold.

Summary of Royalty Acquisition Activity

•In July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance Biopharma, Inc. (“Theravance”) and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy for an upfront payment of $1.31 billion and up to $300 million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25 million in upfront funding and a potential $15 million regulatory milestone payment to support the clinical development of ampreloxetine.

•In June 2022, we acquired an ex-U.S. royalty interest in Gavreto from Blueprint Medicines for an upfront payment of $175 million and contingent sales-based milestones up to $165 million.

•In April 2022, we acquired common stock and a revenue participation right from ApiJect Holdings, Inc. for $50 million.

•In January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (“Cytokinetics”) for $150 million comprised of an upfront payment of $50 million and two additional $50 million payments, conditional upon the initiation of potential pivotal clinical trials for oHCM and nonobstructive hypertrophic cardiomyopathy, respectively. In February 2022, Cytokinetics announced that it initiated the clinical trial for oHCM, which triggered a $50 million payment from us in March 2022. Additionally, we will provide Cytokinetics long-term capital of up to $300 million (“Cytokinetics Commercial Launch Funding”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $50 million funded upon closing.

•In November 2021, we acquired incremental royalty interests in BCX9930 and Orladeyo (berotralstat) from BioCryst for an upfront cash payment of $150 million. Additionally, we paid $50 million to purchase 3,846 thousand shares of BioCryst common stock, which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction. The funds from this transaction will enable further advancement of BCX9930 and support additional investment in the global launch of Orladeyo (berotralstat).

55

•In June 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support its acquisition of Constellation Pharmaceuticals, Inc. (“Constellation”), which closed on July 15, 2021. We agreed to provide up to $2.025 billion of funding to MorphoSys, comprised of an upfront payment of $1.425 billion, additional milestone payments of up to $150 million, up to $350 million of capital (“Development Funding Bonds”). Following an amendment in June 2022, MorphoSys may draw the funding by September 12, 2022. MorphoSys is required to draw a minimum of $150 million of Development Funding Bonds. In connection with the closing of its acquisition of Constellation, we purchased 1,337,552 ordinary shares of MorphoSys for $100 million at a price of €63.35 per ordinary share, based on the average trading price of the ordinary shares over a period preceding the closing of the acquisition.

•In April 2021, we acquired a royalty interest in Oxlumo from Dicerna Pharmaceuticals, Inc. for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. Oxlumo, which has been approved by the FDA and EMA for the treatment of primary hyperoxaluria type 1, is marketed by Alnylam.

•In March 2021, we acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GSK plc for an upfront payment of $342 million and up to $50 million in additional payments contingent on the achievement of regulatory approvals of cabozantinib for prostate cancer and lung cancer in the United States and Europe.

•In January 2021, we acquired a royalty interest in seltorexant from Minerva Neurosciences, Inc. for an upfront payment of $60 million and up to $95 million in additional milestone payments, contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder with insomnia symptoms by Johnson & Johnson.

Additionally, in April 2021, we entered into an agreement with MSCI, a leading provider of critical decision support tools and services, to assist MSCI in the design of a classification framework and index methodologies to expand MSCI’s thematic index suite with the launch of new indexes. In return, we will receive a portion of MSCI’s revenues from those indexes. The financial impact associated with this transaction has not been material to date and is not expected to be material for the year ended December 31, 2022.

Liquidity and Capital Resources

Overview

Our primary source of liquidity is cash provided by operations. For both the six months ended June 30, 2022 and 2021, we generated $1.0 billion and $1.1 billion, respectively, in Net cash provided by operating activities. We believe that our existing capital resources, cash provided by operating activities and our Revolving Credit Facility (defined below) will continue to allow us to meet our operating and working capital requirements, to fund planned strategic acquisitions and R&D funding arrangements, and to meet our debt service obligations for the foreseeable future. We have historically operated at a low level of fixed operating costs. Our primary cash operating expenses, other than R&D funding commitments, include interest expense, our Operating and Personnel Payments, and legal and professional fees.

We have access to substantial sources of funds in the capital markets and we may, from time to time, seek additional capital through a combination of additional debt or equity financings. In July 2021, we issued $1.3 billion of senior unsecured notes. Additionally, we have a Revolving Credit Facility (defined below) which provides for borrowing capacity of up to $1.5 billion that remains undrawn and available to us as of June 30, 2022. As of June 30, 2022 and December 31, 2021, we had total long-term debt outstanding of $7.1 billion and $7.1 billion, respectively.

We have historically funded our acquisition program through free cash flow, equity contributions and debt. Our low operating costs coupled with a lack of capital expenditures and low taxes have contributed to our strong financial profile, resulting in high operating leverage and high conversion of our Adjusted Cash Receipts to Adjusted Cash Flow. We expect to continue funding our current and planned operating costs (excluding acquisitions) principally through our cash flow from operations and our acquisition program through cash flow and issuances of equity and debt. In the past, we have supplemented our available cash and cash equivalents on hand with attractive debt capital to fund certain strategic acquisitions.

56

Our ability to satisfy our working capital needs, debt service and other obligations, and to comply with the financial covenants under our financing agreements depends on our future operating performance and cash flow, which are in turn subject to prevailing economic conditions and other factors, many of which are beyond our control.

Cash Flows

The following table and analysis of cash flow changes presents a summary of our cash flow activity for the six months ended June 30, 2022 and 2021:

(in thousands)For the Six Months Ended June 30,2022 vs. 2021
20222021Change
Cash provided by (used in):
     Operating activities$1,035,222 $1,057,820 $(22,598)
     Investing activities(19,013)(473,134)454,121 
     Financing activities(449,220)(451,085)1,865 

Analysis of Cash Flow Changes

Operating Activities

Cash provided by operating activities decreased by $22.6 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product candidate in the six months ended June 30, 2022. Additionally, interest paid increased by $22.4 million in the six months ended June 30, 2022 due to the first interest payment made on the 2021 Notes. The higher use of cash was partially offset by an increase in cash collections from financial royalty assets of $87.3 million.

Investing Activities

Cash used in investing activities decreased by $454.1 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily driven by a $508.6 million decrease in cash used to acquire financial royalty assets and a $150.4 million increase in the overall net cash provided by marketable securities. Additionally, we paid approximately $62.8 million to acquire equity securities during the six months ended June 30, 2022 compared to the receipt of proceeds of $109.4 million from the sale of all of our Cytokinetics common stock and a portion of our Biohaven common shares during the six months ended June 30, 2021.

Financing Activities

Cash used in financing activities was relatively consistent in the six months ended June 30, 2022 compared to the six months ended June 30, 2021.

Sources of Capital

As of June 30, 2022, our cash and cash equivalents and marketable securities totaled $2.1 billion and $290.4 million, respectively. As of December 31, 2021, our cash and cash equivalents and marketable securities totaled $1.5 billion and $581.9 million, respectively. We intend to fund short-term and long-term financial obligations as they mature through cash and cash equivalents, sales of marketable securities, future cash flows from operations or the issuance of additional debt. Our ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the sales of the underlying pharmaceutical products in which we hold royalties, deterioration in our key financial ratios or credit ratings, or other material unfavorable changes in business conditions. Currently, we believe that we have sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support our growth objectives.

57

Borrowings

Our borrowings at June 30, 2022 and December 31, 2021 consisted of the following (in thousands):
Date of IssuanceMaturityAs of June 30, 2022As of December 31, 2021
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)9/20209/2023$1,000,000 $1,000,000 
$1,000,000, 1.20% (issued at 98.875% of par)9/20209/20251,000,000 1,000,000 
$1,000,000, 1.75% (issued at 98.284% of par)9/20209/20271,000,000 1,000,000 
$1,000,000, 2.20% (issued at 97.760% of par)9/20209/20301,000,000 1,000,000 
$600,000, 2.15% (issued at 98.263% of par)7/20219/2031600,000 600,000 
$1,000,000, 3.30% (issued at 95.556% of par)9/20209/20401,000,000 1,000,000 
$1,000,000, 3.55% (issued at 95.306% of par)9/20209/20501,000,000 1,000,000 
$700,000, 3.35% (issued at 97.565% of par)7/20219/2051700,000 700,000 
Total senior unsecured debt7,300,000 7,300,000 
Unamortized debt discount and issuance costs(193,801)(203,930)
Total long-term debt$7,106,199 $7,096,070 

Senior Unsecured Notes

On July 26, 2021, we issued the 2021 Notes with a weighted average coupon rate of 2.80% and requiring annual interest payments of approximately $36.4 million, paid semi-annually. On September 2, 2020, we issued $6.0 billion of senior unsecured note (the “2020 Notes”) with a weighted average coupon rate of 2.125% and requiring annual interest payments of approximately $127.5 million, paid semi-annually. We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. We refer to the 2020 Notes and 2021 Notes, collectively, as the “Notes.” Indentures governing the Notes contain certain covenants with which we were in compliance as of June 30, 2022.

Senior Unsecured Revolving Credit Facility

On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”). The Credit Agreement amends and restates the credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured Revolving Credit Facility with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026. The Credit Agreement contains certain customary covenants which we were in compliance as of June 30, 2022. The Revolving Credit Facility remains undrawn and available to us as of June 30, 2022.

Uses of Capital

Acquisitions of Royalties

We acquire product royalties in ways that can be tailored to the needs of our partners through a variety of structures:

•Third-party Royalties – Existing royalties on approved or late-stage development therapies with high commercial potential. A royalty is the contractual right to a percentage of top-line sales from a licensee’s use of a product, technology or intellectual property. The majority of our current portfolio consists of third-party royalties.

•Synthetic Royalties/R&D Funding – Newly-created royalties on approved or late-stage development therapies with strong proof of concept and high commercial potential. A synthetic royalty is the contractual right to a percentage of top-line sales created by the developer and/or marketer of a therapy in exchange for funding. A synthetic royalty may also include contingent milestone payments. We also fund ongoing R&D, typically for large biopharmaceutical companies, in exchange for future royalties and/or milestones if the product or indication we are funding is approved.

58

•Launch and Development Capital – Tailored supplemental funding solutions, generally included as a component within a transaction, increasing the scale of our capital. Launch and development capital is generally provided in exchange for a long-term stream of fixed payments with a predetermined schedule around the launch of a drug. Launch and development capital may also include a direct investment in the public equity of a company.

•M&A Related – We acquire royalties in connection with M&A transactions, often from the buyers of biopharmaceutical companies when they dispose of the non-strategic assets of the target company following the closing of the acquisition. We also seek to partner with companies to acquire other biopharmaceutical companies that own significant royalties. We may also seek to acquire biopharmaceutical companies that have significant royalties or where we can create royalties in subsequent transactions.

Additionally, we may identify additional opportunities, platforms or technologies that leverage our capabilities. One example is our strategic alliance with MSCI to develop thematic life sciences indices.

Distributions to Shareholders

We paid dividends to holders of our Class A ordinary shares of $165.3 million and $138.6 million in the six months ended June 30, 2022 and 2021, respectively. We do not have a legal obligation to pay a quarterly dividend or dividends at any specified rate or at all.

Other Funding Arrangements

In January 2022, we entered into a long-term funding agreement with Cytokinetics to provide capital up to $300 million of capital (“Cytokinetics Commercial Launch Funding”) available in five tranches to support Cytokinetics for further development of aficamten and potential commercialization of omecamtiv mecarbil. We funded the initial tranche of $50 million of the Cytokinetics Commercial Launch Funding upon closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones. As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022.

In June 2021, we announced a long-term strategic funding partnership with MorphoSys to support its acquisition of Constellation, which closed on July 15, 2021. As part of the funding agreement, which was amended in the three months ended June 30, 2022 to extend the required draw date, we agreed to provide MorphoSys up to $350 million of Development Funding Bonds to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $150 million. In return, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding. As of June 30, 2022, MorphoSys has not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $300 million under the Development Funding Bonds to be funded in September 2022.

On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”) for a total of $200 million payable on a quarterly basis from the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares and have a remaining commitment of $100.4 million under our Commercial Launch Preferred Equity as of June 30, 2022.

We may have other funding arrangements where we are contractually obligated to fund R&D activities performed by our development partners. We also have funding arrangements related to our equity method investment in the Avillion Entities. As our committed capital requirements are based on phases of development, the completion of which is highly uncertain, only the capital required to fund the current stage of development under such funding arrangements is considered committed capital requirements, which approximate $52.7 million as of June 30, 2022.

59

We also have certain milestone payments that are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. As such, these contingent milestone payments are not considered contractual obligations. In the six months ended June 30, 2022, we made a $50 million payment to Cytokinetics in connection with its initiation of the first pivotal clinical trial in oHCM. In the six months ended June 30, 2021, we made a $100 million payment to Biohaven related to a development milestone that was achieved upon the start of the oral zavegepant Phase 3 program.

Debt Service

As of June 30, 2022, the future principal and interest payments under our Notes over the next five years and thereafter are as follows:

(in thousands)Principal PaymentsInterest Payments
Year
Remainder of 2022$— $81,925 
20231,000,000 163,850 
2024— 156,350 
20251,000,000 156,350 
2026— 144,350 
Thereafter5,300,000 2,070,250 
Total (1)$7,300,000 $2,773,075 
(1)Excludes unamortized debt discount and issuance costs of $193.8 million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.

Operating and Personnel Payments

Under the Management Agreement, we pay quarterly Operating and Personnel Payments equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of our security investments under GAAP as of the end of each quarter. Because the Operating and Personnel Payments are determined based on cash receipts, the amounts are variable. The expenses incurred in respect of Operating and Personnel Payments are expected to comprise the most significant component of G&A expenses on an ongoing basis.

Guarantor Financial Information

Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary (the “Guarantor Subsidiary”). Our remaining subsidiaries (the “Non-Guarantor Subsidiaries”) do not guarantee the Notes. Under the terms of the indenture governing the Notes, Royalty Pharma plc and the Guarantor Subsidiary each fully and unconditionally, jointly and severally, guarantee the payment of interest, principal and premium, if any, on the Notes. As of June 30, 2022, the par value and carrying value of the total outstanding and guaranteed Notes was $7.3 billion and $7.1 billion, respectively.

The following financial information presents summarized combined balance sheet information as of June 30, 2022 and December 31, 2021 and summarized combined statement of operations information for the six months ended June 30, 2022 for Royalty Pharma plc and RP Holdings. All intercompany balances and transactions between Royalty Pharma plc and RP Holdings are eliminated in the presentation of the combined financial statements. RP Holdings’ most significant asset is its investment in operating subsidiaries, which has been eliminated in the table below to exclude investments in Non-Guarantor Subsidiaries. Our operating subsidiaries hold the majority of our cash and cash equivalents, marketable securities and financial royalty assets. As a result, our ability to make required payments on the Notes depends on the performance of our operating subsidiaries and their ability to distribute funds to us. There are no material restrictions on distributions from the operating subsidiaries. Amounts presented below do not represent our total consolidated amounts as of June 30, 2022 and December 31, 2021 or for the six months ended June 30, 2022.

60

Summarized Combined Balance Sheet
(in thousands)As of June 30, 2022As of December 31, 2021
Current assets$57,188 $95,946 
Current interest receivable on intercompany notes due from Non-Guarantor Subsidiaries17,725 16,974 
Non-current assets 3,591 4,145 
Non-current intercompany notes receivable due from Non-Guarantor Subsidiaries2,038,611 2,039,576 
Current liabilities56,646 59,030 
Current interest payable on intercompany notes due to Non-Guarantor Subsidiaries15,370 16,974 
Non-current liabilities7,105,495 7,095,450 
Non-current intercompany notes payable due to Non-Guarantor Subsidiaries1,993,611 2,039,576 
Summarized Combined Statement of OperationsFor the Six Months Ended June 30, 2022
(in thousands)
Interest income on intercompany notes receivable from Non-Guarantor Subsidiaries$28,181 
Other income56 
Operating expenses104,266 
Interest expense on intercompany notes payable with Non-Guarantor Subsidiaries25,826 
Net loss 101,855 

Critical Accounting Policies and Use of Estimates

The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Certain of these policies are considered critical as they have the most significant impact on our financial condition and results of operations and require the most difficult, subjective, or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain. On an ongoing basis, we evaluate our estimates that are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of income and expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Our most critical accounting policies relate to our financial royalty assets. Similarly, the most significant judgments and estimates applied by management are associated with the measurement of our financial royalty assets at amortized cost using the prospective effective interest method. The application of the prospective approach to calculate interest income from our financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties. There have been no material changes to our critical accounting policies and estimates as described in our Annual Report on Form 10-K.

Recent Accounting Pronouncements

See Note 2–Summary of Significant Accounting Policies to our condensed consolidated financial statements for additional information on recently issued accounting standards.


Item 3.         QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the Annual Report on Form 10-K.


61

Item 4.         CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were, in design and operation, effective to the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal controls over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the three months ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness Of Controls

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.

PART II.     OTHER INFORMATION

Item 1.         LEGAL PROCEEDINGS

For a description of our legal proceedings, refer to Note 14–Commitments and Contingencies, which is incorporated herein by reference.

Item 1A.    RISK FACTORS

There have been no material changes with respect to the risk factors disclosed in the Annual Report on Form 10-K.

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition and results of operations.

Item 2.        UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

None.

Issuer Purchases of Equity Securities

None.

Item 3.         DEFAULTS UPON SENIOR SECURITIES

Not applicable.

62

Item 4.        MINE SAFETY DISCLOSURES

Not applicable.

Item 5.         OTHER INFORMATION

Not applicable.

Item 6.         EXHIBITS

The following exhibits are filed as a part of this Quarterly Report on Form 10-Q:


* Filed or furnished herewith
SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


ROYALTY PHARMA PLC
(Registrant)
/s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer
Date: August 4, 2022
/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer
Date: August 4, 2022
63
 EX-31.1 2 rprx-20220630ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Pablo Legorreta, certify that:
1.    I have reviewed this Quarterly Report on Form 10-Q of Royalty Pharma plc;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 4, 2022
/s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer

2
    
 EX-31.2 3 rprx-20220630ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULE 13A-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Terrance Coyne, certify that:
1.    I have reviewed this Quarterly Report on Form 10-Q of Royalty Pharma plc;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 4, 2022

/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer

2
    
 EX-32 4 rprx-20220630ex32.htm EX-32 Document

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with Royalty Pharma plc’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the “Report”), Pablo Legorreta, the Chief Executive Officer and Terrance Coyne, the Chief Financial Officer of Royalty Pharma plc, each does hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), that to his knowledge:
1.    the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.    the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Royalty Pharma plc.

Date: August 4, 2022
/s/ Pablo Legorreta
Name: Pablo Legorreta
Chief Executive Officer
/s/ Terrance Coyne
Name: Terrance Coyne
Chief Financial Officer

 EX-101.SCH 5 rprx-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Purpose link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization and Purpose (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2106103 - Disclosure - Available for Sale Debt Securities link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Available for Sale Debt Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2110104 - Disclosure - Fair Value Measurements and Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2116105 - Disclosure - Financial Royalty Assets link:presentationLink link:calculationLink link:definitionLink 2317303 - Disclosure - Financial Royalty Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2119106 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets link:presentationLink link:calculationLink link:definitionLink 2320304 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2421410 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 2122107 - Disclosure - Intangible Royalty Assets, Net link:presentationLink link:calculationLink link:definitionLink 2323305 - Disclosure - Intangible Royalty Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2424411 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) link:presentationLink link:calculationLink link:definitionLink 2425412 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2126108 - Disclosure - Non-Consolidated Affiliates link:presentationLink link:calculationLink link:definitionLink 2427413 - Disclosure - Non-Consolidated Affiliates (Details) link:presentationLink link:calculationLink link:definitionLink 2128109 - Disclosure - Research & Development ("R&D") Funding Expense link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Research & Development ("R&D") Funding Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2130110 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 2331306 - Disclosure - Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - Borrowings - Schedule of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - Borrowings - Schedule of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 2433416 - Disclosure - Borrowings - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2434417 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details) link:presentationLink link:calculationLink link:definitionLink 2135111 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2336307 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2437418 - Disclosure - Shareholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2438419 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 2139112 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 2340308 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2441420 - Disclosure - Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2142113 - Disclosure - Indirect Cash Flow link:presentationLink link:calculationLink link:definitionLink 2343309 - Disclosure - Indirect Cash Flow (Tables) link:presentationLink link:calculationLink link:definitionLink 2444421 - Disclosure - Indirect Cash Flow (Details) link:presentationLink link:calculationLink link:definitionLink 2145114 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2446422 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2147115 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2348310 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 2449423 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2150116 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2451424 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 rprx-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 rprx-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 rprx-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Milestone payments Payments For Milestones Payments For Milestones Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Consolidated net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Related Party Transactions [Abstract] Total Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code RPSFT Royal Pharmacy Select Finance Trust [Member] Royal Pharmacy Select Finance Trust RP Holdings RP Holdings [Member] RP Holdings Contributions Noncontrolling Interest, Increase from Contributions Noncontrolling Interest, Increase from Contributions Schedule of Balance Of Non-controlling Interests Schedule of Stockholders Equity [Table Text Block] RPCT Royalty Pharma Collection Trust [Member] Royalty Pharma Collection Trust 2024 Long-Term Debt, Maturity, Year Two Debt Instrument [Axis] Debt Instrument [Axis] Contributions from non-controlling interests- other Proceeds From Noncontrolling Interests, Other Proceeds From Noncontrolling Interests, Other Regulatory milestone payments Long Term Funding Partnership, Regulatory Milestone Payments, Aggregate Amount Long Term Funding Partnership, Regulatory Milestone Payments, Aggregate Amount Exchange Offer Transaction Exchange Offer Transaction [Member] Exchange Offer Transaction Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Old RPI Royalty Pharma Investments (Old RPI) [Member] Royalty Pharma Investments (Old RPI) Other (income)/expense Other Income and Expenses [Abstract] Additional paid-in capital Additional Paid in Capital The Notes The Notes [Member] The Notes Interest received Proceeds from Interest Received Required amount to be drawn Long Term Funding Partnership, Covenant, Required Amount Long Term Funding Partnership, Covenant, Required Amount Fair Value Measurement [Domain] Fair Value Measurement [Domain] Financial Instruments [Domain] Financial Instruments [Domain] Basis spread on variable rate (percentage) Debt Instrument, Basis Spread on Variable Rate Research and Development [Abstract] Debt instrument, stated rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Proceeds from sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Other royalty income receivable Increase (Decrease) In Other Royalty Income Receivable Increase (Decrease) In Other Royalty Income Receivable Upon occurrence of a change of control triggering event Debt Instrument, Redemption, Period Three [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Other Other Noncash Income (Expense) Legacy Investors Partnerships and RPSFT Legacy Investors Partnerships and RPSFT [Member] Legacy Investors Partnerships and RPSFT Other liabilities Increase (Decrease) in Other Current Liabilities Net income attributable to Royalty Pharma plc Net Income (Loss) Attributable to Parent Acquisitions of financial royalty assets Payments to Acquire Finance Receivables Financial royalty assets Financing Receivable, after Allowance for Credit Loss, Current Debt Securities Debt Securities [Member] Document Information [Line Items] Document Information [Line Items] Schedule of Repayments of Debt by Year Schedule of Maturities of Long-Term Debt [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Cystic fibrosis franchise Cystic Fibrosis Franchise [Member] Cystic Fibrosis Franchise Reclassification of unrealized gains on available for sale debt securities Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent) Related Party Transaction, Rate, Adjusted Cash Receipts Related Party Transaction, Rate, Adjusted Cash Receipts Expected proceeds from development funding bonds Collaborative Arrangement, Expected Proceeds Collaborative Arrangement, Expected Proceeds Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Redemption price (as a percent) Debt Instrument, Redemption Price, Percentage Ownership [Axis] Ownership [Axis] Related party, rate (as a percent) Related Party Transaction, Rate Investment, Name [Domain] Investment, Name [Domain] Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Related Party [Domain] Related Party [Domain] Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Plan Name [Axis] Plan Name [Axis] Maximum consolidated leverage ratio following qualifying material acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition Long term funding partnership, number of tranches Long Term Funding Partnership, Number of Tranches Long Term Funding Partnership, Number of Tranches Gains on derivative financial instrument Gain on Derivative Instruments, Pretax Supplemental Cash Flow Elements [Abstract] Fair Value Debt Securities, Available-for-Sale Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense Redemption, Period One Debt Securities, Available-For-Sale, Redemption, Period One [Member] Debt Securities, Available-For-Sale, Redemption, Period One Plan Name [Domain] Plan Name [Domain] Statement of Cash Flows [Abstract] Outstanding borrowings Long-Term Line of Credit Entity Address, State or Province Entity Address, State or Province Transfer to Level 1 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Level 1 Fair Value, Inputs, Level 1 [Member] Avillion II Avillion II [Member] Avillion II Changes in other comprehensive income/(loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Purchase commitment, amount outstanding Long Term Purchase Commitment, Amount Outstanding Long Term Purchase Commitment, Amount Outstanding Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Denominator Weighted Average Number of Shares Outstanding, Basic [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Royalty Distribution Payable to Legacy Investors Partnerships Royalty Distribution Payable to Legacy Investors Partnerships [Member] Royalty Distribution Payable to Legacy Investors Partnerships Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Preferred shares, weighted average cost of capital Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital Summary of Available for Sale Debt Securities Debt Securities, Available-for-Sale [Table Text Block] 2020 Equity Incentive Plan 2020 Equity Incentive Plan [Member] 2020 Equity Incentive Plan Related Party Transaction [Domain] Related Party Transaction [Domain] Debt Securities, Available-For-Sale, Redemption, Period [Domain] Debt Securities, Available-For-Sale, Redemption, Period [Domain] Debt Securities, Available-For-Sale, Redemption, Period Other liabilities Other Liabilities Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Receivables [Abstract] Other Commitments [Domain] Other Commitments [Domain] Legal Entity [Axis] Legal Entity [Axis] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Certificates of deposit Certificates of Deposit [Member] Total liabilities Liabilities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Aggregate royalty amount when patents cease Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents Available for sale debt securities Available for sale debt securities, current Debt Securities, Available-for-Sale, Current Document Type Document Type Exchange offering, ownership percentage Sale of Stock, Percentage of Ownership before Transaction Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Senior Notes Due 2031 Senior Notes Due 2031 [Member] Senior Notes Due 2031 Assets: Assets, Fair Value Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense Distributions from equity method investees Proceeds from Equity Method Investment, Distribution, Return of Capital Borrowings Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Common Class B Common Class B [Member] Decrease/(increase) in operating assets: Increase (Decrease) in Operating Assets [Abstract] Financial Instrument [Axis] Financial Instrument [Axis] 2025 Long-Term Debt, Maturity, Year Three Unrealized (losses)/gains included in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Affiliated Entity Affiliated Entity [Member] Revenue Benchmark Revenue Benchmark [Member] Subsequent Event Subsequent Event [Member] Class R Redeemable Stock Class R Redeemable Stock [Member] Class R Redeemable Stock Document Period End Date Document Period End Date Price per share (in USD per share) Debt Securities, Available-For-Sale, Price Per Share Debt Securities, Available-For-Sale, Price Per Share Total assets Assets Debt Disclosure [Abstract] Earnings Per Share [Abstract] Overnight Bank Funding Rate Overnight Bank Funding Rate [Member] Overnight Bank Funding Rate Unsecured Debt Unsecured Debt [Member] Less: Current portion of long-term debt Long-Term Debt, Current Maturities Numerator Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Fair value of outstanding Notes Long-Term Debt, Fair Value Accounting Policies [Abstract] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block] Accrued royalty receivable Accrued Royalty Receivable Accrued Royalty Receivable Other Commitments [Axis] Other Commitments [Axis] Schedule of Cumulative Allowance for Changes in Expected Cash Flows Financing Receivable, Allowance for Credit Loss [Table Text Block] Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Credit Loss, Financial Instrument [Text Block] Gross Carrying Value Financing Receivable, before Allowance for Credit Loss Consolidated net income before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shareholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Earnings per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Forwards Forwards Forward Contracts [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Related Party Transaction [Line Items] Related Party Transaction [Line Items] Cytokinetics Commercial Launch Funding Cytokinetics Commercial Launch Funding [Member] Cytokinetics Commercial Launch Funding Continuing Investors Partnerships Continuing Investors Partnership [Member] Continuing Investors Partnership Schedule of Intangible Royalty Interests Schedule of Finite-Lived Intangible Assets [Table Text Block] Merck Asset - Phase II Clinical Trial Merck Asset - Phase II Clinical Trial [Member] Merck Asset - Phase II Clinical Trial Acquisitions of other financial assets Payments to Acquire Other Investments Marketable securities Debt Securities, Trading Interest income accretion Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss) Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss) Entity Registrant Name Entity Registrant Name Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Subsequent Events Subsequent Events [Text Block] Assignment Agreement - Benefit of Payment Stream Assignment Agreement - Benefit of Payment Stream [Member] Assignment Agreement - Benefit of Payment Stream Financial Royalty Assets Financial Royalty Assets [Member] Financial Royalty Assets Entity Address, City or Town Entity Address, City or Town Long term funding partnership, expected payment Long Term Funding Partnership, Expected Payment Long Term Funding Partnership, Expected Payment Evrysdi Evrysdi [Member] Evrysdi Deferred Shares Deferred Shares [Member] Deferred Shares Operating expenses Operating Expenses [Abstract] Total shareholders’ equity Beginning balance Ending balance Shareholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Basis of consolidation Consolidation, Policy [Policy Text Block] Former Operating and Personnel Payments Former Operating and Personnel Payments [Member] Former Operating and Personnel Payments Asset Class [Domain] Asset Class [Domain] Redemption price, percentage Debt Securities, Available-For-Sale, Redemption Price, Multiple Debt Securities, Available-For-Sale, Redemption Price, Multiple Period of return Collaborative Arrangement, Rights and Obligations, Period of Return Collaborative Arrangement, Rights and Obligations, Period of Return Non-controlling interests Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Royalty Royalty [Member] Common stock, par value (in dollars/pounds per share) Common Stock, Par or Stated Value Per Share (Gains)/losses on derivative financial instruments Unrealized Gain (Loss) on Derivatives Commitments and Contingencies Disclosure [Abstract] Investment, Name [Axis] Investment, Name [Axis] Fair Value Measurements and Financial Instruments Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Intangible Royalty Assets, Net Intangible Assets Disclosure [Text Block] Amount calculated for operating and personal payment Related Party Transaction, Operating and Personal Payment Calculation, Amount Related Party Transaction, Operating and Personal Payment Calculation, Amount Individual Licensees Concentration List Individual Licensees Concentration Risk [Member] Individual Licensees Concentration Risk Research and development funding expense Research and Development Expense Interest payable Interest Payable, Current Funding commitment, outstanding Long Term Funding Commitment, Amount Outstanding Long Term Funding Commitment, Amount Outstanding Cytokinetics Cytokinetics [Member] Cytokinetics Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Two Point One Five Zero Percent Senior Notes Due 2031 Two Point One Five Zero Percent Senior Notes Due 2031 [Member] Two Point One Five Zero Percent Senior Notes Due 2031 Use of estimates Use of Estimates, Policy [Policy Text Block] Derivative collateral received Proceeds From Collateral Received On Derivative Instruments Proceeds From Collateral Received On Derivative Instruments Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total distributions payable to non-controlling interests Due to Related Parties, Noncurrent London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Equity Method Investments and Joint Ventures [Abstract] Subsequent Events [Abstract] Concentration risk (as a percent) Individual licensees exceeding 10% or more of revenue (as a percent) Concentration Risk, Percentage Revenues Revenues Purchases of equity securities Payments To Acquire Equity Securities, FN-NI Payments To Acquire Equity Securities, FN-NI Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Available for Sale Debt Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Interest income Investment income Investment Income, Net Weighted average coupon rate (as a percent) Debt, Weighted Average Interest Rate Commitment to fund agreement Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund Credit Facility [Domain] Credit Facility [Domain] Increase/(decrease) in operating liabilities: Increase (Decrease) in Operating Liabilities [Abstract] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Amortization of intangible assets Amortization of Intangible Assets Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Basic (in dollars per share) Earnings per Class A ordinary share - basic (in dollars per share) Earnings Per Share, Basic Restrictions on selling common stock, period Debt Securities, Available-For-Sale, Restriction Period Debt Securities, Available-For-Sale, Restriction Period Point Seven Five Percent Senior Notes Due 2023 Point Seven Five Percent Senior Notes Due 2023 [Member] Point Seven Five Percent Senior Notes Due 2023 Number of shares purchased (in shares) Debt Securities, Available-For-Sale, Number Of Shares Purchased Debt Securities, Available-For-Sale, Number Of Shares Purchased Requisite service period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Distributions to non-controlling interests Payments to Noncontrolling Interests Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Counterparty Name [Domain] Counterparty Name [Domain] Three Point Three Five Zero Percent Due 2051 Three Point Three Five Zero Percent Due 2051 [Member] Three Point Three Five Zero Percent Due 2051 Treasury Interests Treasury Stock Treasury Stock [Member] Payment of capital Collaborative Arrangement, Rights and Obligations, Payment of Capital Collaborative Arrangement, Rights and Obligations, Payment of Capital Net carrying value Total financial royalty assets, net Financing Receivable, after Allowance for Credit Loss Ownership [Domain] Ownership [Domain] Common stock exchange ratio Common Stock, Exchange Ratio Common Stock, Exchange Ratio Entity Interactive Data Current Entity Interactive Data Current Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Shareholders' Equity Shareholders' Equity and Share-Based Payments [Text Block] Avillion Entities Avillion Entities [Member] Avillion Entities Class B ordinary shares exchangeable for Class A ordinary shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares Money market funds Money Market Funds [Member] Proceeds from available for sale debt securities Proceeds from Sale of Debt Securities, Available-for-Sale Senior Unsecured Revolving Credit Facility Senior Unsecured Revolving Credit Facility [Member] Senior Unsecured Revolving Credit Facility Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Retained Earnings Retained Earnings [Member] Dividends declared and paid Dividends, Common Stock, Cash Debt issued as a percent of par value (as a percent) Debt Instrument, Issuance As A Percent Of Par Debt Instrument, Issuance As A Percent Of Par Three Point Five Five Percent Senior Notes Due 2050 Three Point Five Five Percent Senior Notes Due 2050 [Member] Three Point Five Five Percent Senior Notes Due 2050 Development-stage funding payments - upfront and milestone Payments For Upfront Development Stage Funding Payments For Upfront Development Stage Funding Common Stock Common Stock [Member] Share-based compensation and related issuances of Class A ordinary shares Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Class of Stock [Axis] Class of Stock [Axis] Minimum consolidated coverage ratio Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio Statement [Table] Statement [Table] Percent calculated for operating and personal payment Related Party Transaction, Operating and Personal Payment Calculation, Percent Related Party Transaction, Operating and Personal Payment Calculation, Percent Weighted average effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Number of votes per share Common Stock, Voting Rights, Number Of Votes Common Stock, Voting Rights, Number Of Votes Document Quarterly Report Document Quarterly Report (Gains)/losses on derivative financial instruments Gain (Loss) on Derivative Instruments, Net, Pretax Current assets Assets, Current [Abstract] Senior Notes Due 2051 Senior Notes Due 2051 [Member] Senior Notes Due 2051 Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Retained earnings Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Income AOCI Including Portion Attributable to Noncontrolling Interest [Member] Long term funding partnership, aggregate amount Long Term Funding Partnership, Additional Payments, Aggregate Amount Long Term Funding Partnership, Additional Payments, Aggregate Amount Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Purchases of marketable securities Payments to Acquire Marketable Securities Equity Components [Axis] Equity Components [Axis] Maximum consolidated leverage ratio Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio Fair Value, Recurring Fair Value, Recurring [Member] Related Party Transactions Related Party Transactions Disclosure [Text Block] Royalty Distribution Payable to RP Select Finance Trust Royalty Distribution Payable to RP Select Finance Trust [Member] Royalty Distribution Payable to RP Select Finance Trust Funding Commitments Funding Commitments [Member] Funding Commitments Document Fiscal Year Focus Document Fiscal Year Focus Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Total other (income)/expenses, net Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Cost Finite-Lived Intangible Assets, Gross Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Deferred stock, par value (in dollars per share) Deferred Shares, Par or Stated Value Per Share Deferred Shares, Par or Stated Value Per Share Redeemable stock, redemption price (in euros per share) Redeemable Stock, Redemption Price Per Share Redeemable Stock, Redemption Price Per Share Series A Preferred Stock Debt Securities Series A Preferred Stock [Member] Equity method investment, unfunded commitments Equity Method Investments, Unfunded Commitments Equity Method Investments, Unfunded Commitments Dividends to shareholders Payment Of Dividends To Shareholders Payment Of Dividends To Shareholders Document Transition Report Document Transition Report Local Phone Number Local Phone Number Operating income Operating Income (Loss) Document Information [Table] Document Information [Table] Weighted average Class A ordinary shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, outstanding (in shares) Common shares outstanding Common Stock, Shares, Outstanding Financial royalty assets, net Financing Receivables, Fair Value Disclosure Financing Receivables, Fair Value Disclosure Category of Item Purchased [Axis] Category of Item Purchased [Axis] Unrealized gain/(loss) on available for sale debt securities, Including noncontrolling interest AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Upfront cash payment Collaborative Arrangement, Rights and Obligations, Upfront Payment Collaborative Arrangement, Rights and Obligations, Upfront Payment Operating and personnel payments incurred Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party Contributions from non-controlling interests- R&D Proceeds From Noncontrolling Interests, Research And Development Proceeds From Noncontrolling Interests, Research And Development Adjustments to reconcile consolidated net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income tax expense Income Tax Expense (Benefit) Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Series B Preferred Stock Series B Preferred Stock [Member] Income Statement [Abstract] Credit Loss [Abstract] Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Earnings per Class A ordinary share: Earnings Per Share, Basic [Abstract] Milestone Acceleration Milestone Acceleration [Member] Milestone Acceleration Royalty Investments Royalty Investments [Member] Royalty Investments Bristol-Myers Squibb Bristol-Myers Squibb [Member] Bristol-Myers Squibb Diluted (in shares) Weighted average Class A ordinary shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Intangible Royalty Assets Intangible Royalty Assets [Member] Intangible Royalty Assets Forwards Derivative Liability Gains/(losses) on initial recognition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Equity securities Equity Securities, FV-NI, Noncurrent Dividends declared and paid (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Debt issuance costs Debt Issuance Costs, Gross Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Increase in commitment Other Commitment, Increase (Decrease) Other Commitment, Increase (Decrease) Common stock Common Stock, Value, Issued Carrying Value, net Reported Value Measurement [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] MorphoSys MorphoSys [Member] MorphoSys Preferred Shares Debt securities Preferred Stock [Member] Senior Notes Senior Notes [Member] Class B Holders Class B Holders [Member] Class B Holders Other commitment Other Commitment Beginning balance Ending balance Financing Receivable, Allowance for Credit Loss Schedule of Fair Value Hierarchy Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Installment repayments, percentage of amount drawn Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Debt Securities, Available-For-Sale, Redemption, Period [Axis] Debt Securities, Available-For-Sale, Redemption, Period [Axis] Debt Securities, Available-For-Sale, Redemption, Period Net income attributable to non-controlling interests Less: net income attributable to non-controlling interest Net Income (Loss) Attributable to Noncontrolling Interest Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities Liabilities, Current [Abstract] Net income attributable to Royalty Pharma plc - basic Net Income (Loss) Available to Common Stockholders, Basic Common stock, issued (in shares) Common Stock, Shares, Issued Equity method investments Equity Method Investments Quarterly conversion basis Common Stock, Quarterly Conversion Basis Common Stock, Quarterly Conversion Basis Number of noncontrolling interests Number of Noncontrolling Interests Number of Noncontrolling Interests Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Available for sale debt securities, liabilities current Debt Securities, Available For Sale, Liability, Current Debt Securities, Available For Sale, Liability, Current Preferred shares, fixed payment amount Debt Securities, Available-for-Sale, Fixed Payment Debt Securities, Available-for-Sale, Fixed Payment Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash collected on financial royalty assets Increase (Decrease) In Cash Collections On Financing Receivables Increase (Decrease) In Cash Collections On Financing Receivables Avillion I Avillion I [Member] Avillion I Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Other Other Financial Royalty Asset [Member] Other Financial Royalty Asset Debt issued, amount Debt Instrument, Face Amount EPA Holdings EPA Holdings [Member] EPA Holdings Start of period of return Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date Cash collections from intangible royalty assets Proceeds From Cash Collections From Royalties Received On Intangible Assets Proceeds From Cash Collections From Royalties Received On Intangible Assets Other comprehensive income/(loss) Other Comprehensive Income (Loss), Net of Tax Comprehensive income attributable to Royalty Pharma plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent Additional milestone payments Payments To Acquire Royalty Interest, Additional Milestone Payments Payments To Acquire Royalty Interest, Additional Milestone Payments Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Goodwill and Intangible Assets Disclosure [Abstract] Royalty Income, Other Royalty Income, Other [Member] Royalty Income, Other Other assets Other Assets, Noncurrent Funding Agreement With Biohaven Pharmaceuticals Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals [Member] Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals Unrealized gains on available for sale debt securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Unamortized discount and loan issuance costs on long-term debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Other exchanges Stockholders' Equity, Other Basis of preparation Basis of Accounting, Policy [Policy Text Block] Indirect Cash Flow Cash Flow, Supplemental Disclosures [Text Block] Derivative Instrument Derivative Asset [Member] Derivative Asset Federal Funds Rate Federal Funds Purchased [Member] Treasury interests Treasury Stock, Value Interest rate volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Total debt carrying value Long-Term Debt Other non-operating expense, net Other Nonoperating Income (Expense) Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Statement of Comprehensive Income [Abstract] Xtandi Xtandi [Member] Xtandi Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Net carrying value, before cumulative allowance for credit losses Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows Common Class A Common Class A [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Shares to be purchased Long Term Purchase Commitment, Shares Long Term Purchase Commitment, Shares Losses on equity securities Equity Securities, FV-NI, Gain (Loss) Total current assets Assets, Current Preferred shares, quarterly payments Debt Securities, Available-for-Sale, Quarterly Payments Debt Securities, Available-for-Sale, Quarterly Payments Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Cash collections from financial royalty assets Proceeds From Cash Collections From Royalties Received On Financing Receivables Proceeds From Cash Collections From Royalties Received On Financing Receivables Beginning balance (in shares) Ending balance (in shares) Shares, outstanding (in shares) Shares, Outstanding Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Intangible royalty assets, net Net Carrying Value Finite-Lived Intangible Assets, Net Long term funding partnership, amount Long Term Funding Partnership, Amount Long Term Funding Partnership, Amount Distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Purchases of available for sale debt securities Purchase of available for sale debt securities Payments to Acquire Debt Securities, Available-for-Sale Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Deferred shares, $0.000001 par value; 365,302 and 361,170 issued and outstanding, respectively Deferred Shares, Value, Issued Deferred Shares, Value, Issued Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Vertex Vertex [Member] Vertex The Manager Management [Member] Title of 12(b) Security Title of 12(b) Security Organization and Purpose Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Redemption, Period Two Debt Securities, Available-For-Sale, Redemption, Period Two [Member] Debt Securities, Available-For-Sale, Redemption, Period Two Noncontrolling interest (percentage) Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Distributions from equity method investees Distributions from equity method investees Proceeds from Equity Method Investment, Distribution Total operating expenses/(income), net Costs and Expenses Subsequent Event [Line Items] Subsequent Event [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] Derivative financial instruments Derivative Asset, Noncurrent Class of Stock [Line Items] Class of Stock [Line Items] Share-based compensation and related issuances of Class A ordinary shares (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Investments, Debt and Equity Securities [Abstract] Deferred stock, outstanding (in shares) Deferred Shares, Shares, Outstanding Deferred Shares, Shares, Outstanding Financing Receivable, Allowance for Credit Loss [Roll Forward] Financing Receivable, Allowance for Credit Loss [Roll Forward] Liabilities and shareholders’ equity Liabilities and Equity [Abstract] Fair Value Estimate of Fair Value Measurement [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cost Debt Securities, Available-for-Sale, Amortized Cost Remainder of 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Unamortized debt discount and issuance costs Debt Instrument, Unamortized Discount RPSFT Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member] Legacy Investors Partnerships and Royalty Pharma Select Finance Trust Provision for changes in expected cash flows from financial royalty assets Provision for changes in expected cash flows from financial royalty assets Provision for Other Credit Losses Initial term Related Party Transaction, Initial Term Related Party Transaction, Initial Term 2026 Long-Term Debt, Maturity, Year Four Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Entity Filer Category Entity Filer Category Basic (in shares) Weighted average Class A ordinary shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Current portion of Financial royalty assets Financing Receivable [Member] Tysabri Tysabri [Member] Tysabri Development-stage funding payments - ongoing Payments For Ongoing Development Stage Funding Payments For Ongoing Development Stage Funding Long term funding partnership, initial payment Long Term Funding Partnership, Initial Payment Long Term Funding Partnership, Initial Payment Liabilities: Liabilities, Fair Value Disclosure [Abstract] Commitments and contingencies Commitments and Contingencies Security Exchange Name Security Exchange Name Interest payable Increase (Decrease) in Interest Payable, Net Unrealized gains included in other comprehensive losses Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Cumulative allowance for changes in expected cash flows Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance DPP-IV patents DPP-IV Inhibitors [Member] DPP-IV Inhibitors Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Available for sale debt securities Available for sale debt securities, noncurrent Debt Securities, Available-for-Sale, Noncurrent U.S. government securities US Government Debt Securities [Member] Non-Controlling Interests Noncontrolling Interest [Member] Derivative instrument, current Derivative Asset, Current Risk-adjusted discount rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Financial Royalty Assets Financing Receivables [Text Block] Total liabilities and shareholders’ equity Liabilities and Equity Debt instrument, term Debt Instrument, Term One Point Seven Five Percent Senior Notes Due 2027 One Point Seven Five Percent Senior Notes Due 2027 [Member] One Point Seven Five Percent Senior Notes Due 2027 Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Related Party [Axis] Related Party [Axis] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Other exchanges (in shares) Stockholders' Equity, Other Shares Deferred stock, issued (in shares) Deferred Shares, Shares, Issued Deferred Shares, Shares, Issued Unvested RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Settlement of forwards Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Organization, Consolidation and Presentation of Financial Statements [Abstract] Number of limited partnership interest acquired (in shares) Related Party Transaction, Number of Partnership Interests Acquired Related Party Transaction, Number of Partnership Interests Acquired Level 2 Fair Value, Inputs, Level 2 [Member] Prior to the applicable par call date Debt Instrument, Redemption, Period One [Member] Current Fiscal Year End Date Current Fiscal Year End Date Other royalty cash collections Proceeds From Cash Collections From Other Royalties Received On Financing Receivables Proceeds From Cash Collections From Other Royalties Received On Financing Receivables Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Financial royalty assets, net Financing Receivable, after Allowance for Credit Loss, Noncurrent Net income attributable to Royalty Pharma plc - diluted Net Income (Loss) Available to Common Stockholders, Diluted Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Diluted (in dollars per share) Earnings per Class A ordinary share - diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] One Point Two Zero Percent Senior Notes Due 2025 One Point Two Zero Percent Senior Notes Due 2025 [Member] One Point Two Zero Percent Senior Notes Due 2025 Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Ownership percentage (as a percent) Noncontrolling Interest, Ownership Percentage by Parent Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Dividends Dividends, Cash Other current assets Other Assets, Current Summary of Financial Royalty Assets, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Income from financial royalty assets Increase (Decrease) In Financial Royalty Assets Increase (Decrease) In Financial Royalty Assets Customer Concentration Risk Customer Concentration Risk [Member] Total non-current assets Assets, Fair Value Disclosure, Noncurrent Assets, Fair Value Disclosure, Noncurrent Equity Securities Equity Securities [Member] Current period provision for credit losses, net Financing Receivable, Credit Loss, Expense (Reversal) Agreement with MSCI Agreement with MSCI [Member] Agreement with MSCI (Gains)/losses on equity securities Losses/(gains) on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Entity Address, Address Line One Entity Address, Address Line One Long-term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Two Point Two Zero Percent Senior Notes Due 2030 Two Point Two Zero Percent Senior Notes Due 2030 [Member] Two Point Two Zero Percent Senior Notes Due 2030 Distributions to non-controlling interests- other Payments To Noncontrolling Interests, Other Payments To Noncontrolling Interests, Other Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Imbruvica Imbruvica [Member] Imbruvica Fair Value Disclosures [Abstract] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Interest expense Interest Expense Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Credit Facility [Axis] Credit Facility [Axis] Cytokinetics Funding Commitment Cytokinetics Funding Commitment [Member] Cytokinetics Funding Commitment Unrealized gains on available for sale debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Available for sale debt securities, liabilities noncurrent Debt Securities, Available For Sale, Liability, Noncurrent Debt Securities, Available For Sale, Liability, Noncurrent Long-term Purchase Commitment [Line Items] Long-Term Purchase Commitment [Line Items] Equity [Abstract] Schedule of Borrowings Schedule of Long-Term Debt Instruments [Table Text Block] Subsequent Event [Table] Subsequent Event [Table] Number of classes of stock Number Of Classes Of Voting Stock Number Of Classes Of Voting Stock Entity Tax Identification Number Entity Tax Identification Number Proceeds from equity securities Proceeds From Issuance Of Equity Securities, FN-NI Proceeds From Issuance Of Equity Securities, FN-NI Redemption of debt securities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions Derivative collateral posted Payments For Collateral Posted On Derivative Instruments Payments For Collateral Posted On Derivative Instruments Quarterly payments to affiliates, percent of security investment (as a percent) Related Party Transaction, Rate, Value Of Security Investments Related Party Transaction, Rate, Value Of Security Investments Acquisition Of Limited Partnership Interests In Affiliate Acquisition Of Limited Partnership Interests In Affiliate [Member] Acquisition Of Limited Partnership Interests In Affiliate Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Operating and Personnel Payments Operating and Personnel Payments [Member] Operating and Personnel Payments BioCryst Pharmaceuticals, Inc. BioCryst Pharmaceuticals, Inc. [Member] BioCryst Pharmaceuticals, Inc. Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Measurement Frequency [Axis] Measurement Frequency [Axis] Other royalty income receivable Other Royalty Income Receivable, Current Other Royalty Income Receivable, Current Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Concentrations of credit risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Entity [Domain] Entity [Domain] Assignment Agreement - Funding Obligations Assignment Agreement - Funding Obligations [Member] Assignment Agreement - Funding Obligations City Area Code City Area Code Tremfya Tremfya [Member] Tremfya General and administrative expenses General and Administrative Expense Assets Assets [Abstract] Other current assets and other assets Increase (Decrease) in Other Current Assets Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Gain (loss) on equity securities still held Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Cumulative allowance for credit losses Cumulative allowance for credit losses Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal) Total current assets Assets, Fair Value Disclosure, Current Assets, Fair Value Disclosure, Current Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Distributions payable to non-controlling interests Due to Related Parties, Current Comprehensive income attributable to non-controlling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Legacy Investors Partnerships Legacy Investors Partnerships [Member] Legacy Investors Partnerships Asset Class [Axis] Asset Class [Axis] Accrued royalty receivable Increase (Decrease) In Accrued Royalty Receivable Increase (Decrease) In Accrued Royalty Receivable Share-based compensation Share-Based Payment Arrangement, Noncash Expense 2023 Long-Term Debt, Maturity, Year One Investments in equity method investees Payments to Acquire Equity Method Investments Variable Rate [Axis] Variable Rate [Axis] Non-Consolidated Affiliates Equity Method Investments and Joint Ventures Disclosure [Text Block] Payments for operating and professional costs Payments For Operating Costs and Professional Services Payments For Operating Costs and Professional Services Equity in earnings of equity method investees Equity in income (loss) of non-consolidated affiliates Income (Loss) from Equity Method Investments Three Point Three Zero Percent Senior Notes Due 2040 Three Point Three Zero Percent Senior Notes Due 2040 [Member] Three Point Three Zero Percent Senior Notes Due 2040 Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Research & Development ("R&D") Funding Expense Research, Development, and Computer Software Disclosure [Text Block] Customer [Domain] Customer [Domain] EX-101.PRE 9 rprx-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover - shares
 6 Months Ended
Jun. 30, 2022
Aug. 01, 2022
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 001-39329  
Entity Registrant Name Royalty Pharma plc  
Entity Incorporation, State or Country Code X0  
Entity Tax Identification Number 98-1535773  
Entity Address, Address Line One 110 East 59th Street  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10022  
City Area Code 212  
Local Phone Number 883-0200  
Title of 12(b) Security Class A ordinary shares, par value $0.0001  
Trading Symbol RPRX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0001802768  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Common Class A    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   437,139,178
Common Class B    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   170,080,791
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 2,108,037 $ 1,541,048
Marketable securities 290,402 581,872
Financial royalty assets 639,244 614,351
Accrued royalty receivable 18,032 53,286
Available for sale debt securities 363,700 66,000
Other royalty income receivable 17,315 15,023
Other current assets 67,119 6,631
Total current assets 3,503,849 2,878,211
Financial royalty assets, net 13,423,629 13,718,245
Intangible royalty assets, net 0 5,670
Equity securities 304,447 269,800
Available for sale debt securities 63,000 204,400
Equity method investments 412,076 435,394
Other assets 33,412 4,145
Total assets 17,740,413 17,515,865
Current liabilities    
Distributions payable to non-controlling interests 115,990 107,934
Accounts payable and accrued expenses 12,175 5,620
Interest payable 54,162 57,696
Total current liabilities 182,327 171,250
Long-term debt 7,106,199 7,096,070
Other liabilities 43,700 0
Total liabilities 7,332,226 7,267,320
Commitments and contingencies
Shareholders’ equity    
Deferred shares, $0.000001 par value; 365,302 and 361,170 issued and outstanding, respectively 0 0
Additional paid-in capital 3,570,585 3,507,533
Retained earnings 2,446,132 2,255,179
Non-controlling interests 4,380,938 4,471,951
Accumulated other comprehensive income 13,177 16,491
Treasury interests (2,752) (2,715)
Total shareholders’ equity 10,408,187 10,248,545
Total liabilities and shareholders’ equity 17,740,413 17,515,865
Common Class A    
Shareholders’ equity    
Common stock 44 43
Common Class B    
Shareholders’ equity    
Common stock 0 0
Class R Redeemable Stock    
Shareholders’ equity    
Common stock $ 63 $ 63
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (Parenthetical)
shares in Thousands
Jun. 30, 2022
$ / shares
shares
Jun. 30, 2022
£ / shares
shares
Dec. 31, 2021
$ / shares
shares
Dec. 31, 2021
£ / shares
shares
Deferred stock, par value (in dollars per share) | $ / shares $ 0.000001   $ 0.000001  
Deferred stock, issued (in shares) 365,302 365,302 361,170 361,170
Deferred stock, outstanding (in shares) 365,302 365,302 361,170 361,170
Common Class A        
Common stock, par value (in dollars/pounds per share) | $ / shares $ 0.0001   $ 0.0001  
Common stock, issued (in shares) 437,139 437,139 432,963 432,963
Common stock, outstanding (in shares) 437,139 437,139 432,963 432,963
Common Class B        
Common stock, par value (in dollars/pounds per share) | $ / shares $ 0.000001   $ 0.000001  
Common stock, issued (in shares) 170,081 170,081 174,213 174,213
Common stock, outstanding (in shares) 170,081 170,081 174,213 174,213
Class R Redeemable Stock        
Common stock, par value (in dollars/pounds per share) | £ / shares   £ 1   £ 1
Common stock, issued (in shares) 50 50 50 50
Common stock, outstanding (in shares) 50 50 50 50
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues $ 535,955 $ 554,963 $ 1,098,004 $ 1,127,990
Operating expenses        
Provision for changes in expected cash flows from financial royalty assets 105,714 (243,762) 290,335 48,499
Research and development funding expense 606 3,122 101,106 5,763
Amortization of intangible assets 0 5,733 5,670 11,404
General and administrative expenses 51,843 44,921 103,383 88,077
Total operating expenses/(income), net 158,163 (189,986) 500,494 153,743
Operating income 377,792 744,949 597,510 974,247
Other (income)/expense        
Equity in earnings of equity method investees (737) (17,701) (1,134) (15,783)
Interest expense 46,966 37,426 94,029 74,841
(Gains)/losses on derivative financial instruments (71,805) 1,909 (71,805) 4,464
(Gains)/losses on equity securities (8,024) (55,495) 28,138 (1,309)
Unrealized gains on available for sale debt securities (70,321) (14,015) (53,742) (23,130)
Interest income (10,919) (14,037) (20,448) (30,635)
Other non-operating expense, net 1,035 107 2,792 65
Total other (income)/expenses, net (113,805) (61,806) (22,170) 8,513
Consolidated net income before tax 491,597 806,755 619,680 965,734
Income tax expense 0 0 0 0
Consolidated net income 491,597 806,755 619,680 965,734
Net income attributable to non-controlling interests 187,093 365,979 263,415 455,839
Net income attributable to Royalty Pharma plc $ 304,504 $ 440,776 $ 356,265 $ 509,895
Earnings per Class A ordinary share:        
Basic (in dollars per share) $ 0.70 $ 1.08 $ 0.82 $ 1.28
Diluted (in dollars per share) $ 0.70 $ 1.08 $ 0.82 $ 1.25
Weighted average Class A ordinary shares outstanding:        
Basic (in shares) 436,318 409,344 435,144 399,606
Diluted (in shares) 607,214 607,163 607,207 607,151
Financial Royalty Assets        
Revenues $ 515,350 $ 503,414 $ 1,026,873 $ 1,033,039
Intangible Royalty Assets        
Revenues 2,537 40,127 36,123 76,188
Royalty Income, Other        
Revenues $ 18,068 $ 11,422 $ 35,008 $ 18,763
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net income $ 491,597 $ 806,755 $ 619,680 $ 965,734
Changes in other comprehensive income/(loss):        
Unrealized gains on available for sale debt securities 9,325 6,025 10,950 11,150
Reclassification of unrealized gains on available for sale debt securities (7,988) (13,299) (16,942) (28,790)
Other comprehensive income/(loss) 1,337 (7,274) (5,992) (17,640)
Comprehensive income 492,934 799,481 613,688 948,094
Comprehensive income attributable to non-controlling interests 187,638 362,748 260,948 447,727
Comprehensive income attributable to Royalty Pharma plc $ 305,296 $ 436,733 $ 352,740 $ 500,367
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Class R Redeemable Stock
Common Stock
Common Class A
Common Stock
Common Class B
Common Stock
Class R Redeemable Stock
Deferred Shares
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Income
Non-Controlling Interests
Treasury Interests
Beginning balance (in shares) at Dec. 31, 2020     388,135 218,976 50 316,407          
Beginning balance at Dec. 31, 2020 $ 9,895,815   $ 39 $ 0 $ 63 $ 0 $ 2,865,964 $ 1,920,635 $ 34,395 $ 5,077,036 $ (2,317)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Contributions 14,772                 14,772  
Distributions (316,186)             0   (316,186)  
Dividends (138,564)             (138,564)      
Other exchanges (in shares)     38,810 (38,810)   38,810          
Other exchanges 0   $ 3       548,200   3,805 (551,663) (345)
Share-based compensation and related issuances of Class A ordinary shares (in shares)     61                
Share-based compensation and related issuances of Class A ordinary shares 1,434           1,434        
Net income 965,734             509,895   455,839  
Unrealized gains on available for sale debt securities 11,150               6,060 5,090  
Reclassification of unrealized gains on available for sale debt securities (28,790)               (15,588) (13,202)  
Ending balance (in shares) at Jun. 30, 2021     427,006 180,166 50 355,217          
Ending balance at Jun. 30, 2021 10,405,365   $ 42 $ 0 $ 63 $ 0 3,415,598 2,291,966 28,672 4,671,686 (2,662)
Beginning balance (in shares) at Mar. 31, 2021     392,857 214,255 50 321,128          
Beginning balance at Mar. 31, 2021 9,837,033   $ 39 $ 0 $ 63 $ 0 2,931,249 1,923,771 29,452 4,954,818 (2,359)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Contributions 11,519                 11,519  
Distributions (170,808)                 (170,808)  
Dividends (72,581)             (72,581)      
Other exchanges (in shares)     34,089 (34,089)   34,089          
Other exchanges 0   $ 3       483,628   3,263 (486,591) (303)
Share-based compensation and related issuances of Class A ordinary shares (in shares)     60                
Share-based compensation and related issuances of Class A ordinary shares 721           721        
Net income 806,755             440,776   365,979  
Unrealized gains on available for sale debt securities 6,025               3,348 2,677  
Reclassification of unrealized gains on available for sale debt securities (13,299)               (7,391) (5,908)  
Ending balance (in shares) at Jun. 30, 2021     427,006 180,166 50 355,217          
Ending balance at Jun. 30, 2021 10,405,365   $ 42 $ 0 $ 63 $ 0 3,415,598 2,291,966 28,672 4,671,686 (2,662)
Beginning balance (in shares) at Dec. 31, 2021     432,963 174,213 50 361,170          
Beginning balance at Dec. 31, 2021 10,248,545   $ 43 $ 0 $ 63 $ 0 3,507,533 2,255,179 16,491 4,471,951 (2,715)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Contributions 6,203                 6,203  
Distributions (295,942)                 (295,942)  
Dividends (165,312)             (165,312)      
Other exchanges (in shares)     4,132 (4,132)   4,132          
Other exchanges 0   $ 1       62,047   211 (62,222) (37)
Share-based compensation and related issuances of Class A ordinary shares (in shares)     44                
Share-based compensation and related issuances of Class A ordinary shares 1,005           1,005        
Net income 619,680             356,265   263,415  
Unrealized gains on available for sale debt securities 10,950               6,480 4,470  
Reclassification of unrealized gains on available for sale debt securities (16,942)               (10,005) (6,937)  
Ending balance (in shares) at Jun. 30, 2022   50 437,139 170,081 50 365,302          
Ending balance at Jun. 30, 2022 10,408,187   $ 44 $ 0 $ 63 $ 0 3,570,585 2,446,132 13,177 4,380,938 (2,752)
Beginning balance (in shares) at Mar. 31, 2022     435,316 171,862 50 363,521          
Beginning balance at Mar. 31, 2022 10,141,879   $ 43 $ 0 $ 63 $ 0 3,543,204 2,224,677 12,304 4,364,324 (2,736)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Contributions 2,881                 2,881  
Distributions (146,967)                 (146,967)  
Dividends (83,049)             (83,049)      
Other exchanges (in shares)     1,781 (1,781)   1,781          
Other exchanges 0   $ 1       26,872   81 (26,938) (16)
Share-based compensation and related issuances of Class A ordinary shares (in shares)     42                
Share-based compensation and related issuances of Class A ordinary shares 509           509        
Net income 491,597             304,504   187,093  
Unrealized gains on available for sale debt securities 9,325               5,523 3,802  
Reclassification of unrealized gains on available for sale debt securities (7,988)               (4,731) (3,257)  
Ending balance (in shares) at Jun. 30, 2022   50 437,139 170,081 50 365,302          
Ending balance at Jun. 30, 2022 $ 10,408,187   $ 44 $ 0 $ 63 $ 0 $ 3,570,585 $ 2,446,132 $ 13,177 $ 4,380,938 $ (2,752)
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dividends declared and paid (in dollars per share)   $ 0.17 $ 0.19  
Common Class A        
Dividends declared and paid (in dollars per share) $ 0.19 $ 0.17 $ 0.38 $ 0.34
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Cash collections from financial royalty assets $ 1,181,354 $ 1,094,094
Cash collections from intangible royalty assets 71,377 75,200
Other royalty cash collections 32,716 14,088
Distributions from equity method investees 27,502 22,003
Interest received 3,262 2,332
Derivative collateral received 0 11,470
Derivative collateral posted 0 (9,340)
Development-stage funding payments - ongoing (1,106) (5,763)
Development-stage funding payments - upfront and milestone (100,000) 0
Payments for operating and professional costs (93,003) (81,764)
Interest paid (86,880) (64,500)
Net cash provided by operating activities 1,035,222 1,057,820
Cash flows from investing activities:    
Distributions from equity method investees 0 523
Investments in equity method investees (3,050) (17,427)
Purchases of equity securities (62,785) 0
Proceeds from equity securities 0 109,367
Purchases of available for sale debt securities (79,158) (35,170)
Proceeds from available for sale debt securities 31,250 31,250
Purchases of marketable securities (234,869) (728,025)
Proceeds from sales and maturities of marketable securities 525,907 868,689
Acquisitions of financial royalty assets (175,093) (683,741)
Acquisitions of other financial assets (21,215) 0
Milestone payments 0 (18,600)
Net cash used in investing activities (19,013) (473,134)
Cash flows from financing activities:    
Distributions to non-controlling interests (215,543) (238,197)
Distributions to non-controlling interests- other (72,343) (86,978)
Dividends to shareholders (165,312) (138,564)
Contributions from non-controlling interests- R&D 731 4,080
Contributions from non-controlling interests- other 3,247 8,574
Net cash used in financing activities (449,220) (451,085)
Net change in cash and cash equivalents 566,989 133,601
Cash and cash equivalents, beginning of period 1,541,048 1,008,680
Cash and cash equivalents, end of period $ 2,108,037 $ 1,142,281
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Organization and Purpose
 6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Purpose Organization and Purpose
Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (“IPO”) of our Class A ordinary shares. “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

We control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings’ Class A ordinary shares and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). The Continuing Investors Partnerships (defined below) have a non-controlling interest in RP Holdings through their ownership of RP Holdings Class B Interests. We conduct our business through RP Holdings and its subsidiaries.

RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”). RP Holdings is directly or indirectly owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”) and Royalty Pharma plc. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

RP Management, LLC (the “Manager”), a Delaware limited liability company, is responsible for our management, including our day-to-day operations, pursuant to advisory and management agreements (collectively, the “Management Agreement”).

Exchange Offer Transactions

We consummated an exchange offer on February 11, 2020 to facilitate the IPO. Through the exchange offer, investors which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under senior secured credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”
As a result of the Exchange Offer Transactions, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”). We are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Preparation and Use of Estimates

The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K.

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.

We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.

Basis of Consolidation

The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record Net income attributable to non-controlling interests on our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI, (2) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain conditions are met.

All intercompany transactions and balances have been eliminated in consolidation.

Concentrations of Credit Risk

Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.

The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson & Johnson, Merck & Co., Pfizer, Astellas, Novartis, and Gilead. As of June 30, 2022 and December 31, 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% of our current portion of financial royalty assets and represented the largest individual marketer and payor of our royalties.
We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.

Significant Accounting Policies
There have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2021.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Available for Sale Debt Securities
 6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Available for Sale Debt Securities Available for Sale Debt Securities
Cytokinetics Commercial Launch Funding

On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (“Cytokinetics”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. As part of the funding agreement, we agreed to provide capital (“Cytokinetics Commercial Launch Funding”) of up to $300 million, which is comprised of five tranches, including an initial tranche of $50 million that was funded upon closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”). As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022. Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn.

We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within Available for sale debt securities on the condensed consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within Other liabilities as of June 30, 2022 and within Available for sale debt securities as of December 31, 2021 on the condensed consolidated balance sheets. The unrealized change in fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations.

MorphoSys Development Funding Bonds

On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support its acquisition of Constellation Pharmaceuticals, Inc. that closed on July 15, 2021. As part of the funding agreement, which was amended in the three months ended June 30, 2022 to extend the initial funding date, we agreed to provide MorphoSys up to $350 million of capital (the “Development Funding Bonds”) to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $150 million. Our commitment to fund at least $150 million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding is drawn. As of June 30, 2022, MorphoSys had not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $300 million under the Development Funding Bonds to be funded in September 2022.

We elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within Other liabilities as of June 30, 2022 and within Available for sale debt securities as of December 31, 2021 on our condensed consolidated balance sheets. The unrealized change in fair value of the Development Funding Bond Forward is recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations.
Series A Biohaven Preferred Shares

On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) at a price of $50,100 per preferred share for a total of $125 million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (“FDA”) in February 2020 resulted in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price.

The Series A Biohaven Preferred Shares are classified as Available for sale debt securities on our condensed consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of comprehensive income. In the three and six months ended June 30, 2022, $8.0 million and $16.9 million, respectively, of the unrealized gains were reclassified from other comprehensive income to Interest income in the condensed consolidated statements of operations. In the three and six months ended June 30, 2021, $13.3 million and $28.8 million, respectively, of the unrealized gains were reclassified from other comprehensive income to Interest income in the condensed consolidated statements of operations.

Series B Biohaven Preferred Shares

On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”) for a total of $200 million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between the three months ended March 31, 2025 and the three months ended December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the original issue price of the Series B Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares.

As of June 30, 2022, we have acquired 1,988 shares of Series B Biohaven Preferred Shares. We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which are recorded in aggregate as Available for sale debt securities on the condensed consolidated balance sheets. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations.
The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):

CostUnrealized GainsFair Value Current AssetsNon-Current AssetsCurrent LiabilitiesNon-Current Liabilities (3)Total
As of June 30, 2022
Debt securities (1)$278,759 $84,241 $363,000 $300,000 $63,000 $— $— $363,000 
Forwards (2)— 28,100 28,100 63,700 — — (35,600)28,100 
Funding commitments (2)(9,400)1,300 (8,100)— — — (8,100)(8,100)
Total available for sale debt securities$269,359 $113,641 $383,000 $363,700 $63,000 $— $(43,700)$383,000 
As of December 31, 2021
Debt securities (1)$204,509 $49,191 $253,700 $66,000 $187,700 $— $— $253,700 
Forwards (2)— 16,700 16,700 — 16,700 — — 16,700 
Total available for sale debt securities$204,509 $65,891 $270,400 $66,000 $204,400 $— $— $270,400 
(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date.
(2)There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date.
(3)Reflected within Other liabilities on the condensed consolidated balance sheet.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements and Financial Instruments
 6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements and Financial Instruments . Fair Value Measurements and Financial Instruments
Fair Value Hierarchy

We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

•Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.

•Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.
Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):
As of June 30, 2022As of December 31, 2021
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents
Money market funds$307,797 $— $— $307,797 $598,253 $— $— $598,253 
Commercial paper— 181,681 — 181,681 — 13,997 — 13,997 
Certificates of deposit— 36,001 — 36,001 — 40,954 — 40,954 
Marketable securities
Commercial paper— 87,622 — 87,622 — 207,457 — 207,457 
Certificates of deposit— 178,766 — 178,766 — 374,415 — 374,415 
U.S. government securities— 24,014 — 24,014 — — — — 
Available for sale debt securities
Debt securities (1)— — 300,000 300,000 — — 66,000 66,000 
Forwards (2)— — 63,700 63,700 — — — — 
Derivative instrument (3)— — 63,200 63,200 — — — — 
Total current assets$307,797 $508,084 $426,900 $1,242,781 $598,253 $636,823 $66,000 $1,301,076 
Equity securities275,662 — 28,785 304,447 226,787 — 43,013 269,800 
Available for sale debt securities
Debt securities (1)— — 63,000 63,000 — — 187,700 187,700 
Forwards (2)— — — — — — 16,700 16,700 
Derivative instrument (3)— — 8,600 8,600 — — — — 
Royalty at fair value (4)— — 21,215 21,215 — — — — 
Total non-current assets$275,662 $— $121,600 $397,262 $226,787 $— $247,413 $474,200 
Liabilities:
Available for sale debt securities
Forwards (2)— — (35,600)(35,600)— — — — 
Funding commitments (5)— — (8,100)(8,100)— — — — 
Total non-current liabilities$— $— $(43,700)$(43,700)$— $— $— $— 
(1)Reflects the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. As of June 30, 2022, amounts also include the fair value of the funded portion of the Cytokinetics Commercial Launch Funding.
(2)Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within Other liabilities on the condensed consolidated balance sheet.
(3)Related to the Milestone Acceleration Option (defined below) recorded within Other current assets and Other assets on the condensed consolidated balance sheet.
(4)Recorded within Other assets on the condensed consolidated balance sheet. See Note 8–Non-Consolidated Affiliates for additional discussion.
(5)Related to the fair value of the Cytokinetics Funding Commitments as reflected within Other liabilities on the condensed consolidated balance sheet as of June 30, 2022.

For the three and six months ended June 30, 2022, we recognized gains of $8.0 million and losses of $28.1 million, respectively, on equity securities still held as of June 30, 2022. For the three and six months ended June 30, 2021, we recognized gains of $28.3 million and losses of $10.7 million, respectively, on equity securities still held as of June 30, 2022.
The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities, a royalty interest, a derivative instrument and available for sale debt securities, including the underlying debt securities, related forwards and funding commitments (in thousands):

For the Three Months Ended June 30, 2022For the Three Months Ended June 30, 2021
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentRoyalty at Fair ValueDebt SecuritiesForwards
Balance at the beginning of the period$62,538 $314,000 $(1,200)$(8,400)$— $— $226,800 $22,400 
Purchases28,785 14,579 — — — 21,215 17,585 — 
Losses on equity securities(21,846)— — — — — — — 
Gains on derivative financial instrument— — — — 71,800 — — — 
Unrealized gains included in other comprehensive losses (1) — 9,325 — — — — 6,025 — 
Unrealized gains included in earnings (2)— 31,800 38,221 300 — — 500 13,515 
Settlement of forwards (3)— 8,921 (8,921)— — — 5,115 (5,115)
Transfer to Level 1 (4)(40,692)— — — — — — — 
Redemption of debt securities— (15,625)— — — — (15,625)— 
Balance at the end of the period$28,785 $363,000 $28,100 $(8,100)$71,800 $21,215 $240,400 $30,800 
(1)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.
(2)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.
(3)Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.
(4)Related to transfer restriction expiration of BioCryst common stock.

For the Six Months Ended June 30, 2022For the Six Months Ended June 30, 2021
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentRoyalty at Fair ValueDebt SecuritiesForwards
Balance at the beginning of the period$43,013 $253,700 $16,700 $— $— $— $214,400 $18,600 
Purchases28,785 79,158 — — — 21,215 35,170 — 
Gains/(losses) on initial recognition (1)— 9,400 — (9,400)— — — — 
Losses on equity securities(2,321)— — — — — — — 
Gains on derivative financial instrument— — — — 71,800 — — — 
Unrealized gains included in other comprehensive losses (2) — 10,950 — — — — 11,150 — 
Unrealized gains included in earnings (3)— 30,200 22,242 1,300 — — 500 22,630 
Settlement of forwards (4)— 10,842 (10,842)— — — 10,430 (10,430)
Transfer to Level 1 (5) (40,692)— — — — — — — 
Redemption of debt securities— (31,250)— — — — (31,250)— 
Balance at the end of the period$28,785 $363,000 $28,100 $(8,100)$71,800 $21,215 $240,400 $30,800 
(1)Represents purchase price allocation to arrive at the appropriate fair value on initial recognition.
(2)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.
(3)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.
(4)Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.
(5)Related to transfer restriction expiration of BioCryst common stock.

Valuation Inputs for Recurring Fair Value Measurements

Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.

ApiJect Investment

We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value of equity securities and the revenue participation right that we acquired from ApiJect Holdings, Inc. (“ApiJect”) in April 2022. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant in the event of a sale of the instruments, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 8–Non-Consolidated Affiliates for additional discussion.

Cytokinetics Commercial Launch Funding

We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of June 30, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding requires significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.

We estimated the fair value of the Cytokinetics Funding Commitments as of June 30, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty’s assumed cost of debt, which would impact Cytokinetics’ decision to exercise its option to draw on each respective tranche. This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of 30% and an assumed risk-adjusted discount rate of 15.2%. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.
BioCryst Common Stock

In November 2021, we purchased 3,846 thousand shares of common stock of BioCryst Pharmaceuticals, Inc. (“BioCryst”), calculated based on the volume-weighted average price of BioCryst’s common stock over a period preceding the closing of the transaction. As part of the transaction, we were restricted from selling the BioCryst common stock for six months following the close of the transaction. We determined the fair value of the BioCryst common stock as of December 31, 2021 based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the BioCryst common stock to match the duration of the transfer restriction. This methodology incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which required the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility of BioCryst’s common stock, which would mean that the estimated fair value for the BioCryst common stock could be significantly higher or lower than the fair value determined by management at any particular date. During the three months ended June 30, 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset.

MorphoSys Development Funding Bonds

The fair value of the Development Funding Bond Forward as of June 30, 2022 and December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. As of June 30, 2022, the Development Funding Bonds remain undrawn.

Series A Biohaven Preferred Shares

The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following the FDA approval and starting one-year after FDA approval through the three months ended December 31, 2024. When the FDA approved Nurtec ODT in February 2020, we became entitled to receive a fixed payment amount of $250 million payable in equal quarterly payments between the three months ended March 31, 2021 and the three months ended December 31, 2024.

The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated that there is a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate of 13.7% and 9.5% as of June 30, 2022 and December 31, 2021, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.

Series B Biohaven Preferred Shares

The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of June 30, 2022 and December 31, 2021 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.
Milestone Acceleration Option

On August 7, 2020, we entered into an expanded funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to accelerate the payment of any outstanding zavegepant milestone payments in a lump sum amount (“Milestone Acceleration Option”). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material in prior periods. As of June 30, 2022, the fair value of the Milestone Acceleration Option was $71.8 million, of which $63.2 million was recorded within Other current assets and $8.6 million was recorded within Other assets on the condensed consolidated balance sheet. For the three months ended June 30, 2022, we recorded $71.8 million of unrealized gain related to the change in the fair value of the Milestone Acceleration Option within (Gains)/losses on derivative financial instruments in the condensed consolidated statements of operations.

We estimated the fair value of the Milestone Acceleration Option as of June 30, 2022 using the “with-and-without” methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates, estimated probabilities of achieving the success-based milestones, and the probability that there will be a change of control event in different periods of time, which would result in accelerated milestone payments. Assessing the probability that there will be a change of control event, the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate, probabilities of achieving marketing approval, and our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.

Other Financial Instruments

Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that either provide quoted market prices in active markets for identical or similar securities or observable inputs for their pricing without applying significant adjustments.

Financial Assets Not Measured at Fair Value

Financial royalty assets are measured and carried on the condensed consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts. Where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are presented below (in thousands):

As of June 30, 2022As of December 31, 2021
Fair ValueCarrying Value, netFair ValueCarrying Value, net
Financial royalty assets, net$18,254,440 $13,423,629 $19,047,183 $13,718,245 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Financial Royalty Assets
 6 Months Ended
Jun. 30, 2022
Receivables [Abstract]  
Financial Royalty Assets Financial Royalty Assets
Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.

The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):
As of June 30, 2022
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,347,911 $(54,609)$5,293,302 
Tysabri
(3)
1,759,427 — 1,759,427 
Imbruvica2027-20321,439,443 (417,165)1,022,278 
Xtandi2027-20281,053,621 (153,154)900,467 
Tremfya2031-2032876,834 — 876,834 
Evrysdi
2030-2035 (4)
746,524 (1,992)744,532 
Other2020-20404,824,393 (1,110,515)3,713,878 
Total$16,048,153 $(1,737,435)$14,310,718 
Less: Cumulative allowance for credit losses (Note 6)(247,845)
Total financial royalty assets, net$14,062,873 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

As of December 31, 2021
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,335,641 $(48,636)$5,287,005 
Tysabri
(3)
1,846,069 (16,617)1,829,452 
Imbruvica2027-20321,438,730 (236,871)1,201,859 
Xtandi2027-20281,100,065 (172,101)927,964 
Tremfya2031-2032881,671 — 881,671 
Evrysdi
2030-2035 (4)
727,774 — 727,774 
Other2020-20404,697,591 (909,916)3,787,675 
Total$16,027,541 $(1,384,141)$14,643,400 
Less: Cumulative allowance for credit losses (Note 6)(310,804)
Total financial royalty assets, net$14,332,596 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets
 6 Months Ended
Jun. 30, 2022
Credit Loss [Abstract]  
Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets
The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets on the condensed consolidated balance sheets and includes the following activities:

•the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts, and
•the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights.

The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):
Activity for the Period
Balance at December 31, 2021 (1)$(1,694,945)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(556,020)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets202,726 
Current period provision for credit losses, net (2)62,959 
Balance at June 30, 2022$(1,985,280)
(1)Includes $310.8 million related to cumulative allowance for credit losses.
(2)In the six months ended June 30, 2022, the provision income for credit losses was primarily related to a significant decline in the value of the Tazverik financial royalty asset.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Royalty Assets, Net
 6 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Royalty Assets, Net Intangible Royalty Assets, Net
The following tables summarize the cost, accumulated amortization and net carrying value of our intangible royalty assets as of June 30, 2022 and December 31, 2021 (in thousands):
As of June 30, 2022CostAccumulated AmortizationNet Carrying Value
DPP-IV patents$606,216 $606,216 $— 
Total intangible royalty assets$606,216 $606,216 $— 
As of December 31, 2021CostAccumulated AmortizationNet Carrying Value
DPP-IV patents$606,216 $600,546 $5,670 
Total intangible royalty assets$606,216 $600,546 $5,670 

As of June 30, 2022, the intangible royalty assets were fully amortized as our royalties on Januvia and Janumet expired in the three months ended March 31, 2022. Our royalties on the other DPP-IV products have also substantially ended.
Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate such revenue from licensees based on the geography of the underlying sales as this information may not be provided to us by marketers. For the three months ended June 30, 2022, revenue from intangible royalty assets was not material. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 90% of revenues from intangible royalty assets in the three months ended June 30, 2021. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 93% and 94% of revenues from intangible royalty assets in the six months ended June 30, 2022 and 2021, respectively.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Non-Consolidated Affiliates
 6 Months Ended
Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]  
Non-Consolidated Affiliates Non-Consolidated Affiliates
We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities for which we have elected the fair value option.

ApiJect

During the three months ended June 30, 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for our investments in ApiJect. We are also required to acquire additional common stock in ApiJect if certain milestones are achieved. The fair value of our equity investment was recorded within Equity securities and the fair value of the revenue participation right was recorded within Other assets on the condensed consolidated balance sheet as of June 30, 2022. No amounts were due from ApiJect as of June 30, 2022.

The Legacy SLP Interest

In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI.

The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this quarterly report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the three and six months ended June 30, 2022, we recorded income allocations of $4.7 million and $9.3 million, respectively, within Equity in earnings of equity method investees. During the three and six months ended June 30, 2021, we recorded income allocations of $25.6 million and $30.8 million, respectively, within Equity in earnings of equity method investees. We received cash distributions from the Legacy SLP Interest of $6.8 million and $14.1 million in the three and six months ended June 30, 2022, respectively. We received cash distributions from the Legacy SLP Interest of $4.7 million and $8.6 million in the three and six months ended June 30, 2021, respectively.

The Avillion Entities

We account for our partnership interests in Avillion Financing I, LP and its related entities (“Avillion I”), BAv Financing II, LP and its related entities (“Avillion II,” together with Avillion I, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. During the three and six months ended June 30, 2022, we recorded a loss allocation from the Avillion Entities of $4.0 million and $8.2 million, respectively, within Equity in earnings of equity method investees. During the three and six months ended June 30, 2021, we recorded a loss allocation from the Avillion Entities of $7.9 million and $15.0 million, respectively, within Equity in earnings of equity method investees.

On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4 million during each of the six months ended June 30, 2022 and 2021, respectively.
In May 2018, RPIFT entered into an agreement, which was amended in July 2021 and was further amended in June 2022 to increase the funding amount by $27.5 million, which totaled $150.0 million over multiple years in Avillion II, which is a party to a co-development agreement with AstraZeneca, to fund a portion of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments. As of June 30, 2022 and December 31, 2021, RPIFT had $35.7 million and $11.2 million, respectively, of unfunded commitments related to the Avillion Entities.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Research & Development ("R&D") Funding Expense
 6 Months Ended
Jun. 30, 2022
Research and Development [Abstract]  
Research & Development ("R&D") Funding Expense Research & Development (“R&D”) Funding Expense R&D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. R&D funding expense includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. During the six months ended June 30, 2022 and 2021, we did not enter into any new ongoing R&D funding arrangements. We recognized R&D funding expense of $0.6 million and $101.1 million for the three and six months ended June 30, 2022, respectively. We recognized R&D funding expense of $3.1 million and $5.8 million for the three and six months ended June 30, 2021, respectively. During the six months ended June 30, 2022, R&D funding expense primarily related to upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product candidate.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Borrowings
 6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
Borrowings Borrowings
Our borrowings as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):

Type of BorrowingDate of IssuanceMaturityAs of June 30, 2022As of December 31, 2021
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)
9/20209/2023$1,000,000 $1,000,000 
$1,000,000, 1.20% (issued at 98.875% of par)
9/20209/20251,000,000 1,000,000 
$1,000,000, 1.75% (issued at 98.284% of par)
9/20209/20271,000,000 1,000,000 
$1,000,000, 2.20% (issued at 97.760% of par)
9/20209/20301,000,000 1,000,000 
$600,000, 2.15% (issued at 98.263% of par)
7/20219/2031600,000 600,000 
$1,000,000, 3.30% (issued at 95.556% of par)
9/20209/20401,000,000 1,000,000 
$1,000,000, 3.55% (issued at 95.306% of par)
9/20209/20501,000,000 1,000,000 
$700,000, 3.35% (issued at 97.565% of par)
7/20219/2051700,000 700,000 
Unamortized debt discount and issuance costs(193,801)(203,930)
Total debt carrying value7,106,199 7,096,070 
Less: Current portion of long-term debt— —
Total long-term debt$7,106,199 $7,096,070 
Senior Unsecured Notes

On July 26, 2021, we issued $1.3 billion of senior unsecured notes (the “2021 Notes”) comprised of $600.0 million principal amount of notes due September 2031 and $700.0 million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5 million and we capitalized approximately $12.3 million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively.

On September 2, 2020, we issued $6.0 billion of senior unsecured notes (the “2020 Notes” and, together with the 2021 Notes, the “Notes”). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0 million and we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively.

On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933.

The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.

Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and as of June 30, 2022, we were in compliance with all applicable covenants.

As of June 30, 2022 and December 31, 2021, the fair value of our outstanding Notes using Level 2 inputs was approximately $5.9 billion and $7.2 billion, respectively.

Senior Unsecured Revolving Credit Facility

On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”). The Credit Agreement amended and restated the prior credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement extended the maturity of the Revolving Credit Facility to September 15, 2026. As of June 30, 2022 and December 31, 2021, there were no outstanding borrowings under the Revolving Credit Facility.

The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.
The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. If these financial covenants are not satisfied, the Credit Agreement prohibits us from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of June 30, 2022, RP Holdings was in compliance with these covenants.

Principal Payments on the Notes

The future principal payments for our borrowings as of June 30, 2022 over the next five years and thereafter are as follows (in thousands):

YearPrincipal Payments
Remainder of 2022$— 
20231,000,000 
2024— 
20251,000,000 
2026— 
Thereafter5,300,000 
Total (1)$7,300,000 
(1)Excludes unamortized debt discount and issuance costs of $193.8 million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Shareholders' Equity
 6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Shareholders' Equity Shareholders’ Equity
Capital Structure

We have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. As of June 30, 2022, we had 437,139 thousand Class A ordinary shares and 170,081 thousand Class B ordinary shares outstanding.

An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of June 30, 2022, we had outstanding deferred shares of 365,302 thousand.

In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of £1 each.
Non-Controlling Interests

The net change in the balance of our four non-controlling interests for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands):

RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
March 31, 2022$8,409 $1,756,269 $2,599,646 $— $4,364,324 
Contributions— 1,425 1,456 — 2,881 
Distributions(5,754)(103,385)(37,828)— (146,967)
Other exchanges— — (26,938)— (26,938)
Net Income6,227 61,642 119,224 — 187,093 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,639 2,163 — 3,802 
Reclassification of unrealized gains on available for sale debt securities— (1,404)(1,853)— (3,257)
June 30, 2022$8,882 $1,716,186 $2,655,870 $— $4,380,938 

RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2021$13,528 $1,809,269 $2,649,154 $— $4,471,951 
Contributions— 3,395 2,808 — 6,203 
Distributions(16,013)(207,586)(72,343)— (295,942)
Other exchanges— — (62,222)— (62,222)
Net Income11,367 112,162 139,886 — 263,415 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,925 2,545 — 4,470 
Reclassification of unrealized gains on available for sale debt securities— (2,979)(3,958)— (6,937)
June 30, 2022$8,882 $1,716,186 $2,655,870 $— $4,380,938 

RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
March 31, 2021$13,841 $1,882,655 $3,058,322 $— $4,954,818 
Contributions— 6,654 4,865 — 11,519 
Distributions(12,476)(127,747)(30,585)— (170,808)
Other exchanges— — (486,591)— (486,591)
Net income19,275 133,743 212,961 — 365,979 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,059 1,618 — 2,677 
Reclassification of unrealized gains on available for sale debt securities— (2,337)(3,571)— (5,908)
June 30, 2021$20,640 $1,894,027 $2,757,019 $— $4,671,686 
RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
Contributions— 9,907 4,865 — 14,772 
Distributions(26,129)(222,289)(67,768)— (316,186)
Other exchanges— — (551,663)— (551,663)
Net income34,333 170,000 251,506 — 455,839 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,960 3,130 — 5,090 
Reclassification of unrealized gains on available for sale debt securities— (5,060)(8,142)— (13,202)
June 30, 2021$20,640 $1,894,027 $2,757,019 $— $4,671,686 

The Continuing Investors Partnerships’ ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of June 30, 2022, the Continuing Investors Partnerships owned approximately 28% of RP Holdings with the remaining 72% owned by Royalty Pharma plc.

RP Holdings Class C Special Interest Held by EPA Holdings

EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met.

Dividends

The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. In the six months ended June 30, 2022, we declared and paid two quarterly cash dividends of $0.19 per Class A ordinary share for an aggregate amount of $165.3 million to holders of our Class A ordinary shares. In the six months ended June 30, 2021, we declared and paid two quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $138.6 million to holders of our Class A ordinary shares.

2020 Independent Directors Equity Incentive Plan

On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors.

RSU Activity and Share-based Compensation
We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized on a straight-line basis over the requisite service period of generally one year as part of General and administrative expenses in the condensed consolidated statements of operations. In the three and six months ended June 30, 2022 and 2021, respectively, we did not recognize material share-based compensation expenses.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Earnings per Share
 6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
Basic earnings per share (“EPS”) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares and deferred shares under the two-class method has not been presented.

Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs. For the three and six months ended June 30, 2022 and 2021, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact.

The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share amounts):
For the Three Months Ended June 30,For the Six Months Ended June 30,
2022202120222021
Numerator
Consolidated net income$491,597 $806,755 $619,680 $965,734 
Less: Net income attributable to Continuing Investors Partnerships119,224 212,961 139,886 251,506 
Less: Net income attributable to Legacy Investors Partnerships and RPSFT67,869 153,018 123,529 204,333 
Net income attributable to Royalty Pharma plc - basic304,504 440,776 356,265 509,895 
Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares 119,224 212,961 139,886 251,506 
Net income attributable to Royalty Pharma plc - diluted$423,728 $653,737 $496,151 $761,401 
Denominator
Weighted average Class A ordinary shares outstanding - basic436,318 409,344 435,144 399,606 
Add: Dilutive effects as shown separately below
Class B ordinary shares exchangeable for Class A ordinary shares170,864 197,773 172,035 207,508 
Unvested RSUs32 46 28 37 
Weighted average Class A ordinary shares outstanding - diluted607,214 607,163 607,207 607,151 
Earnings per Class A ordinary share - basic$0.70 $1.08 $0.82 $1.28 
Earnings per Class A ordinary share - diluted$0.70 $1.08 $0.82 $1.25 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Indirect Cash Flow
 6 Months Ended
Jun. 30, 2022
Supplemental Cash Flow Elements [Abstract]  
Indirect Cash Flow Indirect Cash Flow
Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):
For the Six Months Ended June 30,
20222021
Cash flow from operating activities:
Consolidated net income$619,680 $965,734 
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Income from financial royalty assets(1,026,873)(1,033,039)
Provision for changes in expected cash flows from financial royalty assets290,335 48,499 
Amortization of intangible assets5,670 11,404 
Amortization of debt discount and issuance costs10,683 9,583 
(Gains)/losses on derivative financial instruments(71,805)4,464 
Losses/(gains) on equity securities28,138 (1,309)
Equity in earnings of equity method investees(1,134)(15,783)
Distributions from equity method investees27,502 22,003 
Share-based compensation1,005 1,434 
Interest income accretion(16,942)(28,790)
Unrealized gains on available for sale debt securities(53,742)(23,130)
Other2,657 2,049 
Decrease/(increase) in operating assets:
Cash collected on financial royalty assets1,181,354 1,094,094 
Accrued royalty receivable35,254 (988)
Other royalty income receivable(2,292)(4,683)
Other current assets and other assets2,711 3,703 
Increase/(decrease) in operating liabilities:
Accounts payable and accrued expenses6,555 (913)
Interest payable(3,534)758 
Other current liabilities— 2,730 
Net cash provided by operating activities$1,035,222 $1,057,820 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Funding Commitments

We have various funding commitments as of June 30, 2022 as described below. See Note 3–Available for Sale Debt Securities for additional discussion of the respective arrangements.

Cytokinetics Commercial Launch Funding

As of June 30, 2022, $250 million of the Cytokinetics Commercial Launch Funding remained unfunded. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones. As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022.

MorphoSys Development Funding Bonds

As of June 30, 2022, $350 million of the MorphoSys Development Funding Bonds remained unfunded. In July 2022, MorphoSys notified us of its intention to draw $300 million under the Development Funding Bonds to be funded in September 2022.
Series B Biohaven Preferred Shares

As of June 30, 2022, we have a remaining commitment of $100.4 million under the Commercial Launch Preferred Equity to purchase 2,004 shares of Series B Biohaven Preferred Shares on a quarterly basis through the three months ended December 31, 2024.

Other Commitments

We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 8–Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the Management Agreement as described in Note 15–Related Party Transactions, which are variable and primarily based on cash receipts.

Indemnifications

In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such occurrences taking place in the future is remote.

Legal Proceedings

We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions
 6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
The Manager

The Manager is the investment manager of Royalty Pharma and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.

Pursuant to the Management Agreement, we pay quarterly operating and personnel expenses to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months.

During the three and six months ended June 30, 2022, total operating and personnel payments incurred were $36.0 million and $77.2 million, respectively, including the amounts attributable to Old RPI, and were recognized within General and administrative expenses in the condensed consolidated statements of operations. During the three and six months ended June 30, 2021, total operating and personnel payments incurred were $32.4 million and $68.1 million, respectively, including the amounts attributable to Old RPI, and were recognized within General and administrative expenses in the condensed consolidated statements of operations.
Distributions Payable to Non-Controlling Interests

The distributions payable to non-controlling interests represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The distributions payable to non-controlling interests as of June 30, 2022 and December 31, 2021 include the following (in thousands):
As of June 30, 2022As of December 31, 2021
Due to Legacy Investors Partnerships$107,886 $92,608 
Due to RPSFT8,104 15,326 
Total distributions payable to non-controlling interests$115,990 $107,934 

Acquisition from Bristol Myers Squibb

In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement.

As of June 30, 2022 and December 31, 2021, the financial royalty asset of $118.1 million and $130.9 million, respectively, on the condensed consolidated balance sheets represents only our right to the future payment streams acquired from BMS.

Other Transactions

Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI Inc. (“MSCI”). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI’s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI’s revenues from those indexes. No amounts were due from MSCI as of both June 30, 2022 and December 31, 2021. The financial impact associated with this transaction has not been material to date.

In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 8–Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.

RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million is recorded as treasury interests, of which $1.5 million and $1.6 million were held by non-controlling interests as of June 30, 2022 and December 31, 2021, respectively.

Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events
 6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsIn July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance Biopharma, Inc. (“Theravance”) and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy. We made an upfront payment of $1.31 billion in July 2022 and committed up to $300 million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25 million in upfront funding and a potential $15 million regulatory milestone payment to support the clinical development of ampreloxetine.
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of preparation The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K.
Use of estimates
The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.

We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.
Basis of consolidation
The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record Net income attributable to non-controlling interests on our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI, (2) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain conditions are met.
All intercompany transactions and balances have been eliminated in consolidation.
Concentrations of credit risk Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson & Johnson, Merck & Co., Pfizer, Astellas, Novartis, and Gilead.
Fair value measurements
Fair Value Hierarchy

We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

•Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.

•Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Available for Sale Debt Securities (Tables)
 6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Summary of Available for Sale Debt Securities
The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):

CostUnrealized GainsFair Value Current AssetsNon-Current AssetsCurrent LiabilitiesNon-Current Liabilities (3)Total
As of June 30, 2022
Debt securities (1)$278,759 $84,241 $363,000 $300,000 $63,000 $— $— $363,000 
Forwards (2)— 28,100 28,100 63,700 — — (35,600)28,100 
Funding commitments (2)(9,400)1,300 (8,100)— — — (8,100)(8,100)
Total available for sale debt securities$269,359 $113,641 $383,000 $363,700 $63,000 $— $(43,700)$383,000 
As of December 31, 2021
Debt securities (1)$204,509 $49,191 $253,700 $66,000 $187,700 $— $— $253,700 
Forwards (2)— 16,700 16,700 — 16,700 — — 16,700 
Total available for sale debt securities$204,509 $65,891 $270,400 $66,000 $204,400 $— $— $270,400 
(1)Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date.
(2)There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date.
(3)Reflected within Other liabilities on the condensed consolidated balance sheet.
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements and Financial Instruments (Tables)
 6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Hierarchy
The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):
As of June 30, 2022As of December 31, 2021
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents
Money market funds$307,797 $— $— $307,797 $598,253 $— $— $598,253 
Commercial paper— 181,681 — 181,681 — 13,997 — 13,997 
Certificates of deposit— 36,001 — 36,001 — 40,954 — 40,954 
Marketable securities
Commercial paper— 87,622 — 87,622 — 207,457 — 207,457 
Certificates of deposit— 178,766 — 178,766 — 374,415 — 374,415 
U.S. government securities— 24,014 — 24,014 — — — — 
Available for sale debt securities
Debt securities (1)— — 300,000 300,000 — — 66,000 66,000 
Forwards (2)— — 63,700 63,700 — — — — 
Derivative instrument (3)— — 63,200 63,200 — — — — 
Total current assets$307,797 $508,084 $426,900 $1,242,781 $598,253 $636,823 $66,000 $1,301,076 
Equity securities275,662 — 28,785 304,447 226,787 — 43,013 269,800 
Available for sale debt securities
Debt securities (1)— — 63,000 63,000 — — 187,700 187,700 
Forwards (2)— — — — — — 16,700 16,700 
Derivative instrument (3)— — 8,600 8,600 — — — — 
Royalty at fair value (4)— — 21,215 21,215 — — — — 
Total non-current assets$275,662 $— $121,600 $397,262 $226,787 $— $247,413 $474,200 
Liabilities:
Available for sale debt securities
Forwards (2)— — (35,600)(35,600)— — — — 
Funding commitments (5)— — (8,100)(8,100)— — — — 
Total non-current liabilities$— $— $(43,700)$(43,700)$— $— $— $— 
(1)Reflects the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. As of June 30, 2022, amounts also include the fair value of the funded portion of the Cytokinetics Commercial Launch Funding.
(2)Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within Other liabilities on the condensed consolidated balance sheet.
(3)Related to the Milestone Acceleration Option (defined below) recorded within Other current assets and Other assets on the condensed consolidated balance sheet.
(4)Recorded within Other assets on the condensed consolidated balance sheet. See Note 8–Non-Consolidated Affiliates for additional discussion.
(5)Related to the fair value of the Cytokinetics Funding Commitments as reflected within Other liabilities on the condensed consolidated balance sheet as of June 30, 2022.
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation
The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities, a royalty interest, a derivative instrument and available for sale debt securities, including the underlying debt securities, related forwards and funding commitments (in thousands):

For the Three Months Ended June 30, 2022For the Three Months Ended June 30, 2021
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentRoyalty at Fair ValueDebt SecuritiesForwards
Balance at the beginning of the period$62,538 $314,000 $(1,200)$(8,400)$— $— $226,800 $22,400 
Purchases28,785 14,579 — — — 21,215 17,585 — 
Losses on equity securities(21,846)— — — — — — — 
Gains on derivative financial instrument— — — — 71,800 — — — 
Unrealized gains included in other comprehensive losses (1) — 9,325 — — — — 6,025 — 
Unrealized gains included in earnings (2)— 31,800 38,221 300 — — 500 13,515 
Settlement of forwards (3)— 8,921 (8,921)— — — 5,115 (5,115)
Transfer to Level 1 (4)(40,692)— — — — — — — 
Redemption of debt securities— (15,625)— — — — (15,625)— 
Balance at the end of the period$28,785 $363,000 $28,100 $(8,100)$71,800 $21,215 $240,400 $30,800 
(1)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.
(2)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.
(3)Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.
(4)Related to transfer restriction expiration of BioCryst common stock.

For the Six Months Ended June 30, 2022For the Six Months Ended June 30, 2021
Equity SecuritiesDebt SecuritiesForwardsFunding CommitmentsDerivative InstrumentRoyalty at Fair ValueDebt SecuritiesForwards
Balance at the beginning of the period$43,013 $253,700 $16,700 $— $— $— $214,400 $18,600 
Purchases28,785 79,158 — — — 21,215 35,170 — 
Gains/(losses) on initial recognition (1)— 9,400 — (9,400)— — — — 
Losses on equity securities(2,321)— — — — — — — 
Gains on derivative financial instrument— — — — 71,800 — — — 
Unrealized gains included in other comprehensive losses (2) — 10,950 — — — — 11,150 — 
Unrealized gains included in earnings (3)— 30,200 22,242 1,300 — — 500 22,630 
Settlement of forwards (4)— 10,842 (10,842)— — — 10,430 (10,430)
Transfer to Level 1 (5) (40,692)— — — — — — — 
Redemption of debt securities— (31,250)— — — — (31,250)— 
Balance at the end of the period$28,785 $363,000 $28,100 $(8,100)$71,800 $21,215 $240,400 $30,800 
(1)Represents purchase price allocation to arrive at the appropriate fair value on initial recognition.
(2)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.
(3)Recorded within Unrealized gains on available for sale debt securities in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.
(4)Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares.
(5)Related to transfer restriction expiration of BioCryst common stock.
Fair Value Disclosure of Asset and Liability Not Measured at Fair Value Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are presented below (in thousands):
As of June 30, 2022As of December 31, 2021
Fair ValueCarrying Value, netFair ValueCarrying Value, net
Financial royalty assets, net$18,254,440 $13,423,629 $19,047,183 $13,718,245 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Financial Royalty Assets (Tables)
 6 Months Ended
Jun. 30, 2022
Receivables [Abstract]  
Summary of Financial Royalty Assets, Net
The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):
As of June 30, 2022
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,347,911 $(54,609)$5,293,302 
Tysabri
(3)
1,759,427 — 1,759,427 
Imbruvica2027-20321,439,443 (417,165)1,022,278 
Xtandi2027-20281,053,621 (153,154)900,467 
Tremfya2031-2032876,834 — 876,834 
Evrysdi
2030-2035 (4)
746,524 (1,992)744,532 
Other2020-20404,824,393 (1,110,515)3,713,878 
Total$16,048,153 $(1,737,435)$14,310,718 
Less: Cumulative allowance for credit losses (Note 6)(247,845)
Total financial royalty assets, net$14,062,873 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

As of December 31, 2021
Estimated Royalty Duration (1)
Gross Carrying ValueCumulative Allowance for Changes in Expected Cash Flows (Note 6)
Net Carrying Value (5)
Cystic fibrosis franchise
2037 (2)
$5,335,641 $(48,636)$5,287,005 
Tysabri
(3)
1,846,069 (16,617)1,829,452 
Imbruvica2027-20321,438,730 (236,871)1,201,859 
Xtandi2027-20281,100,065 (172,101)927,964 
Tremfya2031-2032881,671 — 881,671 
Evrysdi
2030-2035 (4)
727,774 — 727,774 
Other2020-20404,697,591 (909,916)3,787,675 
Total$16,027,541 $(1,384,141)$14,643,400 
Less: Cumulative allowance for credit losses (Note 6)(310,804)
Total financial royalty assets, net$14,332,596 
(1)Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.
(2)Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.
(3)RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.
(4)Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.
(5)The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)
 6 Months Ended
Jun. 30, 2022
Credit Loss [Abstract]  
Schedule of Cumulative Allowance for Changes in Expected Cash Flows
The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):
Activity for the Period
Balance at December 31, 2021 (1)$(1,694,945)
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets(556,020)
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets202,726 
Current period provision for credit losses, net (2)62,959 
Balance at June 30, 2022$(1,985,280)
(1)Includes $310.8 million related to cumulative allowance for credit losses.
(2)In the six months ended June 30, 2022, the provision income for credit losses was primarily related to a significant decline in the value of the Tazverik financial royalty asset.
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Royalty Assets, Net (Tables)
 6 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Royalty Interests
The following tables summarize the cost, accumulated amortization and net carrying value of our intangible royalty assets as of June 30, 2022 and December 31, 2021 (in thousands):
As of June 30, 2022CostAccumulated AmortizationNet Carrying Value
DPP-IV patents$606,216 $606,216 $— 
Total intangible royalty assets$606,216 $606,216 $— 
As of December 31, 2021CostAccumulated AmortizationNet Carrying Value
DPP-IV patents$606,216 $600,546 $5,670 
Total intangible royalty assets$606,216 $600,546 $5,670 
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Borrowings (Tables)
 6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Borrowings
Our borrowings as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):

Type of BorrowingDate of IssuanceMaturityAs of June 30, 2022As of December 31, 2021
Senior Unsecured Notes:
$1,000,000, 0.75% (issued at 99.322% of par)
9/20209/2023$1,000,000 $1,000,000 
$1,000,000, 1.20% (issued at 98.875% of par)
9/20209/20251,000,000 1,000,000 
$1,000,000, 1.75% (issued at 98.284% of par)
9/20209/20271,000,000 1,000,000 
$1,000,000, 2.20% (issued at 97.760% of par)
9/20209/20301,000,000 1,000,000 
$600,000, 2.15% (issued at 98.263% of par)
7/20219/2031600,000 600,000 
$1,000,000, 3.30% (issued at 95.556% of par)
9/20209/20401,000,000 1,000,000 
$1,000,000, 3.55% (issued at 95.306% of par)
9/20209/20501,000,000 1,000,000 
$700,000, 3.35% (issued at 97.565% of par)
7/20219/2051700,000 700,000 
Unamortized debt discount and issuance costs(193,801)(203,930)
Total debt carrying value7,106,199 7,096,070 
Less: Current portion of long-term debt— —
Total long-term debt$7,106,199 $7,096,070 
Schedule of Repayments of Debt by Year
The future principal payments for our borrowings as of June 30, 2022 over the next five years and thereafter are as follows (in thousands):

YearPrincipal Payments
Remainder of 2022$— 
20231,000,000 
2024— 
20251,000,000 
2026— 
Thereafter5,300,000 
Total (1)$7,300,000 
(1)Excludes unamortized debt discount and issuance costs of $193.8 million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations.
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Shareholders' Equity (Tables)
 6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Schedule of Balance Of Non-controlling Interests
The net change in the balance of our four non-controlling interests for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands):

RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
March 31, 2022$8,409 $1,756,269 $2,599,646 $— $4,364,324 
Contributions— 1,425 1,456 — 2,881 
Distributions(5,754)(103,385)(37,828)— (146,967)
Other exchanges— — (26,938)— (26,938)
Net Income6,227 61,642 119,224 — 187,093 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,639 2,163 — 3,802 
Reclassification of unrealized gains on available for sale debt securities— (1,404)(1,853)— (3,257)
June 30, 2022$8,882 $1,716,186 $2,655,870 $— $4,380,938 

RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2021$13,528 $1,809,269 $2,649,154 $— $4,471,951 
Contributions— 3,395 2,808 — 6,203 
Distributions(16,013)(207,586)(72,343)— (295,942)
Other exchanges— — (62,222)— (62,222)
Net Income11,367 112,162 139,886 — 263,415 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,925 2,545 — 4,470 
Reclassification of unrealized gains on available for sale debt securities— (2,979)(3,958)— (6,937)
June 30, 2022$8,882 $1,716,186 $2,655,870 $— $4,380,938 

RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
March 31, 2021$13,841 $1,882,655 $3,058,322 $— $4,954,818 
Contributions— 6,654 4,865 — 11,519 
Distributions(12,476)(127,747)(30,585)— (170,808)
Other exchanges— — (486,591)— (486,591)
Net income19,275 133,743 212,961 — 365,979 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,059 1,618 — 2,677 
Reclassification of unrealized gains on available for sale debt securities— (2,337)(3,571)— (5,908)
June 30, 2021$20,640 $1,894,027 $2,757,019 $— $4,671,686 
RPSFTLegacy Investors PartnershipsContinuing Investors PartnershipsEPA HoldingsTotal
December 31, 2020$12,436 $1,939,509 $3,125,091 $— $5,077,036 
Contributions— 9,907 4,865 — 14,772 
Distributions(26,129)(222,289)(67,768)— (316,186)
Other exchanges— — (551,663)— (551,663)
Net income34,333 170,000 251,506 — 455,839 
Other comprehensive income/(loss):
Unrealized gains on available for sale debt securities— 1,960 3,130 — 5,090 
Reclassification of unrealized gains on available for sale debt securities— (5,060)(8,142)— (13,202)
June 30, 2021$20,640 $1,894,027 $2,757,019 $— $4,671,686 

The Continuing Investors Partnerships’ ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of June 30, 2022, the Continuing Investors Partnerships owned approximately 28% of RP Holdings with the remaining 72% owned by Royalty Pharma plc.
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Earnings per Share (Tables)
 6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share amounts):
For the Three Months Ended June 30,For the Six Months Ended June 30,
2022202120222021
Numerator
Consolidated net income$491,597 $806,755 $619,680 $965,734 
Less: Net income attributable to Continuing Investors Partnerships119,224 212,961 139,886 251,506 
Less: Net income attributable to Legacy Investors Partnerships and RPSFT67,869 153,018 123,529 204,333 
Net income attributable to Royalty Pharma plc - basic304,504 440,776 356,265 509,895 
Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares 119,224 212,961 139,886 251,506 
Net income attributable to Royalty Pharma plc - diluted$423,728 $653,737 $496,151 $761,401 
Denominator
Weighted average Class A ordinary shares outstanding - basic436,318 409,344 435,144 399,606 
Add: Dilutive effects as shown separately below
Class B ordinary shares exchangeable for Class A ordinary shares170,864 197,773 172,035 207,508 
Unvested RSUs32 46 28 37 
Weighted average Class A ordinary shares outstanding - diluted607,214 607,163 607,207 607,151 
Earnings per Class A ordinary share - basic$0.70 $1.08 $0.82 $1.28 
Earnings per Class A ordinary share - diluted$0.70 $1.08 $0.82 $1.25 
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Indirect Cash Flow (Tables)
 6 Months Ended
Jun. 30, 2022
Supplemental Cash Flow Elements [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures
Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):
For the Six Months Ended June 30,
20222021
Cash flow from operating activities:
Consolidated net income$619,680 $965,734 
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Income from financial royalty assets(1,026,873)(1,033,039)
Provision for changes in expected cash flows from financial royalty assets290,335 48,499 
Amortization of intangible assets5,670 11,404 
Amortization of debt discount and issuance costs10,683 9,583 
(Gains)/losses on derivative financial instruments(71,805)4,464 
Losses/(gains) on equity securities28,138 (1,309)
Equity in earnings of equity method investees(1,134)(15,783)
Distributions from equity method investees27,502 22,003 
Share-based compensation1,005 1,434 
Interest income accretion(16,942)(28,790)
Unrealized gains on available for sale debt securities(53,742)(23,130)
Other2,657 2,049 
Decrease/(increase) in operating assets:
Cash collected on financial royalty assets1,181,354 1,094,094 
Accrued royalty receivable35,254 (988)
Other royalty income receivable(2,292)(4,683)
Other current assets and other assets2,711 3,703 
Increase/(decrease) in operating liabilities:
Accounts payable and accrued expenses6,555 (913)
Interest payable(3,534)758 
Other current liabilities— 2,730 
Net cash provided by operating activities$1,035,222 $1,057,820 
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions (Tables)
 6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
Schedule of Related Party Transactions
The distributions payable to non-controlling interests represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The distributions payable to non-controlling interests as of June 30, 2022 and December 31, 2021 include the following (in thousands):
As of June 30, 2022As of December 31, 2021
Due to Legacy Investors Partnerships$107,886 $92,608 
Due to RPSFT8,104 15,326 
Total distributions payable to non-controlling interests$115,990 $107,934 
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Organization and Purpose (Details)
Feb. 11, 2020
Feb. 29, 2020
RPCT    
Subsidiary, Sale of Stock [Line Items]    
Ownership percentage (as a percent) 66.00%  
Legacy Investors Partnerships | Old RPI    
Subsidiary, Sale of Stock [Line Items]    
Noncontrolling interest (percentage)   18.00%
RPSFT | RPCT    
Subsidiary, Sale of Stock [Line Items]    
Noncontrolling interest (percentage) 34.00%  
Exchange Offer Transaction | Old RPI    
Subsidiary, Sale of Stock [Line Items]    
Ownership percentage (as a percent) 82.00%  
Exchange Offer Transaction | Legacy Investors Partnerships    
Subsidiary, Sale of Stock [Line Items]    
Exchange offering, ownership percentage 82.00%  
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Details)
 6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Feb. 29, 2020
Customer Concentration Risk | Current portion of Financial royalty assets | Vertex      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Concentration risk (as a percent) 32.00% 32.00%  
Legacy Investors Partnerships | Old RPI      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Noncontrolling interest (percentage)     18.00%
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Available for Sale Debt Securities - Narrative (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 07, 2022
USD ($)
tranche
Aug. 07, 2020
USD ($)
$ / shares
shares
Apr. 05, 2019
USD ($)
$ / shares
shares
Jul. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
shares
Jun. 30, 2021
USD ($)
Debt and Equity Securities, FV-NI [Line Items]                  
Long term funding partnership, amount $ 300,000,000                
Long term funding partnership, number of tranches | tranche 5                
Long term funding partnership, initial payment $ 50,000,000                
Required amount to be drawn         $ 50,000,000        
Long term funding partnership, aggregate amount         $ 200,000,000        
Long term funding partnership, expected payment               $ 125,000,000  
Installment repayments, percentage of amount drawn         1.9        
Purchase of available for sale debt securities               79,158,000 $ 35,170,000
Investment income         $ 10,919,000   $ 14,037,000 20,448,000 30,635,000
Subsequent Event                  
Debt and Equity Securities, FV-NI [Line Items]                  
Long term funding partnership, initial payment       $ 25,000,000          
Reclassification out of Accumulated Other Comprehensive Income | Unrealized gain/(loss) on available for sale debt securities, Including noncontrolling interest                  
Debt and Equity Securities, FV-NI [Line Items]                  
Investment income         (8,000,000)   $ 13,300,000 $ 16,900,000 $ 28,800,000
MorphoSys                  
Debt and Equity Securities, FV-NI [Line Items]                  
Commitment to fund agreement         150,000,000        
Redemption price, percentage               2.2  
MorphoSys | Subsequent Event                  
Debt and Equity Securities, FV-NI [Line Items]                  
Expected proceeds from development funding bonds       $ 300,000,000          
MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                  
Debt and Equity Securities, FV-NI [Line Items]                  
Payment of capital         350,000,000     $ 350,000,000  
Commitment to fund agreement         $ 150,000,000        
Period of return         9 years        
Start of period of return         2 years        
Series A Preferred Stock                  
Debt and Equity Securities, FV-NI [Line Items]                  
Purchase of available for sale debt securities     $ 125,000,000            
Preferred Shares | Series A Preferred Stock                  
Debt and Equity Securities, FV-NI [Line Items]                  
Redemption price, percentage               2  
Number of shares purchased (in shares) | shares     2,495            
Price per share (in USD per share) | $ / shares     $ 50,100            
Preferred Shares | Series B Preferred Stock                  
Debt and Equity Securities, FV-NI [Line Items]                  
Number of shares purchased (in shares) | shares   3,992           1,988  
Price per share (in USD per share) | $ / shares   $ 50,100              
Purchase of available for sale debt securities   $ 200,000,000              
Preferred Shares | Redemption, Period One | Series A Preferred Stock                  
Debt and Equity Securities, FV-NI [Line Items]                  
Redemption price, percentage           2   2  
Preferred Shares | Redemption, Period Two | Series B Preferred Stock                  
Debt and Equity Securities, FV-NI [Line Items]                  
Redemption price, percentage               1.8  
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.2
Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Debt and Equity Securities, FV-NI [Line Items]    
Cost $ 269,359 $ 204,509
Unrealized Gains 113,641 65,891
Fair Value 383,000 270,400
Available for sale debt securities, current 363,700 66,000
Available for sale debt securities, noncurrent 63,000 204,400
Available for sale debt securities, liabilities current 0 0
Available for sale debt securities, liabilities noncurrent (43,700) 0
Debt securities    
Debt and Equity Securities, FV-NI [Line Items]    
Cost 278,759 204,509
Unrealized Gains 84,241 49,191
Fair Value 363,000 253,700
Available for sale debt securities, current 300,000 66,000
Available for sale debt securities, noncurrent 63,000 187,700
Available for sale debt securities, liabilities current 0 0
Available for sale debt securities, liabilities noncurrent 0 0
Forwards    
Debt and Equity Securities, FV-NI [Line Items]    
Cost 0 0
Unrealized Gains 28,100 16,700
Fair Value 28,100 16,700
Available for sale debt securities, current 63,700 0
Available for sale debt securities, noncurrent 0 16,700
Available for sale debt securities, liabilities current 0 0
Available for sale debt securities, liabilities noncurrent (35,600) $ 0
Funding Commitments    
Debt and Equity Securities, FV-NI [Line Items]    
Cost (9,400)  
Unrealized Gains 1,300  
Fair Value (8,100)  
Available for sale debt securities, current 0  
Available for sale debt securities, noncurrent 0  
Available for sale debt securities, liabilities current 0  
Available for sale debt securities, liabilities noncurrent $ (8,100)  
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Assets:    
Marketable securities $ 290,402 $ 581,872
Available for sale debt securities 363,700 66,000
Equity securities 304,447 269,800
Available for sale debt securities 63,000 204,400
Liabilities:    
Available for sale debt securities, liabilities current 0 0
Available for sale debt securities, liabilities noncurrent (43,700) 0
Fair Value, Recurring    
Assets:    
Derivative instrument, current 63,200 0
Total current assets 1,242,781 1,301,076
Equity securities 304,447 269,800
Derivative financial instruments 8,600 0
Total non-current assets 397,262 474,200
Liabilities:    
Available for sale debt securities, liabilities noncurrent (43,700) 0
Fair Value, Recurring | Royalty Investments    
Assets:    
Available for sale debt securities 21,215 0
Fair Value, Recurring | Cytokinetics Funding Commitment    
Liabilities:    
Available for sale debt securities, liabilities current (8,100) 0
Level 1 | Fair Value, Recurring    
Assets:    
Derivative instrument, current 0 0
Total current assets 307,797 598,253
Equity securities 275,662 226,787
Derivative financial instruments 0 0
Total non-current assets 275,662 226,787
Liabilities:    
Available for sale debt securities, liabilities noncurrent 0 0
Level 1 | Fair Value, Recurring | Royalty Investments    
Assets:    
Available for sale debt securities 0 0
Level 1 | Fair Value, Recurring | Cytokinetics Funding Commitment    
Liabilities:    
Available for sale debt securities, liabilities current 0 0
Level 2 | Fair Value, Recurring    
Assets:    
Derivative instrument, current 0 0
Total current assets 508,084 636,823
Equity securities 0 0
Derivative financial instruments 0 0
Total non-current assets 0 0
Liabilities:    
Available for sale debt securities, liabilities noncurrent 0 0
Level 2 | Fair Value, Recurring | Royalty Investments    
Assets:    
Available for sale debt securities 0 0
Level 2 | Fair Value, Recurring | Cytokinetics Funding Commitment    
Liabilities:    
Available for sale debt securities, liabilities current 0 0
Level 3 | Fair Value, Recurring    
Assets:    
Derivative instrument, current   0
Total current assets 426,900 66,000
Equity securities 28,785 43,013
Derivative financial instruments   0
Total non-current assets 121,600 247,413
Liabilities:    
Available for sale debt securities, liabilities noncurrent (43,700) 0
Level 3 | Fair Value, Recurring | Milestone Acceleration    
Assets:    
Derivative instrument, current 63,200  
Derivative financial instruments 8,600  
Level 3 | Fair Value, Recurring | Royalty Investments    
Assets:    
Available for sale debt securities 21,215 0
Level 3 | Fair Value, Recurring | Cytokinetics Funding Commitment    
Liabilities:    
Available for sale debt securities, liabilities current (8,100) 0
Commercial paper | Fair Value, Recurring    
Assets:    
Marketable securities 87,622 207,457
Commercial paper | Level 1 | Fair Value, Recurring    
Assets:    
Marketable securities 0 0
Commercial paper | Level 2 | Fair Value, Recurring    
Assets:    
Marketable securities 87,622 207,457
Commercial paper | Level 3 | Fair Value, Recurring    
Assets:    
Marketable securities 0 0
Certificates of deposit | Fair Value, Recurring    
Assets:    
Marketable securities 178,766 374,415
Certificates of deposit | Level 1 | Fair Value, Recurring    
Assets:    
Marketable securities 0 0
Certificates of deposit | Level 2 | Fair Value, Recurring    
Assets:    
Marketable securities 178,766 374,415
Certificates of deposit | Level 3 | Fair Value, Recurring    
Assets:    
Marketable securities 0 0
U.S. government securities | Fair Value, Recurring    
Assets:    
Marketable securities 24,014 0
U.S. government securities | Level 1 | Fair Value, Recurring    
Assets:    
Marketable securities 0 0
U.S. government securities | Level 2 | Fair Value, Recurring    
Assets:    
Marketable securities 24,014 0
U.S. government securities | Level 3 | Fair Value, Recurring    
Assets:    
Marketable securities 0 0
Debt Securities | Fair Value, Recurring    
Assets:    
Available for sale debt securities 300,000 66,000
Available for sale debt securities 63,000 187,700
Debt Securities | Level 1 | Fair Value, Recurring    
Assets:    
Available for sale debt securities 0 0
Available for sale debt securities 0 0
Debt Securities | Level 2 | Fair Value, Recurring    
Assets:    
Available for sale debt securities 0 0
Available for sale debt securities 0 0
Debt Securities | Level 3 | Fair Value, Recurring    
Assets:    
Available for sale debt securities 300,000 66,000
Available for sale debt securities 63,000 187,700
Forwards    
Assets:    
Available for sale debt securities 63,700 0
Available for sale debt securities 0 16,700
Liabilities:    
Available for sale debt securities, liabilities current 0 0
Available for sale debt securities, liabilities noncurrent (35,600) 0
Forwards | Fair Value, Recurring    
Assets:    
Available for sale debt securities 63,700 0
Available for sale debt securities 0 16,700
Liabilities:    
Forwards (35,600) 0
Forwards | Level 1 | Fair Value, Recurring    
Assets:    
Available for sale debt securities 0 0
Available for sale debt securities 0 0
Liabilities:    
Forwards 0 0
Forwards | Level 2 | Fair Value, Recurring    
Assets:    
Available for sale debt securities 0 0
Available for sale debt securities 0 0
Liabilities:    
Forwards 0 0
Forwards | Level 3 | Fair Value, Recurring    
Assets:    
Available for sale debt securities 63,700 0
Available for sale debt securities 0 16,700
Liabilities:    
Forwards (35,600) 0
Money market funds | Fair Value, Recurring    
Assets:    
Cash equivalents 307,797 598,253
Money market funds | Level 1 | Fair Value, Recurring    
Assets:    
Cash equivalents 307,797 598,253
Money market funds | Level 2 | Fair Value, Recurring    
Assets:    
Cash equivalents 0 0
Money market funds | Level 3 | Fair Value, Recurring    
Assets:    
Cash equivalents 0 0
Commercial paper | Fair Value, Recurring    
Assets:    
Cash equivalents 181,681 13,997
Commercial paper | Level 1 | Fair Value, Recurring    
Assets:    
Cash equivalents 0 0
Commercial paper | Level 2 | Fair Value, Recurring    
Assets:    
Cash equivalents 181,681 13,997
Commercial paper | Level 3 | Fair Value, Recurring    
Assets:    
Cash equivalents 0 0
Certificates of deposit | Fair Value, Recurring    
Assets:    
Cash equivalents 36,001 40,954
Certificates of deposit | Level 1 | Fair Value, Recurring    
Assets:    
Cash equivalents 0 0
Certificates of deposit | Level 2 | Fair Value, Recurring    
Assets:    
Cash equivalents 36,001 40,954
Certificates of deposit | Level 3 | Fair Value, Recurring    
Assets:    
Cash equivalents $ 0 $ 0
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements and Financial Instruments - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 05, 2019
Nov. 30, 2021
Feb. 29, 2020
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Gain (loss) on equity securities still held       $ 8,000 $ 28,300 $ (28,100) $ (10,700)  
Restrictions on selling common stock, period   6 months            
Unrealized Gains       113,641   113,641   $ 65,891
Available for sale debt securities       363,700   363,700   66,000
Available for sale debt securities       63,000   63,000   204,400
Fair Value, Recurring                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Derivative instrument, current       63,200   63,200   0
Derivative financial instruments       8,600   8,600   0
Level 3 | Fair Value, Recurring                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Derivative instrument, current               0
Derivative financial instruments               0
BioCryst Pharmaceuticals, Inc. | Level 3                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Number of shares purchased (in shares)   3,846,000            
Milestone Acceleration | Level 3 | Fair Value, Recurring                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Derivative instrument, current       63,200   63,200    
Derivative financial instruments       8,600   $ 8,600    
Cytokinetics Commercial Launch Funding | Level 3                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Interest rate volatility (as a percent)           30.00%    
Risk-adjusted discount rate (as a percent)           15.20%    
Preferred Shares                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Unrealized Gains       84,241   $ 84,241   49,191
Available for sale debt securities       300,000   300,000   66,000
Available for sale debt securities       63,000   63,000   $ 187,700
Preferred Shares | Milestone Acceleration                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Unrealized Gains       $ 71,800   $ 71,800    
Preferred Shares | Debt Securities                
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]                
Number of shares purchased (in shares) 2,495              
Redemption price, percentage           2    
Preferred shares, quarterly payments           $ 15,600    
Preferred shares, fixed payment amount     $ 250,000          
Preferred shares, weighted average cost of capital           13.70%   9.50%
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) - Level 3 - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Equity Securities        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Balance at the beginning of the period $ 62,538   $ 43,013  
Purchases 28,785   28,785  
Losses on equity securities (21,846)   (2,321)  
Transfer to Level 1 (40,692)   (40,692)  
Balance at the end of the period 28,785   28,785  
Debt Securities        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Balance at the beginning of the period 314,000 $ 226,800 253,700 $ 214,400
Purchases 14,579 17,585 79,158 35,170
Gains/(losses) on initial recognition     9,400  
Unrealized gains included in other comprehensive losses 9,325 6,025 10,950 11,150
Unrealized (losses)/gains included in earnings 31,800 500 30,200 500
Settlement of forwards 8,921 5,115 10,842 10,430
Redemption of debt securities (15,625) (15,625) (31,250) (31,250)
Balance at the end of the period 363,000 240,400 363,000 240,400
Forwards        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Balance at the beginning of the period (1,200) 22,400 16,700 18,600
Unrealized (losses)/gains included in earnings 38,221 13,515 22,242 22,630
Settlement of forwards (8,921) (5,115) (10,842) (10,430)
Balance at the end of the period 28,100 $ 30,800 28,100 $ 30,800
Funding Commitments        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Balance at the beginning of the period (8,400)   0  
Gains/(losses) on initial recognition     (9,400)  
Unrealized (losses)/gains included in earnings 300   1,300  
Balance at the end of the period (8,100)   (8,100)  
Derivative Instrument        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Balance at the beginning of the period 0   0  
Gains on derivative financial instrument 71,800   71,800  
Balance at the end of the period 71,800   71,800  
Royalty        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Balance at the beginning of the period 0   0  
Purchases 21,215   21,215  
Balance at the end of the period $ 21,215   $ 21,215  
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) - Level 3 - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Fair Value    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Financial royalty assets, net $ 18,254,440 $ 19,047,183
Carrying Value, net    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Financial royalty assets, net $ 13,423,629 $ 13,718,245
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.2
Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value $ 16,048,153 $ 16,027,541
Cumulative allowance for changes in expected cash flows (1,737,435) (1,384,141)
Net carrying value, before cumulative allowance for credit losses 14,310,718 14,643,400
Cumulative allowance for credit losses (247,845) (310,804)
Net carrying value 14,062,873 14,332,596
Cystic fibrosis franchise    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 5,347,911 5,335,641
Cumulative allowance for changes in expected cash flows (54,609) (48,636)
Net carrying value, before cumulative allowance for credit losses 5,293,302 5,287,005
Tysabri    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 1,759,427 1,846,069
Cumulative allowance for changes in expected cash flows 0 (16,617)
Net carrying value, before cumulative allowance for credit losses 1,759,427 1,829,452
Imbruvica    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 1,439,443 1,438,730
Cumulative allowance for changes in expected cash flows (417,165) (236,871)
Net carrying value, before cumulative allowance for credit losses 1,022,278 1,201,859
Xtandi    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 1,053,621 1,100,065
Cumulative allowance for changes in expected cash flows (153,154) (172,101)
Net carrying value, before cumulative allowance for credit losses 900,467 927,964
Tremfya    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 876,834 881,671
Cumulative allowance for changes in expected cash flows 0 0
Net carrying value, before cumulative allowance for credit losses 876,834 881,671
Evrysdi    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 746,524 727,774
Cumulative allowance for changes in expected cash flows (1,992) 0
Net carrying value, before cumulative allowance for credit losses 744,532 727,774
Aggregate royalty amount when patents cease 1,300,000 1,300,000
Other    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross Carrying Value 4,824,393 4,697,591
Cumulative allowance for changes in expected cash flows (1,110,515) (909,916)
Net carrying value, before cumulative allowance for credit losses $ 3,713,878 $ 3,787,675
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.22.2
Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Financing Receivable, Allowance for Credit Loss [Roll Forward]    
Beginning balance $ (1,694,945)  
Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets (556,020)  
Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets 202,726  
Current period provision for credit losses, net 62,959  
Ending balance (1,985,280)  
Cumulative allowance for credit losses $ 247,845 $ 310,804
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Cost $ 606,216 $ 606,216
Accumulated Amortization 606,216 600,546
Net Carrying Value 0 5,670
DPP-IV patents    
Finite-Lived Intangible Assets [Line Items]    
Cost 606,216 606,216
Accumulated Amortization 606,216 600,546
Net Carrying Value $ 0 $ 5,670
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Royalty Assets, Net - Narrative (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
DPP-IV patents | Revenue Benchmark | Individual Licensees Concentration List      
Finite-Lived Intangible Assets [Line Items]      
Individual licensees exceeding 10% or more of revenue (as a percent) 90.00% 93.00% 94.00%
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.22.2
Non-Consolidated Affiliates (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Feb. 11, 2020
Schedule of Equity Method Investments [Line Items]            
Equity method investments $ 412,076   $ 412,076   $ 435,394  
Equity in income (loss) of non-consolidated affiliates 737 $ 17,701 1,134 $ 15,783    
Distributions from equity method investees     0 523    
Distributions from equity method investees     27,502 22,003    
Legacy Investors Partnerships            
Schedule of Equity Method Investments [Line Items]            
Equity method investments           $ 303,700
Equity in income (loss) of non-consolidated affiliates 4,700 25,600 9,300 30,800    
Distributions from equity method investees 6,800 4,700 14,100 8,600    
Avillion Entities            
Schedule of Equity Method Investments [Line Items]            
Equity in income (loss) of non-consolidated affiliates (4,000) $ (7,900) (8,200) (15,000)    
Equity method investment, unfunded commitments (35,700)   (35,700)   $ (11,200)  
Avillion I            
Schedule of Equity Method Investments [Line Items]            
Distributions from equity method investees     13,400 $ 13,400    
Avillion II | Merck Asset - Phase II Clinical Trial            
Schedule of Equity Method Investments [Line Items]            
Other commitment 150,000   150,000      
Increase in commitment $ 27,500   $ 27,500      
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.22.2
Research & Development ("R&D") Funding Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development funding expense $ 606 $ 3,122 $ 101,106 $ 5,763
Cytokinetics        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development funding expense     $ 100,000  
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.22.2
Borrowings - Schedule of Borrowings (Details) - USD ($)
 6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Unamortized debt discount and issuance costs $ (193,801,000) $ (203,930,000)
Total debt carrying value 7,106,199,000 7,096,070,000
Less: Current portion of long-term debt 0 0
Total long-term debt $ 7,106,199,000 7,096,070,000
Unsecured Debt | Point Seven Five Percent Senior Notes Due 2023    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as a percent) 0.75%  
Debt issued as a percent of par value (as a percent) 99.322%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
Unsecured Debt | One Point Two Zero Percent Senior Notes Due 2025    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as a percent) 1.20%  
Debt issued as a percent of par value (as a percent) 98.875%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
Unsecured Debt | One Point Seven Five Percent Senior Notes Due 2027    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as a percent) 1.75%  
Debt issued as a percent of par value (as a percent) 98.284%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
Unsecured Debt | Two Point Two Zero Percent Senior Notes Due 2030    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as a percent) 2.20%  
Debt issued as a percent of par value (as a percent) 97.76%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
Unsecured Debt | Two Point One Five Zero Percent Senior Notes Due 2031    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as a percent) 2.15%  
Debt issued as a percent of par value (as a percent) 98.263%  
Debt issued, amount $ 600,000,000 600,000,000
Unsecured Debt | Three Point Three Zero Percent Senior Notes Due 2040    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as a percent) 3.30%  
Debt issued as a percent of par value (as a percent) 95.556%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
Unsecured Debt | Three Point Five Five Percent Senior Notes Due 2050    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as a percent) 3.55%  
Debt issued as a percent of par value (as a percent) 95.306%  
Debt issued, amount $ 1,000,000,000 1,000,000,000
Unsecured Debt | Three Point Three Five Zero Percent Due 2051    
Debt Instrument [Line Items]    
Debt instrument, stated rate (as a percent) 3.35%  
Debt issued as a percent of par value (as a percent) 97.565%  
Debt issued, amount $ 700,000,000 $ 700,000,000
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.22.2
Borrowings - Narrative (Details)
Sep. 18, 2020
USD ($)
Sep. 02, 2020
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Jul. 26, 2021
USD ($)
Senior Notes          
Debt Instrument [Line Items]          
Debt issued, amount         $ 1,300,000,000
Unamortized discount and loan issuance costs on long-term debt         27,500,000
Senior Notes | Senior Notes Due 2031          
Debt Instrument [Line Items]          
Debt issued, amount         600,000,000
Senior Notes | Senior Notes Due 2051          
Debt Instrument [Line Items]          
Debt issued, amount         700,000,000
Debt issuance costs         $ 12,300,000
Weighted average coupon rate (as a percent)     2.80%    
Weighted average effective interest rate (as a percent)     3.06%    
Unsecured Debt | The Notes          
Debt Instrument [Line Items]          
Debt issued, amount   $ 6,000,000,000      
Unamortized discount and loan issuance costs on long-term debt   149,000,000 $ (193,800,000)    
Debt issuance costs   $ 40,400,000      
Weighted average coupon rate (as a percent)     2.125%    
Weighted average effective interest rate (as a percent)     2.50%    
Unsecured Debt | The Notes | Level 2          
Debt Instrument [Line Items]          
Fair value of outstanding Notes     $ 5,900,000,000 $ 7,200,000,000  
Unsecured Debt | The Notes | Prior to the applicable par call date          
Debt Instrument [Line Items]          
Redemption price (as a percent)   100.00%      
Unsecured Debt | The Notes | Upon occurrence of a change of control triggering event          
Debt Instrument [Line Items]          
Redemption price (as a percent)   101.00%      
Unsecured Debt | Senior Unsecured Revolving Credit Facility | Revolving Credit Facility          
Debt Instrument [Line Items]          
Debt instrument, term 5 years        
Line of credit, maximum borrowing capacity $ 1,500,000,000        
Outstanding borrowings     $ 0 $ 0  
Maximum consolidated leverage ratio 4.00        
Maximum consolidated leverage ratio following qualifying material acquisition 4.50        
Minimum consolidated coverage ratio 2.50        
Unsecured Debt | Senior Unsecured Revolving Credit Facility | Federal Funds Rate | Revolving Credit Facility          
Debt Instrument [Line Items]          
Basis spread on variable rate (percentage) 0.50%        
Unsecured Debt | Senior Unsecured Revolving Credit Facility | Overnight Bank Funding Rate | Revolving Credit Facility          
Debt Instrument [Line Items]          
Basis spread on variable rate (percentage) 0.50%        
Unsecured Debt | Senior Unsecured Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility          
Debt Instrument [Line Items]          
Basis spread on variable rate (percentage) 1.00%        
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.22.2
Borrowings - Schedule of Repayments of Debt by Year (Details) - Unsecured Debt - The Notes - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 02, 2020
Debt Instrument [Line Items]    
Remainder of 2022 $ 0  
2023 1,000,000  
2024 0  
2025 1,000,000  
2026 0  
Thereafter 5,300,000  
Total 7,300,000  
Unamortized discount and loan issuance costs on long-term debt $ (193,800) $ 149,000
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.22.2
Shareholders' Equity - Narrative (Details)
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2022
noncontrolling_interest
shares
class
vote
$ / shares
Jun. 30, 2021
$ / shares
shares
Jun. 30, 2022
noncontrolling_interest
shares
class
vote
£ / shares
Jun. 30, 2022
USD ($)
noncontrolling_interest
shares
class
vote
$ / shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Mar. 31, 2022
shares
Dec. 31, 2021
shares
Mar. 31, 2021
shares
Dec. 31, 2020
shares
Jun. 15, 2020
shares
Class of Stock [Line Items]                    
Number of classes of stock | class 2   2 2            
Number of votes per share | vote 1   1 1            
Quarterly conversion basis 1   1 1            
Number of noncontrolling interests | noncontrolling_interest 4   4 4            
Dividends declared and paid (in dollars per share) | $ / shares   $ 0.17   $ 0.19            
Dividends declared and paid | $       $ 165.3 $ 138.6          
Requisite service period       1 year            
Deferred Shares                    
Class of Stock [Line Items]                    
Shares, outstanding (in shares) 365,302,000 355,217,000 365,302,000 365,302,000 355,217,000 363,521,000 361,170,000 321,128,000 316,407,000  
Common Class A                    
Class of Stock [Line Items]                    
Common shares outstanding 437,139,000   437,139,000 437,139,000     432,963,000      
Dividends declared and paid (in dollars per share) | $ / shares $ 0.19 $ 0.17   $ 0.38 $ 0.34          
Common Class A | 2020 Equity Incentive Plan                    
Class of Stock [Line Items]                    
Shares reserved for future issuance (in shares)                   800,000
Common Class B                    
Class of Stock [Line Items]                    
Common shares outstanding 170,081,000   170,081,000 170,081,000     174,213,000      
Class R Redeemable Stock                    
Class of Stock [Line Items]                    
Common shares outstanding 50,000   50,000 50,000     50,000      
Shares, outstanding (in shares) 50,000   50,000 50,000            
Redeemable stock, redemption price (in euros per share) | £ / shares     £ 1              
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.22.2
Shareholders' Equity - Summary of Noncontrolling Interests (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance $ 10,141,879 $ 9,837,033 $ 10,248,545 $ 9,895,815
Contributions 2,881 11,519 6,203 14,772
Distributions (146,967) (170,808) (295,942) (316,186)
Net income 491,597 806,755 619,680 965,734
Other exchanges 0 0 0 0
Unrealized gains on available for sale debt securities 9,325 6,025 10,950 11,150
Reclassification of unrealized gains on available for sale debt securities (7,988) (13,299) (16,942) (28,790)
Ending balance 10,408,187 10,405,365 10,408,187 10,405,365
Non-Controlling Interests        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance 4,364,324 4,954,818 4,471,951 5,077,036
Contributions 2,881 11,519 6,203 14,772
Distributions (146,967) (170,808) (295,942) (316,186)
Net income 187,093 365,979 263,415 455,839
Other exchanges (26,938) (486,591) (62,222) (551,663)
Unrealized gains on available for sale debt securities 3,802 2,677 4,470 5,090
Reclassification of unrealized gains on available for sale debt securities (3,257) (5,908) (6,937) (13,202)
Ending balance 4,380,938 4,671,686 4,380,938 4,671,686
Non-Controlling Interests | RPSFT        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance 8,409 13,841 13,528 12,436
Contributions 0 0 0 0
Distributions (5,754) (12,476) (16,013) (26,129)
Net income 6,227 19,275 11,367 34,333
Other exchanges 0 0 0 0
Unrealized gains on available for sale debt securities 0 0 0 0
Reclassification of unrealized gains on available for sale debt securities 0 0 0 0
Ending balance 8,882 20,640 8,882 20,640
Non-Controlling Interests | Legacy Investors Partnerships        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance 1,756,269 1,882,655 1,809,269 1,939,509
Contributions 1,425 6,654 3,395 9,907
Distributions (103,385) (127,747) (207,586) (222,289)
Net income 61,642 133,743 112,162 170,000
Other exchanges 0 0 0 0
Unrealized gains on available for sale debt securities 1,639 1,059 1,925 1,960
Reclassification of unrealized gains on available for sale debt securities (1,404) (2,337) (2,979) (5,060)
Ending balance 1,716,186 1,894,027 1,716,186 1,894,027
Non-Controlling Interests | Continuing Investors Partnerships        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance 2,599,646 3,058,322 2,649,154 3,125,091
Contributions 1,456 4,865 2,808 4,865
Distributions (37,828) (30,585) (72,343) (67,768)
Net income 119,224 212,961 139,886 251,506
Other exchanges (26,938) (486,591) (62,222) (551,663)
Unrealized gains on available for sale debt securities 2,163 1,618 2,545 3,130
Reclassification of unrealized gains on available for sale debt securities (1,853) (3,571) (3,958) (8,142)
Ending balance 2,655,870 2,757,019 2,655,870 2,757,019
Non-Controlling Interests | EPA Holdings        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Beginning balance 0 0 0 0
Contributions 0 0 0 0
Distributions 0 0 0 0
Net income 0 0 0 0
Other exchanges 0 0 0 0
Unrealized gains on available for sale debt securities 0 0 0 0
Reclassification of unrealized gains on available for sale debt securities 0 0 0 0
Ending balance $ 0 $ 0 $ 0 $ 0
Non-Controlling Interests | RP Holdings        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Noncontrolling interest (percentage) 72.00%   72.00%  
Non-Controlling Interests | RP Holdings | Continuing Investors Partnerships        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Noncontrolling interest (percentage) 28.00%   28.00%  
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.22.2
Earnings per Share (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Earnings per Class A ordinary share:        
Common stock exchange ratio 1   1  
Numerator        
Net income $ 491,597 $ 806,755 $ 619,680 $ 965,734
Less: net income attributable to non-controlling interest 187,093 365,979 263,415 455,839
Net income attributable to Royalty Pharma plc - basic 304,504 440,776 356,265 509,895
Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares 119,224 212,961 139,886 251,506
Net income attributable to Royalty Pharma plc - diluted $ 423,728 $ 653,737 $ 496,151 $ 761,401
Denominator        
Weighted average Class A ordinary shares outstanding - basic (in shares) | shares 436,318 409,344 435,144 399,606
Class B ordinary shares exchangeable for Class A ordinary shares (in shares) | shares 170,864 197,773 172,035 207,508
Unvested RSUs (in shares) | shares 32 46 28 37
Weighted average Class A ordinary shares outstanding - diluted (in shares) | shares 607,214 607,163 607,207 607,151
Earnings per Class A ordinary share - basic (in dollars per share) | $ / shares $ 0.70 $ 1.08 $ 0.82 $ 1.28
Earnings per Class A ordinary share - diluted (in dollars per share) | $ / shares $ 0.70 $ 1.08 $ 0.82 $ 1.25
Class B Holders        
Numerator        
Less: net income attributable to non-controlling interest $ 119,224 $ 212,961 $ 139,886 $ 251,506
Legacy Investors Partnerships and RPSFT        
Numerator        
Less: net income attributable to non-controlling interest $ 67,869 $ 153,018 $ 123,529 $ 204,333
XML 65 R56.htm IDEA: XBRL DOCUMENT v3.22.2
Indirect Cash Flow (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Supplemental Cash Flow Elements [Abstract]        
Net income $ 491,597 $ 806,755 $ 619,680 $ 965,734
Adjustments to reconcile consolidated net income to net cash provided by operating activities:        
Income from financial royalty assets     (1,026,873) (1,033,039)
Provision for changes in expected cash flows from financial royalty assets 105,714 (243,762) 290,335 48,499
Amortization of intangible assets 0 5,733 5,670 11,404
Amortization of debt discount and issuance costs     10,683 9,583
(Gains)/losses on derivative financial instruments     (71,805) 4,464
Losses/(gains) on equity securities (8,024) (55,495) 28,138 (1,309)
Equity in earnings of equity method investees (737) (17,701) (1,134) (15,783)
Distributions from equity method investees     27,502 22,003
Share-based compensation     1,005 1,434
Interest income accretion     (16,942) (28,790)
Unrealized gains on available for sale debt securities $ (70,321) $ (14,015) (53,742) (23,130)
Other     2,657 2,049
Decrease/(increase) in operating assets:        
Cash collected on financial royalty assets     1,181,354 1,094,094
Accrued royalty receivable     35,254 (988)
Other royalty income receivable     (2,292) (4,683)
Other current assets and other assets     2,711 3,703
Increase/(decrease) in operating liabilities:        
Accounts payable and accrued expenses     6,555 (913)
Interest payable     (3,534) 758
Other liabilities     0 2,730
Net cash provided by operating activities     $ 1,035,222 $ 1,057,820
XML 66 R57.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2022
Jun. 30, 2022
Jun. 30, 2022
Long-term Purchase Commitment [Line Items]      
Funding commitment, outstanding   $ 250,000,000 $ 250,000,000
Required amount to be drawn   50,000,000  
Long term funding partnership, aggregate amount   200,000,000  
Long term funding partnership, expected payment     125,000,000
MorphoSys | Subsequent Event      
Long-term Purchase Commitment [Line Items]      
Expected proceeds from development funding bonds $ 300,000,000    
MorphoSys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Long-term Purchase Commitment [Line Items]      
Payment of capital   350,000,000 350,000,000
Funding Agreement With Biohaven Pharmaceuticals      
Long-term Purchase Commitment [Line Items]      
Purchase commitment, amount outstanding   $ 100,400,000 $ 100,400,000
Shares to be purchased   2,004 2,004
XML 67 R58.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Apr. 16, 2021
Dec. 08, 2017
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2021
Dec. 31, 2020
Related Party Transaction [Line Items]                    
Total distributions payable to non-controlling interests     $ 115,990   $ 115,990     $ 107,934    
Total financial royalty assets, net     14,062,873   14,062,873     14,332,596    
Shareholders' equity     10,408,187 $ 10,405,365 10,408,187 $ 10,405,365 $ 10,141,879 10,248,545 $ 9,837,033 $ 9,895,815
Treasury Stock                    
Related Party Transaction [Line Items]                    
Shareholders' equity     (2,752) (2,662) (2,752) (2,662) (2,736) (2,715) (2,359) (2,317)
Non-Controlling Interests                    
Related Party Transaction [Line Items]                    
Shareholders' equity     $ 4,380,938 4,671,686 $ 4,380,938 4,671,686 $ 4,364,324 4,471,951 $ 4,954,818 $ 5,077,036
Agreement with MSCI                    
Related Party Transaction [Line Items]                    
Initial term 7 years                  
The Manager | Operating and Personnel Payments                    
Related Party Transaction [Line Items]                    
Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)     6.50%   6.50%          
Quarterly payments to affiliates, percent of security investment (as a percent)     0.25%   0.25%          
Amount calculated for operating and personal payment         $ 1,000          
Percent calculated for operating and personal payment         0.3125%          
Operating and personnel payments incurred     $ 36,000   $ 77,200          
The Manager | Former Operating and Personnel Payments                    
Related Party Transaction [Line Items]                    
Operating and personnel payments incurred       $ 32,400   $ 68,100        
Affiliated Entity | Royalty Distribution Payable to Legacy Investors Partnerships                    
Related Party Transaction [Line Items]                    
Total distributions payable to non-controlling interests     107,886   107,886     92,608    
Affiliated Entity | Royalty Distribution Payable to RP Select Finance Trust                    
Related Party Transaction [Line Items]                    
Total distributions payable to non-controlling interests     8,104   8,104     15,326    
Affiliated Entity | Assignment Agreement - Benefit of Payment Stream | Bristol-Myers Squibb                    
Related Party Transaction [Line Items]                    
Related party, rate (as a percent)   50.00%                
Affiliated Entity | Assignment Agreement - Funding Obligations | Bristol-Myers Squibb                    
Related Party Transaction [Line Items]                    
Related party, rate (as a percent)   50.00%                
Total financial royalty assets, net     118,100   $ 118,100     130,900    
Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate                    
Related Party Transaction [Line Items]                    
Number of limited partnership interest acquired (in shares)         27,210          
Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Treasury Stock                    
Related Party Transaction [Line Items]                    
Shareholders' equity     4,300   $ 4,300          
Affiliated Entity | Acquisition Of Limited Partnership Interests In Affiliate | Non-Controlling Interests                    
Related Party Transaction [Line Items]                    
Shareholders' equity     $ 1,500   $ 1,500     $ 1,600    
XML 68 R59.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events (Details) - USD ($)
$ in Millions
 1 Months Ended
Jan. 07, 2022
Jul. 31, 2022
Subsequent Event [Line Items]    
Long term funding partnership, initial payment $ 50  
Subsequent Event    
Subsequent Event [Line Items]    
Upfront cash payment   $ 1,310
Additional milestone payments   300
Long term funding partnership, initial payment   25
Regulatory milestone payments   $ 15
XML 69 rprx-20220630_htm.xml IDEA: XBRL DOCUMENT 0001802768 2022-01-01 2022-06-30 0001802768 us-gaap:CommonClassAMember 2022-08-01 0001802768 us-gaap:CommonClassBMember 2022-08-01 0001802768 2022-06-30 0001802768 2021-12-31 0001802768 us-gaap:CommonClassAMember 2021-12-31 0001802768 us-gaap:CommonClassAMember 2022-06-30 0001802768 us-gaap:CommonClassBMember 2021-12-31 0001802768 us-gaap:CommonClassBMember 2022-06-30 0001802768 rprx:ClassRRedeemableStockMember 2021-12-31 0001802768 rprx:ClassRRedeemableStockMember 2022-06-30 0001802768 rprx:FinancialRoyaltyAssetsMember 2022-04-01 2022-06-30 0001802768 rprx:FinancialRoyaltyAssetsMember 2021-04-01 2021-06-30 0001802768 rprx:FinancialRoyaltyAssetsMember 2022-01-01 2022-06-30 0001802768 rprx:FinancialRoyaltyAssetsMember 2021-01-01 2021-06-30 0001802768 rprx:IntangibleRoyaltyAssetsMember 2022-04-01 2022-06-30 0001802768 rprx:IntangibleRoyaltyAssetsMember 2021-04-01 2021-06-30 0001802768 rprx:IntangibleRoyaltyAssetsMember 2022-01-01 2022-06-30 0001802768 rprx:IntangibleRoyaltyAssetsMember 2021-01-01 2021-06-30 0001802768 rprx:RoyaltyIncomeOtherMember 2022-04-01 2022-06-30 0001802768 rprx:RoyaltyIncomeOtherMember 2021-04-01 2021-06-30 0001802768 rprx:RoyaltyIncomeOtherMember 2022-01-01 2022-06-30 0001802768 rprx:RoyaltyIncomeOtherMember 2021-01-01 2021-06-30 0001802768 2022-04-01 2022-06-30 0001802768 2021-04-01 2021-06-30 0001802768 2021-01-01 2021-06-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2022-03-31 0001802768 rprx:DeferredSharesMember 2022-03-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001802768 us-gaap:RetainedEarningsMember 2022-03-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0001802768 us-gaap:NoncontrollingInterestMember 2022-03-31 0001802768 us-gaap:TreasuryStockMember 2022-03-31 0001802768 2022-03-31 0001802768 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001802768 us-gaap:CommonClassAMember 2022-04-01 2022-06-30 0001802768 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001802768 rprx:DeferredSharesMember 2022-04-01 2022-06-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-04-01 2022-06-30 0001802768 us-gaap:TreasuryStockMember 2022-04-01 2022-06-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2022-06-30 0001802768 rprx:DeferredSharesMember 2022-06-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001802768 us-gaap:RetainedEarningsMember 2022-06-30 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember 2022-06-30 0001802768 us-gaap:TreasuryStockMember 2022-06-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-03-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-03-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2021-03-31 0001802768 rprx:DeferredSharesMember 2021-03-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001802768 us-gaap:RetainedEarningsMember 2021-03-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-03-31 0001802768 us-gaap:NoncontrollingInterestMember 2021-03-31 0001802768 us-gaap:TreasuryStockMember 2021-03-31 0001802768 2021-03-31 0001802768 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001802768 us-gaap:CommonClassAMember 2021-04-01 2021-06-30 0001802768 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001802768 rprx:DeferredSharesMember 2021-04-01 2021-06-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-04-01 2021-06-30 0001802768 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-06-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-06-30 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2021-06-30 0001802768 rprx:DeferredSharesMember 2021-06-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001802768 us-gaap:RetainedEarningsMember 2021-06-30 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember 2021-06-30 0001802768 us-gaap:TreasuryStockMember 2021-06-30 0001802768 2021-06-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2021-12-31 0001802768 rprx:DeferredSharesMember 2021-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001802768 us-gaap:RetainedEarningsMember 2021-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2021-12-31 0001802768 us-gaap:TreasuryStockMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-06-30 0001802768 us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001802768 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001802768 rprx:DeferredSharesMember 2022-01-01 2022-06-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-06-30 0001802768 us-gaap:TreasuryStockMember 2022-01-01 2022-06-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-31 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-12-31 0001802768 rprx:ClassRRedeemableStockMember us-gaap:CommonStockMember 2020-12-31 0001802768 rprx:DeferredSharesMember 2020-12-31 0001802768 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001802768 us-gaap:RetainedEarningsMember 2020-12-31 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2020-12-31 0001802768 us-gaap:TreasuryStockMember 2020-12-31 0001802768 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-06-30 0001802768 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001802768 us-gaap:CommonClassAMember 2021-01-01 2021-06-30 0001802768 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001802768 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001802768 rprx:DeferredSharesMember 2021-01-01 2021-06-30 0001802768 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001802768 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-06-30 0001802768 us-gaap:TreasuryStockMember 2021-01-01 2021-06-30 0001802768 rprx:ExchangeOfferTransactionMember rprx:LegacyInvestorsPartnershipsMember 2020-02-11 2020-02-11 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember rprx:ExchangeOfferTransactionMember 2020-02-11 0001802768 rprx:RoyaltyPharmaCollectionTrustMember 2020-02-11 0001802768 rprx:RoyaltyPharmaCollectionTrustMember rprx:LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember 2020-02-11 0001802768 rprx:RoyaltyPharmaInvestmentsOldRPIMember rprx:LegacyInvestorsPartnershipsMember 2020-02-29 0001802768 rprx:VertexMember us-gaap:FinanceReceivablesMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001802768 rprx:VertexMember us-gaap:FinanceReceivablesMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001802768 2022-01-07 2022-01-07 0001802768 rprx:MorphoSysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-06-30 0001802768 rprx:MorphoSysMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-04-01 2022-06-30 0001802768 rprx:MorphoSysMember 2022-04-01 2022-06-30 0001802768 rprx:MorphoSysMember 2022-01-01 2022-06-30 0001802768 rprx:MorphoSysMember us-gaap:SubsequentEventMember 2022-07-01 2022-07-31 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2019-04-05 2019-04-05 0001802768 us-gaap:SeriesAPreferredStockMember 2019-04-05 2019-04-05 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember 2022-01-01 2022-03-31 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember 2022-01-01 2022-06-30 0001802768 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-04-01 2022-06-30 0001802768 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-06-30 0001802768 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-04-01 2021-06-30 0001802768 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-06-30 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-08-07 2020-08-07 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember rprx:DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember 2022-01-01 2022-06-30 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-06-30 0001802768 us-gaap:PreferredStockMember 2022-06-30 0001802768 us-gaap:ForwardContractsMember 2022-06-30 0001802768 rprx:FundingCommitmentsMember 2022-06-30 0001802768 us-gaap:PreferredStockMember 2021-12-31 0001802768 us-gaap:ForwardContractsMember 2021-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-06-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-06-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-06-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-06-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2022-06-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForwardContractsMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 rprx:MilestoneAccelerationMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 rprx:RoyaltyInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 rprx:CytokineticsFundingCommitmentMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2022-03-31 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-04-01 2022-06-30 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2022-04-01 2022-06-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2022-04-01 2022-06-30 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2021-04-01 2021-06-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2022-04-01 2022-06-30 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2022-04-01 2022-06-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2022-04-01 2022-06-30 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2021-04-01 2021-06-30 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001802768 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-06-30 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-06-30 0001802768 us-gaap:RoyaltyMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-06-30 0001802768 us-gaap:SeriesAPreferredStockMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-06-30 0001802768 rprx:FundingCommitmentsMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-06-30 0001802768 rprx:DerivativeAssetMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-06-30 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-06-30 0001802768 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-06-30 0001802768 us-gaap:FairValueInputsLevel3Member rprx:CytokineticsCommercialLaunchFundingMember 2022-01-01 2022-06-30 0001802768 rprx:BioCrystPharmaceuticalsIncMember us-gaap:FairValueInputsLevel3Member 2021-11-01 2021-11-30 0001802768 2021-11-01 2021-11-30 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-06-30 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-02-01 2020-02-29 0001802768 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001802768 rprx:MilestoneAccelerationMember us-gaap:PreferredStockMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-06-30 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0001802768 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0001802768 rprx:CysticFibrosisFranchiseMember 2022-06-30 0001802768 rprx:TysabriMember 2022-06-30 0001802768 rprx:ImbruvicaMember 2022-06-30 0001802768 rprx:XtandiMember 2022-06-30 0001802768 rprx:TremfyaMember 2022-06-30 0001802768 rprx:EvrysdiMember 2022-06-30 0001802768 rprx:OtherFinancialRoyaltyAssetMember 2022-06-30 0001802768 rprx:CysticFibrosisFranchiseMember 2021-12-31 0001802768 rprx:TysabriMember 2021-12-31 0001802768 rprx:ImbruvicaMember 2021-12-31 0001802768 rprx:XtandiMember 2021-12-31 0001802768 rprx:TremfyaMember 2021-12-31 0001802768 rprx:EvrysdiMember 2021-12-31 0001802768 rprx:OtherFinancialRoyaltyAssetMember 2021-12-31 0001802768 rprx:DPPIVInhibitorsMember 2022-06-30 0001802768 rprx:DPPIVInhibitorsMember 2021-12-31 0001802768 us-gaap:SalesRevenueNetMember rprx:IndividualLicenseesConcentrationRiskMember rprx:DPPIVInhibitorsMember 2021-04-01 2021-06-30 0001802768 us-gaap:SalesRevenueNetMember rprx:IndividualLicenseesConcentrationRiskMember rprx:DPPIVInhibitorsMember 2022-01-01 2022-06-30 0001802768 us-gaap:SalesRevenueNetMember rprx:IndividualLicenseesConcentrationRiskMember rprx:DPPIVInhibitorsMember 2021-01-01 2021-06-30 0001802768 rprx:LegacyInvestorsPartnershipsMember 2020-02-11 0001802768 rprx:LegacyInvestorsPartnershipsMember 2022-04-01 2022-06-30 0001802768 rprx:LegacyInvestorsPartnershipsMember 2022-01-01 2022-06-30 0001802768 rprx:LegacyInvestorsPartnershipsMember 2021-04-01 2021-06-30 0001802768 rprx:LegacyInvestorsPartnershipsMember 2021-01-01 2021-06-30 0001802768 rprx:AvillionEntitiesMember 2022-04-01 2022-06-30 0001802768 rprx:AvillionEntitiesMember 2022-01-01 2022-06-30 0001802768 rprx:AvillionEntitiesMember 2021-04-01 2021-06-30 0001802768 rprx:AvillionEntitiesMember 2021-01-01 2021-06-30 0001802768 rprx:AvillionIMember 2021-01-01 2021-06-30 0001802768 rprx:AvillionIMember 2022-01-01 2022-06-30 0001802768 rprx:AvillionIIMember rprx:MerckAssetPhaseIIClinicalTrialMember 2022-06-30 0001802768 rprx:AvillionEntitiesMember 2022-06-30 0001802768 rprx:AvillionEntitiesMember 2021-12-31 0001802768 rprx:CytokineticsMember 2022-01-01 2022-06-30 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2022-01-01 2022-06-30 0001802768 rprx:PointSevenFivePercentSeniorNotesDue2023Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2022-01-01 2022-06-30 0001802768 rprx:OnePointTwoZeroPercentSeniorNotesDue2025Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2022-01-01 2022-06-30 0001802768 rprx:OnePointSevenFivePercentSeniorNotesDue2027Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2022-01-01 2022-06-30 0001802768 rprx:TwoPointTwoZeroPercentSeniorNotesDue2030Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2022-01-01 2022-06-30 0001802768 rprx:TwoPointOneFiveZeroPercentSeniorNotesDue2031Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2022-01-01 2022-06-30 0001802768 rprx:ThreePointThreeZeroPercentSeniorNotesDue2040Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2022-01-01 2022-06-30 0001802768 rprx:ThreePointFiveFivePercentSeniorNotesDue2050Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 rprx:ThreePointThreeFiveZeroPercentDue2051Member us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 rprx:ThreePointThreeFiveZeroPercentDue2051Member us-gaap:UnsecuredDebtMember 2022-01-01 2022-06-30 0001802768 rprx:ThreePointThreeFiveZeroPercentDue2051Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 us-gaap:SeniorNotesMember 2021-07-26 0001802768 rprx:SeniorNotesDue2031Member us-gaap:SeniorNotesMember 2021-07-26 0001802768 rprx:SeniorNotesDue2051Member us-gaap:SeniorNotesMember 2021-07-26 0001802768 rprx:SeniorNotesDue2051Member us-gaap:SeniorNotesMember 2022-06-30 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 rprx:TheNotesMember us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:UnsecuredDebtMember 2020-09-02 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:UnsecuredDebtMember 2020-09-02 2020-09-02 0001802768 rprx:TheNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 rprx:TheNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2020-09-18 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2022-06-30 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2021-12-31 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember rprx:OvernightBankFundingRateMember 2020-09-18 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember us-gaap:FederalFundsPurchasedMember 2020-09-18 2020-09-18 0001802768 us-gaap:RevolvingCreditFacilityMember rprx:SeniorUnsecuredRevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-09-18 2020-09-18 0001802768 rprx:ClassRRedeemableStockMember 2022-01-01 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2022-03-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2022-03-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-03-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2022-03-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2022-04-01 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2022-04-01 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-04-01 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2022-04-01 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2021-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2022-01-01 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2022-01-01 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-01-01 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2022-01-01 2022-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2021-03-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2021-03-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2021-03-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2021-03-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2021-04-01 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2021-04-01 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2021-04-01 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2021-04-01 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2020-12-31 0001802768 us-gaap:NoncontrollingInterestMember rprx:RoyalPharmacySelectFinanceTrustMember 2021-01-01 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:LegacyInvestorsPartnershipsMember 2021-01-01 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2021-01-01 2021-06-30 0001802768 us-gaap:NoncontrollingInterestMember rprx:EPAHoldingsMember 2021-01-01 2021-06-30 0001802768 rprx:RPHoldingsMember us-gaap:NoncontrollingInterestMember rprx:ContinuingInvestorsPartnershipMember 2022-06-30 0001802768 rprx:RPHoldingsMember us-gaap:NoncontrollingInterestMember 2022-06-30 0001802768 rprx:A2020EquityIncentivePlanMember us-gaap:CommonClassAMember 2020-06-15 0001802768 rprx:ClassBHoldersMember 2022-04-01 2022-06-30 0001802768 rprx:ClassBHoldersMember 2021-04-01 2021-06-30 0001802768 rprx:ClassBHoldersMember 2022-01-01 2022-06-30 0001802768 rprx:ClassBHoldersMember 2021-01-01 2021-06-30 0001802768 rprx:LegacyInvestorsPartnershipsAndRPSFTMember 2022-04-01 2022-06-30 0001802768 rprx:LegacyInvestorsPartnershipsAndRPSFTMember 2021-04-01 2021-06-30 0001802768 rprx:LegacyInvestorsPartnershipsAndRPSFTMember 2022-01-01 2022-06-30 0001802768 rprx:LegacyInvestorsPartnershipsAndRPSFTMember 2021-01-01 2021-06-30 0001802768 rprx:LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember 2022-06-30 0001802768 rprx:OperatingAndPersonnelPaymentsMember srt:ManagementMember 2022-06-30 0001802768 rprx:OperatingAndPersonnelPaymentsMember srt:ManagementMember 2022-01-01 2022-06-30 0001802768 rprx:OperatingAndPersonnelPaymentsMember srt:ManagementMember 2022-04-01 2022-06-30 0001802768 rprx:FormerOperatingAndPersonnelPaymentsMember srt:ManagementMember 2021-04-01 2021-06-30 0001802768 rprx:FormerOperatingAndPersonnelPaymentsMember srt:ManagementMember 2021-01-01 2021-06-30 0001802768 rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember srt:AffiliatedEntityMember 2022-06-30 0001802768 rprx:RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember srt:AffiliatedEntityMember 2021-12-31 0001802768 rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember srt:AffiliatedEntityMember 2022-06-30 0001802768 rprx:RoyaltyDistributionPayableToRPSelectFinanceTrustMember srt:AffiliatedEntityMember 2021-12-31 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementBenefitOfPaymentStreamMember srt:AffiliatedEntityMember 2017-12-08 2017-12-08 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember srt:AffiliatedEntityMember 2017-12-08 2017-12-08 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember srt:AffiliatedEntityMember 2022-06-30 0001802768 rprx:BristolMyersSquibbMember rprx:AssignmentAgreementFundingObligationsMember srt:AffiliatedEntityMember 2021-12-31 0001802768 rprx:AgreementWithMSCIMember 2021-04-16 2021-04-16 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember 2022-01-01 2022-06-30 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember us-gaap:TreasuryStockMember 2022-06-30 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember us-gaap:NoncontrollingInterestMember 2022-06-30 0001802768 rprx:AcquisitionOfLimitedPartnershipInterestsInAffiliateMember srt:AffiliatedEntityMember us-gaap:NoncontrollingInterestMember 2021-12-31 0001802768 us-gaap:SubsequentEventMember 2022-07-01 2022-07-31 shares iso4217:USD iso4217:USD shares iso4217:GBP shares pure rprx:tranche rprx:class rprx:vote rprx:noncontrolling_interest 0001802768 --12-31 2022 Q2 false 10-Q true 2022-06-30 false 001-39329 Royalty Pharma plc X0 98-1535773 110 East 59th Street New York NY 10022 212 883-0200 Class A ordinary shares, par value $0.0001 RPRX NASDAQ Yes Yes Large Accelerated Filer false false false 437139178 170080791 2108037000 1541048000 290402000 581872000 639244000 614351000 18032000 53286000 363700000 66000000 17315000 15023000 67119000 6631000 3503849000 2878211000 13423629000 13718245000 0 5670000 304447000 269800000 63000000 204400000 412076000 435394000 33412000 4145000 17740413000 17515865000 115990000 107934000 12175000 5620000 54162000 57696000 182327000 171250000 7106199000 7096070000 43700000 0 7332226000 7267320000 0.0001 0.0001 437139000 437139000 432963000 432963000 44000 43000 0.000001 0.000001 170081000 170081000 174213000 174213000 0 0 1 1 50000 50000 50000 50000 63000 63000 0.000001 0.000001 365302000 365302000 361170000 361170000 0 0 3570585000 3507533000 2446132000 2255179000 4380938000 4471951000 13177000 16491000 2752000 2715000 10408187000 10248545000 17740413000 17515865000 515350000 503414000 1026873000 1033039000 2537000 40127000 36123000 76188000 18068000 11422000 35008000 18763000 535955000 554963000 1098004000 1127990000 105714000 -243762000 290335000 48499000 606000 3122000 101106000 5763000 0 5733000 5670000 11404000 51843000 44921000 103383000 88077000 158163000 -189986000 500494000 153743000 377792000 744949000 597510000 974247000 737000 17701000 1134000 15783000 46966000 37426000 94029000 74841000 71805000 -1909000 71805000 -4464000 8024000 55495000 -28138000 1309000 70321000 14015000 53742000 23130000 10919000 14037000 20448000 30635000 -1035000 -107000 -2792000 -65000 113805000 61806000 22170000 -8513000 491597000 806755000 619680000 965734000 0 0 0 0 491597000 806755000 619680000 965734000 187093000 365979000 263415000 455839000 304504000 440776000 356265000 509895000 0.70 1.08 0.82 1.28 0.70 1.08 0.82 1.25 436318000 409344000 435144000 399606000 607214000 607163000 607207000 607151000 491597000 806755000 619680000 965734000 9325000 6025000 10950000 11150000 7988000 13299000 16942000 28790000 1337000 -7274000 -5992000 -17640000 492934000 799481000 613688000 948094000 187638000 362748000 260948000 447727000 305296000 436733000 352740000 500367000 435316000 43000 171862000 0 50000 63000 363521000 0 3543204000 2224677000 12304000 4364324000 -2736000 10141879000 2881000 2881000 146967000 146967000 0.19 83049000 83049000 1781000 -1000 -1781000 1781000 -26872000 -81000 26938000 16000 0 42000 509000 509000 304504000 187093000 491597000 5523000 3802000 9325000 4731000 3257000 7988000 437139000 44000 170081000 0 50000 63000 365302000 0 3570585000 2446132000 13177000 4380938000 -2752000 10408187000 392857000 39000 214255000 0 50000 63000 321128000 0 2931249000 1923771000 29452000 4954818000 -2359000 9837033000 11519000 11519000 170808000 170808000 0.17 72581000 72581000 34089000 -3000 -34089000 34089000 -483628000 -3263000 486591000 303000 0 60000 721000 721000 440776000 365979000 806755000 3348000 2677000 6025000 7391000 5908000 13299000 427006000 42000 180166000 0 50000 63000 355217000 0 3415598000 2291966000 28672000 4671686000 -2662000 10405365000 432963000 43000 174213000 0 50000 63000 361170000 0 3507533000 2255179000 16491000 4471951000 -2715000 10248545000 6203000 6203000 295942000 295942000 0.38 165312000 165312000 4132000 -1000 -4132000 4132000 -62047000 -211000 62222000 37000 0 44000 1005000 1005000 356265000 263415000 619680000 6480000 4470000 10950000 10005000 6937000 16942000 437139000 44000 170081000 0 50000 63000 365302000 0 3570585000 2446132000 13177000 4380938000 -2752000 10408187000 388135000 39000 218976000 0 50000 63000 316407000 0 2865964000 1920635000 34395000 5077036000 -2317000 9895815000 14772000 14772000 0 316186000 316186000 0.34 138564000 138564000 38810000 -3000 -38810000 38810000 -548200000 -3805000 551663000 345000 0 61000 1434000 1434000 509895000 455839000 965734000 6060000 5090000 11150000 15588000 13202000 28790000 427006000 42000 180166000 0 50000 63000 355217000 0 3415598000 2291966000 28672000 4671686000 -2662000 10405365000 1181354000 1094094000 71377000 75200000 32716000 14088000 27502000 22003000 3262000 2332000 0 11470000 0 9340000 1106000 5763000 100000000 0 93003000 81764000 86880000 64500000 1035222000 1057820000 0 523000 3050000 17427000 62785000 0 0 109367000 79158000 35170000 31250000 31250000 234869000 728025000 525907000 868689000 175093000 683741000 21215000 0 0 18600000 -19013000 -473134000 215543000 238197000 72343000 86978000 165312000 138564000 731000 4080000 3247000 8574000 -449220000 -451085000 566989000 133601000 1541048000 1008680000 2108037000 1142281000 Organization and Purpose <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the initial public offering (“IPO”) of our Class A ordinary shares. “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control Royalty Pharma Holdings Ltd. (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K. tax resident, through our ownership of RP Holdings’ Class A ordinary shares and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”). The Continuing Investors Partnerships (defined below) have a non-controlling interest in RP Holdings through their ownership of RP Holdings Class B Interests. We conduct our business through RP Holdings and its subsidiaries. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”). RP Holdings is directly or indirectly owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”) and Royalty Pharma plc. Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”). </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RP Management, LLC (the “Manager”), a Delaware limited liability company, is responsible for our management, including our day-to-day operations, pursuant to advisory and management agreements (collectively, the “Management Agreement”).</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer Transactions </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consummated an exchange offer on February 11, 2020 to facilitate the IPO. Through the exchange offer, investors which represented 82% of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships. The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under senior secured credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”</span></div>As a result of the Exchange Offer Transactions, we own indirectly an 82% economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”). We are legally entitled to 82% of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66% of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”). The remaining 34% of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust. 0.82 0.82 0.82 0.66 0.34 Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Preparation and Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI, (2) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain conditions are met. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances have been eliminated in consolidation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co., Pfizer, Astellas, Novartis, and Gilead. As of June 30, 2022 and December 31, 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32% of our current portion of financial royalty assets and represented the largest individual marketer and payor of our royalties.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile. To date, we have not experienced any significant losses with respect to the collection of income or revenue on our royalty assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div>There have been no material changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, all adjustments considered necessary to present fairly the results of the interim periods have been included and consist only of normal and recurring adjustments. Certain information and footnote disclosures have been condensed or omitted as permitted under GAAP. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2021, included in our Annual Report on Form 10-K. <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to monitor the impact from the COVID-19 pandemic on our operational and financial performance. To date, certain marketers have commented that the performance of products on which we own royalties have been impacted by the COVID-19 pandemic. However, the COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of Royalty Pharma and all majority-owned and controlled subsidiaries, as well as variable interest entities, where we are the primary beneficiary. We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance. For consolidated entities where we own or are exposed to less than 100% of the economics of such entity, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We report non-controlling interests related to the portion of ownership interests of consolidated subsidiaries not owned by us which are attributable to: (1) the Legacy Investors Partnerships’ ownership of approximately 18% in Old RPI, (2) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, (3) a de minimis interest in RPCT held by RPSFT and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”). Income will not be allocated to EPA Holdings until certain conditions are met. </span></div>All intercompany transactions and balances have been eliminated in consolidation. 0.18 Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale securities, financial royalty assets, derivatives and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances as of June 30, 2022 and December 31, 2021 were held with State Street and Bank of America. Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson &amp; Johnson, Merck &amp; Co., Pfizer, Astellas, Novartis, and Gilead. 0.32 0.32 Available for Sale Debt Securities <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (“Cytokinetics”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil. As part of the funding agreement, we agreed to provide capital (“Cytokinetics Commercial Launch Funding”) of up to $300 million, which is comprised of five tranches, including an initial tranche of $50 million that was funded upon closing. In the three months ended June 30, 2022, we amended the long-term funding agreement with Cytokinetics to increase the required draw amount. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”). As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022. Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement. The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of June 30, 2022 and within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2021 on the condensed consolidated balance sheets. The unrealized change in fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys Development Funding Bonds</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support its acquisition of Constellation Pharmaceuticals, Inc. that closed on July 15, 2021. As part of the funding agreement, which was amended in the three months ended June 30, 2022 to extend the initial funding date, we agreed to provide MorphoSys up to $350 million of capital (the “Development Funding Bonds”) to be drawn by September 12, 2022. MorphoSys is required to draw a minimum of $150 million. Our commitment to fund at least $150 million of the Development Funding Bonds is recognized as the Development Funding Bond Forward. Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years, with the first payment beginning two years after the funding is drawn. As of June 30, 2022, MorphoSys had not drawn any amount under the Development Funding Bonds. In July 2022, MorphoSys notified us of its intention to draw $300 million under the Development Funding Bonds to be funded in September 2022. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument. The Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of June 30, 2022 and within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2021 on our condensed consolidated balance sheets. The unrealized change in fair value of the Development Funding Bond Forward is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”) at a price of $50,100 per preferred share for a total of $125 million. The approval of Nurtec ODT by the U.S. Food and Drug Administration (“FDA”) in February 2020 resulted in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024. In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Biohaven Preferred Shares are classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our condensed consolidated balance sheets. The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income. In the three and six months ended June 30, 2022, $8.0 million and $16.9 million, respectively, of the unrealized gains were reclassified from other comprehensive income to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations. In the three and six months ended June 30, 2021, $13.3 million and $28.8 million, respectively, of the unrealized gains were reclassified from other comprehensive income to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Series B Biohaven Preferred Shares </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $50,100 per preferred share (the “Commercial Launch Preferred Equity”) for a total of $200 million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024. Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards. Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between the three months ended March 31, 2025 and the three months ended December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the original issue price of the Series B Biohaven Preferred Shares. Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we have acquired 1,988 shares of Series B Biohaven Preferred Shares. We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which are recorded in aggregate as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheets. We believe the fair value option most accurately reflects the nature of these instruments. The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Liabilities (3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">269,359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113,641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">383,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">383,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span> on the condensed consolidated balance sheet. 300000000 5 50000000 50000000 200000000 125000000 200000000 1.9 350000000 150000000 150000000 2.2 P9Y P2Y 300000000 2495 50100 125000000 2 2 -8000000 16900000 13300000 28800000 3992 50100 200000000 1.8 1.8 1.8 1988 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below summarizes our available for sale debt securities recorded at fair value as of June 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Current Liabilities (3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">269,359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113,641</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">383,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">363,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">383,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available for sale debt securities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,891</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">204,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">270,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Cost for Series A Biohaven Preferred Shares represents amortized cost. Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments. The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">There are no costs associated with the forwards. The cost associated with the funding commitments represents the fair value on the purchase date. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities</span> on the condensed consolidated balance sheet. 278759000 84241000 363000000 300000000 63000000 0 0 363000000 0 28100000 28100000 63700000 0 0 -35600000 28100000 -9400000 1300000 -8100000 0 0 0 -8100000 -8100000 269359000 113641000 383000000 363700000 63000000 0 -43700000 383000000 204509000 49191000 253700000 66000000 187700000 0 0 253700000 0 16700000 16700000 0 16700000 0 0 16700000 204509000 65891000 270400000 66000000 204400000 0 0 270400000 . Fair Value Measurements and Financial Instruments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Hierarchy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instrument (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">307,797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">508,084</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">426,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,242,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">598,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">636,823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,301,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instrument (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty at fair value (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">275,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">397,262</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">247,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">474,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. As of June 30, 2022, amounts also include the fair value of the funded portion of the Cytokinetics Commercial Launch Funding.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Milestone Acceleration Option (defined below) recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet. See Note 8–Non-Consolidated Affiliates for additional discussion.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the fair value of the Cytokinetics Funding Commitments as reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet as of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 30, 2022. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, we recognized gains of $8.0 million and losses of $28.1 million, respectively, on equity securities still held as of June 30, 2022. For the three and six months ended June 30, 2021, we recognized gains of $28.3 million and losses of $10.7 million, respectively, on equity securities still held as of June 30, 2022.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities, a royalty interest, a derivative instrument and available for sale debt securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the underlying debt securities, related forwards and funding commitments (in thousands): </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instrument</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62,538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">314,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,400)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">226,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains on derivative financial instrument</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in other comprehensive losses (1) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of forwards (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer to Level 1 (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redemption of debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">363,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">240,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to transfer restriction expiration of BioCryst common stock.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instrument</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(losses) on initial recognition (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains on derivative financial instrument</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in other comprehensive losses (2) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of forwards (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,842)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer to Level 1 (5) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redemption of debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">363,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">240,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents purchase price allocation to arrive at the appropriate fair value on initial recognition.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to transfer restriction expiration of BioCryst common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Inputs for Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ApiJect Investment</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value of equity securities and the revenue participation right that we acquired from ApiJect Holdings, Inc. (“ApiJect”) in April 2022. Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant in the event of a sale of the instruments, which would mean that the estimated fair value could be significantly higher or lower. Refer to Note 8–Non-Consolidated Affiliates for additional discussion. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of June 30, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments. Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding requires significant judgement. Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Cytokinetics Funding Commitments as of June 30, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model. This methodology simulates the likelihood of future discount rates exceeding the counterparty’s assumed cost of debt, which would impact Cytokinetics’ decision to exercise its option to draw on each respective tranche. This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of 30% and an assumed risk-adjusted discount rate of 15.2%. We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding. Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioCryst Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we purchased 3,846 thousand shares of common stock of BioCryst Pharmaceuticals, Inc. (“BioCryst”), calculated based on the volume-weighted average price of BioCryst’s common stock over a period preceding the closing of the transaction. As part of the transaction, we were restricted from selling the BioCryst common stock for six months following the close of the transaction. We determined the fair value of the BioCryst common stock as of December 31, 2021 based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the BioCryst common stock to match the duration of the transfer restriction. This methodology incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which required the use of significant judgement. Our estimated volatility could be reasonably different than the actual volatility of BioCryst’s common stock, which would mean that the estimated fair value for the BioCryst common stock could be significantly higher or lower than the fair value determined by management at any particular date. During the three months ended June 30, 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MorphoSys Development Funding Bonds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Development Funding Bond Forward as of June 30, 2022 and December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input. Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower. As of June 30, 2022, the Development Funding Bonds remain undrawn.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $15.6 million following the FDA approval and starting one-year after FDA approval through the three months ended December 31, 2024. When the FDA approved Nurtec ODT in February 2020, we became entitled to receive a fixed payment amount of $250 million payable in equal quarterly payments between the three months ended March 31, 2021 and the three months ended December 31, 2024. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the Series A Biohaven Preferred Shares as of June 30, 2022 and December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated that there is a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate of 13.7% and 9.5% as of June 30, 2022 and December 31, 2021, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Biohaven Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of June 30, 2022 and December 31, 2021 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions. Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement. Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Acceleration Option</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, we entered into an expanded funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time. If Biohaven effects any change of control event, then we will have the option to cause Biohaven to accelerate the payment of any outstanding zavegepant milestone payments in a lump sum amount (“Milestone Acceleration Option”). The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material in prior periods. As of June 30, 2022, the fair value of the Milestone Acceleration Option was $71.8 million, of which $63.2 million was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $8.6 million was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheet. For the three months ended June 30, 2022, we recorded $71.8 million of unrealized gain related to the change in the fair value of the Milestone Acceleration Option within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Gains)/losses on derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of operations. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimated the fair value of the Milestone Acceleration Option as of June 30, 2022 using the “with-and-without” methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios. The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario. For the second scenario, the prospective cash flows are estimated assuming they remain payable over time. The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option. This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates, estimated probabilities of achieving the success-based milestones, and the probability that there will be a change of control event in different periods of time, which would result in accelerated milestone payments. Assessing the probability that there will be a change of control event, the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate requires significant judgement. As of June 30, 2022, we estimated a high probability of a change of control event within the next year. Our estimate of a risk adjusted discount rate, probabilities of achieving marketing approval, and our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S. government securities. We measure the fair value of these financial instruments with the help of third-party pricing services that either provide quoted market prices in active markets for identical or similar securities or observable inputs for their pricing without applying significant adjustments.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Not Measured at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets are measured and carried on the condensed consolidated balance sheets at amortized cost using the effective interest method. The current portion of financial royalty assets approximates fair value. Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts. Where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales. These projected future royalty payments by asset along with any projected incoming or outgoing milestone payments are then discounted to a present value using appropriate individual discount rates. The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are presented below (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,254,440 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,423,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,047,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,718,245 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Hierarchy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt. Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our condensed consolidated balance sheets. For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety. Long-term debt and financial royalty assets are reported at their amortized costs on our condensed consolidated balance sheets but for which fair values are disclosed. The remaining financial instruments are reported on our condensed consolidated balance sheets at amounts that approximate fair values.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes assets and liabilities measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,797 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">598,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instrument (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">307,797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">508,084</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">426,900</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,242,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">598,253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">636,823</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,301,076</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative instrument (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty at fair value (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">275,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">397,262</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">247,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">474,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forwards (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding commitments (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(43,700)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares. As of June 30, 2022, amounts also include the fair value of the funded portion of the Cytokinetics Commercial Launch Funding.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares as recorded within current assets as of June 30, 2022 and within non-current assets as of December 31, 2021. As of December 31, 2021, the amount also reflects the fair value of our obligations to fund the Development Funding Bonds as recorded within non-current assets. As of June 30, 2022, the fair value of our obligations to fund the Development Funding Bonds was reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the Milestone Acceleration Option (defined below) recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet. See Note 8–Non-Consolidated Affiliates for additional discussion.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to the fair value of the Cytokinetics Funding Commitments as reflected within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet as of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span>June 30, 2022. 307797000 0 0 307797000 598253000 0 0 598253000 0 181681000 0 181681000 0 13997000 0 13997000 0 36001000 0 36001000 0 40954000 0 40954000 0 87622000 0 87622000 0 207457000 0 207457000 0 178766000 0 178766000 0 374415000 0 374415000 0 24014000 0 24014000 0 0 0 0 0 0 300000000 300000000 0 0 66000000 66000000 0 0 63700000 63700000 0 0 0 0 0 0 63200000 63200000 0 0 0 0 307797000 508084000 426900000 1242781000 598253000 636823000 66000000 1301076000 275662000 0 28785000 304447000 226787000 0 43013000 269800000 0 0 63000000 63000000 0 0 187700000 187700000 0 0 0 0 0 0 16700000 16700000 0 0 8600000 8600000 0 0 0 0 0 0 21215000 21215000 0 0 0 0 275662000 0 121600000 397262000 226787000 0 247413000 474200000 0 0 -35600000 -35600000 0 0 0 0 0 0 -8100000 -8100000 0 0 0 0 0 0 -43700000 -43700000 0 0 0 0 8000000 -28100000 28300000 -10700000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities, a royalty interest, a derivative instrument and available for sale debt securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the underlying debt securities, related forwards and funding commitments (in thousands): </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instrument</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62,538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">314,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,400)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">226,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains on derivative financial instrument</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in other comprehensive losses (1) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of forwards (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer to Level 1 (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redemption of debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">363,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,100)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">240,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the three months ended June 30, 2022, amounts also reflect unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to transfer restriction expiration of BioCryst common stock.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding Commitments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Instrument</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forwards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">253,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">214,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(losses) on initial recognition (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains on derivative financial instrument</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in other comprehensive losses (2) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains included in earnings (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of forwards (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,842)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer to Level 1 (5) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redemption of debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">363,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8,100)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">240,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents purchase price allocation to arrive at the appropriate fair value on initial recognition.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of comprehensive income for unrealized gains related to Series A Biohaven Preferred Shares.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Recorded within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Unrealized gains on available for sale debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations for the unrealized change in fair value in the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward. For the six months ended June 30, 2022, amounts also reflect the unrealized change in fair value in the funded portion of the Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the fair value attributed to the Series B Forwards that were settled simultaneously with the acquisition of the Series B Biohaven Preferred Shares, which is included in the fair value of the Series B Biohaven Preferred Shares. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Related to transfer restriction expiration of BioCryst common stock.</span></div> 62538000 314000000 -1200000 -8400000 0 0 226800000 22400000 28785000 14579000 21215000 17585000 -21846000 71800000 9325000 6025000 31800000 38221000 300000 500000 13515000 8921000 -8921000 5115000 -5115000 -40692000 -15625000 -15625000 28785000 363000000 28100000 -8100000 71800000 21215000 240400000 30800000 43013000 253700000 16700000 0 0 0 214400000 18600000 28785000 79158000 21215000 35170000 9400000 -9400000 -2321000 71800000 10950000 11150000 30200000 22242000 1300000 500000 22630000 10842000 -10842000 10430000 -10430000 -40692000 -31250000 -31250000 28785000 363000000 28100000 -8100000 71800000 21215000 240400000 30800000 0.30 0.152 3846000 P6M 2 15600000 250000000 0.137 0.095 71800000 63200000 8600000 71800000 Estimated fair values based on Level 3 inputs and related carrying values for the non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are presented below (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,254,440 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,423,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,047,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,718,245 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 18254440000 13423629000 19047183000 13718245000 Financial Royalty Assets<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (5)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,347,911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,609)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,293,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,759,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,759,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,439,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(417,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,824,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,110,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,713,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,048,153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,737,435)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,310,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247,845)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,062,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.326%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,697,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(909,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,787,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,027,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,384,141)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,643,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,332,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of June 30, 2022 and December 31, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (5)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,347,911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,609)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,293,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,759,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,759,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,439,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(417,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,824,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,110,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,713,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,048,153</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,737,435)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,310,718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247,845)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,062,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.923%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.326%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Royalty Duration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Allowance for Changes in Expected Cash Flows (Note 6)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cystic fibrosis franchise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2037 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,335,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tysabri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,846,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,829,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Imbruvica</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,438,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xtandi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tremfya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2031-2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evrysdi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030-2035 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,774 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020-2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,697,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(909,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,787,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,027,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,384,141)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,643,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Cumulative allowance for credit losses (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,332,596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography. There can be no assurances that our royalties will expire when expected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Royalty is perpetual; year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RPIFT acquired a perpetual royalty on net sales of Tysabri. We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $1.3 billion.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The net carrying value by asset is presented before the allowance for credit losses. Refer to Note 6–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.</span></div> 5347911000 54609000 5293302000 1759427000 0 1759427000 1439443000 417165000 1022278000 1053621000 153154000 900467000 876834000 0 876834000 746524000 1992000 744532000 4824393000 1110515000 3713878000 16048153000 1737435000 14310718000 247845000 14062873000 1300000000 5335641000 48636000 5287005000 1846069000 16617000 1829452000 1438730000 236871000 1201859000 1100065000 172101000 927964000 881671000 0 881671000 727774000 0 727774000 4697591000 909916000 3787675000 16027541000 1384141000 14643400000 310804000 14332596000 1300000000 Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheets and includes the following activities:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts, and</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,694,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(556,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,985,280)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $310.8 million related to cumulative allowance for credit losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In the six months ended June 30, 2022, the provision income for credit losses was primarily related to a significant decline in the value of the Tazverik financial royalty asset.</span></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Activity for the Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,694,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(556,020)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision for credit losses, net (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,985,280)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes $310.8 million related to cumulative allowance for credit losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In the six months ended June 30, 2022, the provision income for credit losses was primarily related to a significant decline in the value of the Tazverik financial royalty asset.</span></div> 1694945000 556020000 202726000 -62959000 1985280000 310800000 Intangible Royalty Assets, Net<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the cost, accumulated amortization and net carrying value of our intangible royalty assets as of June 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the intangible royalty assets were fully amortized as our royalties on Januvia and Janumet expired in the three months ended March 31, 2022. Our royalties on the other DPP-IV products have also substantially ended.</span></div>Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees. Such revenue is earned from sales occurring primarily in the United States and Europe; however, we do not have the ability to disaggregate such revenue from licensees based on the geography of the underlying sales as this information may not be provided to us by marketers. For the three months ended June 30, 2022, revenue from intangible royalty assets was not material. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 90% of revenues from intangible royalty assets in the three months ended June 30, 2021. Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 93% and 94% of revenues from intangible royalty assets in the six months ended June 30, 2022 and 2021, respectively. <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the cost, accumulated amortization and net carrying value of our intangible royalty assets as of June 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DPP-IV patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible royalty assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606,216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,546 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 606216000 606216000 0 606216000 606216000 0 606216000 600546000 5670000 606216000 600546000 5670000 0.90 0.93 0.94 Non-Consolidated Affiliates<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity method investments or as equity securities for which we have elected the fair value option.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ApiJect</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, we acquired common stock and a revenue participation right from ApiJect. We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for our investments in ApiJect. We are also required to acquire additional common stock in ApiJect if certain milestones are achieved. The fair value of our equity investment was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the fair value of the revenue participation right was recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet as of June 30, 2022. No amounts were due from ApiJect as of June 30, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Legacy SLP Interest</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired a special limited partnership interest in the Legacy Investors Partnerships (the “Legacy SLP Interest”) from the Continuing Investors Partnerships for $303.7 million in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy SLP Interest entitles us to the equivalent of performance distribution payments that would have been paid to the general partner of the Legacy Investors Partnerships and an income allocation on a similar basis. Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference. The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence. The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time. The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this quarterly report. Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period. During the three and six months ended June 30, 2022, we recorded income allocations of $4.7 million and $9.3 million, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in earnings of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the three and six months ended June 30, 2021, we recorded income allocations of $25.6 million and $30.8 million, respectively, within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity in earnings of equity method investees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received cash distributions from the Legacy SLP Interest of $6.8 million and $14.1 million in the three and six months ended June 30, 2022, respectively. We received cash distributions from the Legacy SLP Interest of $4.7 million and $8.6 million in the three and six months ended June 30, 2021, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Avillion Entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our partnership interests in Avillion Financing I, LP and its related entities (“Avillion I”), BAv Financing II, LP and its related entities (“Avillion II,” together with Avillion I, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities. During the three and six months ended June 30, 2022, we recorded a loss allocation from the Avillion Entities of $4.0 million and $8.2 million, respectively, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in earnings of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the three and six months ended June 30, 2021, we recorded a loss allocation from the Avillion Entities of $7.9 million and $15.0 million, respectively, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity in earnings of equity method investees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif. Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer. The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer. We received distributions from Avillion I of $13.4 million during each of the six months ended June 30, 2022 and 2021, respectively.</span></div>In May 2018, RPIFT entered into an agreement, which was amended in July 2021 and was further amended in June 2022 to increase the funding amount by $27.5 million, which totaled $150.0 million over multiple years in Avillion II, which is a party to a co-development agreement with AstraZeneca, to fund a portion of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments. As of June 30, 2022 and December 31, 2021, RPIFT had $35.7 million and $11.2 million, respectively, of unfunded commitments related to the Avillion Entities. 303700000 4700000 9300000 25600000 30800000 6800000 14100000 4700000 8600000 -4000000 -8200000 -7900000 -15000000 13400000 13400000 27500000 150000000 -35700000 -11200000 Research &amp; Development (“R&amp;D”) Funding Expense R&amp;D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. R&amp;D funding expense includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties. During the six months ended June 30, 2022 and 2021, we did not enter into any new ongoing R&amp;D funding arrangements. We recognized R&amp;D funding expense of $0.6 million and $101.1 million for the three and six months ended June 30, 2022, respectively. We recognized R&amp;D funding expense of $3.1 million and $5.8 million for the three and six months ended June 30, 2021, respectively. During the six months ended June 30, 2022, R&amp;D funding expense primarily related to upfront and milestone development-stage funding payments of $100.0 million to Cytokinetics to acquire a royalty on a development-stage product candidate. 600000 101100000 3100000 5800000 100000000 Borrowings<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193,801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,106,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,106,199 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Senior Unsecured Notes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, we issued $1.3 billion of senior unsecured notes (the “2021 Notes”) comprised of $600.0 million principal amount of notes due September 2031 and $700.0 million principal amount of notes due September 2051. Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022. The 2021 Notes were issued at a total discount of $27.5 million and we capitalized approximately $12.3 million in debt issuance costs primarily composed of underwriting fees. The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80% and 3.06%, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2020, we issued $6.0 billion of senior unsecured notes (the “2020 Notes” and, together with the 2021 Notes, the “Notes”). We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities. Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year. The 2020 Notes were issued at a total discount of $149.0 million and we capitalized approximately $40.4 million in debt issuance costs primarily comprised of underwriting fees. The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.125% and 2.50%, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the treasury rate, plus a make-whole premium as defined in the indenture. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101% of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary. We are required to comply with certain covenants under our Notes and as of June 30, 2022, we were in compliance with all applicable covenants.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the fair value of our outstanding Notes using Level 2 inputs was approximately $5.9 billion and $7.2 billion, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Senior Unsecured Revolving Credit Facility</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”). The Credit Agreement amended and restated the prior credit agreement that our subsidiary RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $1.5 billion for general corporate purposes. The Credit Agreement extended the maturity of the Revolving Credit Facility to September 15, 2026. As of June 30, 2022 and December 31, 2021, there were no outstanding borrowings under the Revolving Credit Facility. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5% and (3) the one month adjusted LIBOR, plus 1% or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin. The applicable margin for the Revolving Credit Facility varies based on our public debt rating. Accordingly, the interest rates for the Revolving Credit Facility fluctuates during the term of the facility based on changes in the applicable interest rate and future changes in our public debt rating.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Credit Agreement that governs the Revolving Credit Facility contains certain customary covenants, that among other things, require us to maintain (i) a consolidated leverage ratio at or below 4.00 to 1.00 (or at or below 4.50 to 1.00 following a qualifying material acquisition) of consolidated funded debt to consolidated EBITDA, each as defined and calculated with the ratio level calculated with further adjustments as set forth in the Credit Agreement and (ii) a consolidated coverage ratio at or above 2.50 to 1.00 of consolidated EBITDA to consolidated interest expense, each as defined and calculated with further adjustments as set forth in the Credit Agreement. All obligations under the Revolving Credit Facility are unconditionally guaranteed by us. Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed. If these financial covenants are not satisfied, the Credit Agreement prohibits us from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets. As of June 30, 2022, RP Holdings was in compliance with these covenants. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Principal Payments on the Notes</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future principal payments for our borrowings as of June 30, 2022 over the next five years and thereafter are as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Excludes unamortized debt discount and issuance costs of $193.8 million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations. <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Our borrowings as of June 30, 2022 and December 31, 2021 consisted of the following (in thousands):</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 0.75% (issued at 99.322% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.20% (issued at 98.875% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 1.75% (issued at 98.284% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 2.20% (issued at 97.760% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$600,000, 2.15% (issued at 98.263% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.30% (issued at 95.556% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,000,000, 3.55% (issued at 95.306% of par)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$700,000, 3.35% (issued at 97.565% of par)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9/2051</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193,801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt carrying value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,106,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,106,199 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,096,070 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1000000000 0.0075 0.99322 1000000000 1000000000 1000000000 0.0120 0.98875 1000000000 1000000000 1000000000 0.0175 0.98284 1000000000 1000000000 1000000000 0.0220 0.97760 1000000000 1000000000 600000000 0.0215 0.98263 600000000 600000000 1000000000 0.0330 0.95556 1000000000 1000000000 1000000000 0.0355 0.95306 1000000000 1000000000 700000000 0.0335 0.97565 700000000 700000000 193801000 203930000 7106199000 7096070000 0 0 7106199000 7096070000 1300000000 600000000 700000000 27500000 12300000 0.0280 0.0306 6000000000 149000000 40400000 0.02125 0.0250 1 1.01 5900000000 7200000000 P5Y 1500000000 0 0 0.005 0.005 0.01 4.00 4.50 2.50 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future principal payments for our borrowings as of June 30, 2022 over the next five years and thereafter are as follows (in thousands):</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,300,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Excludes unamortized debt discount and issuance costs of $193.8 million as of June 30, 2022, which are amortized through interest expense over the remaining life of the underlying debt obligations. 0 1000000000 0 1000000000 0 5300000000 7300000000 -193800000 Shareholders’ Equity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Structure</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two classes of voting shares: Class A ordinary shares and Class B ordinary shares, each of which has one vote per ordinary share. The Class A ordinary shares and Class B ordinary shares vote together as a single class on all matters submitted to a vote of shareholders, except as otherwise required by applicable law. Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company. As of June 30, 2022, we had 437,139 thousand Class A ordinary shares and 170,081 thousand Class B ordinary shares outstanding. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares. Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one-for-one basis for Class A ordinary shares on a quarterly basis. Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares. As of June 30, 2022, we had outstanding deferred shares of 365,302 thousand. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights. The Class R redeemable shares may be redeemed at our option in the future. Any such redemption would be at the nominal value of £1 each.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Non-Controlling Interests</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net change in the balance of our four non-controlling interests for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,756,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,599,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,364,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,881 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103,385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,802 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,716,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,655,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72,343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(295,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,716,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,655,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,882,655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,058,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,954,818</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(486,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(486,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,743 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365,979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,894,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,757,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,671,686</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(222,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(316,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,894,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,757,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,671,686</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Continuing Investors Partnerships’ ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of June 30, 2022, the Continuing Investors Partnerships owned approximately 28% of RP Holdings with the remaining 72% owned by Royalty Pharma plc.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RP Holdings Class C Special Interest Held by EPA Holdings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis. Investments made during each two-year period are grouped together as separate portfolios (each, a “Portfolio”). Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”). The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest. The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors. The holders of Class B ordinary shares do not have any rights to receive dividends; however, the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings. In the six months ended June 30, 2022, we declared and paid two quarterly cash dividends of $0.19 per Class A ordinary share for an aggregate amount of $165.3 million to holders of our Class A ordinary shares. In the six months ended June 30, 2021, we declared and paid two quarterly cash dividends of $0.17 per Class A ordinary share for an aggregate amount of $138.6 million to holders of our Class A ordinary shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Independent Directors Equity Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020, our 2020 Independent Director Equity Incentive Plan was approved and became effective, whereby 800 thousand Class A ordinary shares have been reserved for future issuance to our independent directors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSU Activity and Share-based Compensation</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan. Share-based compensation expense is recognized on a straight-line basis over the requisite service period of generally one year as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span> in the condensed consolidated statements of operations. In the three and six months ended June 30, 2022 and 2021, respectively, we did not recognize material share-based compensation expenses. 2 1 437139000 170081000 1 365302000 50000 1 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net change in the balance of our four non-controlling interests for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands): </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,409</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,756,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,599,646</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,364,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,881 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103,385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,802 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,716,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,655,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,809,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,649,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,471,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(207,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72,343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(295,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,470 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,716,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,655,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,380,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,882,655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,058,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,954,818</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170,808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(486,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(486,591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,743 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365,979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,894,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,757,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,671,686</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">RPSFT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Legacy Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Continuing Investors Partnerships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EPA Holdings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,939,509</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,125,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,077,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(222,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(316,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,090 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,894,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,757,019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,671,686</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Continuing Investors Partnerships’ ownership in RP Holdings decreases as the Continuing Investors Partnerships exchange RP Holdings Class B Interests held for Class A ordinary shares. As of June 30, 2022, the Continuing Investors Partnerships owned approximately 28% of RP Holdings with the remaining 72% owned by Royalty Pharma plc.</span></div> 4 8409000 1756269000 2599646000 0 4364324000 0 1425000 1456000 0 2881000 5754000 103385000 37828000 0 146967000 0 0 26938000 0 26938000 6227000 61642000 119224000 0 187093000 0 1639000 2163000 0 3802000 0 1404000 1853000 0 3257000 8882000 1716186000 2655870000 0 4380938000 13528000 1809269000 2649154000 0 4471951000 0 3395000 2808000 0 6203000 16013000 207586000 72343000 0 295942000 0 0 62222000 0 62222000 11367000 112162000 139886000 0 263415000 0 1925000 2545000 0 4470000 0 2979000 3958000 0 6937000 8882000 1716186000 2655870000 0 4380938000 13841000 1882655000 3058322000 0 4954818000 0 6654000 4865000 0 11519000 12476000 127747000 30585000 0 170808000 0 0 486591000 0 486591000 19275000 133743000 212961000 0 365979000 0 1059000 1618000 0 2677000 0 2337000 3571000 0 5908000 20640000 1894027000 2757019000 0 4671686000 12436000 1939509000 3125091000 0 5077036000 0 9907000 4865000 0 14772000 26129000 222289000 67768000 0 316186000 0 0 551663000 0 551663000 34333000 170000000 251506000 0 455839000 0 1960000 3130000 0 5090000 0 5060000 8142000 0 13202000 20640000 1894027000 2757019000 0 4671686000 0.28 0.72 0.19 165300000 0.17 138600000 800000 P1Y Earnings per Share<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (“EPS”) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period. Diluted EPS is calculated by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued. Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares and deferred shares under the two-class method has not been presented.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one-for-one basis. Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan. We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs. For the three and six months ended June 30, 2022 and 2021, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share amounts):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356,265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509,895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653,737 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496,151 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436,318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effects as shown separately below</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class B ordinary shares exchangeable for Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,214 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,207 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.70 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share amounts):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Continuing Investors Partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to Legacy Investors Partnerships and RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,504 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356,265 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509,895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139,886 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Royalty Pharma plc - diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653,737 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496,151 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436,318 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: Dilutive effects as shown separately below</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class B ordinary shares exchangeable for Class A ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average Class A ordinary shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,214 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,207 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607,151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Class A ordinary share - diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.70 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.08 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.25 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 491597000 806755000 619680000 965734000 119224000 212961000 139886000 251506000 67869000 153018000 123529000 204333000 304504000 440776000 356265000 509895000 119224000 212961000 139886000 251506000 423728000 653737000 496151000 761401000 436318000 409344000 435144000 399606000 170864000 197773000 172035000 207508000 32000 46000 28000 37000 607214000 607163000 607207000 607151000 0.70 1.08 0.82 1.28 0.70 1.08 0.82 1.25 Indirect Cash Flow<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,026,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,033,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,049 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,181,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,094,094 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Increase/(decrease) in operating liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,035,222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,057,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile consolidated net income to net cash provided by operating activities are summarized below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile consolidated net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,026,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,033,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for changes in expected cash flows from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gains)/losses on derivative financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71,805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Losses/(gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains on available for sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,049 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Decrease/(increase) in operating assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash collected on financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,181,354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,094,094 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalty receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other royalty income receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Increase/(decrease) in operating liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,035,222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,057,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 619680000 965734000 1026873000 1033039000 290335000 48499000 5670000 11404000 10683000 9583000 71805000 -4464000 -28138000 1309000 1134000 15783000 27502000 22003000 1005000 1434000 16942000 28790000 53742000 23130000 -2657000 -2049000 1181354000 1094094000 -35254000 988000 2292000 4683000 -2711000 -3703000 6555000 -913000 -3534000 758000 0 2730000 1035222000 1057820000 Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Commitments</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various funding commitments as of June 30, 2022 as described below. See Note 3–Available for Sale Debt Securities for additional discussion of the respective arrangements. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cytokinetics Commercial Launch Funding</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, $250 million of the Cytokinetics Commercial Launch Funding remained unfunded. Cytokinetics is required to draw $50 million if a certain contingency is met and has the option to draw the remaining $200 million upon the occurrence of certain regulatory and clinical development milestones. As of June 30, 2022, we expect $125 million of the $200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by December 31, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MorphoSys Development Funding Bonds </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, $350 million of the MorphoSys Development Funding Bonds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">remained unfunded. In July 2022, MorphoSys notified us of its intention to draw $300 million under the Development Funding Bonds to be funded in September 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Series B Biohaven Preferred Shares</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2022, we have a remaining commitment of $100.4 million under the Commercial Launch Preferred Equity to purchase 2,004 shares of Series B Biohaven Preferred Shares on a quarterly basis through the three months ended December 31, 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commitments to advance funds to counterparties through our investment in the Avillion Entities. Please refer to Note 8–Non-Consolidated Affiliates for details of these arrangements. We also have requirements to make Operating and Personnel Payments over the life of the Management Agreement as described in Note 15–Related Party Transactions, which are variable and primarily based on cash receipts.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts. The maximum exposure under such agreements is indeterminable until a claim, if any, is made. However, no such claims have been made against us to date and we believe that the likelihood of such occurrences taking place in the future is remote. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to legal actions with respect to a variety of matters in the ordinary course of business. Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages. Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved. We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.</span></div> 250000000 50000000 200000000 125000000 200000000 350000000 300000000 100400000 2004 Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Manager</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Manager is the investment manager of Royalty Pharma and its subsidiaries. The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Management Agreement, we pay quarterly operating and personnel expenses to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5% of the cash receipts from royalty investments for such quarter and 0.25% of the value of our security investments under GAAP as of the end of such quarter. The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $1 million per quarter and 0.3125% of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022, total operating and personnel payments incurred were $36.0 million and $77.2 million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations. During the three and six months ended June 30, 2021, total operating and personnel payments incurred were $32.4 million and $68.1 million, respectively, including the amounts attributable to Old RPI, and were recognized within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions Payable to Non-Controlling Interests</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distributions payable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The distributions payable to non-controlling interests as of June 30, 2022 and December 31, 2021 include the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:56.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distributions payable to non-controlling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,990 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,934 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition from Bristol Myers Squibb</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”). On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an entity related to us. Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50% of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50% of the funding obligations owed to BMS under the Purchase Agreement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the financial royalty asset of $118.1 million and $130.9 million, respectively, on the condensed consolidated balance sheets represents only our right to the future payment streams acquired from BMS. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Transactions</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI Inc. (“MSCI”). On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI’s thematic index suite with the launch of new indexes. In return, we will receive a percentage of MSCI’s revenues from those indexes. No amounts were due from MSCI as of both June 30, 2022 and December 31, 2021. The financial impact associated with this transaction has not been material to date. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary. As a result, we became a special limited partner in the Legacy Investors Partnerships. The Legacy Investors Partnerships own a non-controlling interest in Old RPI. Refer to Note 8–Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries. The total investment of $4.3 million is recorded as treasury interests, of which $1.5 million and $1.6 million were held by non-controlling interests as of June 30, 2022 and December 31, 2021, respectively. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.</span></div> 0.065 0.0025 1000000 0.003125 36000000 77200000 32400000 68100000 <div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distributions payable to non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT. The distributions payable to non-controlling interests as of June 30, 2022 and December 31, 2021 include the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:56.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to Legacy Investors Partnerships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due to RPSFT</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total distributions payable to non-controlling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,990 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,934 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 107886000 92608000 8104000 15326000 115990000 107934000 0.50 0.50 118100000 130900000 P7Y 27210 4300000 1500000 1600000 Subsequent EventsIn July 2022, we acquired all of the equity interests in Theravance Respiratory Company, LLC from Theravance Biopharma, Inc. (“Theravance”) and Innoviva, Inc. which entitles us to the right to receive royalties on the annual worldwide sales of Trelegy. We made an upfront payment of $1.31 billion in July 2022 and committed up to $300 million in additional payments contingent upon the achievement of certain sales milestones. Additionally, we agreed to provide Theravance $25 million in upfront funding and a potential $15 million regulatory milestone payment to support the clinical development of ampreloxetine. 1310000000 300000000 25000000 15000000 EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 71 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 436 303 1 false 112 0 false 9 false false R1.htm 0001001 - Document - Cover Sheet http://royaltypharma.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations Sheet http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) Sheet http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) Statements 7 false false R8.htm 1007008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101101 - Disclosure - Organization and Purpose Sheet http://royaltypharma.com/role/OrganizationandPurpose Organization and Purpose Notes 9 false false R10.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 2106103 - Disclosure - Available for Sale Debt Securities Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecurities Available for Sale Debt Securities Notes 11 false false R12.htm 2110104 - Disclosure - Fair Value Measurements and Financial Instruments Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments Fair Value Measurements and Financial Instruments Notes 12 false false R13.htm 2116105 - Disclosure - Financial Royalty Assets Sheet http://royaltypharma.com/role/FinancialRoyaltyAssets Financial Royalty Assets Notes 13 false false R14.htm 2119106 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets Notes 14 false false R15.htm 2122107 - Disclosure - Intangible Royalty Assets, Net Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet Intangible Royalty Assets, Net Notes 15 false false R16.htm 2126108 - Disclosure - Non-Consolidated Affiliates Sheet http://royaltypharma.com/role/NonConsolidatedAffiliates Non-Consolidated Affiliates Notes 16 false false R17.htm 2128109 - Disclosure - Research & Development ("R&D") Funding Expense Sheet http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense Research & Development ("R&D") Funding Expense Notes 17 false false R18.htm 2130110 - Disclosure - Borrowings Sheet http://royaltypharma.com/role/Borrowings Borrowings Notes 18 false false R19.htm 2135111 - Disclosure - Shareholders' Equity Sheet http://royaltypharma.com/role/ShareholdersEquity Shareholders' Equity Notes 19 false false R20.htm 2139112 - Disclosure - Earnings per Share Sheet http://royaltypharma.com/role/EarningsperShare Earnings per Share Notes 20 false false R21.htm 2142113 - Disclosure - Indirect Cash Flow Sheet http://royaltypharma.com/role/IndirectCashFlow Indirect Cash Flow Notes 21 false false R22.htm 2145114 - Disclosure - Commitments and Contingencies Sheet http://royaltypharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 22 false false R23.htm 2147115 - Disclosure - Related Party Transactions Sheet http://royaltypharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 23 false false R24.htm 2150116 - Disclosure - Subsequent Events Sheet http://royaltypharma.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 2307301 - Disclosure - Available for Sale Debt Securities (Tables) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables Available for Sale Debt Securities (Tables) Tables http://royaltypharma.com/role/AvailableforSaleDebtSecurities 26 false false R27.htm 2311302 - Disclosure - Fair Value Measurements and Financial Instruments (Tables) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables Fair Value Measurements and Financial Instruments (Tables) Tables http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments 27 false false R28.htm 2317303 - Disclosure - Financial Royalty Assets (Tables) Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsTables Financial Royalty Assets (Tables) Tables http://royaltypharma.com/role/FinancialRoyaltyAssets 28 false false R29.htm 2320304 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables) Tables http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets 29 false false R30.htm 2323305 - Disclosure - Intangible Royalty Assets, Net (Tables) Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables Intangible Royalty Assets, Net (Tables) Tables http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet 30 false false R31.htm 2331306 - Disclosure - Borrowings (Tables) Sheet http://royaltypharma.com/role/BorrowingsTables Borrowings (Tables) Tables http://royaltypharma.com/role/Borrowings 31 false false R32.htm 2336307 - Disclosure - Shareholders' Equity (Tables) Sheet http://royaltypharma.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://royaltypharma.com/role/ShareholdersEquity 32 false false R33.htm 2340308 - Disclosure - Earnings per Share (Tables) Sheet http://royaltypharma.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://royaltypharma.com/role/EarningsperShare 33 false false R34.htm 2343309 - Disclosure - Indirect Cash Flow (Tables) Sheet http://royaltypharma.com/role/IndirectCashFlowTables Indirect Cash Flow (Tables) Tables http://royaltypharma.com/role/IndirectCashFlow 34 false false R35.htm 2348310 - Disclosure - Related Party Transactions (Tables) Sheet http://royaltypharma.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://royaltypharma.com/role/RelatedPartyTransactions 35 false false R36.htm 2402401 - Disclosure - Organization and Purpose (Details) Sheet http://royaltypharma.com/role/OrganizationandPurposeDetails Organization and Purpose (Details) Details http://royaltypharma.com/role/OrganizationandPurpose 36 false false R37.htm 2405402 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies 37 false false R38.htm 2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails Available for Sale Debt Securities - Narrative (Details) Details 38 false false R39.htm 2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) Sheet http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details) Details 39 false false R40.htm 2412405 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details) Details 40 false false R41.htm 2413406 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails Fair Value Measurements and Financial Instruments - Narrative (Details) Details http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables 41 false false R42.htm 2414407 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details) Details 42 false false R43.htm 2415408 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) Sheet http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details) Details 43 false false R44.htm 2418409 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details) Sheet http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details) Details 44 false false R45.htm 2421410 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) Sheet http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details) Details 45 false false R46.htm 2424411 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details) Details 46 false false R47.htm 2425412 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details) Sheet http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails Intangible Royalty Assets, Net - Narrative (Details) Details 47 false false R48.htm 2427413 - Disclosure - Non-Consolidated Affiliates (Details) Sheet http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails Non-Consolidated Affiliates (Details) Details http://royaltypharma.com/role/NonConsolidatedAffiliates 48 false false R49.htm 2429414 - Disclosure - Research & Development ("R&D") Funding Expense (Details) Sheet http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails Research & Development ("R&D") Funding Expense (Details) Details http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense 49 false false R50.htm 2432415 - Disclosure - Borrowings - Schedule of Borrowings (Details) Sheet http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails Borrowings - Schedule of Borrowings (Details) Details 50 false false R51.htm 2433416 - Disclosure - Borrowings - Narrative (Details) Sheet http://royaltypharma.com/role/BorrowingsNarrativeDetails Borrowings - Narrative (Details) Details 51 false false R52.htm 2434417 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details) Sheet http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails Borrowings - Schedule of Repayments of Debt by Year (Details) Details 52 false false R53.htm 2437418 - Disclosure - Shareholders' Equity - Narrative (Details) Sheet http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity - Narrative (Details) Details 53 false false R54.htm 2438419 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details) Sheet http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails Shareholders' Equity - Summary of Noncontrolling Interests (Details) Details 54 false false R55.htm 2441420 - Disclosure - Earnings per Share (Details) Sheet http://royaltypharma.com/role/EarningsperShareDetails Earnings per Share (Details) Details http://royaltypharma.com/role/EarningsperShareTables 55 false false R56.htm 2444421 - Disclosure - Indirect Cash Flow (Details) Sheet http://royaltypharma.com/role/IndirectCashFlowDetails Indirect Cash Flow (Details) Details http://royaltypharma.com/role/IndirectCashFlowTables 56 false false R57.htm 2446422 - Disclosure - Commitments and Contingencies (Details) Sheet http://royaltypharma.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://royaltypharma.com/role/CommitmentsandContingencies 57 false false R58.htm 2449423 - Disclosure - Related Party Transactions (Details) Sheet http://royaltypharma.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://royaltypharma.com/role/RelatedPartyTransactionsTables 58 false false R59.htm 2451424 - Disclosure - Subsequent Events (Details) Sheet http://royaltypharma.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://royaltypharma.com/role/SubsequentEvents 59 false false All Reports Book All Reports rprx-20220630.htm rprx-20220630.xsd rprx-20220630_cal.xml rprx-20220630_def.xml rprx-20220630_lab.xml rprx-20220630_pre.xml rprx-20220630ex311.htm rprx-20220630ex312.htm rprx-20220630ex32.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rprx-20220630.htm": { "axisCustom": 1, "axisStandard": 31, "contextCount": 436, "dts": { "calculationLink": { "local": [ "rprx-20220630_cal.xml" ] }, "definitionLink": { "local": [ "rprx-20220630_def.xml" ] }, "inline": { "local": [ "rprx-20220630.htm" ] }, "labelLink": { "local": [ "rprx-20220630_lab.xml" ] }, "presentationLink": { "local": [ "rprx-20220630_pre.xml" ] }, "schema": { "local": [ "rprx-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 556, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 5, "total": 5 }, "keyCustom": 84, "keyStandard": 219, "memberCustom": 65, "memberStandard": 41, "nsprefix": "rprx", "nsuri": "http://royaltypharma.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://royaltypharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106103 - Disclosure - Available for Sale Debt Securities", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecurities", "shortName": "Available for Sale Debt Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110104 - Disclosure - Fair Value Measurements and Financial Instruments", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments", "shortName": "Fair Value Measurements and Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - Financial Royalty Assets", "role": "http://royaltypharma.com/role/FinancialRoyaltyAssets", "shortName": "Financial Royalty Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CreditLossFinancialInstrumentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119106 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CreditLossFinancialInstrumentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122107 - Disclosure - Intangible Royalty Assets, Net", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet", "shortName": "Intangible Royalty Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126108 - Disclosure - Non-Consolidated Affiliates", "role": "http://royaltypharma.com/role/NonConsolidatedAffiliates", "shortName": "Non-Consolidated Affiliates", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128109 - Disclosure - Research & Development (\"R&D\") Funding Expense", "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense", "shortName": "Research & Development (\"R&D\") Funding Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130110 - Disclosure - Borrowings", "role": "http://royaltypharma.com/role/Borrowings", "shortName": "Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135111 - Disclosure - Shareholders' Equity", "role": "http://royaltypharma.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139112 - Disclosure - Earnings per Share", "role": "http://royaltypharma.com/role/EarningsperShare", "shortName": "Earnings per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142113 - Disclosure - Indirect Cash Flow", "role": "http://royaltypharma.com/role/IndirectCashFlow", "shortName": "Indirect Cash Flow", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145114 - Disclosure - Commitments and Contingencies", "role": "http://royaltypharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147115 - Disclosure - Related Party Transactions", "role": "http://royaltypharma.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150116 - Disclosure - Subsequent Events", "role": "http://royaltypharma.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Available for Sale Debt Securities (Tables)", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables", "shortName": "Available for Sale Debt Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Fair Value Measurements and Financial Instruments (Tables)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables", "shortName": "Fair Value Measurements and Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317303 - Disclosure - Financial Royalty Assets (Tables)", "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsTables", "shortName": "Financial Royalty Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320304 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "rprx:DeferredSharesParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:DeferredSharesParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "rprx:DeferredSharesParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:DeferredSharesParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323305 - Disclosure - Intangible Royalty Assets, Net (Tables)", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables", "shortName": "Intangible Royalty Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331306 - Disclosure - Borrowings (Tables)", "role": "http://royaltypharma.com/role/BorrowingsTables", "shortName": "Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2336307 - Disclosure - Shareholders' Equity (Tables)", "role": "http://royaltypharma.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340308 - Disclosure - Earnings per Share (Tables)", "role": "http://royaltypharma.com/role/EarningsperShareTables", "shortName": "Earnings per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343309 - Disclosure - Indirect Cash Flow (Tables)", "role": "http://royaltypharma.com/role/IndirectCashFlowTables", "shortName": "Indirect Cash Flow (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2348310 - Disclosure - Related Party Transactions (Tables)", "role": "http://royaltypharma.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i8fc135510e2d49c6b0cd406c917f4076_I20200211", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization and Purpose (Details)", "role": "http://royaltypharma.com/role/OrganizationandPurposeDetails", "shortName": "Organization and Purpose (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i8fc135510e2d49c6b0cd406c917f4076_I20200211", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskPercentage1", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i5fd5281c06f745a289028be5720b9cfa_D20220101-20220630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskPercentage1", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i5fd5281c06f745a289028be5720b9cfa_D20220101-20220630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "ib51ffa317e2b426684502864dfacf80c_D20220107-20220107", "decimals": "-6", "first": true, "lang": "en-US", "name": "rprx:LongTermFundingPartnershipAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Available for Sale Debt Securities - Narrative (Details)", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "shortName": "Available for Sale Debt Securities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "ib51ffa317e2b426684502864dfacf80c_D20220107-20220107", "decimals": "-6", "first": true, "lang": "en-US", "name": "rprx:LongTermFundingPartnershipAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)", "role": "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "shortName": "Available for Sale Debt Securities - Summary of Available for Sale Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TradingSecuritiesDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Fair Value Hierarchy (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i467ecc55a5c146ce9f323a91de3f9cf8_I20220630", "decimals": "-3", "lang": "en-US", "name": "rprx:AssetsFairValueDisclosureCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Fair Value Measurements and Financial Instruments - Narrative (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "shortName": "Fair Value Measurements and Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "icc0ee976221e43ac94bfd0056a40c5bc_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails", "shortName": "Fair Value Measurements and Financial Instruments - Summary of Change in Carrying Value of Level 3 Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "icc0ee976221e43ac94bfd0056a40c5bc_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i5c8b4208854b4a00a19fae7046aab65c_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:FinancingReceivablesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)", "role": "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "shortName": "Fair Value Measurements and Financial Instruments - Schedule of Estimated Fair Values Based on Level 3 Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i5c8b4208854b4a00a19fae7046aab65c_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:FinancingReceivablesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details)", "role": "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails", "shortName": "Financial Royalty Assets - Summary of Financial Royalty Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i5bce62e7437a4451aba53bcceaf66c3c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421410 - Disclosure - Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)", "role": "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "shortName": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets - Schedule of Cumulative Allowance for Changes in Expected Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i5bce62e7437a4451aba53bcceaf66c3c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424411 - Disclosure - Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails", "shortName": "Intangible Royalty Assets, Net - Schedule of Intangible Royalty Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i52e0a35567124c7891aeaa93c83c35c8_D20210401-20210630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425412 - Disclosure - Intangible Royalty Assets, Net - Narrative (Details)", "role": "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "shortName": "Intangible Royalty Assets, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i52e0a35567124c7891aeaa93c83c35c8_D20210401-20210630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427413 - Disclosure - Non-Consolidated Affiliates (Details)", "role": "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "shortName": "Non-Consolidated Affiliates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i9fb0f3822f7448c3b9edb5542ba8571e_I20200211", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Research & Development (\"R&D\") Funding Expense (Details)", "role": "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails", "shortName": "Research & Development (\"R&D\") Funding Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i691fe772f8474c9883cd86d770776fc5_D20220101-20220630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432415 - Disclosure - Borrowings - Schedule of Borrowings (Details)", "role": "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "shortName": "Borrowings - Schedule of Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "ie5a03d177ab2440997f9376d5899a918_I20210726", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433416 - Disclosure - Borrowings - Narrative (Details)", "role": "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "shortName": "Borrowings - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "ie5a03d177ab2440997f9376d5899a918_I20210726", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "icf036923cf324ce78882338a4fb17702_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434417 - Disclosure - Borrowings - Schedule of Repayments of Debt by Year (Details)", "role": "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails", "shortName": "Borrowings - Schedule of Repayments of Debt by Year (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "icf036923cf324ce78882338a4fb17702_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:NumberOfClassesOfVotingStock", "reportCount": 1, "unitRef": "class", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437418 - Disclosure - Shareholders' Equity - Narrative (Details)", "role": "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "shortName": "Shareholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DividendsCommonStockCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i4a1f6430e214497599d013c1c8969e8d_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438419 - Disclosure - Shareholders' Equity - Summary of Noncontrolling Interests (Details)", "role": "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "shortName": "Shareholders' Equity - Summary of Noncontrolling Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i63f4135a52e24cdc8a877de0528e91ef_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "rprx:CommonStockExchangeRatio", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441420 - Disclosure - Earnings per Share (Details)", "role": "http://royaltypharma.com/role/EarningsperShareDetails", "shortName": "Earnings per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i94e4c0864e8a4b97ad3a6377d7f9e0ef_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444421 - Disclosure - Indirect Cash Flow (Details)", "role": "http://royaltypharma.com/role/IndirectCashFlowDetails", "shortName": "Indirect Cash Flow (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": "-3", "lang": "en-US", "name": "rprx:IncreaseDecreaseInFinancialRoyaltyAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "rprx:LongTermFundingCommitmentAmountOutstanding", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446422 - Disclosure - Commitments and Contingencies (Details)", "role": "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i6a315f10c1cf4a62aaa0baa77b9a57f6_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449423 - Disclosure - Related Party Transactions (Details)", "role": "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i5bce62e7437a4451aba53bcceaf66c3c_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "ib51ffa317e2b426684502864dfacf80c_D20220107-20220107", "decimals": "-6", "first": true, "lang": "en-US", "name": "rprx:LongTermFundingPartnershipInitialPayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451424 - Disclosure - Subsequent Events (Details)", "role": "http://royaltypharma.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "ic1e28652abed4e02b4f0c82dcc887d19_D20220701-20220731", "decimals": "-7", "lang": "en-US", "name": "rprx:CollaborativeArrangementRightsAndObligationsUpfrontPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i74012a9aba134af29fa48477d04dde00_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "role": "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i74012a9aba134af29fa48477d04dde00_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i4cc3706dd64341cca85ff2f3da538efa_D20210401-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)", "role": "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Purpose", "role": "http://royaltypharma.com/role/OrganizationandPurpose", "shortName": "Organization and Purpose", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rprx-20220630.htm", "contextRef": "i47de2e5cf85a447480e5095a1109a20c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 112, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://royaltypharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "rprx_A2020EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Equity Incentive Plan", "label": "2020 Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "A2020EquityIncentivePlanMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_AccruedRoyaltyReceivable": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued Royalty Receivable", "label": "Accrued Royalty Receivable", "terseLabel": "Accrued royalty receivable" } } }, "localname": "AccruedRoyaltyReceivable", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_AcquisitionOfLimitedPartnershipInterestsInAffiliateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition Of Limited Partnership Interests In Affiliate", "label": "Acquisition Of Limited Partnership Interests In Affiliate [Member]", "terseLabel": "Acquisition Of Limited Partnership Interests In Affiliate" } } }, "localname": "AcquisitionOfLimitedPartnershipInterestsInAffiliateMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AgreementWithMSCIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement with MSCI", "label": "Agreement with MSCI [Member]", "terseLabel": "Agreement with MSCI" } } }, "localname": "AgreementWithMSCIMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AssetsFairValueDisclosureCurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, Fair Value Disclosure, Current", "label": "Assets, Fair Value Disclosure, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsFairValueDisclosureCurrent", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_AssetsFairValueDisclosureNoncurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, Fair Value Disclosure, Noncurrent", "label": "Assets, Fair Value Disclosure, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsFairValueDisclosureNoncurrent", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_AssignmentAgreementBenefitOfPaymentStreamMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assignment Agreement - Benefit of Payment Stream", "label": "Assignment Agreement - Benefit of Payment Stream [Member]", "terseLabel": "Assignment Agreement - Benefit of Payment Stream" } } }, "localname": "AssignmentAgreementBenefitOfPaymentStreamMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AssignmentAgreementFundingObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assignment Agreement - Funding Obligations", "label": "Assignment Agreement - Funding Obligations [Member]", "terseLabel": "Assignment Agreement - Funding Obligations" } } }, "localname": "AssignmentAgreementFundingObligationsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_AvillionEntitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Avillion Entities", "label": "Avillion Entities [Member]", "terseLabel": "Avillion Entities" } } }, "localname": "AvillionEntitiesMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_AvillionIIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Avillion II", "label": "Avillion II [Member]", "terseLabel": "Avillion II" } } }, "localname": "AvillionIIMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_AvillionIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Avillion I", "label": "Avillion I [Member]", "terseLabel": "Avillion I" } } }, "localname": "AvillionIMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_BioCrystPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioCryst Pharmaceuticals, Inc.", "label": "BioCryst Pharmaceuticals, Inc. [Member]", "terseLabel": "BioCryst Pharmaceuticals, Inc." } } }, "localname": "BioCrystPharmaceuticalsIncMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_BristolMyersSquibbMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bristol-Myers Squibb", "label": "Bristol-Myers Squibb [Member]", "terseLabel": "Bristol-Myers Squibb" } } }, "localname": "BristolMyersSquibbMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_ClassBHoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class B Holders", "label": "Class B Holders [Member]", "terseLabel": "Class B Holders" } } }, "localname": "ClassBHoldersMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "domainItemType" }, "rprx_ClassRRedeemableStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class R Redeemable Stock", "label": "Class R Redeemable Stock [Member]", "terseLabel": "Class R Redeemable Stock" } } }, "localname": "ClassRRedeemableStockMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_CollaborativeArrangementExpectedProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Expected Proceeds", "label": "Collaborative Arrangement, Expected Proceeds", "terseLabel": "Expected proceeds from development funding bonds" } } }, "localname": "CollaborativeArrangementExpectedProceeds", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund", "label": "Collaborative Arrangement, Rights and Obligations, Maximum Commitment To Fund", "terseLabel": "Commitment to fund agreement" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumCommitmentToFund", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsPaymentOfCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Payment of Capital", "label": "Collaborative Arrangement, Rights and Obligations, Payment of Capital", "terseLabel": "Payment of capital" } } }, "localname": "CollaborativeArrangementRightsAndObligationsPaymentOfCapital", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Period of Return", "label": "Collaborative Arrangement, Rights and Obligations, Period of Return", "terseLabel": "Period of return" } } }, "localname": "CollaborativeArrangementRightsAndObligationsPeriodOfReturn", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date", "label": "Collaborative Arrangement, Rights and Obligations, Period of Return, Start Date", "terseLabel": "Start of period of return" } } }, "localname": "CollaborativeArrangementRightsAndObligationsPeriodOfReturnStartDate", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_CollaborativeArrangementRightsAndObligationsUpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment", "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment", "terseLabel": "Upfront cash payment" } } }, "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_CommonStockExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Exchange Ratio", "label": "Common Stock, Exchange Ratio", "terseLabel": "Common stock exchange ratio" } } }, "localname": "CommonStockExchangeRatio", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "pureItemType" }, "rprx_CommonStockQuarterlyConversionBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Quarterly Conversion Basis", "label": "Common Stock, Quarterly Conversion Basis", "terseLabel": "Quarterly conversion basis" } } }, "localname": "CommonStockQuarterlyConversionBasis", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "rprx_CommonStockVotingRightsNumberOfVotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Voting Rights, Number Of Votes", "label": "Common Stock, Voting Rights, Number Of Votes", "terseLabel": "Number of votes per share" } } }, "localname": "CommonStockVotingRightsNumberOfVotes", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "rprx_ContinuingInvestorsPartnershipMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continuing Investors Partnership", "label": "Continuing Investors Partnership [Member]", "terseLabel": "Continuing Investors Partnerships" } } }, "localname": "ContinuingInvestorsPartnershipMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_CysticFibrosisFranchiseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cystic Fibrosis Franchise", "label": "Cystic Fibrosis Franchise [Member]", "terseLabel": "Cystic fibrosis franchise" } } }, "localname": "CysticFibrosisFranchiseMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_CytokineticsCommercialLaunchFundingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cytokinetics Commercial Launch Funding", "label": "Cytokinetics Commercial Launch Funding [Member]", "terseLabel": "Cytokinetics Commercial Launch Funding" } } }, "localname": "CytokineticsCommercialLaunchFundingMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_CytokineticsFundingCommitmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cytokinetics Funding Commitment", "label": "Cytokinetics Funding Commitment [Member]", "terseLabel": "Cytokinetics Funding Commitment" } } }, "localname": "CytokineticsFundingCommitmentMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "rprx_CytokineticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cytokinetics", "label": "Cytokinetics [Member]", "terseLabel": "Cytokinetics" } } }, "localname": "CytokineticsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "rprx_DPPIVInhibitorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DPP-IV Inhibitors", "label": "DPP-IV Inhibitors [Member]", "terseLabel": "DPP-IV patents" } } }, "localname": "DPPIVInhibitorsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio", "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio", "terseLabel": "Maximum consolidated leverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatio", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition", "label": "Debt Instrument, Covenant Terms, Maximum Consolidated Leverage Ratio, Following Qualifying Material Acquisition", "terseLabel": "Maximum consolidated leverage ratio following qualifying material acquisition" } } }, "localname": "DebtInstrumentCovenantTermsMaximumConsolidatedLeverageRatioFollowingQualifyingMaterialAcquisition", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio", "label": "Debt Instrument, Covenant Terms, Minimum Consolidated Coverage Ratio", "terseLabel": "Minimum consolidated coverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMinimumConsolidatedCoverageRatio", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtInstrumentIssuanceAsAPercentOfPar": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Issuance As A Percent Of Par", "label": "Debt Instrument, Issuance As A Percent Of Par", "terseLabel": "Debt issued as a percent of par value (as a percent)" } } }, "localname": "DebtInstrumentIssuanceAsAPercentOfPar", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "percentItemType" }, "rprx_DebtSecuritiesAvailableForSaleFixedPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Fixed Payment", "label": "Debt Securities, Available-for-Sale, Fixed Payment", "terseLabel": "Preferred shares, fixed payment amount" } } }, "localname": "DebtSecuritiesAvailableForSaleFixedPayment", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_DebtSecuritiesAvailableForSaleLiabilityCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available For Sale, Liability, Current", "label": "Debt Securities, Available For Sale, Liability, Current", "terseLabel": "Available for sale debt securities, liabilities current" } } }, "localname": "DebtSecuritiesAvailableForSaleLiabilityCurrent", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_DebtSecuritiesAvailableForSaleLiabilityNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available For Sale, Liability, Noncurrent", "label": "Debt Securities, Available For Sale, Liability, Noncurrent", "terseLabel": "Available for sale debt securities, liabilities noncurrent" } } }, "localname": "DebtSecuritiesAvailableForSaleLiabilityNoncurrent", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "rprx_DebtSecuritiesAvailableForSaleNumberOfSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Number Of Shares Purchased", "label": "Debt Securities, Available-For-Sale, Number Of Shares Purchased", "terseLabel": "Number of shares purchased (in shares)" } } }, "localname": "DebtSecuritiesAvailableForSaleNumberOfSharesPurchased", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "rprx_DebtSecuritiesAvailableForSalePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Price Per Share", "label": "Debt Securities, Available-For-Sale, Price Per Share", "terseLabel": "Price per share (in USD per share)" } } }, "localname": "DebtSecuritiesAvailableForSalePricePerShare", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "rprx_DebtSecuritiesAvailableForSaleQuarterlyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Quarterly Payments", "label": "Debt Securities, Available-for-Sale, Quarterly Payments", "terseLabel": "Preferred shares, quarterly payments" } } }, "localname": "DebtSecuritiesAvailableForSaleQuarterlyPayments", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period", "label": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]", "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Axis]" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodAxis", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period", "label": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]", "terseLabel": "Debt Securities, Available-For-Sale, Redemption, Period [Domain]" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodDomain", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period One", "label": "Debt Securities, Available-For-Sale, Redemption, Period One [Member]", "terseLabel": "Redemption, Period One" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodOneMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption, Period Two", "label": "Debt Securities, Available-For-Sale, Redemption, Period Two [Member]", "terseLabel": "Redemption, Period Two" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPeriodTwoMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DebtSecuritiesAvailableForSaleRedemptionPriceMultiple": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Redemption Price, Multiple", "label": "Debt Securities, Available-For-Sale, Redemption Price, Multiple", "terseLabel": "Redemption price, percentage" } } }, "localname": "DebtSecuritiesAvailableForSaleRedemptionPriceMultiple", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_DebtSecuritiesAvailableForSaleRestrictionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Restriction Period", "label": "Debt Securities, Available-For-Sale, Restriction Period", "terseLabel": "Restrictions on selling common stock, period" } } }, "localname": "DebtSecuritiesAvailableForSaleRestrictionPeriod", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "rprx_DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital", "label": "Debt Securities, Available-for-Sale, Weighted Average Cost Of Capital", "terseLabel": "Preferred shares, weighted average cost of capital" } } }, "localname": "DebtSecuritiesAvailableForSaleWeightedAverageCostOfCapital", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "rprx_DeferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares", "label": "Deferred Shares [Member]", "terseLabel": "Deferred Shares" } } }, "localname": "DeferredSharesMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_DeferredSharesParOrStatedValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Par or Stated Value Per Share", "label": "Deferred Shares, Par or Stated Value Per Share", "terseLabel": "Deferred stock, par value (in dollars per share)" } } }, "localname": "DeferredSharesParOrStatedValuePerShare", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "rprx_DeferredSharesSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Shares, Issued", "label": "Deferred Shares, Shares, Issued", "terseLabel": "Deferred stock, issued (in shares)" } } }, "localname": "DeferredSharesSharesIssued", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "rprx_DeferredSharesSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Shares, Outstanding", "label": "Deferred Shares, Shares, Outstanding", "terseLabel": "Deferred stock, outstanding (in shares)" } } }, "localname": "DeferredSharesSharesOutstanding", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "rprx_DeferredSharesValueIssued": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Shares, Value, Issued", "label": "Deferred Shares, Value, Issued", "terseLabel": "Deferred shares, $0.000001 par value; 365,302 and 361,170 issued and outstanding, respectively" } } }, "localname": "DeferredSharesValueIssued", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_DerivativeAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Asset", "label": "Derivative Asset [Member]", "terseLabel": "Derivative Instrument" } } }, "localname": "DerivativeAssetMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rprx_EPAHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EPA Holdings", "label": "EPA Holdings [Member]", "terseLabel": "EPA Holdings" } } }, "localname": "EPAHoldingsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_EquityMethodInvestmentsUnfundedCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investments, Unfunded Commitments", "label": "Equity Method Investments, Unfunded Commitments", "terseLabel": "Equity method investment, unfunded commitments" } } }, "localname": "EquityMethodInvestmentsUnfundedCommitments", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_EvrysdiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Evrysdi", "label": "Evrysdi [Member]", "terseLabel": "Evrysdi" } } }, "localname": "EvrysdiMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_ExchangeOfferTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange Offer Transaction", "label": "Exchange Offer Transaction [Member]", "terseLabel": "Exchange Offer Transaction" } } }, "localname": "ExchangeOfferTransactionMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) On Initial Recognition", "terseLabel": "Gains/(losses) on initial recognition" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossOnInitialRecognition", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Redemptions", "terseLabel": "Redemption of debt securities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRedemptions", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancialRoyaltyAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Royalty Assets", "label": "Financial Royalty Assets [Member]", "terseLabel": "Financial Royalty Assets" } } }, "localname": "FinancialRoyaltyAssetsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "rprx_FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 1.0, "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows", "label": "Financing Receivable, Allowance For Credit Loss, Changes In Expected Cash Flows", "negatedLabel": "Cumulative allowance for changes in expected cash flows" } } }, "localname": "FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 2.0, "parentTag": "us-gaap_NotesReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)", "label": "Financing Receivable, Allowance for Credit Loss, Cumulative Adjustment And Credit Loss Expense (Reversal)", "negatedLabel": "Cumulative allowance for credit losses", "terseLabel": "Cumulative allowance for credit losses" } } }, "localname": "FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails", "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense", "label": "Financing Receivable, Change in Present Value, Decreases To Cumulative Allowance, Reversal Of Expense", "terseLabel": "Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets" } } }, "localname": "FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense", "label": "Financing Receivable, Change in Present Value, Increases To Cumulative Allowance, Expense", "negatedTerseLabel": "Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets" } } }, "localname": "FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents", "label": "Financing Receivable, Covenant, Triggering Amount For Expiration Of Patents", "terseLabel": "Aggregate royalty amount when patents cease" } } }, "localname": "FinancingReceivableCovenantTriggeringAmountForExpirationOfPatents", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows", "label": "Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows", "totalLabel": "Net carrying value, before cumulative allowance for credit losses" } } }, "localname": "FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FinancingReceivablesFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivables, Fair Value Disclosure", "label": "Financing Receivables, Fair Value Disclosure", "terseLabel": "Financial royalty assets, net" } } }, "localname": "FinancingReceivablesFairValueDisclosure", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_FormerOperatingAndPersonnelPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Operating and Personnel Payments", "label": "Former Operating and Personnel Payments [Member]", "terseLabel": "Former Operating and Personnel Payments" } } }, "localname": "FormerOperatingAndPersonnelPaymentsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_FundingCommitmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Funding Commitments", "label": "Funding Commitments [Member]", "terseLabel": "Funding Commitments" } } }, "localname": "FundingCommitmentsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rprx_ImbruvicaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Imbruvica", "label": "Imbruvica [Member]", "terseLabel": "Imbruvica" } } }, "localname": "ImbruvicaMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_IncreaseDecreaseInAccruedRoyaltyReceivable": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Accrued Royalty Receivable", "label": "Increase (Decrease) In Accrued Royalty Receivable", "negatedTerseLabel": "Accrued royalty receivable" } } }, "localname": "IncreaseDecreaseInAccruedRoyaltyReceivable", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IncreaseDecreaseInCashCollectionsOnFinancingReceivables": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Cash Collections On Financing Receivables", "label": "Increase (Decrease) In Cash Collections On Financing Receivables", "terseLabel": "Cash collected on financial royalty assets" } } }, "localname": "IncreaseDecreaseInCashCollectionsOnFinancingReceivables", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IncreaseDecreaseInFinancialRoyaltyAssets": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Financial Royalty Assets", "label": "Increase (Decrease) In Financial Royalty Assets", "negatedTerseLabel": "Income from financial royalty assets" } } }, "localname": "IncreaseDecreaseInFinancialRoyaltyAssets", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IncreaseDecreaseInOtherRoyaltyIncomeReceivable": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Other Royalty Income Receivable", "label": "Increase (Decrease) In Other Royalty Income Receivable", "negatedTerseLabel": "Other royalty income receivable" } } }, "localname": "IncreaseDecreaseInOtherRoyaltyIncomeReceivable", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_IndividualLicenseesConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Licensees Concentration Risk", "label": "Individual Licensees Concentration Risk [Member]", "terseLabel": "Individual Licensees Concentration List" } } }, "localname": "IndividualLicenseesConcentrationRiskMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_IntangibleRoyaltyAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Royalty Assets", "label": "Intangible Royalty Assets [Member]", "terseLabel": "Intangible Royalty Assets" } } }, "localname": "IntangibleRoyaltyAssetsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "rprx_InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)", "label": "Investment Income, Net, Reclassification Of Available For Sale Debt Securities Gain (Loss)", "negatedTerseLabel": "Interest income accretion" } } }, "localname": "InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LegacyInvestorsPartnershipsAndRPSFTMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Investors Partnerships and RPSFT", "label": "Legacy Investors Partnerships and RPSFT [Member]", "terseLabel": "Legacy Investors Partnerships and RPSFT" } } }, "localname": "LegacyInvestorsPartnershipsAndRPSFTMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "domainItemType" }, "rprx_LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust", "label": "Legacy Investors Partnerships and Royalty Pharma Select Finance Trust [Member]", "terseLabel": "RPSFT" } } }, "localname": "LegacyInvestorsPartnershipsAndRoyaltyPharmaSelectFinanceTrustMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_LegacyInvestorsPartnershipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Investors Partnerships", "label": "Legacy Investors Partnerships [Member]", "terseLabel": "Legacy Investors Partnerships" } } }, "localname": "LegacyInvestorsPartnershipsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails", "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_LongTermDebtMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, After Year Four", "label": "Long-Term Debt, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturityAfterYearFour", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermFundingCommitmentAmountOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long Term Funding Commitment, Amount Outstanding", "label": "Long Term Funding Commitment, Amount Outstanding", "terseLabel": "Funding commitment, outstanding" } } }, "localname": "LongTermFundingCommitmentAmountOutstanding", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermFundingPartnershipAdditionalPaymentsAggregateAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Additional Payments, Aggregate Amount", "label": "Long Term Funding Partnership, Additional Payments, Aggregate Amount", "terseLabel": "Long term funding partnership, aggregate amount" } } }, "localname": "LongTermFundingPartnershipAdditionalPaymentsAggregateAmount", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermFundingPartnershipAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Amount", "label": "Long Term Funding Partnership, Amount", "terseLabel": "Long term funding partnership, amount" } } }, "localname": "LongTermFundingPartnershipAmount", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermFundingPartnershipCovenantRequiredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Covenant, Required Amount", "label": "Long Term Funding Partnership, Covenant, Required Amount", "terseLabel": "Required amount to be drawn" } } }, "localname": "LongTermFundingPartnershipCovenantRequiredAmount", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermFundingPartnershipExpectedPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Expected Payment", "label": "Long Term Funding Partnership, Expected Payment", "terseLabel": "Long term funding partnership, expected payment" } } }, "localname": "LongTermFundingPartnershipExpectedPayment", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermFundingPartnershipInitialPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Initial Payment", "label": "Long Term Funding Partnership, Initial Payment", "terseLabel": "Long term funding partnership, initial payment" } } }, "localname": "LongTermFundingPartnershipInitialPayment", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple", "label": "Long Term Funding Partnership, Installment Repayments, Amount Drawn, Multiple", "terseLabel": "Installment repayments, percentage of amount drawn" } } }, "localname": "LongTermFundingPartnershipInstallmentRepaymentsAmountDrawnMultiple", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "pureItemType" }, "rprx_LongTermFundingPartnershipNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Number of Tranches", "label": "Long Term Funding Partnership, Number of Tranches", "terseLabel": "Long term funding partnership, number of tranches" } } }, "localname": "LongTermFundingPartnershipNumberOfTranches", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "rprx_LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Funding Partnership, Regulatory Milestone Payments, Aggregate Amount", "label": "Long Term Funding Partnership, Regulatory Milestone Payments, Aggregate Amount", "terseLabel": "Regulatory milestone payments" } } }, "localname": "LongTermFundingPartnershipRegulatoryMilestonePaymentsAggregateAmount", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermPurchaseCommitmentAmountOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Purchase Commitment, Amount Outstanding", "label": "Long Term Purchase Commitment, Amount Outstanding", "terseLabel": "Purchase commitment, amount outstanding" } } }, "localname": "LongTermPurchaseCommitmentAmountOutstanding", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals", "label": "Long Term Purchase Commitment, Funding Agreement With Biohaven Pharmaceuticals [Member]", "terseLabel": "Funding Agreement With Biohaven Pharmaceuticals" } } }, "localname": "LongTermPurchaseCommitmentFundingAgreementWithBiohavenPharmaceuticalsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "rprx_LongTermPurchaseCommitmentShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Purchase Commitment, Shares", "label": "Long Term Purchase Commitment, Shares", "terseLabel": "Shares to be purchased" } } }, "localname": "LongTermPurchaseCommitmentShares", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "rprx_MerckAssetPhaseIIClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merck Asset - Phase II Clinical Trial", "label": "Merck Asset - Phase II Clinical Trial [Member]", "terseLabel": "Merck Asset - Phase II Clinical Trial" } } }, "localname": "MerckAssetPhaseIIClinicalTrialMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "rprx_MilestoneAccelerationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Acceleration", "label": "Milestone Acceleration [Member]", "terseLabel": "Milestone Acceleration" } } }, "localname": "MilestoneAccelerationMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "rprx_MorphoSysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MorphoSys", "label": "MorphoSys [Member]", "terseLabel": "MorphoSys" } } }, "localname": "MorphoSysMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "rprx_NoncontrollingInterestIncreaseFromContributions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Increase from Contributions", "label": "Noncontrolling Interest, Increase from Contributions", "terseLabel": "Contributions" } } }, "localname": "NoncontrollingInterestIncreaseFromContributions", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_NumberOfClassesOfVotingStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Classes Of Voting Stock", "label": "Number Of Classes Of Voting Stock", "terseLabel": "Number of classes of stock" } } }, "localname": "NumberOfClassesOfVotingStock", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "rprx_NumberOfNoncontrollingInterests": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Noncontrolling Interests", "label": "Number of Noncontrolling Interests", "terseLabel": "Number of noncontrolling interests" } } }, "localname": "NumberOfNoncontrollingInterests", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "rprx_OnePointSevenFivePercentSeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Seven Five Percent Senior Notes Due 2027", "label": "One Point Seven Five Percent Senior Notes Due 2027 [Member]", "terseLabel": "One Point Seven Five Percent Senior Notes Due 2027" } } }, "localname": "OnePointSevenFivePercentSeniorNotesDue2027Member", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_OnePointTwoZeroPercentSeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Point Two Zero Percent Senior Notes Due 2025", "label": "One Point Two Zero Percent Senior Notes Due 2025 [Member]", "terseLabel": "One Point Two Zero Percent Senior Notes Due 2025" } } }, "localname": "OnePointTwoZeroPercentSeniorNotesDue2025Member", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_OperatingAndPersonnelPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating and Personnel Payments", "label": "Operating and Personnel Payments [Member]", "terseLabel": "Operating and Personnel Payments" } } }, "localname": "OperatingAndPersonnelPaymentsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_OtherCommitmentIncreaseDecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Commitment, Increase (Decrease)", "label": "Other Commitment, Increase (Decrease)", "terseLabel": "Increase in commitment" } } }, "localname": "OtherCommitmentIncreaseDecrease", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "rprx_OtherFinancialRoyaltyAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Financial Royalty Asset", "label": "Other Financial Royalty Asset [Member]", "terseLabel": "Other" } } }, "localname": "OtherFinancialRoyaltyAssetMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_OtherRoyaltyIncomeReceivableCurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Royalty Income Receivable, Current", "label": "Other Royalty Income Receivable, Current", "terseLabel": "Other royalty income receivable" } } }, "localname": "OtherRoyaltyIncomeReceivableCurrent", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rprx_OvernightBankFundingRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Overnight Bank Funding Rate", "label": "Overnight Bank Funding Rate [Member]", "terseLabel": "Overnight Bank Funding Rate" } } }, "localname": "OvernightBankFundingRateMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_PaymentOfDividendsToShareholders": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Of Dividends To Shareholders", "label": "Payment Of Dividends To Shareholders", "negatedTerseLabel": "Dividends to shareholders" } } }, "localname": "PaymentOfDividendsToShareholders", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForCollateralPostedOnDerivativeInstruments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Collateral Posted On Derivative Instruments", "label": "Payments For Collateral Posted On Derivative Instruments", "negatedTerseLabel": "Derivative collateral posted" } } }, "localname": "PaymentsForCollateralPostedOnDerivativeInstruments", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForMilestones": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Milestones", "label": "Payments For Milestones", "negatedTerseLabel": "Milestone payments" } } }, "localname": "PaymentsForMilestones", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForOngoingDevelopmentStageFunding": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Ongoing Development Stage Funding", "label": "Payments For Ongoing Development Stage Funding", "negatedTerseLabel": "Development-stage funding payments - ongoing" } } }, "localname": "PaymentsForOngoingDevelopmentStageFunding", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForOperatingCostsAndProfessionalServices": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Operating Costs and Professional Services", "label": "Payments For Operating Costs and Professional Services", "negatedTerseLabel": "Payments for operating and professional costs" } } }, "localname": "PaymentsForOperatingCostsAndProfessionalServices", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsForUpfrontDevelopmentStageFunding": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Upfront Development Stage Funding", "label": "Payments For Upfront Development Stage Funding", "negatedTerseLabel": "Development-stage funding payments - upfront and milestone" } } }, "localname": "PaymentsForUpfrontDevelopmentStageFunding", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireEquitySecuritiesFNNI": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Equity Securities, FN-NI", "label": "Payments To Acquire Equity Securities, FN-NI", "negatedTerseLabel": "Purchases of equity securities" } } }, "localname": "PaymentsToAcquireEquitySecuritiesFNNI", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Royalty Interest, Additional Milestone Payments", "label": "Payments To Acquire Royalty Interest, Additional Milestone Payments", "terseLabel": "Additional milestone payments" } } }, "localname": "PaymentsToAcquireRoyaltyInterestAdditionalMilestonePayments", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_PaymentsToNoncontrollingInterestsOther": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Noncontrolling Interests, Other", "label": "Payments To Noncontrolling Interests, Other", "negatedTerseLabel": "Distributions to non-controlling interests- other" } } }, "localname": "PaymentsToNoncontrollingInterestsOther", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_PointSevenFivePercentSeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Point Seven Five Percent Senior Notes Due 2023", "label": "Point Seven Five Percent Senior Notes Due 2023 [Member]", "terseLabel": "Point Seven Five Percent Senior Notes Due 2023" } } }, "localname": "PointSevenFivePercentSeniorNotesDue2023Member", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables", "label": "Proceeds From Cash Collections From Other Royalties Received On Financing Receivables", "terseLabel": "Other royalty cash collections" } } }, "localname": "ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Cash Collections From Royalties Received On Financing Receivables", "label": "Proceeds From Cash Collections From Royalties Received On Financing Receivables", "terseLabel": "Cash collections from financial royalty assets" } } }, "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Cash Collections From Royalties Received On Intangible Assets", "label": "Proceeds From Cash Collections From Royalties Received On Intangible Assets", "terseLabel": "Cash collections from intangible royalty assets" } } }, "localname": "ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromCollateralReceivedOnDerivativeInstruments": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Collateral Received On Derivative Instruments", "label": "Proceeds From Collateral Received On Derivative Instruments", "terseLabel": "Derivative collateral received" } } }, "localname": "ProceedsFromCollateralReceivedOnDerivativeInstruments", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromIssuanceOfEquitySecuritiesFNNI": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance Of Equity Securities, FN-NI", "label": "Proceeds From Issuance Of Equity Securities, FN-NI", "terseLabel": "Proceeds from equity securities" } } }, "localname": "ProceedsFromIssuanceOfEquitySecuritiesFNNI", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromNoncontrollingInterestsOther": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Noncontrolling Interests, Other", "label": "Proceeds From Noncontrolling Interests, Other", "terseLabel": "Contributions from non-controlling interests- other" } } }, "localname": "ProceedsFromNoncontrollingInterestsOther", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_ProceedsFromNoncontrollingInterestsResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Noncontrolling Interests, Research And Development", "label": "Proceeds From Noncontrolling Interests, Research And Development", "terseLabel": "Contributions from non-controlling interests- R&D" } } }, "localname": "ProceedsFromNoncontrollingInterestsResearchAndDevelopment", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "rprx_RPHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RP Holdings", "label": "RP Holdings [Member]", "terseLabel": "RP Holdings" } } }, "localname": "RPHoldingsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_RedeemableStockRedemptionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Stock, Redemption Price Per Share", "label": "Redeemable Stock, Redemption Price Per Share", "terseLabel": "Redeemable stock, redemption price (in euros per share)" } } }, "localname": "RedeemableStockRedemptionPricePerShare", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "rprx_RelatedPartyTransactionInitialTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Initial Term", "label": "Related Party Transaction, Initial Term", "terseLabel": "Initial term" } } }, "localname": "RelatedPartyTransactionInitialTerm", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "durationItemType" }, "rprx_RelatedPartyTransactionNumberOfPartnershipInterestsAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Number of Partnership Interests Acquired", "label": "Related Party Transaction, Number of Partnership Interests Acquired", "terseLabel": "Number of limited partnership interest acquired (in shares)" } } }, "localname": "RelatedPartyTransactionNumberOfPartnershipInterestsAcquired", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Amount", "label": "Related Party Transaction, Operating and Personal Payment Calculation, Amount", "terseLabel": "Amount calculated for operating and personal payment" } } }, "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationAmount", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rprx_RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Operating and Personal Payment Calculation, Percent", "label": "Related Party Transaction, Operating and Personal Payment Calculation, Percent", "terseLabel": "Percent calculated for operating and personal payment" } } }, "localname": "RelatedPartyTransactionOperatingAndPersonalPaymentCalculationPercent", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RelatedPartyTransactionRateAdjustedCashReceipts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Rate, Adjusted Cash Receipts", "label": "Related Party Transaction, Rate, Adjusted Cash Receipts", "terseLabel": "Quarterly payments to affiliates, percent of adjusted cash receipts (as a percent)" } } }, "localname": "RelatedPartyTransactionRateAdjustedCashReceipts", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RelatedPartyTransactionRateValueOfSecurityInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Rate, Value Of Security Investments", "label": "Related Party Transaction, Rate, Value Of Security Investments", "terseLabel": "Quarterly payments to affiliates, percent of security investment (as a percent)" } } }, "localname": "RelatedPartyTransactionRateValueOfSecurityInvestments", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rprx_RoyalPharmacySelectFinanceTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royal Pharmacy Select Finance Trust", "label": "Royal Pharmacy Select Finance Trust [Member]", "terseLabel": "RPSFT" } } }, "localname": "RoyalPharmacySelectFinanceTrustMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Distribution Payable to Legacy Investors Partnerships", "label": "Royalty Distribution Payable to Legacy Investors Partnerships [Member]", "terseLabel": "Royalty Distribution Payable to Legacy Investors Partnerships" } } }, "localname": "RoyaltyDistributionPayableToLegacyInvestorsPartnershipsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyDistributionPayableToRPSelectFinanceTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Distribution Payable to RP Select Finance Trust", "label": "Royalty Distribution Payable to RP Select Finance Trust [Member]", "terseLabel": "Royalty Distribution Payable to RP Select Finance Trust" } } }, "localname": "RoyaltyDistributionPayableToRPSelectFinanceTrustMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyIncomeOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Income, Other", "label": "Royalty Income, Other [Member]", "terseLabel": "Royalty Income, Other" } } }, "localname": "RoyaltyIncomeOtherMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Investments", "label": "Royalty Investments [Member]", "terseLabel": "Royalty Investments" } } }, "localname": "RoyaltyInvestmentsMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyPharmaCollectionTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Pharma Collection Trust", "label": "Royalty Pharma Collection Trust [Member]", "terseLabel": "RPCT" } } }, "localname": "RoyaltyPharmaCollectionTrustMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "rprx_RoyaltyPharmaInvestmentsOldRPIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Pharma Investments (Old RPI)", "label": "Royalty Pharma Investments (Old RPI) [Member]", "terseLabel": "Old RPI" } } }, "localname": "RoyaltyPharmaInvestmentsOldRPIMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_SeniorNotesDue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due 2031", "label": "Senior Notes Due 2031 [Member]", "terseLabel": "Senior Notes Due 2031" } } }, "localname": "SeniorNotesDue2031Member", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_SeniorNotesDue2051Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due 2051", "label": "Senior Notes Due 2051 [Member]", "terseLabel": "Senior Notes Due 2051" } } }, "localname": "SeniorNotesDue2051Member", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_SeniorUnsecuredRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Revolving Credit Facility", "label": "Senior Unsecured Revolving Credit Facility [Member]", "terseLabel": "Senior Unsecured Revolving Credit Facility" } } }, "localname": "SeniorUnsecuredRevolvingCreditFacilityMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "rprx_TheNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Notes", "label": "The Notes [Member]", "terseLabel": "The Notes" } } }, "localname": "TheNotesMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "domainItemType" }, "rprx_ThreePointFiveFivePercentSeniorNotesDue2050Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Five Five Percent Senior Notes Due 2050", "label": "Three Point Five Five Percent Senior Notes Due 2050 [Member]", "terseLabel": "Three Point Five Five Percent Senior Notes Due 2050" } } }, "localname": "ThreePointFiveFivePercentSeniorNotesDue2050Member", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_ThreePointThreeFiveZeroPercentDue2051Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Three Five Zero Percent Due 2051", "label": "Three Point Three Five Zero Percent Due 2051 [Member]", "terseLabel": "Three Point Three Five Zero Percent Due 2051" } } }, "localname": "ThreePointThreeFiveZeroPercentDue2051Member", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_ThreePointThreeZeroPercentSeniorNotesDue2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Three Zero Percent Senior Notes Due 2040", "label": "Three Point Three Zero Percent Senior Notes Due 2040 [Member]", "terseLabel": "Three Point Three Zero Percent Senior Notes Due 2040" } } }, "localname": "ThreePointThreeZeroPercentSeniorNotesDue2040Member", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_TremfyaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tremfya", "label": "Tremfya [Member]", "terseLabel": "Tremfya" } } }, "localname": "TremfyaMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_TwoPointOneFiveZeroPercentSeniorNotesDue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point One Five Zero Percent Senior Notes Due 2031", "label": "Two Point One Five Zero Percent Senior Notes Due 2031 [Member]", "terseLabel": "Two Point One Five Zero Percent Senior Notes Due 2031" } } }, "localname": "TwoPointOneFiveZeroPercentSeniorNotesDue2031Member", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_TwoPointTwoZeroPercentSeniorNotesDue2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Two Zero Percent Senior Notes Due 2030", "label": "Two Point Two Zero Percent Senior Notes Due 2030 [Member]", "terseLabel": "Two Point Two Zero Percent Senior Notes Due 2030" } } }, "localname": "TwoPointTwoZeroPercentSeniorNotesDue2030Member", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "rprx_TysabriMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tysabri", "label": "Tysabri [Member]", "terseLabel": "Tysabri" } } }, "localname": "TysabriMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "rprx_VertexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vertex", "label": "Vertex [Member]", "terseLabel": "Vertex" } } }, "localname": "VertexMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "rprx_XtandiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xtandi", "label": "Xtandi [Member]", "terseLabel": "Xtandi" } } }, "localname": "XtandiMember", "nsuri": "http://royaltypharma.com/20220630", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r358", "r498", "r499", "r502", "r630" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r49", "r51", "r115", "r116", "r294", "r333" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/EarningsperShareDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r203", "r348", "r350", "r610" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_ManagementMember": { "auth_ref": [ "r204", "r501" ], "lang": { "en-us": { "role": { "label": "Management [Member]", "terseLabel": "The Manager" } } }, "localname": "ManagementMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r203", "r348", "r350", "r610" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r201", "r271", "r272", "r348", "r349", "r542", "r608", "r609" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r201", "r271", "r272", "r348", "r349", "r542", "r608", "r609" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r50", "r51", "r115", "r116", "r294", "r333" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/EarningsperShareDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r52", "r53", "r54", "r58", "r67", "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]", "terseLabel": "Unrealized gain/(loss) on available for sale debt securities, Including noncontrolling interest" } } }, "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r56", "r57", "r58", "r594", "r618", "r622" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r25", "r507" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r119", "r120", "r121", "r387", "r388", "r389", "r434" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile consolidated net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "auth_ref": [ "r208", "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of Cumulative Allowance for Changes in Expected Cash Flows" } } }, "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r101", "r313", "r324", "r325", "r483" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r101", "r260", "r265" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r55", "r58", "r67", "r68", "r69", "r416" ], "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r16", "r112", "r189", "r193", "r199", "r232", "r277", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r409", "r417", "r460", "r505", "r507", "r562", "r592" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r31", "r112", "r232", "r277", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r409", "r417", "r460", "r505", "r507" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r220" ], "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r218", "r255" ], "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r214", "r219", "r255", "r567" ], "calculation": { "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r217", "r255" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 3.0, "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Available for sale debt securities", "verboseLabel": "Available for sale debt securities, current" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r13", "r217", "r255" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 2.0, "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Available for sale debt securities", "verboseLabel": "Available for sale debt securities, noncurrent" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of preparation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r456", "r457" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value, net" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r11", "r103" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 1.0, "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r97", "r103", "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r97", "r469" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Indirect Cash Flow" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlow" ], "xbrltype": "textBlockItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r21", "r22", "r23", "r110", "r112", "r140", "r145", "r157", "r160", "r162", "r170", "r171", "r172", "r232", "r277", "r282", "r283", "r284", "r288", "r289", "r330", "r331", "r334", "r335", "r337", "r460", "r638" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r41", "r572", "r598" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r268", "r269", "r270", "r273", "r629" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends declared and paid (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r119", "r120", "r434" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars/pounds per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r337" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares outstanding", "verboseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23", "r507" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r63", "r65", "r66", "r78", "r579", "r603" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to Royalty Pharma plc" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r63", "r65", "r77", "r407", "r421", "r578", "r602" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r179", "r180", "r203", "r458", "r459", "r628" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r179", "r180", "r203", "r458", "r459", "r623", "r628" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r179", "r180", "r203", "r458", "r459", "r623", "r628" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r175", "r589" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r179", "r180", "r203", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Individual licensees exceeding 10% or more of revenue (as a percent)", "verboseLabel": "Concentration risk (as a percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r179", "r180", "r203", "r458", "r459", "r628" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r108", "r411" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r80" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses/(income), net" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Credit Loss [Abstract]" } } }, "localname": "CreditLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CreditLossFinancialInstrumentTextBlock": { "auth_ref": [ "r241", "r248", "r249", "r251", "r252", "r256", "r257" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.", "label": "Credit Loss, Financial Instrument [Text Block]", "terseLabel": "Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets" } } }, "localname": "CreditLossFinancialInstrumentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r178", "r203" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r109", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r307", "r314", "r315", "r317", "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/Borrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r19", "r20", "r111", "r117", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r322", "r323", "r324", "r325", "r484", "r563", "r564", "r590" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percentage)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r20", "r318", "r564", "r590" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "totalLabel": "Total" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r290", "r322", "r323", "r482", "r484", "r485" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt issued, amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r38", "r321", "r482", "r484" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Weighted average effective interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r38", "r291" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, stated rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r39", "r111", "r117", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r322", "r323", "r324", "r325", "r484" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Prior to the applicable par call date" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "Upon occurrence of a change of control triggering event" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price (as a percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r39", "r111", "r117", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r322", "r323", "r324", "r325", "r338", "r341", "r342", "r343", "r481", "r482", "r484", "r485", "r588" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r303", "r481", "r485" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedTerseLabel": "Unamortized debt discount and issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r303", "r319", "r322", "r323", "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Unamortized discount and loan issuance costs on long-term debt" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Available for Sale Debt Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "negatedTerseLabel": "Unrealized gains on available for sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt Securities" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Weighted average coupon rate (as a percent)" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 4.0, "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative instrument, current" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 3.0, "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Derivative financial instruments" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r47", "r48", "r51", "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Forwards" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "terseLabel": "Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares" } } }, "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r344", "r585" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "negatedTerseLabel": "Dividends" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "verboseLabel": "Dividends declared and paid" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r32", "r114", "r280", "r282", "r283", "r287", "r288", "r289", "r499" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Distributions payable to non-controlling interests" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r40", "r114", "r280", "r282", "r283", "r287", "r288", "r289", "r499" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due to Related Parties, Noncurrent", "terseLabel": "Total distributions payable to non-controlling interests" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r79", "r128", "r129", "r130", "r131", "r132", "r137", "r140", "r160", "r161", "r162", "r166", "r167", "r435", "r436", "r580", "r604" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings per Class A ordinary share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Earnings per Class A ordinary share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r79", "r128", "r129", "r130", "r131", "r132", "r140", "r160", "r161", "r162", "r166", "r167", "r435", "r436", "r580", "r604" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Earnings per Class A ordinary share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r163", "r164", "r165", "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r67", "r68", "r69", "r119", "r120", "r121", "r124", "r133", "r135", "r169", "r237", "r337", "r344", "r387", "r388", "r389", "r397", "r398", "r434", "r470", "r471", "r472", "r473", "r474", "r476", "r495", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r74", "r96", "r101", "r599" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Distributions from equity method investees", "verboseLabel": "Distributions from equity method investees" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r12", "r190", "r229" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Non-Consolidated Affiliates" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliates" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "auth_ref": [ "r453" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 1.0, "parentTag": "rprx_AssetsFairValueDisclosureNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.", "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFVNINoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "terseLabel": "Losses on equity securities" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r228", "r605" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedLabel": "(Gains)/losses on equity securities", "negatedTerseLabel": "Losses/(gains) on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r224", "r591", "r624", "r625", "r626" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity Securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r305", "r322", "r323", "r455" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss": { "auth_ref": [ "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income from asset (liability) measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value, Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)", "terseLabel": "Gain (loss) on equity securities still held" } } }, "localname": "FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r438", "r439", "r450" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r442", "r450" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r442", "r450" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r438", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r305", "r322", "r323", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r439", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r305", "r322", "r323", "r438", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r438", "r439", "r440", "r441", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]" } } }, "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r305", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]", "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements and Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r305", "r351", "r352", "r357", "r359", "r439", "r514" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r305", "r322", "r323", "r351", "r352", "r357", "r359", "r439", "r515" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r305", "r322", "r323", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r439", "r516" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r443" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Unrealized (losses)/gains included in earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "terseLabel": "Unrealized gains included in other comprehensive losses" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "terseLabel": "Purchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "auth_ref": [ "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "terseLabel": "Settlement of forwards" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "terseLabel": "Transfer to Level 1" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r442" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r305", "r322", "r323", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r448", "r452" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalFundsPurchasedMember": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Short term borrowing where a bank borrows, at the federal funds rate, from another bank.", "label": "Federal Funds Purchased [Member]", "terseLabel": "Federal Funds Rate" } } }, "localname": "FederalFundsPurchasedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Financing Receivable [Member]", "terseLabel": "Current portion of Financial royalty assets" } } }, "localname": "FinanceReceivablesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r221", "r222", "r225", "r226", "r227", "r241", "r245", "r246", "r247", "r251", "r256", "r257", "r258", "r259", "r316", "r336", "r425", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r638", "r639", "r640", "r641", "r642", "r643", "r644" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "auth_ref": [ "r29", "r207", "r240", "r242", "r244", "r568", "r647", "r649", "r650" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, Allowance for Credit Loss", "negatedPeriodEndLabel": "Ending balance", "negatedPeriodStartLabel": "Beginning balance" } } }, "localname": "FinancingReceivableAllowanceForCreditLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesTextBlock": { "auth_ref": [ "r210", "r213" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financing receivable.", "label": "Financing Receivables [Text Block]", "terseLabel": "Financial Royalty Assets" } } }, "localname": "FinancingReceivablesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r14", "r264" ], "calculation": { "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r261", "r262", "r264", "r266", "r543", "r547" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r264", "r547" ], "calculation": { "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r261", "r263" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r264", "r543" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Value", "verboseLabel": "Intangible royalty assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forwards", "verboseLabel": "Forwards" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r423" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "(Gains)/losses on derivative financial instruments" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainOnDerivativeInstrumentsPretax": { "auth_ref": [ "r423" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain on Derivative Instruments, Pretax", "terseLabel": "Gains on derivative financial instrument" } } }, "localname": "GainOnDerivativeInstrumentsPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r73", "r189", "r192", "r195", "r198", "r200", "r560", "r575", "r582", "r606" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Consolidated net income before tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r74", "r101", "r187", "r229", "r574", "r599" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity in earnings of equity method investees", "verboseLabel": "Equity in income (loss) of non-consolidated affiliates" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r113", "r134", "r135", "r188", "r394", "r399", "r400", "r607" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r100" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r100" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Interest payable" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "Decrease/(increase) in operating assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Liabilities [Abstract]", "terseLabel": "Increase/(decrease) in operating liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r100" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedTerseLabel": "Other current assets and other assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r100" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": { "auth_ref": [ "r142", "r143", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r162" ], "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares", "terseLabel": "Class B ordinary shares exchangeable for Class A ordinary shares (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r141", "r142", "r144", "r162", "r360" ], "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Unvested RSUs (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Royalty Assets, Net" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r71", "r186", "r480", "r483", "r581" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r94", "r98", "r104" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r82", "r84" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "negatedLabel": "Interest income", "verboseLabel": "Investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r224", "r561", "r584", "r627", "r645" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Available for Sale Debt Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r112", "r194", "r232", "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r410", "r417", "r418", "r460", "r505", "r506" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r112", "r232", "r460", "r507", "r566", "r597" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r10", "r37", "r112", "r232", "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r410", "r417", "r418", "r460", "r505", "r506", "r507" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r20", "r564", "r590" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Outstanding borrowings" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r20", "r304", "r320", "r322", "r323", "r564", "r593" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Total debt carrying value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedNetLabel": "Less: Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "terseLabel": "Fair value of outstanding Notes" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r117", "r275", "r309" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r117", "r275", "r309" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r117", "r275", "r309" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r117", "r275", "r309" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r117" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r20" ], "calculation": { "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-Term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-Term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r39", "r276" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r46", "r112", "r232", "r277", "r282", "r283", "r284", "r288", "r289", "r460", "r565", "r596" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distributions" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Noncontrolling interest (percentage)" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails", "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership percentage (as a percent)" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInMinorityInterestRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]" } } }, "localname": "MovementInMinorityInterestRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r97", "r99", "r102" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r61", "r64", "r69", "r75", "r102", "r112", "r123", "r128", "r129", "r130", "r131", "r134", "r135", "r158", "r189", "r192", "r195", "r198", "r200", "r232", "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r436", "r460", "r576", "r600" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to Royalty Pharma plc" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r61", "r64", "r69", "r134", "r135", "r413", "r420" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://royaltypharma.com/role/EarningsperShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: net income attributable to non-controlling interest", "verboseLabel": "Net income attributable to non-controlling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r128", "r129", "r130", "r131", "r137", "r138", "r159", "r162", "r189", "r192", "r195", "r198", "r200" ], "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income attributable to Royalty Pharma plc - basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r139", "r146", "r147", "r148", "r149", "r159", "r162" ], "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income attributable to Royalty Pharma plc - diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r122", "r123", "r124", "r125", "r126", "r127", "r130", "r136", "r166", "r211", "r212", "r234", "r235", "r236", "r237", "r238", "r239", "r387", "r388", "r389", "r395", "r396", "r397", "r398", "r401", "r402", "r403", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r478", "r479", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r544", "r545", "r546", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r119", "r120", "r121", "r344", "r405" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-Controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other (income)/expenses, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r205", "r206", "r569" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Financial royalty assets" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Financial royalty assets, net" } } }, "localname": "NotesAndLoansReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableGross": { "auth_ref": [ "r24", "r209", "r240", "r246", "r250", "r253", "r254", "r646", "r647", "r648" ], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": { "order": 2.0, "parentTag": "rprx_FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "Financing Receivable, before Allowance for Credit Loss", "terseLabel": "Gross Carrying Value" } } }, "localname": "NotesReceivableGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r205", "r250" ], "calculation": { "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Total financial royalty assets, net", "totalLabel": "Net carrying value" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r189", "r192", "r195", "r198", "r200" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r6", "r422" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Purpose" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurpose" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r30", "r507" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r15" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Other commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r62", "r65", "r67", "r68", "r70", "r76", "r337", "r470", "r475", "r476", "r577", "r601" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income/(loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Changes in other comprehensive income/(loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r62", "r65", "r407", "r408", "r415" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income attributable to non-controlling interests" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r56", "r59", "r60", "r223" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "negatedTerseLabel": "Reclassification of unrealized gains on available for sale debt securities" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r52", "r56" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gains on available for sale debt securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other (income)/expense" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r571" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r102" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other non-operating expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r86", "r89", "r216" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedTerseLabel": "Purchases of available for sale debt securities", "verboseLabel": "Purchase of available for sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r90" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedTerseLabel": "Investments in equity method investees" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireFinanceReceivables": { "auth_ref": [ "r91" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith.", "label": "Payments to Acquire Finance Receivables", "negatedLabel": "Acquisitions of financial royalty assets" } } }, "localname": "PaymentsToAcquireFinanceReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r216" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r91" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedTerseLabel": "Acquisitions of other financial assets" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r92" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Distributions to non-controlling interests" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofEstimatedFairValuesBasedonLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares", "verboseLabel": "Debt securities" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "auth_ref": [ "r88", "r96" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "terseLabel": "Distributions from equity method investees" } } }, "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInterestReceived": { "auth_ref": [ "r93" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest received on loans and other debt instruments during the current period.", "label": "Proceeds from Interest Received", "terseLabel": "Interest received" } } }, "localname": "ProceedsFromInterestReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r86", "r87", "r216" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from available for sale debt securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r61", "r64", "r69", "r95", "r112", "r123", "r134", "r135", "r189", "r192", "r195", "r198", "r200", "r232", "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r407", "r412", "r414", "r420", "r421", "r436", "r460", "r582" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://royaltypharma.com/role/EarningsperShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Consolidated net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/EarningsperShareDetails", "http://royaltypharma.com/role/IndirectCashFlowDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanLossesExpensed": { "auth_ref": [ "r243", "r573" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable.", "label": "Financing Receivable, Credit Loss, Expense (Reversal)", "negatedTerseLabel": "Current period provision for credit losses, net" } } }, "localname": "ProvisionForLoanLossesExpensed", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CumulativeAllowanceandtheProvisionforChangesinExpectedCashFlowsfromFinancialRoyaltyAssetsScheduleofCumulativeAllowanceforChangesinExpectedCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForOtherCreditLosses": { "auth_ref": [ "r100", "r573" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions.", "label": "Provision for Other Credit Losses", "terseLabel": "Provision for changes in expected cash flows from financial royalty assets", "verboseLabel": "Provision for changes in expected cash flows from financial royalty assets" } } }, "localname": "ProvisionForOtherCreditLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r358", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r358", "r498", "r499", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related Party Transaction, Rate", "terseLabel": "Related party, rate (as a percent)" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "Operating and personnel payments incurred" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r358", "r498", "r502", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r496", "r497", "r499", "r503", "r504" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r391", "r541", "r631" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development funding expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "terseLabel": "Research & Development (\"R&D\") Funding Expense" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r344", "r507", "r595", "r617", "r622" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r119", "r120", "r121", "r124", "r133", "r135", "r237", "r387", "r388", "r389", "r397", "r398", "r434", "r613", "r615" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r72", "r112", "r184", "r185", "r191", "r196", "r197", "r201", "r202", "r203", "r232", "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r460", "r582" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.", "label": "Sale of Stock, Percentage of Ownership before Transaction", "terseLabel": "Exchange offering, ownership percentage" } } }, "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r179", "r203" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsSummaryofFinancialRoyaltyAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Summary of Financial Royalty Assets, Net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FinancialRoyaltyAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r39", "r117", "r322", "r324", "r338", "r341", "r342", "r343", "r481", "r482", "r485", "r588" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Borrowings" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r140", "r145", "r160", "r162", "r167" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r5", "r112", "r231", "r232", "r460" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/NonConsolidatedAffiliatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value Hierarchy" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r261", "r263", "r543" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetNarrativeDetails", "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetScheduleofIntangibleRoyaltyInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r261", "r263" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Royalty Interests" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IntangibleRoyaltyAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Repayments of Debt by Year" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r500", "r502" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of Related Party Transactions" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r392", "r393" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ResearchDevelopmentRDFundingExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r21", "r22", "r23", "r110", "r170", "r171", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Balance Of Non-controlling Interests" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt and Equity Securities, FV-NI [Line Items]", "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r21", "r22", "r337" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Debt Securities", "verboseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsSummaryofChangeinCarryingValueofLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r21", "r22", "r337" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r100" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Interest rate volatility (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-adjusted discount rate (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r347", "r390" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Shares, outstanding (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r107", "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r21", "r22", "r23", "r110", "r112", "r140", "r145", "r157", "r160", "r162", "r170", "r171", "r172", "r232", "r277", "r282", "r283", "r284", "r288", "r289", "r330", "r331", "r334", "r335", "r337", "r460", "r638" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical", "http://royaltypharma.com/role/Cover", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r44", "r67", "r68", "r69", "r119", "r120", "r121", "r124", "r133", "r135", "r169", "r237", "r337", "r344", "r387", "r388", "r389", "r397", "r398", "r434", "r470", "r471", "r472", "r473", "r474", "r476", "r495", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquityNarrativeDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r119", "r120", "r121", "r169", "r542" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r337", "r344" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation and related issuances of Class A ordinary shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r344", "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation and related issuances of Class A ordinary shares" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r68", "r112", "r119", "r120", "r121", "r124", "r133", "r232", "r237", "r344", "r387", "r388", "r389", "r397", "r398", "r405", "r406", "r419", "r434", "r460", "r470", "r471", "r476", "r495", "r614", "r615" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Shareholders' equity", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other exchanges" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/ShareholdersEquitySummaryofNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "terseLabel": "Other exchanges (in shares)" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r477", "r509" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r477", "r509" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r477", "r509" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r477", "r509" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails", "http://royaltypharma.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r508", "r510" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/OrganizationandPurposeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TradingSecuritiesDebt": { "auth_ref": [ "r8", "r18", "r214", "r215" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails": { "order": 2.0, "parentTag": "rprx_AssetsFairValueDisclosureCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Trading", "terseLabel": "Marketable securities" } } }, "localname": "TradingSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r221", "r222", "r225", "r226", "r227", "r316", "r336", "r425", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r638", "r639", "r640", "r641", "r642", "r643", "r644" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsNarrativeDetails", "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r43", "r345" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock", "verboseLabel": "Treasury Interests" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://royaltypharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r43", "r345", "r346" ], "calculation": { "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury interests" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/AvailableforSaleDebtSecuritiesNarrativeDetails", "http://royaltypharma.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/FairValueMeasurementsandFinancialInstrumentsScheduleofFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r101" ], "calculation": { "http://royaltypharma.com/role/IndirectCashFlowDetails": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedTerseLabel": "(Gains)/losses on derivative financial instruments" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/IndirectCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails", "http://royaltypharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://royaltypharma.com/role/BorrowingsScheduleofRepaymentsofDebtbyYearDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r173", "r174", "r176", "r177", "r181", "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/BorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r139", "r162" ], "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average Class A ordinary shares outstanding - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r137", "r162" ], "calculation": { "http://royaltypharma.com/role/EarningsperShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average Class A ordinary shares outstanding - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations", "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted average Class A ordinary shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://royaltypharma.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "https://asc.fasb.org/topic&trid=2134446" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2062-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2538-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2538-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2574-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2597-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2600-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "54", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2603-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196772" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196816" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r347": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r422": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498357-110258" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r504": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r510": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r561": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13(3)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r584": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r627": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r632": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "https://asc.fasb.org/subtopic&trid=2197926" }, "r633": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r634": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r635": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r636": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r637": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r638": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r639": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r640": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r641": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r642": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r643": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r644": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r645": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r646": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1404" }, "r647": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(1)" }, "r648": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(2)" }, "r649": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(3)" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r650": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1405" }, "r651": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" } }, "version": "2.1" } ZIP 77 0001802768-22-000035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001802768-22-000035-xbrl.zip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

=7_&H.6.U@^/.'R?]W%&\VVE&C!_:@G_>_# 8ICQD9\UZJ"HETN"D M6=EN6G/Q[GCP[F$#D-'@J)?.WOF&;'4'@/NA@L.7H! M42X5*^-/+GYP,AZ-L=]H1:/K\D;73Y.0+ZK !2--B)&ASTT&8IV+ M8)VB,FM4R(BHO/,;FR!ME_/9*G"+9M8LPV[FNKIM@\Z_[D29U>3)K.^_-)C, M'$A?7?ZCDT:P)X/AQ-$?CX>]<#)NTI(.!_N#?G,?P\%1O?W7N_6.*HO&!)E% M(=.;@DQLCBR34%@!IQEP8UB(%EG6146.(CC$!C*7\N5.H@$_DCJX),=@B[PI /0S[,K?@P2X/)DGR8+PE4>A]R8A_S<$#P61 ^ M^]M3\#'*"*F28RZ*9GN"%LP9+YA5V7$TV2>>/JTMD(-##LX=.C@1' ;E;1#. M@4P9G1"Y.-#9%B^TOX:#0QA9#"/3<9@JM\BBSHY2[1X&62%#4^JKXM!ZJ'#1 M;F-3=@.@0C ML^6A.=G=V0S-26;(O +78,@:S6,(J"D$LRP'A^!,<%X"G+GB3KI<)R+6 *!U M'JH5:_!UAAF5R7<)9W(/KTGHZ>B6]5;QD#,3@7L&P7#FG$J,1RMERL5;#DWU M0A"ZJ_WLA@=B]$UM8R6:$\V70'/M?,#"1=(I0901,8OZMRR+]M8!)YJO+LTG MNS*^WI'AN%?%8F ^^LQ YU@][LQ9X4G))$20TC85+*477?^-G OB.?G<1.E; MH[3CO#A9O6P=*Y,YHH[)%13H#C/K45^]$@6QLE5@(%9>:Z$O::5D%@XQ@_#&@8%D M,_"BG/6!0L,K3<@YQW7DZ*)&)G26#'CP#(M6+.:$403EM#$;FX)W@>NN,K-G M=I!+NVBAH9\G3WS],_7>;_ZG_KBXY2^N%7-C .>PV/Q/&/[\.>ONJA];6F\( M?M$=DRL^[(WKM\5O=Q! [:#G.790KAK " M89R;%=!^ROW1V:N)Z-C\<^GUL1][>%3;4O^AJ? U>K"P$-_1[_R6-=16OAN, M>LUC_7"8CW#<>Y]_^:>7QF\N,/K%I\Z?'_[Y(QCJC9^,+__(+7;49=TBFWN" MKZ7X\N>;X<7-O,/7F85AQK\K$.J]/L2C?_!TM/'S5TTZ[O4OKFUE_?+IIE_] M >XU#T"]XP?ZW7B!Y_Z*'YOY\#$.7]=[;^Q^>G[PY^[.UF']R_/#^L?> MH_W#YYV#QYWGM3V/?C_X<^?1L^>3S#[[2^?1T[]V#U_<7?O<#U+MI]U^Y=?@ MI%XTC;J=_"'F.AR\R]5TFC3V#A[746<\^G<+6O;M=OQU@=_%;_4'AJ3)J/>9 MGI-AMK;T"-^-\L.+%[]_HR@!_P, M0^?UTLZ_^?SM!Y.WIGR&\_?\ VTO?YL_$)=_]!N750^4LG35&[BJUFIEKKHZ MNIH'0E_^R;9=U?'E6^S-W*M^H/SRGZSF7LV5KGI>0W+*^Y5\XC_-3T:\F/KP M9N(S+V_1S/SJG#C1V4C0IK#(=E-%N+/5F0QF!\-ZXS@\[9QM1KNTWN1*M_77 M>]369V=M?993SL<3YV,]6[N32QX.ZVSY.\VK]CP<_'/V6JYF4[?JO39S;3SJ M/,%>8M43W\9WC>>^SJU^EL=8_S%U'N&P7^]ZO;LXQI/CDZ-)^&=2 [[S51'X M3N>L#/PZ2[ _Z+/MS['PSD4P?*W[_7"8<712AZ3[T=I!95;G;%WDJW;.]\Z$ MN(YW]D5I@Q^I4= ^];X_T*U7>[K>7^O>>G=2QDV,^ M#M575^([IW5\ZZ"LKQ?H?R05J75':"U63DF)5.]&ER A@ @V9%%RTM:;:)TT MYQM^A%2"RBG-I-$\>_ORM\=O]W8>_[V_\_KCP!5S*#);RZR-MCF4(S)OE6.*NX(Z"U2Y M.91#R:Z?4['M6EDL=YY.N%H)@_.-]$<3!E@= M5Z: 1U%[-0;R+=I@K!^GC54',2GERZ3B@8%#R9IS"I@M.EAI30@N;VP*"UTI M5L9BR;<@WV+96**BCRW"&)_&F T@T4I5)T;",U A,Y<<,*&-EK(I! GA\IJ/ M+<48.1Y7<3R*X2$FFYV4!H**+D1(P%V6(6>)_!J.!QGE(D8IIHT20N0V",." MPSH1L,ZQ$'QFBB-WH20 CG,/L6BI/9);06[%LJ%#(8L[()6<)I74RJ5<#//. M* 9% 4/K9'W*8@RQ"42E-/6-"I"*51E:B: QTTMUVM5F8:130CFEWDJ,0 /NLD$AKP#H)-&$21 MW,901^@[74@=9UC>L(9X:P-C5[$.7/&>"MT#(B $%$6"3K[4I][X?VMI]P1SI:(L^=3 M.)/@@ZL^-S.) X-B@7F.R)0M4))4R*7;V!2F"UX0RXAE;6CT0A5%E8@F25'J MXQT-HDQ<&Z6,BZ;H$(EE*\RRWA3+M,J\.0"!I1BK:^9<9,&)PHIO3AASPD)J MDHN[8$77:\(9X:P5C5ZDF+RL@S/4Z68V6H R&%)V4(=H!&M,<=\(G%$Q^=4! MV^D4V%0VX(01S->^9F JXES$AFY&B8!&Y,9)D]WJM"^ME#SQC'AV\\N9(68C MLP5E$4 +#*A5J%I@,28J>HY?@NAIF4=9&_VSAO?9E\I]V[K6?;\^3RR>:T>35R MQLY7V!=\\.9W\8WFZY'"I# I3 J3PJ0P*4P*D\*D,"E,"I/"I'"K X )G1$< M@G498H%@(.F2DTK9J2#2""S9Y<>G1C\-WPP\/YX?U=ONQJ>^<'P\' MQU_%,BC>M[1XW^FWCWUH5#YYOGSN]T347-.:T>370]&/PG]_%MU& @!0F MA4EA4I@4)H5)85*8%":%26%2F!0FA=NY0V-I*QH7N3/ MX;RO(AF7I37_?I873=&^947[FDC?S&H'9H,Y),ZT5)P!J,)0:V!*8A8I>5-\ MV=B47G<]R.OOTB"[)3*V0.%%R+BTM0XB8YO).+,.DD*2$8)GRB3)0$;#T!MD MANL -HCDO&\9&6][5T?JO;^CE9#WO93[:=3YZ5_?LN0G>3@I9#MET3X#%X&[ M8%4$[U,HUN8 64J;=);E.Q:]N_]XVJ2W!\?'@_YD.]>G>[OX\FT MW]_9A1?_>_EV_VW5Z>TCM7_X6K_<^?5X3[@/>SM_Z_W#1Q_VW^[6SSS]\$H9 M 3E;QY*3B4&0@7D,FHGB5*J8CR*KC4W^0+D9T^Z\R\/.]A&.1IVMSF!8+0>' MIYU).>;/5C\QC?N1-T"9&:0P*4P*D\*D,"E,"I/"I# I3 JW(WRGP1ME=++! M9,A">,.U-A)B$E)E^-YD?S9\]VF"WTSL*0:WQ!G_;-7B"%)@\L@R.,O 162A M&,%,#CIY%>M_F]HK1G>5N$X,CHR/\$8*D\*D\%JLL-$0?6-#].PR60Q69LZ9 MM%XQR*XP;PPRH4,$)VMW!6S9$'T/]@H=C-_D82=_B&^P_SK?L]U"BQV9&3F7 M=8+@T09L:M*ZZ+3Q(50*"6$B7Y@^LU4=)[WQ_/S+B49+HM%%*M.7AS9!"$8* MQ83SHLX72F9>\,(L-[4G%?CD9%-*6ZA9%%&Z31MV%B_!&J]<,GIBEF1SB]G< MZ8S-20XR)A^(HX8%YDSL!*PYQ2BD7T=? 2-H=F M\<#(+@=+S"/FK8_"BV0P<0]&Y4HS[4#GX+2.S:F@-DBI UYE:S:%1&]T&6+F M>&)3_6\C0;"0H'*MQ$HXI3U#Z9V+V@)/:F-3"HJ*MB(J>@OE$,B]N T[G*YN M ,I C(ZS9.M$"D3VS(EBF(@Q"3C*31./W^7^""<&B?W4&>8C'-J/1"?9C_=)! MN:2NP#T[O[0-"7R[M5=RVCD95NF>U%8,TMD:R.3GKTV/;G_1H42Q12AV.INY M!Q#K.,0+"U"0-9E#%6*B.NY>"&%-*BJ;C4V %ATYL/9F2+LD2&%2F!0FA4EA M4I@4)H7;K/#M9E%<:<;T7SPZR9=-F&CA8VFSJ9F\"N&4M$X%9D$Y!C(KAL@] M"S:4*(U*$NML2G0YUS2A(@B2PJ0P*4P*WQ>%[WQYC%RE.PL\SRR?\2(P)B$8 MYU 86(S,:6F8+&"%\-F')NV^;;[2/:AAL9_'G5X_#H[S_2I?0Z/ M>N_S^?]1I]JR^Q]X1AJ/F\->Z/ZUI=;2O;S^* *RR\K+K]WN#7>.]]J M^^=AO>_Z7?NO7SF5ZJ-0,@,,P$ GP9JS&IA7PKB$/(.+&YNF"ZV*RY,MW^"J M/]GR:MCR[K0MITKN+-&QI)H3"1 RPPR%R>)\S,X&:"IW0Q MA1=!Y:TM[!$J6X;*F96]9*.76@-3!B,#5)'YY'7U?(+1Q1@4-E>GI[(2KG-R M\A(M^3N+>JDW>G>$I\U]YF]O"J3?I-]<_#?7JB"SG3N4_(I'S3FE'1QW_CCI MYX[BW4XS#OS0YO;SYH?!,.4A.VO60U5M/PU.FF7HIC47[XX'[QXV6!@-CGKI M[)UOR':'0_!\W18[SM0'CC)*X71Q()((B6,64IL@ )3@KW:O6&A^V_T1*@\M2_=$T30QNYA;@->\'2XOSAJ!=E"XI6$;?SK M;]8YVI#$(B- @NJ)P0(='=7)JGSJR:Q1Q]+IM&/[Q'HP( ML&A00&99D)DM-#=9;8K5PGF+F7?2%PZP'O%S,P(LE6D6F M"9(T=V'WE"+#F$6,\6"Q,0[6.UC]"C>Q)H7#% [S$!QF96"R(@XSC4"I]3T& M]"/VN@5\E@2?N0*'5FI&I1"("($1-X0B1VT">RHWJ\62&V_')P:%X!2"\Y@$ M1\E$J8R14LLU;)F>:R>"4C8ED2*Y \$I,+(5(:^6MXX;[9'0@,M<8HERQ3*D M@E4PQYA@&8 >-H7"3:'G\Y$*1A>,+AC]X!CM94PA6$NMQ=PYK)F7G@47550X M85TP>G,QNJJ-=CE[PE(3-&<,>6(\XDD*I&%VD6?,4MBF0XQ@Q-,FY[))V-5F M?$'I@M(%I1_.S6&2DHPZ02/EABLG!*?."^QI8)X5)KW1*#V7V!\]2RYICAC% M G&B *6]B\@:HL&*(MA[M;5-6).H^7S@ M$%H@M$/[RS@V"1$E/>)<$]<&D+ M)J_57E!#N10%HC<:HN4OB>1+%-)P@6J?6"$!>FYH]A$CG4(*F;GAU37!#WUX3'A5<'K3<#K M_3F\IHI1PR+*W3(05TP#I;8"11I"DA8'YGAV?"AQEZH1!2O7"A@*5MZ%T4K+ MB$A@;!*?N)746HN=M4HY8X5*LC#:34;(N<(Z$>96*$,0,_"#6Z,1S#=!AEA* M=23&)EY5$X0-LTET<3ST.I5PJP_]=FI[QZW.2#[B;.Z1 MJN^KW_[M6RL,3O)TO, UT Q+S@R_>?CVB^JMF0D:OF=>**VN?!N_(%=_])K; MLA>,E;O>QUV%8!MSU\V1JWQ!Q-6?G+GK[8M%W<_W+W%7C:]^]^?OBCE=^5W% M"V96OP;S6/6M[CHLV#6Z8+C147PVV+IJTD<[$L[[T:+U(>%K1E*?YM+LQ MQ5XOAIL>#_2YU_TV6_)UHQYU!\::C0';;KRQK8#V.HV7]JPUL.U;U.*[19W# M39?/NSBP\,?0>&5['1CUTUX,WI^?GK?M )ZW*KC;N%1QM]&H:^X^91$<=#OH MY<29T1AY,Y[TO!_UHNV?P^;U/)ZV"^C6J!U;EYYS,8\CY"X\;BKC]&=21]=/ M>C=OB4_K>7=.N^>=P?-YWC*_3_MYR_P^[>M7LER5"\4QH=989PGC-E&3+-=C''P=_O;TXW#V&,7[\=O#Y[06,Z^3@Z*1]GWR\8>_F#L' M_;Q/_M[=XX>[_L?!YQUZL/N?]N%?KPB,D_[]^,: MQN_Q]_T?'\C^CU>?A-;2D("1%-$BSI1"VCF"G#%"!,*]$6YKFVG=)&P^A_%. MQY"/'@^R61$?BY7T9R,^-B2F8TEDFH_I6!DLE9I?CP!7%[-PI9,(7 N%HK$, M\40HTI%ZI%24 BL;O< 5_-='=84J0JWN VWB-R::())3%DNHS>@K5O;E.BF47)3-+9P MB\(M5@U+I1;7&L$8GH4QS%/$,A#$!"%@(L$K8Q-!*2BE+17$*7-U*:XUA;%" M/&Y#/&P@CLN0O%.)8]C/)#-*:V^D#C8Q>P?B491R&:4DLTI)8Y"<\(@ 1,B 1[I3;.95%@K,#8 MJ)FVHD0Q)Y2@&<2TB4F:!,O<)R]("(\)8X62W0G+Q"R695\.]4SDO'R!N \$ MZ40%PL$31AUFU,A6@NKF0DNX*7A@1N+@=-%3B,M<+;!<-:: M@3.O98P:\(NH7.,Y.H%<5!K!##/"8J LL:UMQIO,%"PK6+86#[U,,)!C22KF M$Z4Q!QJ#36H),UJ+X"V1KF#9!F/9Q0R6T>0MET0CJVAED[KL7XM(<\TDB92! M;;JU+9I8J29F);:QP-E://12=8.Q(R;ES=DGKB4VW&DG!/51<09FZ-5X5NH& M;PRP';R< 39!@Q%:6129R^E@V"+G;$0<^TA38IKRF)UMC,R??OYLU>""9P7/ M[IV>46]#5!)V9V=Y\LXJ@B7F5GM,F16ZT+,-1K%9SQGFTE#/, I8JIS4&I Q MVB$C..?)16#D=FO;-+4134TVP]I<.BD_5?^M9U+^8G6NZD9EU8$YN+H"PW5A M9PN>>3."RX9'\4LNO,53?*^!?47"1<)%PD7"1<)%PD7"1<)%PD7"3UW"MR_8 M7.:BK/8BX364\#)=P"3&7#NJF+.<\:2I99@Q%SDSQHCP:9=B2C#\#U4OKFP' MUCOK??]UL?]OK^-SR>CXNM<]O>3U*([!E3D&+Q:%$*%=&AAASGW'>5&J^*V)1SP* &ROA)0"0:6NT5LFYP+C6R1)%G!P MYP4 -P< YTY&$L8)6^:18A@ T F&3"[\F:C4W"1F:,!K"( W''[WU;_CO"MS_=QWY7PJ7K7*C;BR M+-1RY49<619JN7(CKBP+M5RY$5>6A5JNW(@K'[H^3FA]?:2HQJ^M$#NAW_CE M?ZYSB[R)O:IWV*Q[1 0LK(E<.\&CD-IC#R\MB]HZHO$-[I&]@]>S_I&7W=/3 M;J>JBS4>V^C+7]K^R1O;"F/W!B[NC9L3-X[V!OLSA?G@?NWX[W<7?_\5SASE M\F\8Z]]'.P+&_&7_KP_LX(]WGP_^V&/P'1>'?[UE!T>_?\[C.-C]&^[WX1/, M=_"4<"0,QSGO(R#GM4"48ZIL-%ICO;6-7[#Y_AF-L]AKO&S;?K^QT^CV0%EL M[Z)1-;V;>$TJ;5C*&;FQF50E5ZU(N$BX2+A(N$BX2+A(N$BX2+A(>$TDO)K8 MVHV=BZ4*_*\ZN'9L_6>KOT0[K-0=,.R)^>?1JQ\'1S"^MY^8X$Q@EY /UB'. MC$*.X8@B)KDIIJ8!YU(V3#?%@J:8MX]W*%"XH5!8)%PD7"2\AA)^U&C&LDG? MXR;]87:3%CA10T1 D6N%>$H8:9,LDLQ[$1PS5IHUVZ2?06&0P\%)[#7B=W]B M.\?QF94&N1)\JA.=_FS#:1]H")@%3C@7+CDCZ\3'IK&\!($UQ2Z]9 M)1Q #Q,+HNI[ M7!1N'1CXPDW01XVYXH1@I;@V$O['B ]Z.9M*Z;BWGBN, M8@@.<:\US@2NO M*'?(4L809YPAESQ'^?2 .N&EL6)K6W#=I'A=4>^9U[PK^+A&^,B254X3FHBA M7$1AB;4^44U]LHP;5?!QK?&Q.FJ]?,QJO'+<,8NDBQ%Q(@5RBCH4G0HL.)4B M2T +FQJ+-<7')ZF3CUK0KNCB@^CB_JPNZDA5)$!//,,)=-%+Y)@VB$D+-K@D MS#,);$60II3SAQ[%K_K8BJAM]$)Z+*7GW&-O!!;!2I6<-X"IMSGL* >+]Z-K M;V=UC6KNC,8,42L$XIPDI(,/2"81(DXJJ$!@W^/SNU[1L\:B^R+'A$@K0-]"0#S)@!S5 B4"<^I8E(3S=:Q5_="E,AY!$RMO/'*V M'_,CGI[%3M]6*FD[H=&+;3N -UK]_KGM>/C2;KJBPL'/!0=N;&CR.@0'[L&L MQ+![W@/1O8&GZ(;Z:*7Z^7N>T9=3$UIP;"D<>SL?%:BBPP0@"K'$0Z7@99%PD7"1<)'PQK"J^SE,*ZSJ\9S4\X=MG$3"5*)(&4D0 M!S*%-/$181>9YSHQZ^/Z\:K2/J%_9M>-[4&?W;[I6K'"IUW'Q<5 MJ^&>CH0?\Z"V M(-Q](=S< :QVUL4D/%*65\G&!#F8."2=BP00+K*/(F=?NMK')YT_?.7-NC&/WZ]\L1K"4'@+(;K;=ARCW*/U9Q1K\N(-_,> M*SK-K_!6K3?V?>CT(HSB1PR-8]OJ]!LYR?NK;;6M:\?,"1I]V/F!1+A!HQ_] M>:\U:#VWGB^% Q<)%PD7"1<)%PD7"1<)%PD7"1<)KXF$GWD$P%K-Q9.4\,.6 MQK[LGZ\\DR^G'9-[E5]R8K7_N]O.\OP#;/?LQC_LO!\;Z3N]5A_>FL[ .HB# MPW1DOQ=O_^J\_<>+2FI[*YWWTB'&A$/'?9ET4%@##9G+S(4622(6ZZ0,]XBPB0)$=Y+ M,M>S%DVA]1W:#!9-WI"^ND63-T23YU.4.3:$$X6LQ11QPC72WB44 .F%-"I2 M@T&361,60M'DPGJ>A(278CT/=098L'+-L'+N$% YQ1ALF,@) E@I*0/4I $I M(;$7!@?JPM8VU4VU(&;B4;"R5)HN5V[$E4^JTK1:N.G\;MNYKW###AK_.>_$ M!L/-1MXQ?BH+?_CXKML+L8?JQ_J5 4J$[GD^V\Y/,WIWT#W[-0-(O]MNA?J= M:\3VB)OU8KDMUW[81&:HQL$28[A(TJ;H@>!Z$01ECKI/>[=L]E#=_/!\T!_8 M3I95V5U7MKM^?C7?<#AZH9C) 3;1Y5))AB##A$6$XJ 33HDIO[7-J6IB+.]X:7 #E;Y]G M@;WI]BJB/QCT6NY\D .3CKH'W4X>1Z_;AN$?[\&( (L&!626!9G6#,A@ID-R MQ"'!=>YJ3CBR2FG@\SIX3;0(P660N1)?'L4;\#/!@RLB!BL\P"H2 :.VN%C@+KPF'6 UXN9N %UK.VEB4D% SY+@<_!R!GRD MT\$"O8'U1AGB@AOD@.\@#9C$8XJ:43<^6R@$IQ"<1R0XGFOKF%&.:,UIB%83 M$I/F(JIDB#!W(#@%1I:#D5D_#/%$N>0$8MQXQ'&0N:,F1H(Q2X6+R4:3B_(7 M^E+HRT/0EY5!17'!/ J^S+I@B&3.4:X13!]&/ %#L499E+!S7&FM,0M;VY(5 MAE(8RB,R%(N)!EU@43C,:$N8 P#3KG M:5MDI&%(,HU#$@GF3V]M,R&:E*C"80J'>0@.LS(P*2Z8=0*?PUD73%(N2"\X M8EX0Q"783M8&CGBP/'GO3?*TN&!617 *.!=P7@$X8X8UU3%HHB3G5FG#%7:" M&[ P/9/Q,<&YT,,[(O2L=TMCJC6S&F&"%>*Y=J&E3J-(+>:4).6I!7K8Y#EU MR(7@.(MH1+JU(".';<,ZT=IRI)[8!(8V-L@>A-ANBY M,A#"*D<8T&<))A/BG#FD8>:14+BA]7R)9ICH% M-E8H'%72T7-FL^/:6N*PC5H$9M75,-V'QX17!:\W :_?SN*UD9A()202.!#$ MHTR UR;7H_!42B&(9C([/J2\2]6>@I5K!0P%*^]TT!<$8S02;6WDQ$C-)0\J MNI>/60&&8+']+]?[YR3J[K8?6]EL$#R: MCNJ.O[8&\&W^^@GB'";H?8P-ZWWW%$9S ;)K=+H#^+Y!MS$XB?T(,&0!$ 8Q MGX!V0NSTZU>5T&W^W;!N>!?Z0*WSU7UPIB.%W"P[#/>OV6WE]_MJ+ M;3MH?8V_?6N%P/(1ZV $YX.K/_* $K]*OC2/25P6Q?3//-H* M$Y-BF'GI$G:>.T9U-(YKYYVTRA-F/C&^-?K026_T!&?V."+7B_8+L@D>\%?; M_F8O^EO_O"2'TU9G-"!%8<2S\KK]\FWEZ8?'?"'.!DNL^EM^[#%5YJI]N5*0 M=X[KS_=^/UGX=_O7^\Y]$_"5J_['4 GKKG<-/0_\<: MC/_ZT7X88>C50SVUO6/0U+RGU7I2;4 3_*MV/!AOVY[UXZ^C%[^-0E!:G>IK MJP_]-KS7$#3A=K,;7B67^NT)'KS -28,2Y<-OWGX]HOJK9GMNWY/RA=:TRO? MQB_(E>]==UL"@,'93]WV^O<$N_I+[S18<:O;WE >;L1@<.8OB\*/S-RE"\R] M>K4_C'4SJP.+K9O7W5XF%(WWK>^-?;CZI-]X!1M#&!>0NT01[RJDJ42AG\GX M63_Q@3U';U-=[\:G?58B(\LLJO4NS'B[9WYI^R>-U.Y^ZS=2KWO:Z)[%'C!K M8/79$OQ:U=C]=055&N?7QK)K["9AW^4>RP]RIK9),(6+E M'ABNE8D=U^M>V/;@HF'[_3B8ZR&YC$P>V1=Y.W'YZ D?R:=XNT=;PJ?( M58@T"I^TL)PKKG$4V A+"#:68E\5!Z>CXN#T:N=B[ZSW_=A=]!,,_''9>U\NOWO_C>/@_[]UT?V]]&K[P=_O$[C E_O\??]'V\)?-\G M[6S@@F D3<2(FYB0C30AP21G)"3C>:[QU22:-)G@=^T%?.]]I6[\RMD]I2#9 MDT2RE;4Y*$BVGDCV8P[)F-'<.8Z2H!%Q$BQR-'A$(C?"BT@RN^MZYCD6T'6=7!8(Z+$[N3PYKK8WGK&=:J(*NJT* MW<:U$*?0#2?#/0@3,9D\\#3%$% SA;Q02F@;M5-D:UL!25/S=4!^[OSU$0KW MW&CX/W>E?VQ:4Y3^'I5^CM(D;!-+6"" =(.XHPXYB2FBWAOIG3*>&5!ZT:1X MOH#AXRG]\W*D5?W/QJ3%S[";GZ(O:]B(;K/I2S5'Q4I[:$A[/\]CG)8I$ R M+0GP&,8PTB0H% @S(:7@:0!(8[2IR'Q6QL8[FXKV/P:/*=K_2-H_1VB,=9$E M&1&55@.A<3G"WV'$C*<,$Q8%S=YFWL0+^FP7!\W#J/%NJU_'>T^\,[&*"V^< MQL%)-S1:G:^Q/XBQ^&;NG=R,@O3KP/S]2OY[E?ASB.UNZVLKQ$[H'_8N35H! ML96!6&N>PB0KM=4$(Z$54!CB([(8C#2>*#<2*T-HW-JFJBD6M!@OKIBGHN,K M;Z1==/S1='S^,$GP:+F*2 !?05RXA'3.)&?4>PHDA=LBH],6URC:1@95@695H9,"P)V,#>1*2V1X4XASH4%9-(> ML2@#B?"&\R&7_*0+,J6+_^2I*/3*R4=1Z =2Z 5Q*T)Z+212B8 1H4A$&O@% M AM#"46L9ECGT@>,K9-"/S.7"'SJ:Y6=6IWM6-"/'")]%]KQ'$RD>SSC&<_" MQ)T[F:2]#AA*YU42\KIWA]@(V#I<$)#BI?$Z8(VX=!)@2P6DF;*(PE0;JX0U MSE_='**X09Z*CM_C2<[/Z7CA)W=2]#E^$G4P(A()FBTM:#OGN8J>1\8X3AQ5 MDEFWM4U(DZL2A+)>!.6LVQ\4K\A#T1-[4:'1ZVYO@EQOJADHW.0>(6M!D EF MD28>,"+4Y@+-FB*M/454 2D))&B'^<"7%KVS09GRV^LZK"6 M_-0LO<^3]/I\?C7!Y%KY^;7^<6E.3\+/7@3@W;"0T80NP/@,(]+Z_/ M6A"4#_4\%""[=R#;FRC*7F9)V"G$]Y, MS0)G41OM^!GG-IW9UC.+X'D4TC3*@QC)_0V(_2!N1ENS#8'-#_.T M2%.L"><>J< )X@2XD3,NH4B(\58Z0?.IDI9-K8O/YFEJ\,HSF8H&WZ<&SQ(? M2U505D8$BLR ^/"$3()7$5NJ*7,"*[RU+7E3K(O7]1ET (%E7Q>B.^MU<_6 MT' 7"]N W,4;\7'_HQ['7&5MW.>+8* ME*T.RC[.DQ'IF:?,R^RCH4!&=$16 C?Q1&EE36+8QZJ .!--2N>3,>^EP>KM M-MP[-5B]OT[7#^U >J:0M'(*52#ID2!IEEW)1#7C,&\L&85XB P9@@-*T7FI ME'745MU9L%!-L*4*)-V*^HU&,6[16_?:7+%EM^GW> 8\>;937EW8<(6=\M:E M&5[I=W??52TWUE>S+E6DEJM^]RX.SGN=P_32GN5^T24$9R4,Y,N\440=#T1A MA9P/#'$<'+)4&\2CCI$H(YUDZQB"4_RT:QI;=P^Z7W1\.1V?M3*XX-PP8G,E M?HZX9 E9:PW"T4;*J!#4B*UM0>]Y22:":\=T8BY!'9'"A0T&VM$B0O"XFB8!DY" M5)/3^7Z'ZQA0]\3<*6_.>_[$]N%^W33B(_WHSWL_?ZZ\L6;4XT?YSX#5^_%$ MO#XXV"M(M3JD6E 9P=@89>YC1H.AB(M@D&5POJ'E"+L=.,H*@H&$I$ M$*0QH4A2(JT4T@2'2QWNIZ_9]U>'>QG-+M;%'=5[EHXP+6WP.>2+1: C2>7R MEL8AZX-EWF,BM,IE34R3R7E'2"F__0C>$/O5MMJYF7!5$*$/ZQ_TS V*>V0M M#FIV1K/SNMM[#W,S0;-=F*2"9JM#LP5E$"*C-$FMD63!(FY(0#JDB(CVB8O$ M.$EN:UN9)L!:\94\20V__P.;HN$/J.&S?,58427^(6T,1IQ*C6P2''E@*QA@ M/(E<>I^))EG0+623\P$WA:E<X$ M#QP,+Q]4IBJ2(22IJ?J]QKT7-'US-9_E* M] #B,1I$0:MSG(E&QJF$N%9,"^6(C^NHYL_8O7)J>U_BH"(MQ:.R#AZ5_?&$ M3)"KH-;J4&M!W21)K?9E9Q MI&R<(Z4H]KTK]BP=2F:1),] M9_])]ICTZ[X;=C#4D-5RE.=@8]V[*V6G$_;K^;DX3 75[A?5%E164E$*ZW-A M7)\DH!JC2$LF$*981Z*-)8+G!$/1!(Q;(RNK.%,VS)E2%/UA%7TN:T>QH(VT M2&,;L[839+FP*'*)<:":A*1S/5?=E'K>+EE;=THIAOVX$%/9(_U67;H%Z%5J M=6S'MVR[T>M>V/;@HF'[_?B3S46>A;%X_UZ@U]6(M<<+ M.K)*&V6@&.D@&.+,<&1CQ-49([4)&-M0'7BXH1I9DU 9 ;&N;DB8E=W%9%[_.,_+K+*?2)9_PY[7Y8D:;=31<); H8J(6 M<6XE1_W@7]>OH]'K[CRNML;ST%!H]5S MBU%VL[(*;!V'@DX*<>DHTD)AI*+B03&/!5]==G/Q=*ROU7!OW5.OTN)B)JR* M6(P<&Y@3)R1HL3 :<:4]LB$2I'VPR5KNN,CM=713EDYA#]\I[+P?P1_%R].%YX=4MF_/LC2:N-.>Y!T#[L:#XK&5&:.\ RT(RB.M$D,&!(FD) MIL)A'JOF/*:)R0IZNI=F74\$&5; 9 HRK! 66<;9HU//DJ3;-*I-CCNQ0N=_D: M=!L@"I2WWUZWWCU2DH----(>]RQOIP7I G<':TT6Z; ME]ET&+MMJK/-:QPW[_ZO/3W[;?=YN6[6HM/8%5;>N]B/MN=/=CIA-WZ-[>Y9 MAN<"M$L![8(Z Y$IS:AR"$RXJD(N1YJ#9<>=Q=$KKE1.[U-L/AFY%&YZ*LI\ M?\W%EE3F0JE6J.ESE,H(*IE.B 3G$)%@(RB.B!-B% GXXZ362U$<)7$80);>V M69/R.U>:++Z>M57M!RG#+@,N RX#/CI9[K,)4C1Q)05R M]5SM8-?/FV$:)*D8EL@$'A"/EB)-.% WSXB+@C& EFRHY]N M=G2!AON&AEDS3G 7N P28<5R(1AFD%$^(1\Y@2W!4X490(,@3:Q74##R0;*C M[^I]7@\:M-CM4M&@$]LYCID#580H=SRJ7L3_/6]]!74H!>@>,)\RPUC^_ZN) M\-_%G'+B!S'D-W8ZX?(?IJY\ X_;!=SSO6C[<3?6_\+O[?,\!:^^UU/]S@[B MJY2B+X=N*T3#!(R^00=Y0@8SBM"MX%IU7P!F]M"RF;YNXM4XK' M>FU18N4YF@4E-A@EYES?406*34(X:(LX["!(8TF1-XP[S033/N1H1]:4^,Z! M..N7^+G.].CE582HV7#QN-7I9']1-S7.*I4J\8)7X)]P/DH:%6<*6)(@UEG! M'#RY35)ZYC_M9=@CE)%[A+V"8JM#L05G\YY8KA2.B"4+EI_U"MEH'=*,"YN$ MYM8:0+&FX&#[\?D\L1)0^%2TG7H;HI),$F=Y\LXJ8#286^TQ95;H2MMQT?9- MTO99S@+4-5HK!:(N6S8R:J2=<@BL7N?RQ .]S=J.<6X'^01#"M>#M5Q3Q6TQ M:XGPUROYRDTB&'K;ZD?[E<$$A.YY[H-=>=SNX-5>-P'^SZ-(9DWP?[%(EL!_ M:1D1B6!/?.)64FLM=M8JY8P5*LD*_^_;%5;P?V7X?[2@/K(4DF)M(X)=("(> M>4361(><$X2+1+G0:FN;-@G@/V;ST9@C!7L$)O-S!O,J-/R1W7$%W@N\KP#> M<1",T4@T:#XG1FHN>5"1X\2T,@[7QGR!]TV"][DR= I33TA >5[!F \8.2(9 M2E((R[& _3SW'VX23IM4SSLE"[PO:Y'\ M=T]A-!?9>=KI#F)5MV9P$OL1<,>>AQ;H>\:<$#O]^E4E<9O_/.G%VA_ 'ZKB M4"_F!5&I?5(,,R]=PLYSQZB.QG'MO)-6><+,)Z:VICYT*]$.GT9P$,!9MVX5 M^VLOMNV@]37^]JT5!B%L7TS]L+ M.C?R&G[H9%QM_LP>1^1ZT7Y!-L$#_FK;W^Q%?^N?E]<_+/[A@!2%$:^/O.9V MTDI>[PX_[OQY]+'QYM\[[_9W&F_^?+D.:GKMD \.CUZ];QP=-H[^_:KQ\O!@ M]]7!^U>[^=7[PS_W=G>.X)?7>P<[!R_W=OYLO#^"/^R_.CAZO_8/]LN'@YT/ MNWLP_G_,C?76(]KI =K<91SU=@#[#]A-[^:JM[<9F_G>%-!=AY_(" M7^D2("\:0VY[<'X*M_ KB-^YS&,/>\>VT_I13>W+\58%OP!_?=.#3:TSJ'X] M3*]'>]?[\=:UV^K[=K=_WHM',*;?VUW_Y7$Y*]X?<5;@I?M'H75PM/_CX,<' M=K +_/.H#3SSOU\ (8!+>K;_QW]._][=P< _V_'?[R[^_BN<./WP_H M'MG_L<\.CCP&_GER^-?KUM]_O<7[1YG7>AC'WU_V=]^E@]T]?/#V$Z4RZ$0C M2M0:Q"DVR#EG$4E,R&B4,"+6ADBKJ:8K2)&=2]L>W#1>'-BP4QKG+5]H]4'F3=>=8[;K?Y)XPS8-2ACNW4Z9'L5(VRT M.H"29QDHX8\53F9BV&C;;_WLM\Z?SA.7__\7F'C '$_LH/'-]ALYBJ4BB-WZ M(V?#N85/30AD=5Q_WFN<]2+@<>SWX6*051497-TT6=]JMP;UE?DV+3"$,]L< MCK>;$@@$WOLE]R6E^+>]-X?5*_+;/_)7Y9N_;-M^O['3 *,!%+YW49=D[+]H M##]R63;-X<>K;QM>\;*6QOBMX9^_Q=F_G/='?\B#'_X1QC#Z:R^F+,%N8\%\ MY$^T!OU&_]SU6Z%E>UD&63$N$VYG^ZU%#/NF%7<;$V4=5NI?8)#TXG"5]8YC M?]!PYQ<@-9A-U^J>50+S\;RRWQJ]2HZCU6(;[6BS_==(]5J%S[0ZG>[7(<3X M7K??KVX]?R=X=D"0WL6+!HP@?WSZDZW.#9]J@$5QT@BM7O2#]D4]EYW1K\.6 MN>-WOYW$3N-;;B?=&W1@E-]:\-E:XUJU\>6[J!H"F#$13#H@Y@T/HJJ^+#9\ECC,&2L4KYT/H#M;"*IYLSHQL.Q=?MW^'2K M[DHY$6Y5^R)+H OV,RA1>R2<;N^)K\5A_OFLPOZ[V\[KK-_XC,'GW9OQ M&R,0 FG#%+5 5/'NX)I??7CQ_UXT!O8[8$D_ET(<-.%#O>[Y\4D%=MUOL*+Z M)ZVS?(>9\1#UVU5@6-WZRLM_G[O\ERETG/K8^/IQKOY(#B\:1_")E_5>FA=7 MW2D/UD_C3:T&>=!PXQ 3S /@7&QWO_VC<6*_PLJ\LNY*7NW3WS\2!0RO=;4P MYH=9:7UV<615RG)TYWT81G]RQ^F/+X+J%_,D_,GHP?2SMVH A0TIUO*M9'M9 M.^JYK0AU \BZ:>R]W/GOE);L3?XZT9-O)RU_,F0E>[W,2>#QVC%G"L$*Z/?C MH $/ E"8[UNSA(O*ZPR+!2!SS!1B-7^CJ-G&868(C:,>/'[M#)U;8T- '#[7 MN1_RD/E=>NJQFI-19M<\@#)L ^,G/&QG9=J;K/T9 8ZA%[YF"HBS.&%0%_FS MC0_OQXI12:O9^/--!I/="/B0=\@1FIQ-U*=9?;):U)UJXP*@'G_O]$U>VHO3 M_ #]##!]0/QX>I;OM>">H.K=XY@K;C0O4Z(;-'G,PBIDF:,[+QIO>JU:ROFN MUTQ7LS$49T4KQS+Z"EK7/>]/#_4R+/T9CZV_N&%T+Q;8SD]);??'&@-3_^?+ M2P*JW^M-[U1SBZO=LBZKU<5HTVKF]0N0>08ST\H.^4PQLL*=3GU3:Q2[7KT3 M[ 4:=!'\T^B>Q=KG K,*!D'_W((JPQ*PX6L+=*XF3E-:;H][L3;,&[],T*!] M<6DI3IZQL3.Z?CR_*YO=A_?8+W:@7 =L2[B!UG&]UEMP__STM&)$=HK(5G9> MMH9>1]<[ST2$D&8CQRW.8']>%V #9KHQ9@(SMVD.&Z]G3*@WG5X\JQU#\*U7 MGKQVSD]=+CMTR5_EB0B!4<*-DYQ2[5C$6%+!F<(F^3J3!.=@:C1Z,7T*2V>= M5^^!YQVF]X.N__(F]K*S%I;V83H<$9G?(^A;G)KT\=DJHL_,4;7_^9@<['Q2 MC&F='$':))HS7.$53QYYX[6W+(:@X]:VGJ\S_W\R<&Z"^M?U3W MA77NSWN]#*NMX2L?:XLZ1 ?#JNAQ;;: [N3-O!_ANFS@P \@14.U'%GGO[2& M=V[U,_#7-\OGM4.F9\,.-?E%/L+--\O[ M5V MI5R\G&=<-2^'5C=,]#(+].719<=O+Y[:5I6=N]SRX5+F>E98 6G@)F6ZX2$TMJIX*-6 M>&N;S1>!K1<3+(3L,!I[[6ZV>Q:X"]_'O 1_"BC?3X!RRL-<(_*4OW71]RUT M\;Z8)_$K="#>,GB/;2T3"O'0$3[TWB-\WL-#ME++V\Y@Q_ON>9Z,XS?==LO# MIKHV<3L78WV]J.+"3_=^'/[QGY.#'V_)_N=C?OC7N\^@KUD7OQ_\M7W=RW'A%_ ]Y1 X7U&;W57(T M4#4;M_,^>^A V4#!IZ:B,9F+QF@R;@SD63):Y^:17GZRZ"(.GGGKJ>46MD6" M+?:8:B$; "@B0)!#8EJ8C6 MLZK'A1#)81M#<%RE8 -F+GEFM6=@]OM94,DL\5(FPD^E'E1&^%FE(W49X7S+ M7JAX0^7=M!.0 BL'/GZ6 RN.(_"/RG"']V-U%#KTKG[H5$.H(D0K!=RIEI\= M3+CN]8!W+P[ 9YGOKGK4Z^5.PL4T' M<,!6V+ A\\1Z5\W[;@O65/"F,_ET\Z_8&5:P"7-X@&+UM]$^Z MY^T<;P9/8ZL/P3@^GW=J%UA%3*J3Z GAN8GF=,)0VNWJHF':Y@E,47U.F8\Z M.Y/H^XMH>)A^>['1@-;47/,G_NS__Q_VR>S"3 M#M/82'J&+/YP!UB\-@DDAIQ1'O$D";)8>(3!H*9&*:'BG*F_EIB7386S*3L8 MUOK/&0NU'F:MSA%NE1IFO0>MJJ(#^M.A:*!6I_9+!/D,%U&=<=#OGY^>U6J+K2JT#G4SJT^&E]-LI#JY'^8-Y+R?L=Q&!P+UQ2. FMTGLAT'H#;>;F 554?^ MOC)K\H!G[Y#.X0$SSCW12&Q")QD)F;94*[(+YNE(@F YP\H;IVJ\//SOWBXB MI@'###&?F7=K=!\'80XWV,F*F8JC@5GJ5NNJV?##G?;4]K[$08Y'KK936"ZG M=_N-UB< MPSCD^<<[@=6=E\R)S9E >:UE@]"$#0?X-1AJZU>U< M;+?@:QNM01WZ:OL@.0?+L=WZ$ML5#1KZ"NI,FQ?S-O^T0^ )A*".G9&7TFN7 M\^W>XUY_:53%?W?P]E/DC%HB,)*<4,2C3,CI$)%PQD9O6"">SMI#,@D>1(I: M$\MC!)*01"XDYTDP\,-M#%/X66I04>*:EM<^P_Z"X_&* \"^VKCHNIW/Y6K#$LO=N85Q.MN2&HZBB M"'O9:1+&9&$]"O+D!C U%0-R5WR'.AJECLV++P=0Y M7^]IDD11D\2:I%^]9,:.@]$,9$H_1(HYCG(JLGS,K M^-?&+^0?-X> C')/+V5OVC-@D]\K"P)@9;D@(F:3<3BF" R"Y\KG(L!V9IWF MAEB%W2B(B)HG'T3TP/QC__,7=KCS*7I)0A .,>T]X@I+9%T0B'E%KR MD5\>-4YB>YC(^?[U49W\P/]116F^>K,SOG?.QASOAZ/SQ.D+)I4LKAGAY53M MES.IVC=D:K]LO >AOZU@*N4AM"F>IT_0@WID?:R&>J[;&I MF'>#821J'L-I',PE6J[0+EHG +[&*7\CH][>:0^S8$85 @;3V7UY&3G;SD1I MVG"..4JW8X=GUG[:^+F5MW8C3$Y0^0RQ(_:0;<\ZQ^A=J_]EP],>[]\Y-,$:D:B8M8;'I<5 )_OPIYH"5U82<*?/V:8ZKU/8I@+H_-PB M'R;2]6"NQD=DM1G8JL_)KNP0V1RZZRKJ5>7E#-PVP"Y"%,)V]7969&)1. 8F9/3)U3 MT)]^XY*$NE/OH..>#=/#FYR4=2L99GH_.H7L99>D/P#1O1Q/7 M7KU-US'64OS==KY,Q1[58QNY X9CKAJE#_T4EVWP^-W' M.C.U\1J>M <"VHU5V ]L\?WS7N6N?3FL1)-WJWJ*7BQ7A>WI[=HHP^-2E]4,'&,*-L"!L3#WJW]CWWJP)! MU4E8CO^H(NCFRU6-/?*+HMN:C5?G/5A-4X?+_7%*YK=NKQV:HU)5U^'4*&DH MU$<45=VL7M?"PP_3CZ<.$F8+29S9B\N%I^ &YY/CL>PNB[6HCV,7T.'L9%R= MJK8Z*Q?_M&Q&Y;%J^61UKW LAOH8:EH@XR.*$R"UTY7%,H.MAUR1^E&-L7'M MK\JCX%NP<#-.CHM?-//Q6JZ!D1UE\,9_@1S'[\W&[ZWN<>PT&SO._;<5FXW_ M=$^ LW4:_]>>GOTV^JW9V <:^&7XQY?=%\W&FP1+N@>?ZX,-#.R]V3CH?LU? M/2SI]4X+L[KJCR^P^(04Z[#&_:^29&5Z>J.^53_:RODO>\6:+/@=+5$5-^5 M_^@245TBJA__P4I$]3W]MYJ(ZALCI.>2[P3F6@4%H,.MIS2J&R8LRJT..^F_=%NFBVGRLU1U\H9V72MWL@:@X\E, FF(KFR;6._ MUH%U.;0/K"D8@#CH,%\2#L,&QR'65W: M_^?/6C?"Z7QC4*2U M*7]]"/JM8MJ7CU-?)C7VEGGZ#W2_?/WM\(^/VRQ<^EP(!>C;.1Y:TQFZ2Z].7Y; M-B%D'HQN?J#+ DB:)1>YA25/> +08K"6O9#1:F:\))M0 *"*Z7EY,>A^@;\. M>] M*KPQ *UI=\^J>^Y<83,FIGD_T6IS%?#'+.+WJN MU:X2RC+]&R=KS#Y ];S5;Z$^V>I^;87)P=:BX5^]&J8;H9R?Y?O]SQ)]19T@ M*5E&5*2.4PF*)S#5DH=D85.8V@ 4&KVXU&!4CK:#WEGO^Z]_PJ0=P9P-AS85 MK;-3Y:#?M\_.F:YNE>PCDI*$>8F(HXM; /*,61A M8D+D.(;,.QC&V7';WQ2>8 $P\B4C*(!"/ M5"$GA$!)2"$ =U-P;&L[M;[&N172&$[R]"E6KH(U:KHT?#NODW5$DKUZF&_J M"L %418OD6/\R0DJE&&Y2'8D"(PZC734$1$N>& ,"Z/-UK:X 4(FO;ZJ;DO# MM(-,UF%:&8]+.P<>O;;,+_QQ>6/5%E+" D#27@# F%PDVQ/KHO!& D(2* M&];LT'PM /=D5LLE2_/'*[+_=F4 E\,5JSUQ*O9XTNWP=JZ,Z6C"*N^^==+M M#BL/+$#**4"<3E_)N[>[F#LMH"\:KRQ\U\B\R9M[9?74&3$H908[#$FIXI*K M/]25*JK$TM;W1EXUG6![C?^M"P'E4.INN]W]5L<,,CY_17V UA_8=KM"\5Y$ MX^8E@VYV#"Y=+ON.2G9[[7_@G M)6U02E'D&0,[2Z6 +.@-4MA:QF."B="Y);I98(E7?M4J[[J2:L4O.T^TM,GH M>+VJNSTT W-)L49.89\FV<,CP_$1X.W HSE,]8YU?#U Q7KE?._,IV3D#DM3 M206/G>$][ >U*,-[F.[0Z)_$*DT$L+,U+ 5@,Z&M$W9[,>6YK5=TQPZ&%8XN M^#7[H2\DM%^MW=VTGU_T0<=FKA&1BOT=Y#< M?''\S6)(^7@\0RT=)>MDSWFG XRH"N*;\ISW&O4-[$.;Q\5 *N2D:H_O+F4;%8?O;\8VFCMJE!/-S\!T $B MAF%:MSD0K].RLDTV/"5HW>YD(8\=IBX.@6MTB#7ZBG%(Y/QQ^T0VRQ^;&TQM M8BH10@-73ABPH),C0JO A.!UPZN;W!NYZY)U50#RU[@S(4;OJLI,.YUPZ$ ' M:R4?NCD.T\LZ2*#X-Q9[PXY_'!Q_,BYHGP_.(TD1<4DUTC1I1)CV4KO<9B^? MGM]X1E"E7@]C,J8*;%R)/-/ZY&)MS&6_P/O<;*#:[PD=^2(FJV_1296MJXZ< MGRY["LL4AQTMF42YYUHPZV12C!NO@P [-"[G@%MFA>[;[WG $Y)PU,W"*0MU MX4+]O'.1$[9@N023'.(D!L0M#<@:KY!,DF#.$I;1;VV3FQ;J,(U]+/FJ6_9Y MIS)UVM'VE_/O6Z,",4H2JW'.R+2)>,IS0@#Q.:AN2?=264/WMX;HP),?(OHLAUD6@W_1:/CY[W^?^Y[UO5:2:%Y%8P"QJ M">(!8^0BAC4H>* ^$24MSNWBYI-.Y[V?0UMU: M?O1)'3;^S13=RM /?='7% MVNP+NB[F_:>VR)^E;=7QP6%Z5ZWP^7"V<-X;A[,]M]4C +R"</=A]^^-P=Y\=?'[[8__'\2=JG7:* M:)0X!7)OG$6:6(JB5-AQ9;&M"C'<'#5T\[(;VIK#K;/5F3(V:T.SG"5.GR7> MQ%>7/]F:%#:K_?(W?L.01Z^OY[R'RZ[NM=(MGELG;NP;'2"#[D% MAH\YAY-'#JM#*I*DBS:X1.O*L->LD4ETPJCXT"C[YZB[XZL0BMF%,EE">4$5 M#^;BE;+_??_;)\=@/<"L("6B0UQCCG(18.2-H]XH TB1;I$V5OL'JDY.7^L5 M&T3?.-P]&C7N^O#B?>X"UZU[Z.WVSH\;.R%'O/2'57['0/5Z=V>,46#7 MOHZN5U6.R;VG'1_]#).(:F?[<@?*F+A$O%(N.LRU<,Y*0117W D" MA&VN;%@B7Z-K>X5)+G0PZ*#,WIC5XQ9&G(40^*19R )PM= M'0U==]C<[;6.6[DM[IAYC?>]_/8M]MW1^3,LN[K#W>0,>BK5JS]U"'EU,..^ MA4%,/'%3/:L673WKNN/756"X?.LJ^@)&9#O#R(LZ8'28BC9N*#QYE-YX?=Y> M-#"<-'DW5FVR^]5!VM!+.&QXW>NV&[F6Y*!J\]O)0ZM2^*KR@I=3[KT]ARD: MW[,*' DQGC9KK<]E*& JA@_2K+ZK>SZ 6:B]C;>8SBGN,VY8N!QN>!.9-AS, M.&NY#U)+";LN@*E1E"K"'R80I>#&/&Y\AM^_?4I1<&=R=AZ8I+FJGD#&TMP? MURO!9*8BYOYQX\7DK=P]O5[&P^[NK5Y]EE45;5I^#5^E# M6=CXXO_&AGO*Q MX='M0#Y379_;Y]5G][:_9@<3:W[4M*(CI=F#W5OOT4_T8.F^'^+:(2]SL%35 MFXNPM_=SC&==0GJ&K&3NG[/JKRL;M8QU&92PGA,CI21Y[[6>>6+@!94D,N9O MBGT'6S-7+H975]>XK=ME'L1B2BX.AOEQC.%ZL;_KO^]_WL$Y/EES+YU@*(D< M("I81-I*B50T@3L:A&9L:UN_N"D6)J^6I5:#49IQ,&6YTMPFHT7 U!+L+,<\ M>'-3F1I1%L%J%@&!12!(PMX1C8@FL @]P@)L84; D MW)/EX%XH'732/G+G>>),)9F!*Q\04C\H@EKWTG&J-# %,!\VC-@301)NVMJE^,=_GO5% M?!-!?&6>@#4+2/C]&NMQ\VL([)P?G\.ZJROLX_D*^U-F]-6":(S.^1O_G[VO M;6KK2-K^*RKJ_I"M8KSSTO/F[$.5$Y)LM@+>)/9N)5][NE^\CX[[ZEGYO-??O^=]QZ_ MF564:>6/9N<]#X_//^.Q(^^2L1 ER%PR:Y>5E0&(!JOT5"WK!NUXS\D.K)3A M./OT[$6/A;@E&?(][#Y[\B)$0T4J+P* 8SM0&M80 @FT66<9HT/P&UMF,\9S MC@H>SWECIB7 >_U8AEM=33V68:F4]_Q:[O[^7.Z\^T/O_OA".F>--EFDE$([ M.N\%>DE"8_ NN.JHX.7B&LZF>%C,D/1AE1V7-'K/:=<(A[CF,NOA$+>QV("5 MWN)EK>"<"*X8 29K$9+-HMDV:!RKPSXMDR3UDP>7$QV^:875EG,4GV;J6LY) MO)@?XKV_9RE%X(+3_^^_=W*RCYRYM(ZO8V0=>[#J M^"^^XL/8O?=@7V;X["6&S\ASW6BS )>_QJ^.SX==SEVL+>,^6>5+VQPUB,F4 MXIS7V4A34?6\!;<$[]UM_NS'%Z"C;D5/12BF'=?,7J1B4"B=,868)(!I&5S/ M,6DOZQ[^Q'J_E=B)\73Z/CP*^4N\4-M?RE)ZU7ZY:OC%DNI:1]>:H>NOG56C MZW@!7QI:UXN\^,2M+Q%YT1?UFBSJE8N,LXOZ]*3Z,JOZGF]375249";)3O:! MRB4W@L@C>,SD7/&0E,6:2$H3:Y$\9ZJL%"A](^AJ*'JW^XZ?]>.+@CH&D$9H M5:0 9U,[G&"%+#QC/H"ND>TJM1G#.3BZS)[0H]%5DD4LJQ.=9PF=IC3]*%%R M$Q6G=4KN8T39G48?72Y%]G];L//>F$YTXL7Y7C[%Q_1LDH_+Y3]8<@4MK)X> MOG;'X6N7RXOP8%,?*-ES'_3LE+O':N5_,6L-!277>O!F-#UZ]0HG M?(/I[*#$$KK3>X7PXPI&%R5(6TSS]<5, SHXXFZ4Z=\>KS"PY[AC[_49;N5$ MY)96\O64'I^^^+*,IZ_W\.WC\?YL>&9?^I('X3>6_"=*$#_KRS]I,DMA<")8 M9JTY_OB#3O!('NL%AQ/^OYP^^>3C1[./_GY8%C_3\E&,YL*/Y2-UX6>?NFUX M)*V[TET__9D)5_MF;^O-M+6/0&]K;^MGVNK\4G?]^XR[C_F;1423*?]OPVQ\ M,!I+<\$\EB,UDS^G]_O$I?KU7^WB+Q>LDGF1"B^;3KS\F;2XJ[1&[GB1EY3OUB+,>B-[(T\_P&7EB)U]F^84F1A2WLF M1;;G-JB_4 N*Q&5Z*T?WH,__=ZT>GNW9I-UU2%V[3/UC'256;7-- 514H=00 MK/1).^^,QPOJ'YMY?]F\AVS.?_;J@ ?G'96V9_)5.R2S7&2=N9^NM9>_O/IK M[^FK;]0O^E][N[]__]?3[_[U;O_/=MR]__>X_>[O;W^B=[>_5KZ]^T;N_ M[[PY_0X_Z^A7_=S]\NP_O__RZKG>^?T;;M,W;W:_^^;-+__]]H]?__M<[CS[ MYOOOW [OJH[8_G7#\^^.=SY6?ZU\^Y'M;/]_$5,GJ*I610_.]M/ M66!41C@74BT:2I3M;+\/F]Y>E*CE.O!HS'I)F%R*R^<>.2\/.E=UKKHZ5^5\ M].IHKX62?3H3E&=HN8HZB)=JK/4U5GJ[5F6^D.]H%2M-LVI MF*L7(%-FJ\](@:13(.6J3;ZS5&>I 71MP%9?M_5N1I7:D;O/GJ@7(197R59! M/(L"G$2!Z)U(V27(*&6H.,1-^K6*7#X?E.\SY'RA+XY:UY?K\KE$>Y_IJ"B? M7+2R!BJ0BXQ%YBHA!26SK*G<3GA65YNNQDAO%R.S%',0.#0"?0PML(&Y*%4M M(@#SD?R*J1O1!:$BE*#ZH(GPLK!:DH@0QFP0L\25>/0A@V6BKP1'3932/FA*&D%L($D M)I&/%64VSENF)KNTYM&S MM=PU5>U^O1@3X-!&+,D(:3,(8#U$Q!;YG5 1:9.DKW%C*V["M32/X850KC? M;P7?/1A@V%A?# ;(*A>L)'+TGK&N6M: D$2 &IWR417E6J%$,ZAPQ [X^R;1 MN]%Q"^A>S FB96%T)R$#&QZ@@Q*!DA3#/!PEX;FP6Y8)HJ4-O)HR2J"93!9Y-"[M#NT.ZQ (/%]&(L0(W6 MH80L8@XLKUL"F>"+%Q6H1$S2%E,[J.\IJ._$?N^Q . ^7PL0)&:YU6!2"D% M 3EH!KPVHA95+<^\ U/6VHSO^.[[CLH9-]2(H##@]=W6+1MB9KIEPW%N+#,SY 3LYP_1,LG9KE*=M+MI'N[I-M#5FZ= MB1="5FI!K7,T0@?;"EW4(A)SLS J\A^\"[HYJ90RF^Z<8CR=B3L3=R:^ATS< M=RAN@6P7(H@LY$@V>>$C2@&L!3/91BUTLE56#-)6O;%EPOD)"SO9WL-L)YW+ M.Y??$9?W?"^KI_2%("^4X"39++)K>\[9*!$CJ]-2FH \KRIX?YR#]KR$+YW2 MN_[<.7>-.+=[\6^$=A<"\*"&$+-/(@5* D!'D6H)0BJ;:JTZA>;JNR#S=V?= MSKJ==0?,NCTL\NY<=0MAD2HQF[H8A,M:"I#>"-0E"Q-*(BHYH/U$BJ3.M9UK M.]=>MM.7B6:[.MGV:-7AL>]\M*KT)(,B*7(VK.B&D 1:%5MT&UGE0BP6-[;@ M_.V%2V>NZN37R>_..SU@\[Z3W#BTU:*4$$.LT +V%O84?[KY6 M%1_/U]J>3$<'=;1-F5XEFHR,VARQ[J4NS/MX2R$;_1Z#"(.YC]WL][A']W@ MF76W/SXT-_I"7>O0XL V0'K=\D]L<[#(=:#))J4A587&MB0SLAAPZ&.:;7,H MI8WJA^"&N=WQ])S,P"T!?=)8A"-HF8&+%<&E*+(WGN>YH ]U8TM+V+1R\1#< MO<\WTKFJ.>^4V"GP'Y0:9!,N%B8NH /26LA9C@.242 JJL.0AD='%2S7$3?JUBNJ]H)K[P>0- M3LK52[B?T^7[45#B,G1D,7LG7;120B5*6277$OLIQVLWQ]L)S^IJT]48Z9ST MY)9(5S0@4C&5"2DF$;)" 8HUIDA!IVQ7IC6=3PJ#2(G8@7TKP.ZQ3+<.^<72 M[0IX;J,7B$X*<-Z(X)05OF!.I$-TOI5N=ZM003KB'QSBNV5Q"Z!>B/XQA:0& MYT366@G(48MD7!+9>!NB+C%+\P! ?<-'NCIGW"YG=-?.2EEC(5(F0*:46H)V M$P/K_)8$JLK\H<'P5+<\[:YK_QW7/;CD7N![(;B$P-J@00NR,K-U7UHI6 _" M.^L;/6846F86W ':CETM0B- 8!O> M>?Q$DM(.Z@[J'K\P!%PO%&NW(%607D#+0 SH@PA5DR!2%<%64U3?B>^X[OMR MPX;UO,>_1@-.!RFJUY7M;);92<8LC,TJ>^MC+4/-;;K<*$UB0&,%;GLLD]S\W0V7[GV9/# M!;8OR=4:?191!B>@G>M)H+V(/I;L?.1_>'&BF_N3UG=UB!YXV&PG\T[F0R'S M'CQS!PS_=H[A%5MC:',2.H?0JLB32,JQK6Z",:YZ9W79V')V,YR3":@3?"?X M3O #&9$!$'S?D[D-#M^=U]*MR1:,L@(E-BW=0JLTY$6UH)/*(&=;K=K+3;C7 MQ3?6AL3O.+E3EQ%=1@Q.1O144COJ\9$-0IO@ 006)%8X1>6R&&1 M 63,Q]OS7?'O=#X@\NIT?H=TWL-?[W#__22BG6E<[;S[ YX^>2').+!D!-B8 M6@9^)Y(/6@!F25%;LB%='"C72;R3>"?Q@8S(0$F\ASO? (_OG.5QN_OC"];! M09)/@B=-,IE[(U+U660JD5!'*J5V'N\\WGF\\WAWI0Z%QM^KX^]VMY^_81HW MJ MI'X51V0OP)$5$RH)4J#J0(CUT>3_!*G-/MPO#\]G!R]:A<_&CWC/[3' MC7 Z/C,^?#F[LO+ZY/=?OST\^(-[SDMGRJUZ]8HF?.7>Z <\VL\O M1]_R53P&W(:Z1_FD!17'D]&?N'=$(R;L]I?W;2C\D$>C]\"X/PM-#VVA\>1- M>++Y__V#V2Q.SY_&D]232\QVF\?,,SP^G*V/^75UR5D]8>-=7FR3<3Y^WZ3U M>/\(C^GYTO,^=X=CL4JLW7NKI?,N@+0QY%;UU647LH>0\K&.P-^A\J1):A52 M!>=<]3(!JPH!8I69?-%@G+'VHN> T:FH:(JV#@RH5"J1#BD$#$5[F'].-:@* M*AM3C4!9\<-,+:8HU@]<(GU'Z]@,;1W_=,P<)XMQO#^ZV?;-;OAX?,A","\Q M7D]YG4]&>R?6^]D36PO+>?$O=S"_YZ_=JZ[YSZ_A4RK@[S)4IS/YM3_336;\ MDG /]S.-IB^)#A\M,VB+LN%X'+?^D29_WUH4',?M]$8:;E&5*4,RK!K&U+"? M'/JL3'PQZ^*"M#FC(OU^-#TK!J62G[-Q9K,&__B(+#^V:L"S#DPVUV#9 MJF%.DV1EM*B4C*AE?K'-5HV62BHQ>^&,G#=HOF7J_D]C[NWQ-.\=3(^8UY_Q M [[:.\A_W*UYHG9_/C%/7OT"? _8??4C[+)YL/ONI]]W?__UY>XK-C>>\7?> M_6N\\]V/YM?O=O]@4V./_OG3VU__6UXG#:Z9,#OO?M._;O^F=G]_8G:_V]'\ M#,WFQMZ._M[LO/K^S:_;Y8]?]$]L:GPO=]_],2N[JU(VPE," 35:$:I2@O@? MBQ.*.I9Y3F?I8G75U9&L4)1.MI:0^8]8R*9H-T;$1M_KMK0F1[2Q]6C41GXT M&_K1#F$;^&/9BOME].UXG\'1E*GO/VAEBW+S E7IPL5['E+.1??G>_-Q[\ED M3T4JI7("7H;H?(%2F1&"3Q'C>UO]QI?QF:'\-W--?GO\\V$OZ=]>1.^SE[D( M"=2\5Z[%DDGDMS467ZJO0/-+]*[X\$(Y?#Y#GL'1/\CM;F MZ,W+,5ML-&U6_I@EDC/07 /:?7DCNNA23?A8659PO!I_:%,U M4H]'S_>QM+7-D_._HX/VZS4S+C^<%>BV_?4G\01._J#3V6QV(F:^8#IN^0CX M+VV=O/K HS,;;K;C,&Z#WS:*-D='^ZPH'/*-VP-.5MW!1^KP.;9\G_F;FWG] M>/3C_'0OS//^P>'I&N#)JN^UC#-[/[.)/N8#W-L;39DJQY7GG-?!"0>T&QTD M[L"?;4]PMCOS9)V\ZZO@5E>!>3SZ]_'T'QQS\;%2-UL M$_K?$<_*1U3>YC(='+[\:)Z9T^=$Q5DV:++E:/_# KCJ# ]&I#X]N@@*S6 = M3P\;HAA*X[:VZRCC].5L$&8OVICR&+7+-T_P-DOK\B&1R^;LFL.W'_VI<%/_ MQ 9$?O/Y9#";H\G!6]SCFXQ9;V[,>R+C#W@9-&U@]H5'HZ_OH&W'SZ/)(3+C MG--,7F$3>GTPF0F*F7#A9<6?O:9C(OJPS*9MR^" 9V.9+0.6+]]>R&$G_,6/ MSCB9C(^?_.%!F[/U/5-N&DU>I!>-QE-^9FO&R58&*S3/)G(VI!]Z=CJHI\K=N2/ZL9O@'9WC_[(RTAY7C MK0$JQSO%W >>ZJ90GC_X'[7O4LUHA'3BHCAFI]>O)P=_,?8./UHFCZZQG7Q5 M ^"$,2PPI;P^F([;C1]/:&^&DR_?C,OARU.O])EOG?CKY(>O8.+>'QU>_)4S M#G.O M^>G#Z?OY)N5/3W]Y\L.S7T;__N>3GW:>C/[]P]?+&)1WVN3=I\^^^7GT[.GH MV3^_&7W]='?[F]V?O]ENKWY^^L/WVT^>\9MOO]]]LOOU]T]^&/W\C/^P\\WN MLY\'W[$OGN\^>;[]/;?_;Q?H&4NTZ,F$2>HZ[3C6/@OE@\F,4QXW%^BD7;6Q M-;J?_RZAM7UBI_"S.W]S.X4AZ%!19RK*0JHN6DJ.1[@6\$FCNC?;3D\^[+3\ M<&:GY63_<2:8S^Q,\7#AZ*>F,TV:X)PE15O9_NT-[JO^G%]2.=JCI_7]#NMQ MQY_LES/=/NWUT_WW?9QU\5G3'!_VWNLO+RRH@#6!*%XYP>! $56UPB;KJ1IR M"G >)MGX$JM)7DN"Z!,&H))+()]"K?3YO=HA&%;/9D$&;1MPMOMX;'LH,@CX.+$!6*T\1E-KR.MVL:LKD=+;ID)M:N3G*>WQS5L7Y+K-= M+Z;M,E,T/T0UG*?O%Q[4R3BU9Z<#-DV^F!D'!T<\"&7ZM\<7 I9[]!NK."T MZWBT3_IZJ@3.PK-XU/?P]90>G[[XDO7JUWOX]O%X?S9VLR]]>7*O$\V1;S,^@L_EH_4A9]]ZK;^ MD?,7?_-3=_WT9R9 ;VMO:V]K;^M-M#78I>[ZF2S5G\\UKQ:N/>?\P;'5-:1X M^RR-[(WLC?R[]'OT>_QP#NL2++ M[#AUDWZD[;!Y<(=I_^U)%/8LI\+R%3Z7K3\\M"XOG['JO!X.)/74M2LK*YE4 MD)*<+QD 8U!>2_0)7-;D8YFEGCH)OOI4ZJDF2)_LE_;KFP_B])SSV__;G]O?_U] MY]W.?Y^_F\\]]?39;]#NO?OLB?WUNY_^V-W^3>[^]YLW3Y\]-[^\^O:/G=_W M7O$W_^)GU]WQ22;O5F+YW8]J9_OYBXQ8%=HD9#16 +D@8J8J;" 9/$0H!!M; M1OI-'_V 2BNOR'#K)+66),5+5T+@VX!Q0#F%Q,N[:@D.+"10-TQ2PTMQ>E_X MZ=T\/[D:J]$0!8&/ J25 GTIPE1"]5AJ=T&-0ALC6A1LN3-5N>)%DCJ(E*1K!KQ4W@S1SEM1<.M] M"? Z4P'I-;ZFR86!KOIR0W N\]YG?@H6',7J2 /K3LJG )G8',C@DB+9?7G# MI*:WB[%01DH5D8P(OK3,5I9M.U6D*,5F0V2,TB:,L4[ZVJ *9M%SE6 MPF6SK%D1O^G CBZHKXKHA9@.@S9['Y1@3;O5Z6NE)\$HD6/)"HQA+4QU0;W^ MB#;&6O"%IUY:*,8C J/;5\HZ$$.Y[^$/&=:+H1 9B]:%(DOJ60[X& 52M@)4 M)9)10RL3OJ7,9KQ^/&F']6!A[5,LII:$019 B:FYF:.-6@)9J*X+ZL$B>CYV MP+H6Q>2*4,6T33*VJX,G)S19GL",06O?)?7Z0YJ).T>%1D/; F>=&SS):F+. MK(2#[Y)ZV+A>\+9K13XR2PN53!4@T8J(5@DR5@9#SMN:!BBI'U@VE:];4^JL MW,LL"WNA686]*_G>N-8L;:[UPUF4!UB6!51J192U2F521]!K'+'9$GR Z!91)IIHS5-"NIMBV M\*7%*"58ZFF%!@WK!9\[DS*;$SFP)1% ,$$K$1)80=E5'_@C26ICR[A-*:^] MD]]1/5A49T4N,)8!?02G6&@'XX+UV5FT$5*7TP,%](++W9,-A4H047HIP >5.%K-"DD;3V6+J?7'M4>"#*%E, PK%,)2DG+;U1D M8@_8/>Y#!?2"QYT\I8S:"Y MGR<8$JD4UKX=%>\+**ESE]/KC^AJM8[9HU(E M@,PF6"D-ZD*>I;1ULN_C#QG6BQYWEQ*K71&$S-X(8$X6*>HH,D&1E:R)(6YL M@=R,%CJLUQ;6NLJJT1DB= UQQ0P)QE0R>BBLUU0#Q;1"Q[W$$@9)(%:,Z)3 M3B*$4D3R,?%*-D"U=$F]_I FBR8KF4D& \8;K$8J9&@SKIVU/8W9L'&]X'%/ M/F@9BQ;)QBB =2X1C")1:[2YQ.2KQ %*ZEYDK%]Y+ZY\ $7&=F9E=3#MT6A* M^6@R/AQ3KS36[]'OT>_1)76_\IY<^="".%>1,>DA6+S95U]TR48I XI:>0$; MI/9W5C*_A-IW6'\-I"6#FP!FHL MQ(3.LCB8E%#R#Q,2: Q= @\!O0M;RXZ7IM:0A,)VV#JG+$)I9R<2 U-1]-7* M+H'7'[[&:T!;;?2L0$NBF'3VMK1"F54%LW3>HRZ!;Q[#\Q*8(*C<3D:$F*2 MFED"6Q>$E+8284[&F"Z!UQ["OI"J@1&:K 1 %L4M8S#R7X(/J.*R7M\N@6\2 MO4_G)7#5,?BDE="HBH#4DI>KI 5$68MU&7*T70*O/WP-DK,E6<=J,\04DI?* M5<7*F&9].BT=A]4E\,W;P"<1THSC=[O;S]_L_O@"B2U?YEQ!JNUDQ9 %1IM$ M;M5Z ^HJ,6QL:>DWP:YA/%%@"Y)9"[O0G@8 M -Z9![!TR3B7G:BES)1H$LE:+9)/Q@8CLVY*=!?#ZP[@$(#1RX*X1#:$@\'H MLDUL^U*24BU?O*R+X5M \?-Y%'L96($F%+E5582(06#0)*ID+1J]A&IPB&+X MH54"6F%RHH>00BU#14J)"H &G6P(M67+3&"-+@YUWUR_>S[:671O8RT5(T7! M(J2V\QALVE,HPD9#*H)GKJH] ^+ZPQ<\Z>IU!*L4I$#16^N#\LY92EHO7?VG MZQ0WC^'YS74%T=<2G!^CIY!S0 "'QBV=9*B+X)O'\()_FXE7HB5! MV3.&0TL99B0KU"I$+*X0>-]%\/IC.&J0% Q$"1F2CT%Z%L5196.1;/%];WT( M\%UP< =+)=N<1"K(>G/,52!/F9!)UD *J:1N!3\ ^$KK77")F\- !NG04=1H MK4V9:J+0=]8'@^%S'-SD=''9.A&A%%:D/0BV>HS04(NW6@;C[<:6\; )RG84 MKRV*G76:]3!+2 82JEAR @F$7M6K2XG< #Q? V>=J/<54"D0R:!&3SD5%S;B%I=/X=3%\"RA><'!7 M5%BK0J%#85N8DA0QLFZ-H"5E,$E9'*(8?F 'MY\_^OG1Z+<#;M'^*]H_7";G MRD,/O#$)LF+#,!DI(6J;4,NB>($''6/P?8-] )3TXZ*/FX*M0:HH,IMU A)$ M@>B24%!=D+E*J7O.P8< 7X\!?/0F$X!S$)(RM5"I5>OLE>T;[,/!\/P&>XU! M!ZH,VM@J^B4L#<-%E,1FG9?)F.;CUK IU9#R"W8(K[@0AP]1J6R\<6P96 HY MZ8ILZ0<*BO0JSX!V"7QE]"ZXN)53I:2,PF!@P]X&*X*V55"45B6G/4K7)?#Z MPQ>RE\$&TN J9&TC(G!_C9(N)7]R]*1+X$%@>%X">S(1R2NABJ56:".(-*M> M:2BJ&)5F1NX2>/TAW))>%8FN2@^0MAZB03:F^N3X$]"YXN$UB]!9M MADY#>>=U$G.[8$ >,&YC;I"#5"%"]8*<)!$M& $&T,Q^IHJF= !O/X -I*GVWOK M0O# %A1""=[D+)57T6G7 3P, "_XM5$SS8:H1:3(9F]R7D3,4I",#F1).M0T M1 _@-(A3_[$\=ZL<@@O_]&45SI#)RWET[[O=1'Z/?H]^CU65D?D1:3)@\^QQQ;/7 7O?0V^-R.TB)8M:QKXKTH^O9@\C,+ MHH_ULP_OOCZ:3&B_*VRK4=A^.:=P _E"0%:T([0"R#D1=52BV.1:,$%1I4?] M/ !@!Z^+3KZE>4^ H:!CU= %_HNL6BU?N*$#^XZ />^(-$62\;J%$'@O(!HE MHI1!5 FU8/:. G5@KS^PC70YJ2:MDP,;&=+2*Y!160U*.WDKP.YA!M=#]T*H M$"*%$!P(;0*T0L(@0@U6^$#26&]M\GICRTBYR>NPHWMMT1UK(DC8$F)D"&B# ML]7IE#68D!%O1Q_OZ+XFNAIE2*L7H#NQA _NV=XF[44L+HNB@J\FF#RKGMBAO>[0=IY%LTV.%T !L#G$MK$659:H38EP M*]#N&OEU\;T0F!2=*SRI3E@VKQG?08J$U0EIM:I@":6*&UO.=95\K>$MDVP' M8Q$(-5"549$LNEC('@M;:AW>]P+>"V%+AFK(ID:10D(VN9%$ E B9U^*\C%* MGP<([Y66FQBXGYZ1\@8G93KZ0E_-0?\0D@)!J(@0M*0LKE]=H'0']G"!;9QS(',*Q@*4&F,U6 (:9516MP3L;E%<#]V[ M\V*[$I$$KX0U1@N0;$HD4Y3@:55L3M3HJV-[PFSZZ]L3'=R#!7>JFG7P ! P M@30R2 S2!@6N4HS0HV_N!;CG17=5U4$K"AUS<@)L-"+5%(2S.A<3HLR%.KC7 M'MQLEZ&:>>\L*^<>HO/.16N2Q^!"Z%Z\@>/ZZ<="&UXXBZBA;0):18SKFD6$ M6$6)!0-A+5&O+F:V WNPP/;6R5: V*:4 +/&5BM.U:PBVEK+[?CP.K"O;FM_ M<,^K77[.TRY^MQ&H2U*;" M!7240BHLLU51.G5H#QW:._/03AK!Z9J$SM 25VLI,&%DT:T\L>$5K.M2^P% M.Y?J6T5?%;*%XBJOBQ"2*C&EJ*M;.N=>A_9=0?OY/+31JU"C ^%S!0'*589V M"<(D1ZU8%3@W2.?7BH[/#]D;O\W?^A,/QW_2:+P_/9P-.%88Q"0$UL(&DG$K%6J$*+ML?D/ < H,QJOBC2I@ 5B"T%K M\*EFB9EM@PL ;*\$X.YUNQZ*%USJ1#>,41KLY3SM:BS0I@):ZC*JJY*KS^ K?7:VER4C@BZ92]( MR9 VEJ34V2R]V=X!?,.V\*(KG*S5R50KX*3,'(BDO!9 .40O@PL*.H37'\*R M@"_BV-98^C?I^9;_R)J]S@$/=&^9BL1SBC[LN&NZ2#2:&).#QX_;A1PO1@;UQ&K>6?EYQ#&X[_ MNZ&^#T1;.+_3MQB ,GD]^>OQL8+P+8XG_\&](]H>3_/>P?1H0GW__$9C44XR M2/(,55;QE7"4BH#8ZN/EFD6(M4;M,_@X2PWK-_G%@MIP"I [T&JO%HRW'$+O M. *W4VRGV!6%"'6*O<-HH=/*&;XXBJUXH6ZG *5W C4E(:WS/@;FW*HWMJP, MFS) I]A.L9UB;Y-B9?%! ]0<0@855.(W[;1F99XEBJY3[. H=J%\2L2ZS1M2-;H-UF/"<,I%-LI]A.L3=(L=<-L>L4>X>!=B<4 M&V*1QI(703;?OG%2I.*-4!:5\]4:&^W&EMK4H#=]4)UD.\EVDKU-DKUN"&0G MV3N,ACPA69Y?QJN]+,T0#6F(5+3)50&B55P(6YERFW^2-;O.WY8S;#+J3;"?9 M3K*WO!][O3#B3K)W&5%\2K+)%92>G)!*L?X*THH@T0K245=*N9IP<7FKSK&= M8SO'WB#'7C?.NW/L789\GW*L+Y@-5A(ARJ;(QB+0ZBQ*)@A44W ^M2U9(]6F M]*[3[%*1Z*>M.&FOG7'HJ@^:+'&/"SM[MK_7>4!O9&]D;V1OY"H;N5:'),X7 M7=_\[VA\^'8T?9^WM=>.O.$$E<9K/(R8.XGA*^. MX_GX'47&AN106&I9.JI!D2HY8<&SY6\C:;>ZG)4=QX/%\77#G;M0OGTP+\0[ M>^](5^\$!1M8*(?0A+(6U6@;M"T2LF&A'#9]L!W+:XOE5:6N[%B^12S/"^;H M KH@LP@6I8 4HX@Q:J%2U!%"];EE@S<2-@$63^!V,*\+F%>5PK*#^?; O!# MF8RO"J01T684$)T3*4(6UOD2DB&5I&?!K!U+Y@[F]07SJM)9=FOY=JSEQ2C! M:E2NMBK1O*@"5%&,:>17,@"6:G-VIMO+ZX_D566U[&+Y-N&\$(]6L4A)N8AB M6^4WMI($&FF%JJKD9 FK2AM;8#:E6HSY[6A>%S2O*L%E1_-MHGDA\LEJXVJV M1>C:\JI8644$0R(7.OE!7*VS[$)0T3)H\^!QS M3&"JBUYZ&WS.@?5VL$N'&BQ;>+MOJ*Q89_M^,8S(6>NMN/[>!UTSDP$9&M?0*9%16@]). MWA:V^X;+]0"^$&X4BTS@2BNM25Z ]DJ@CU&4:H,MQ7EOW:S(YGF'>3N^UP7? ML2:"Q!HXN P!;7"V.IVR!A,RXJWIY1W?U\3WO !'UL"E+" 29"? Z_8J9*%C M1*FQ6E=]Q_?:X[OJ*$DKHYC4P5:6XH%_N^)30A627=8YTG7S.X/V0D"2K)G5 M+R<%%F4$!&-$+$4+R#Y*C!I0K:Z^;L?V8+%M+!0R:"54#^!K!.>E0B]32J48 MW;$]>&R?$Z04:E46BQ=9JB) U98YTCL1#!JHR*I)%%\N*'!;(JD/\OD!\(9JI6O0F)RD, MZ, Z.LMSE"J)4)(U5 S6$H<(\15%,]T+_SVCY0U.RG3TA;Z:X_XAE ^'4!$A M:I710I2$M@3MP:I0JE8Q=^?>P.EI9]%Q;W14/(%56.=:2GJ;!<:01(H!BXP4 M;5Z=3TT+%=-!1M@M,R,K:]3367MG/@?# N!]NQ/7QLS^_[6X7! MFE2%]PW;13.VV_8!%4V6E/).YX[M!X!MXYP#F5,P%J#4&*O!$M HH[+JV+X' MV%[PV3-)U]+*&AA7G( JLT@)9UFX(ZJ:3+70L;W^V$Y5LR(> (FD$;R_ =I M@P)7*4:XM:";A>7K;/&BN@48]LDAG5*1AC^JZI6D0VI8WO]L1T] MHIHY\RQKYQZB\\Y%UN@\!A="=^H-']N+&40@D8\&A(XFM/U^ULEK4"*@8MZV M5F:U.I=>Q_9@L>VM:VGYDDTI 6:-K,$%57GVT=9:;LVEU[%]=7M[T6&?0\F5 M52\1R5:6W%(U7[T4IBK*:$PLI#NZUQ_=VOML)5:3H$*T*:"C%%)AR:V*TJE[ M\^X+Q!<<]BW>+GE)PCJ6XA"3%J&H(!Q6&ZA"];4Y[-TJG'D=X8-%>"[51TI* MA6RAN)HTAI!4B2G%ECBH(_R^('S!7V]\K@&#%U:U J( 4J2*1@!6(!W(9DD# M1/AGW/5E/'V]AV];8^G3I-"O[%?>Y)5]H?8K[\65#Z#:T39_ZT\\'/])H_'^ M]'!R](HUC-$7IFFJ1Q]&_KC09M^@6;%NE\\$.STW3Y_]H5XD'V.4MAVE M(!)@:A4I8FJIV5$E'4(IKI^G6'\,KZK8455&CCN&;MXH_A!ZII]M/ MWNS\]L*R%AT+9)%* 49Q)!%*#*Q3^^PAY*IES]+Y %"\JH)&'<6W@.*=>10' MIUB!TEHHZV)#<3.*T0BKF8')%$W0=Z@? (I750R1!0_@/I%/QV\Q;W#MR,\'%4<3T9_XMX1C;Z GO7C MPE-(N9+*Q50@#\K&J$*T2* M1@7%]1.& Z>H7Q:S?FBRDFU\$F0(6F"C%2'H M*FRJ-0:7,I-4/Z>P_M@VRF57V6ZL.@%JEU#S@B (U6:#J71L#Q_;\Z>'I356 M9K1"46GUC&41*(,4U85,H>J:S>J4CX[MP6*;+7Y-Z'TJA-"V_I_.\'P!=2?Z1$N>BLA34N"\C*"+0M_P>BUNA:*VFN:0,IB\NC*9'=N#Q3:X"%ALU-([<)B#A^PM*5^+3L;?6GZ MCNVKV]V+V3_(D-3!>M;$,P@ 5M'1H18Z(Z90?$'?<^D^ '17%VOPR:8<" @5 MMH2Z8).-[5]:VGG7T7V'Z%Y(_*%02Q5+%@35"W!*LH*>LD!%U6124>:>N>L! MH#M%L+;:$E%)J)*"*C(%);VVO#!TU\OO [H7DWZXD)'("&1I+2!9$*$:)8@R M5.6"K4A#1/=:G5'WYV+SV<$A[HUXN,4)#D8XBV6Y;(1$.I@4FHC#@]>/VVA/ M#_;&9=1:_WF^&MJ0_-\-]7T@''U^IV_QD/[D]>2OQ\<14]_B>/*?%B2R/9[F MO8/IT83Z3NA-G]<_V2YQ.:J("*(:J06$FD5 9N:2#"F=0-L6IJ"]W71.+Y#R M*4;N0)VX6@C741N%J+-OUWA4D4SBM_I2C\:A)%'1. 'H2 M,2@GG#=)^F!JB9_0>CO!=H+M!'N#!"N+#QJ@YA RJ* 2OVE9PRNS+%'\;.AM M5V/O-M/%"DN\LVUFVL^P- MLNQU4Y!TEKW;1"0G+,MSYZ7-Q,IK2V,0JQ(AJBA,JZ<=='"YVHTM-E V==\L MZ"S;6?9V6?:Z&6(ZR]YMLI@3EL7@5'*N"&5TJQ==LTBQ!&'!@4<9M%>LRVKM M-GWPG64[RW:6O57'US5S^/0MV;O+Y',:BA"=P5!M$!IM$D#@12*IA4DV0E%0 M;/5]4[93;*?8.]J4O5Z"I:[(WG&NI5.>M2KY:I04)K=S5EEF$4P ?@L2; X4 M"K$J"WX3E.D\VWFV\^QM\NQU4V!UGKWC;%BG/.L#%JF,$YZ<$H"01M.&FOG9'HJB/]E[C'A9T]V]_K/* WLC>R-[(W M1PK7?H]^C MW^-^W*.7Y.U7WHLK^T+M5]Z+*_M"[5?>BRO[0NU7WHLK'T!Q@O_QP#NL:(]S&-'N1DV+7Y[,'F#DS(=?:&O M5J;EG+ZO75HJ"!41HE89+41):$O0'JP*I6H5\^4+*9_9*>[AGJMPC[][?B;% MR7.Y^^R;OUY KAEFQT)E @&VD(BU6.%"AI*Q4"AJB*6B5KUS^=#A6S04;8+3 M,MJ6+C+57%(IQOE@7 ZVPW<0\'T[!U]R-N@8K*@&HP *)$)L69W!%1N#M&68 ME=XZ?)> [Q>7P:]QSH',*1@+4&J,O")*0*.,RNI3^)UR-_G5%8#<8]6NA^;= M>6'L"GJC20DLN0I((8@4JF%P:RO)V,C*U,:6L>?F:5A033N.[R&.4]6L.P> M@ FDD4$BLWA0X"K%"++C>( X7I#*7E'+8"6B-HZELJVL5-2N3J\:N&?KHSS7N[__IE[4 M:'PH10J76OES[:S A$40Q8JU*D55=W5Z_>'KK6MYSI)-*0%FC57FH&I6$6VM M!3I\AP#?,V>7U>[OO\#NCR^*\CQQ.@N+!AC H$0(D(7#2EF;5@!]=06..H ' M"V#M?;82JTE0(=H4T%$*J;#\547II0L<=0#?+(!WY@'LHZG!H10)# E 1!%4 MEB(7E*AX0BEB!_#Z SB7ZB,EI4*V4%Q-&D-(JL248COFW@$\# _GP>P3<:4 ME)6H+&L%2%=$S$X+%X"\]5;/TN -#\ K"N^Y'PYM[@:WF?OYZM7X\!7M'TY' M7]BK^;8?0LDE63.IK&N(;,T[HH3$6F:I.4>"2'&I#)T?5U6:K[YTRDYOO^X) MCE9+4?.;[!%R#Y.1MB*R/VH(I>*A+^\^N#>_N5;L>QA>\XU%2T@:B M<$Y9 =$9$:M50A$D)N^"%.3&5MA4UW*J=7 /%]Q!I5!M,=*G!"FF&&70(8/, MU?%GT,%];\ ]+\!3B:&4)$KD!.6$S3D7!.K@187J@Z\2YG\":HD\ED8@LM05H$T5T 42MRBI2+I?PB83_'=;K M FNR/@678E$J ,D8@B\Q6!=<]K'*Y4HD=5C?O2?^&-:$1=M$S1,/2D!@1"?/ MQK:AE@UD<$E*7:NWP:"A)/4J?9Z]6-.*23XOQC(4 MLAAL!$'&>0%@LN"9]<(8\+84:;U9PU)-UT3S_2@QTNF\T_GGZ+R"9!U.1H>V M0$DN03+1JQBB=X:\ZG0^;#J?=X*9S'QNO!1%IR0@JR1B=$KX1-K%F%.*IM-Y MI_-.Y_>'SB\3WR"+#QJ@YA RJ* 2OVGG$"N3.E%T-Q+?T"M1W0R[+\0OA0A% MZDS"4@T"HM(B9$E"!M3M8(3*66]L@=GTJ\@*T,FUDVLGU[,)"IVGG*U%FQ6X M3+$:;3"J0J;&7$,GU_M$KO.JLV[I-F0[T &A"'"QBFA "XFU9*^2T;63:R?7 M3JXWLA%AJ+8*J:8ZTH#5!VM4I 2RHI2IKM1SV#R4HKX1T>F\T_E:TKFU7EN;B](106-$GY(A;2Q)-F#-9Y,O M=#J_VWWEQA0$;1,GN+ ""%D3F3=L42N$[HG= [H:\EH73:1A]32Z:STH#=3N@W0.@+,;M4R*@6S1=JL@)L]2)0C$)KY4)5 MQJ).G= [H7="7TM"9V6\0-7,Y45"VWHAD"4QLUMEE8PK/2W9"?T&"'TA6ENG M$*532E@%10 9$-%%(Q1/L"K!1"J?J.31"?WR(>9_/VRKG7^7\9];_^ ?IXT^ M>8)HI/G8N%,F'>\7QL!CH<*,U5_N5'HQ(>N=DH M,!OM43Z#+Z$_>.:'109W_YF1_$SW\R^FI\\!+_I/W1OR=4BU@--[/ M>T>%+FA*Y37(MWM],)EQZ\E?OWY[>/ ']Y27RG3T]<&K5S3)8]P;_8!'^_GE MZ"11WJ/WJ_O^+!5]CY;*P=%D=) 8I]CFAJ\XF$W7[$K,_SL:3\?''WR\K#ZQ M7D8X'4TH-Q(IHS?CPY?C_='I40N<3NEP=L7\@IHMQI.KSQ[.^.@;VY3I5:+) MR*C9M]3IVESX8/.X [,U>KQ$)U<;@VWZD_8.7K=$C:=+\3FAIOWR<8P^;3Q9'6. M.6)*S;38GXDW;,.7< _W,XVF+XD.[R/OF.'QSMYL9'DQMW'?&>_1]/" D? D M9]JCR6RMCYZ^GOWZHE#EN_(\\&)_\[<%< UP6<^1U!VN;&;/08W/Z'B [GY@ MUASR,#S(#QZU]VM1LL9%H]V#0QJ%F06JOMQE+>/KLU]X4BL+5WXYG16/;]/2 M&)5UZ3*>YJ/IE-_,+>X3(W;WB+7N<;["8N?OMUV1\?[1,8G/]AZR\256D[R6 M!-$G#$ EET ^A5J)CG=2^#M4GK2=#!.2LX0F&FO!L*&-Y#QHP)Q<$:CL M\$#UD1Q=M+ ^LJ5.5<2OSZ08[WKB#>'SV#(9U%"^'[F_SX'T3L;R?*;X//(_ MLI@>+?9EM""MC[NW]8\T^?O6A:+\+)?Q?>WJ);>22XW+M\S4;9$=OIPPP3?K M=SK^:_2*O_=R.J+9ALF&_OG[17GN]/B!OV;VKW]R=F][L=S<_0O_SWV[T=_;W9>?7]FU^WRQ^_Z)\J MM]T^W7[^;G?[-_OTV?=RY\T+%364:*1(UA[LYXH5#_SOB*1M-W_NTF$_YXM%+GK'S]OL>C2Y)@&HE! @YMX1I MI3@PH'+&8&O5U12TAD<'9XM8G1*@Z@0XB+6K=WY\H5VPT5;)8^-(@ \D0LNP M5+Q,68&Q1<%L[9H;8T 3FKO7U_3_V7OSIK:29'WXJYP@[HWHCE#1M2_V!!&T ML7L\;P/=-I[^V?\X:@790N)*PC;^]&_6.9)8)!89,$=0/=.TX"RJJLQ\P2]CQ,F(=8_\O+%^$ZOU&FMW8G$*#B;IT:!)Y3P;9F\2QOW\ M:S>,#Z8%$&>>FF2&\>DCUH'[V9^UP-2SWW-[OO-__<>U_] M]>_--]N;U5]_OKC:"VK!D'=V]UZ^K?9VJ[U_OZQ>[.YLO=QY^W(K?WJ[^^?K MKO-_^LWN[!'[9?[NR];?W$?GFWL_ENZS6,_]=+_-0;C&AS MV+6]VXRCB=R%')*M,>593L0/\UUK&]5J_K.$U]_\7!A^T)J"^J8^!B*X2]*( MZ"2L6 I<.6K)Q4!E2%+G;E_@(RO.HW$:C$?C?"[W!&/1S0K()@'5._"SVSYL([_H#!YSR)5?7O.X?'8]S.+[OZ^@P3'X/AO1[;^ _/S5# M 'SHW:V7'T-BBKI@$ -[#7$)_K/C)")B,0/_62HJ^1SI33(),V>]EYQ[836% M9^#_6"AM&-A4$8$>?*7CX-1LX?^9*A8I5J=NW_;J: M!WPT6)EDG?H8@9T+-[OQV7?>2W#V=.%_-#K[$'S0U&GEY$ F;Z,-3O*O%]=L M0J205_6K'8:F6"PM.KRTYI7!,0PKC'Y]-@_0RR=1+S%J-_[5L/#,2JW+%&'I M>O9H%)]-/SP/W=%1SYX\Z_;K!:@?>@Y,O@_VW,2T!4F\6*58#Z:Y?&KIK>/& MVINTQ)U\\^3R>GWI0M7EY)I8!VUQZ66\3BY_](K7ZG705#_TUJNO,2JWOF=US1>O_;\ M!#9_[X*M2(U+_'/VW5S,#B_>=S-- NS528#M)OC_>GYZ,NLT3U0U3SJ M92?GEOW6/'JZ?>^F.TS:O8HO&_?E=!_7#;CT^JD_G?7+F^#*ZMU"AFO/K"S; M3()<=5SFT6]6QW;8:.8]N]8OB^4F* M9^4KO4P#1YN1I_?)_7)@"W9QG=QO]OO9Y4W*18_@K<.PD7J7;< *]$! MXV8+=/,.&,O-_8$Z7-QLTDO4.7F/8S1*4DHB9]8;[E+ 6$C+L1?.3]HUL\LZ M7,PE+2?IRFPG_-,='\QE*4?GTY3GU_\ACWQ<[6WQS&?W*Q$<;VWB9<^V]O>^M-;I7Q?>>/_\#W M[//=?UY_>__IH+>[]1GO;.U_W][Z3]KN3KJ.OL7?MK__3;:WWGU4N9^)MQ9) M[#SB@F!D)4M(YGXG6! 1.5[;D+0CF/XY33"NW6#P(TTPEA+I!SX>M6!RP>3I MS@W"L4O.)\\B)RQ:1K5*U#D!0&TX+IC\"##Y^T5,9HQ;X6A BD>"N)$>V:@B MBM0IA:T6-K*U#49X!R_HK5] N8!R >5E)[W,P2:1)^LR45XQL0ZZZA!01N&>&(1&2P56- )V$'A*)->VR = M>JN#3PHX%G!LRZ27 4=G<_S 6*RBYMA&!]ZEHI3H*)2F*19P?$S@R"Z"([=> M)LH#BB(:L%V=0@Y+B9C0PH.NM)@!..H.+^!8P/%1@.,R7>%3 $3$W&@;>*3& M,:JL-"%%2K6,NAWN_*-K,_S3T%!,T7!G[^^3G6PJ,IM;;W"$G;5@*GJ!+*4> M$?B[)]0*R>Q/[C%\/CGXO$][G\H&%\P/C+AM'1! MF9@XL50G%64@ 6//:>*-S4T>&N-+&.)V90W;L^.IM_'.WB;Y:*74RB2.HN,& M<P&5C8T*$Y60BU0A;DA VGF+@DI,)^Y5X"*C\L+P< 'E M&X#R(ZB]OG"H7ZO0?C%[_'4\] =V=,6> KKUX+X/H%_1KT"_G<&_B?SE<9>.A.Q(V"1YTIC' ,R M1! 4++:".*(X#[F59T=I<4D;QF7/O&O14:0%"29(H)R+7@$O.!HY2QK\,19% M"$8Z;G44!0D>&Q+,U;!!L(GK+! Q!.,N* $6:<->.> M2^=TXLEYS6FTT1LPI[4GWE]WRDE!EU5#E_FTIT\6>VDP(L0RQ*-G2&NAP=.R M^?@;01A/X%JICBA!EE6#@I::@RN7<6C?@,N=YC:LFT&+#_G)PWMN"4 MJ!]*%"Y8@=707,OL'[R#3.$E&PF;QJVG#>!>?=GI+G>46C%+KS=+9S4?9YS> MD%N8*&F18<0CKD5 #CN*"!,>6Y\T9HW3J[F\_:[ %E6\/6ZQ_C&#M%"I4*E0 MJ5"I4*E0J5#I9^^,*I1?*^I;SPJ5*^4*E4?CWJHI)W_6&$47R/H=JO M8R?=ON\=YS-\N_UJ,#Z(0YCYX=$P'L3^*$=3>DT5RB_DU^II59VT-,Q8@L&/ M<>OPM)#H]40:7_=WLRR^."N*<&UP&$NYT1V[*G/[BY56R0.#(.6)0MQ:C;0. M 46)7>(Z!>I!8Y@.H[>N@2]H43"]4*E0J5"I4*E0J12SE*V?Q3)NCV4\OS]4 M62D])@0)D9MP<2>0!A9!AB?KL>9*&[:V(3NXF,:K!AE555P8) MHQWV81ZCZAFQ-%+MN.AJ?1H(X(O)X)'BI%S9T;.@O:"S,6HM#1(*&,1 MCY8BRRQ#F$7LJ.=,@JE@6:2"T"!B,LJT%AN*^"\C_G.G$T\:UCMHZP[1+0'7-#1:M%?[BM-\= M,LP=&Z>< 5>-,&2])HC+J)'3+"+/M8H$4^L-6=L@K"-6H&GVRB7$VC?@Y M\ZG=^02VMKR-XW&OUM#5(&6-^M4.PZCZA?U8FKI4>"A3\7"A8 MIK_U':2E+^EO74"A]: PEX\VUGBEM4 Z68VX\QZY8 E*6#@C2+)!B% .N4*E0J5"I%3G#E:7\(\D9%EOJ?FRI^02BC2$HR2TR20CPL/*!(Y$[ M9)A)-&K#DDUK&Z)#;I\E:#&^/$HL6,;#NH,<8O&P5A85YI*'G)BHDZ3(>Z$0 M3R9D9\LB!LS C*1>*7H9*K3(Q7H$&8G5VT>W-X1G4QQ6XT'U9_P2>Q6I?N%/ M;-=<.TYONT/LG5)UM'L\WDTU75D!X3L#X7,'P/F3G;W/'RU1P@I)4"*)(\ZP M1Y89AXA)'OY5/$2YML%Q1QIZ"Q NA5VKX)L7*A4J%2H5*A4J%2H5*I5])H7R M13Y;0:5'$&)9O:+/-S'$PZ,ZKC!(58AN7(UF1[27NL\61!Y+*N*'PV%W4/AY M(1PV/!I^N\M8V*GXE3S$78; YLH_;728,ZE08I(B[IQ$3F"%@!%,""[HD.S: M!A$=N:#U8HOR$ 4-"F87*A4J%2H5*CT.*I6"O'NP?.^@(J]8OBMI^<[7Y>'D M9**!(T?S>3R:.60)?&*."H4=YSC$8OJN'!RT5!$\@BA>FPNEU$)>^-WV;-_' MRHZK\4&L8C_D:%[^> 3O&X1E@[QN, QQB)HI/6/ (&%P#-A>Y9E,KXX'1\\R M[XP&O6YHKEPK16U;N/]YD)5I":XL7I(EK SM%598)Q^PX#99'1DVP1H9G XJ MB(^O?_I^ZOHUQ:"X*X,"[JW#:.<-"A(M5=F6H%PBGJ) )BF+P,; T3.938JU M#:H[2L\;%%.!>Q"-^2,)K[N0^ =.9Q:X+W!_!W#/I%#2A*"%(#Q9HH/,9:16 M!"898[+ _:. ^[G&D-9ICB5&PEF"LI[/G3,DPM(31812,8*M#2S0P0N:0Q:\ M+WA?\+X]2[($WENLO4E"19$BIQZDGTB2E C$..^T+GC_&/!^;L>>#,9BK@3" MSH!YSUS(6W@YXB(QRQQASLO:O"<%[@O"!+\OJ!Y M[H:U"/>7WB58<+?@[B/&W65.PY+6XB25M41RSXT+,?'HA <$-CZ88F:O/MJ^ M'L_V9>^]P]N?_B8?G;*4$\T1Z-F(.(T&6144PD8Q)DET1-FU#;7XG,QB9A>X M+W#?GB59 NZE!IRG)'E&$S?*:&UQ--)9XTB*\0HKN\#]JL#]YAFXGQC71D:2 M!.%(4LH1UP(C4/P*:2M-H$Q[*<"XIJ1#%S1"*G#_.';_%A525,A=J)" J;%" M&# 5N8[UMY\W]EZ]W7G[X]>>C ; M6,J>0D"<68\T-0I%$R.Q*5 E R@1CCN\. VMT"(%\0OBWP'B4RD)> A<)P,_ M'/ST@4E)78A!2NX*XC\.Q']W$?&38)*#'T1GP[<_/K8I>E_4J9#,$4#]47\%*Z?;O=W3U M"Y]UQZ >_ U6JWK7'T:X]SL,;]]V^Z,*C#C[Q79[F>[9,JI&8/]<[*I4/=@2 MKVUT^_6N,##M@-5&,?-SO]:C=ARS>H;_U$WQ\_8Q/S@\&L8#N*_[)5;=/OS> M3.KXXK2'L5<_/QY4;V%8,-K-ZO?NX,!^B?WJKV%,<3B$RV\/[#".UF=&P>J( M!2UB4<1B(A:#HSBL?:)1/97\W!F!\ >VOY^EI4K@:E5?LI-435X_D8W?+Y>- MSND]KZ;G[]I^J)_>RHW2!T?U^;ROP'0&GJA^AP%/[US/'^H[QP?#&*M#F/7! M*.\%A=?_Y[@?*_ 2JIQ;ZE3V$(QOF YXB0.0WM2+?GS36:3C^HU'@^&T:US^ MZXN3\> SK"O8UZ/JQ>#P, Y]U_:J/^UQWQ_,!CR=S+G;IQ?S8]UQO="K"!*L M?2!1$W;4D.V4D'8\'G;=\02QSW'FC.O&!W9@>'O?&MA\' MQZ/>20T\];/6_]]Q=]0]RPPW8?2O!UW@B^XH*Y;><>:H*7^=#O3&KUNOJA5D M&-X^AIGI\?'TZ U87>"6)D 5OQUU&^S+I %JO!B>C,;94 "P@?$/_.>E!;=Q MQ3\=C\;=='(I:3;^Y8:_;5SZ[ODWP7.U]3T+.32Q UC,#W+88QTW8;V)AFOD\L?O>*U0%4C?NBM5U]CFI>QKLA8S3K5EU]MUUA7:5U; M,-9[K$]8B?DO,5:%V4.NZMT$=J^O4YF_=T%>T(-JC<,VI<&F;LO;[K=JNW%: M7LX[+9?VHEYFA>Z!IN81+SHYM^BWYL_3+/I-$SGM7L.7X/B,3\ ]N;9?^C)3 M?SKKMY4#0&7U?ER":U>]+-MRRS8?;"HKN*38#KM?[#@G!5[W1^/A<5[$LH9+ MK>&;P8GM@>ZPXRJ7Y%1U,4U;39Q'M_I%\?PDQ=,2UVFU#NJY48M/%_>[_7Y6 M9#_6Z'.R $^RP'2YN3^6$E*G:?#$4TF5XT$1G;2 90B)T,BLGFP:()214D)Z MUR6D_OO./_\Y_+#W-__P*7R&L?6:LM'?N]N'VV1WKW?X?N\U^?#/>WZQA!3& M2-X??NC!' YW*'S7'_^MRT:W_WA]\O[[.['[SX>#[4__[7WX=)"VN^>.?L8P MOH_*"D"=DPKCCEUTA ?A&J>%MIQYK[V77"LK$Q8T M\F(H/P90)A=!F3(<6+0"F2 TXD$Z9)ABB&LQP."APO!\?L(AQ;'B@'$QC% MJ &$I?!@(^.$\C9H'Y,RG(?9&5@%CPL>%SS^F7@<$L=.>,*LBR"<1"$1N%2%P0Y;SWB6MEG*-**E/P>+7Q^-N90_C8SI;__M$; M' 5- E&6(N)*"J0U5D@**GC2TA 3"R"O_IGF!>0+R$^SA=&1&)+V7!(.!IFV M/ 8G;(?W.>:0G'[GC,G"?D&4!(VXU('T4&D7&<;)& M$6%U[AS,5[SIXRHA?4'E@LK34_*(#B1)L+H<>,5@B"?F:#16DH2IE+2@\J- MY9,+J.R<4V!B>Z1PY&!_>XDTD1P1CQ-+4@9CR-H&T1U90+G=K1>7+AZ_T/*W M51B^F.A_'0_]@1U=L=6!+C??A9KK 5%\\;270'$E,07WF5$=#(\L6I 21YB0 M$D!=R/1QJSZ5@V""?OKQ'#/J%4B_,T@_F2^5IC98<+$X,E:G7)87D ["(*=B M8EX:GK"KSSU5>OZ$CA_K=]NB1N4%"6;[)*(R,D8KK.5<1$,#%I8&*K5(V,>" M!(\-">8*=*VWROG(4""&Y5JPA!PV 6$.4$!Y)$+ZM0UE.D3H@@2KA023B'BA M4J%2H5*ATA.@TA*VCV846Q*-%L%SHX(Q4<6H(T\.S!_LB^WSV&R?^<2R=A[( M2BART5K$B73(&4F0PHE$+(F3.EQZ4.'C@8+[B$,]=7C!+LGD,2/**:Z4=D$Z M8QF5F N+G:CAA4SAY><>9U3@Y5[@92Z;*0C63B6&B T)<2\C>'F44-!2>["UB80V=Z%93.$_\GD.O_W2&P!DCG[-!SMT M >YSH_\A .Q^OVD#?^88F:48?\%Z/&;&7TS^5A2P/4HJ/400>'@T_':79DH6 MP#]!^G;[KQO!>W,J=\5RN2O+9>?%?% XL\ $< M9;&V8186815@:#4P%/A>!2K]LLQ^82L2LX9QPRDGA#H?HM&:>X!J'"R_ 7Z/ M8+[PJ0#YB@/YW-9B;(E, >";,:,0=\: !RH5HE%&!3S! =4O _(YN[:@0TO0 MH6!XH=)J[_0IE%\IRA]*^^['2GKD%Q ^[,#7@[7^Y+:"(B,H6")@YQ@D,N M\M,(H,Q*9K7T+G?A[+!\#-(/NP$E!;4*"JQ0J5"I4*E0J5"I4*E0J=3'%F;M_V?2Y?ZEY_DF$)^)6P;*%2H5*A4J%2H5*+ M:C4CQQ%'A;7->[.Y%A[#'V22GC%-R-*;UK*EL-L_/>;X])3CT5_#.+;?2F#^ MS@+SYUI-OZ.[6_L?>51""AF1#S@@[IE!QJFZY%(YY;U+*:QM*-+1I=)RU<3Z MT8%OJ?]XJI0O5"KU'RM8__&N/XPPBN\Q5/MU1*3;][WC +]V^]5@?!"',//# MHV$\B/U1CI$T>[VJ7^BOU=,J$&EI2+ $;A]\4]<];#^?UOR\GDCCZ_YNEL47 M9T41K@T.8ZD,NF,'9&ZGE\,V&@QN1](4'!!-*7+"!$2YPH*I0%,^,YW@CA%E MB_J*P44!]4*E0J5"I4*EE:52J3QY6IV9BFG\8*;Q?/LFS:-0V$N$E?*(V\"1 M5HGFTM0$!8 MVV"X0TM=P2/&!AXM<3+$J)3BD7$CM$_@[1CL%5;:%&QX_-A +F(#LS$HS@PX M,\0B[@A&6E"%E'$F64\5\W1M@](.Y;1@PZ/%ACMH&U:P8<6Q8:Y?&/! "-AC M9(+1B"OKD%$.?CANO?-.*0L^).FP8C:L&C04QZ]0J12-MI?RCS:#<49U%^V\ MC':>STA@L-18PAZ1I,!TIXHC;;Q",E E7/(,_KRV(8IR?L3"+QC5(B5K)=8\ M>6&$\-PP 7-6G@G26N$O=OL=(L/%(]JM(M0[)Y%GV"!N%4;.<(E45"1I&HWA MH7;J@1U:#PXMR8+]K&&4.\N=3^W.)[#[Y&T69-A(Q9PCBQ'OD M*(8?4K"@(P-?]')4*)VFVPH(Q80K5"I4*E1J189O92G_2#)\Q9BZ'V-J/MT7 MF'*>2X^LS]4XF$ID0HHH>.QQ= Y+UVS.Y[Y1*%_DLQ54:FWD9/6J--_$$ ^/ZFC!((&#[\9/]I3X1Y>9?)14 M6B;(=0>5FA>"7,.CX;>[C'"=BE_)&MQ98&M[;W.\?2YK\(Y^]%H2%H1'$N.( M.-$&:8\IL@SK$+R2CO*U#48Z=$$WPQ9E#0H<%- N5"I4*E0J5'H<5"H%=/=@ M^MY!!5TQ?5?4]-U[5^=TP?S]OO/];[;S]T:W-ADUI(X=]MS_9]K.RX&A_$*O9##M/ECT?POD%8 M-B;K!L,0AZB9TC,&9 ^#8\#L*L]D>G4\.'J6.6(TZ'5#<^5:V6C;POW/@ZQ, M2]!B\9(L83WHO'D1Z^0#%MPFJR/#)E@C@]-!!?'Q]4_?V5R_IA@*=VO!'\E-W M(?$/G'TL<%_@_@[@'IP")4T(6@C"DR4Z2,N,LR(PR1B3!>X?!=Q?3(E(A3FG M7B(1K45<.(H\+WA>\;\^2+('W%FMODE!1 MI @ X"PADB0E C'.@]57\/XQX/W.1?/>,8:E%0DQ2Q7B"J#>8*D ]+4ER@KA M':[->U+@OL!]F["MP/VMDD$1RYA;9&-!-:<2VY"PY#JPP(B0.EV.]_>_QZ\ M_]T#_T5#7YLD T\!2>LXXL0JI'VP"(B/H_+2QY#6-A;C_M*;^@KN%MQ]Q+B[ M3/FIM!8GJ:PEDGMN7(B)1R<\(+#QP10S>_71]O5XMHUZ[QW>_O1>?-2<41<= M0Y)2BKC1#AFO)%(F45OOLI=T;4.1CBYF=H'[-F%;@?O;P+T$+UI2DCRCB1ME MM+8X&NFL<23!@1.9*=)V(W"F!D>)<(2ZL13HD4"(!8ZE%"(H+4"(<=WAQ&UJA M10KB%\2_ \2G4A+P$;A.!GXX^.D#DY*Z$(.4W!7$?QR([R\B?B!,.E#QB-D$ M;@--#&GL/7SR.M# B:]W).,2)WH$VQ1^&V?Y@_^&[I>-*35WC@^! K[Y/8-" MMW]L&_+";=-W3A9?<*#.T6#4S3<\&\8>W/DE/O_:#>.#*>J<>6JRT/CT$>M@ M68_'ES]R9E$]@$<W9^YSBJ.>^YO=]YM_[KVO_OKWYIOMS>JO M/U^<7XL6#GEG=^_EVVIOM]K[]\OJQ>[.ULN=MR^W\J>WNW^^WMK<@U]>O=[9 MW'GQ>O//ZNT>_&'[Y<[>V]9/[)=W.YOOME[#^'^=&^N-1[0Y[-K>;<;18!WH MW<&PQH9G@*UQF.]:VZA6\Y]+5G/C7V[XV\8BV;\ CQ.3(TEMM3 11_"9HG$: M5*9Q7B?",,>NL;/@F1@VLQ43X8*WWM$4-8\<:VT,8>!7!:D,6%IKEWV/229A M!IK-2\Z]L)HZ3N#_6"CPRN5Y()GH*Y2-]&=,3BWW+A"M/WZ&B*Y]B)^KMAMN M)K\^C-&0>?C.M'V MT$:M]V^Z/,"/:+[?:R MO95=F&H$CLK%SF;5@RWQVD:W7_,Q VPVBAF.[)?&[S T=F.AO_4QTCDG9Y^ M< @R<@#W90GH]N'W9E+'%Z==&X3P&\C+6Q@6C':S^KT[.+!?8K_Z:QA3' [A M\ML#"S*WBF+!BE@4L9B(Q> H-L;0J)Y*?NZ,0( FZ>]G:3FK'R:OG\C&[Y?+ M1N?TGE?30ZMM/]1/;^4C" 9']:'6K\ . YZH?H/ 95A9]SW![,A3Z=S[O;IQ?Q8=UPO]2K"!&\? M3-3$'35D.R6D'8^'77<\P>QSO#GCN_$!&#U?XQ#XJ3Y>".2@>WC<&]M^'!R/ M>BC,;9 M>@ ,@O$/_.<+LGQEQ&F>-&N7>V@W>>X>//=+%>)B7SZ'M)L%:F+@M=Z8A;ZK M'#ROZK!W=29\/EI^IC=9H0F'4[HN[I[%;QAC^QWTV-7 MV6)UF\4ZSOHXKUCJ]FV_5BE@4XR'QXU&]CT+SZ!3>?(0@209?.H^Y]L";SN?P'QSLOUTQ;D M@;FRGOX_8/^,NXWUDUDDLV:VD[(Q9$<'5QC'!X, /)D%=\I@#:-V)GHL M7P%VC?#0N6=/+;EF&)EAOP#K[6>[$P S>USV*%.KD[$62- ]S'&&>8T80=V. M3\Z:SM,W#V%$?;CIR.:,1/>H$:0Z2S'5YXVVSHHS#0>'U93H_Q[T\LAA%J_[ M?KWZ);=WHOCYY'+]&WG^:Q:?S:-AMU=;DNO5[O'P=* 3 ;[=W.'WXUZ B=C1 MH _^PDGE,BD2:)UL^,(DL@ /1MDJR:8-O,F= ) O@Y&>@!3 ^4( M4 53CL-UP/C)N7 [ U@?7;?,(L]W!GWTXJQ_L9E2G1"-C6;(2CC3#1;C%![7 M+S=OG@8ZW+Q*\Y^SO+C82I[X93=UQ&IO]IQKF$6IPED&[=17K4-6_?%PT&MD_KQ8@\D*SDL&!>L]0,>P_OXC>])XFU/WNA[AM<," MDR..ZGG>9H#5X$ML//9P?&I!+^%+#V,-Y:.S.%1].@[[M;&S&)ZOFMJ-L#=> M>.C.8+A>AF]',,ISBWR6;#6O=0_SHDZN#GRVSV-N@%>/^3(:WG#-3E]N M,P>.C[.JNXQO\VBZJ1H-.G>]&*<#.O-HB.,XA.$U- 2DL@T#Y:R'[9],B D" M/JRRPKK&3EY1&_"F('M=W&HAKC:8:*OM7'Q5O;##WJ")IC0,V5B5,,?]"8!, M(B*CV4T3I.GFC#2,L)&\0\"/YCNG[_\C#N!=X)E7OP\'7_M=6,'M0?X*Y&QV MHW*&*]]Y. BQMU[M'8 3=O;+)U\7FX!1K_LY]KH'@T'=^#$=C\&+.B_\(Y K M'V.8CJ]1#UM:.>YP49@7R'F:67X[[G9;U[> 0B<6YI)T_756>C22XN M?LLP"*9?-T=BCZ8INC"T7W.(.5IX(:Q.%O2-#%X<7R_$LYPQKR1F7/#BC M,4^:$16E#DP8=LV9(?1B65X=&OL]4QX8]"CV1S6[;0Z'&7?R['X_.;WEKT85 M;N;HWZR>;S//L6F4_+)&T!C^.YO@&YCOK!@/T=6LQNO%?[\Y^?!/.'*4RP^? M]K]M?]^G'[;VRG>RL_F181H2XPDQF3CB3!+D&.>("$,%%\PXY7-5W5Q%W?\V5L4I M3UVEI7\V6\U5>]XI6[V!F;X:QOAZ(D6%J[?'YVD5A/*4-1UYQPJD:76 MH*0%S:?'6!GCV@81Z_.'(O_O>O5/;-(\4\8Z-7JZ\32!==[8F0#I?E8%@^%) M-AX\Z,IW3S@(= M> 9NY_V%/,7I,)K*I9-:^TWG<%/CS9ZR:_O-W25B[4^ONI.7ZLY2W?GP$RO5 MG??TS]+5G5?>LK D\]I2SHNEGX: JL8N8@=V5W).B425E $39TADEZ)%VR*P ML]3NBR:U^S:G=A]OP/5UO]K)#C;8T]F))YV&J.Q"'3(W$(.6^"O]YY=>XHG"UPH=_.TC^;T]JJ M5X/A6[ U=FHG8#2)P5)0<):P!=>MH[F<,[-S0NIXE,W/AO:3XLE9^<.YNHB_X)9#Z^-QO67H M8KYM>MLTX=:9Q=:SQ5DSWJ"Q+\'P!3,2S>73FB+F,]\XB\.<'U(./=O)21[P M4/1GHCB]P>A,)+2N^FBFNEYMCFIC=\&U6C[J>J%I=<@TQP@F,J40U(N!:(.T M\/#B+C-8T!ZX)V9QP9?=3YF/DN 3>8W&RY(V/%X&JN?JR&:X(@=WWL<\'[*\=(#3Z4^R3@UUCALZWB !=>Y[9K[L&=][ MD>/=)$K.#_!*8%O:JYX2?#%-?F)6I=HZ'DYI,SX8QGAE#>]E/-&4XV5],(F& M+)Y79N'IX[-:$#OCF+SQ9?(+J9.=X_FDSPH7%-3VW38(RL'@[B/.8"DTE%=?DNY9SMD^/ MDOTK6Y/;Q[UQ]Z@7YUT(&.K,A9CXVOB).1/;W]_!?/[^MOW)BYU/+^&[WGW$ M@C.O?4".L0">17+())R MO>'1QO*),>'NWM]?P:/%UDGB-4<.N _Q8#1RQ#MDM&"$"ZWM)*TZ'^]IFM M /Q?^$+X<:=8^ 7^UN[65&?A7=$'CB)#^"Z_",BQZX"=XZ[M8[NL9Y M_Y^/]0[W*G6_G59$3C8)+LOOPG < V4ZN, ](9I@' BW*@H;E"4UOV/X?\WO M\(&:<_PNE^#W5WF\$UXOK+Z8U=_CG?V/.$@FI(V K@)8W0J)C$F N$IBQFUR M-:LO.G[[/*=?@9'3.EK@L/'7.&'-!9R\G7?:G)H#4R?U9CS_*.L."?UYEM>9 M6'+C;_U@B?=IE.ELJ?=R!70W\O-&"XO KZS';4I9\C>$TWA*=[:EJ-GHAFS/3@'S^TG#3BO3KRL 7>H!?SY>ZS@9> MN]39B;SYDC<]".K5Z(-$57DVRSK?/]O(9TLHFG\F.9;-)L7R8C :[Z87S7ZE M)URJMK>)M[?V/T90'PG[?+:/EV!(T8B,) 1Y1X$DUG&J4NZKMJXN*7M!P)2]IJPDT(5H@0N%!6L"BU44TJ",]209210O<[ISLX;DXFPT-N&DQ437R& M'+<686W!XB->Z'R"JUF?;SO_OS=76YTS!=V]D\Z#Q.BN5\/W%KN['XNGU9&W M*WH\/-'(VQ4K4@O-@I8Q-[<*L\J?!>3N9,??3S,#E[*V0,1/<:(QLNI%RD97 M>\S!19G?&W+!G5F+2]EMG0?>6)?+",XG6G\$[46E#$_:.JX.D5 M?XM2_%V*OQ]^8J7X^Y[^N9O6OH^A7KLI<)EM<]J<&C)YDKNUX?)X;>G=?K5Y MO ]#KU3G-/-1"WRS67=0EYE\@Z'E.'.:ML/8'\:F/JON:S6JM>'@ MQ/9F[7]&QT#DT6BRT7NVQ>TTL]D8F+#2Z]7K=#K\"!:5K^W:D\L;$HQSMNGK MQ(S-SS66W&P+MK>Y#G#VSKS$,]NY,0DG6:6Z_\%)-0 O8&R;A3^S$J<;\V;F M=C;#J][QX1%,\'":E)I62U_)X=,2ZEPE&:LK;ZV#GK 4X!N%S!, A-TOM1UT MID"G7O/&VIOL"1SX[D7S+D?9^X-Q+N2,PZ9564Y%PY,3G^.*>IQY!_#J0>?O M6B8WQTWT2MD@@N-<*:D5L9AHZA.53&AYR1F1XN+VWXMAL@M!-##OFR8"X8_A M8#0Z;0;[A^WV?X^Y/=2>_?9D[[SM;G[[M[[V"D'RG1RFCID77* M(QX51TX(CZB+%"="O* N']J[KN=K(":YN4YFF88YEV$)B[UEB@3,7.""1TE\@\;)+LY%E(UWO^X*2L>W?,( MKVY4G?5F&\1E9]#W16)N+#$G.W]_%"HZ*5)"!EN#>#* F910)+Q3P6%CC4AK M&WI!]<[*"4P+!&5:K+FX/[JS/9O#>:.#&,>G;/RLQ.'-_,N JL%Y0_@1$]\W+-; ,]MC?EBA]US MJ9G)*2YUP6CNBE,GY2Z4Y$^3+#[.JOG.5.G7^^6^#LZD8D8^]N%[!J/&TX8W MSUJP77P.+E\2ISCK\=>][VZP9%, Z Y'IZ,X+46DG\4ZV6;+1:\=G8"U0_PR^*]GTW3P#/[,N\S M*=LY<]]%O, MK<:Q>C6SJU[/VU4_L,^Y#7;(JX6'9'RMF>^4%QJDF6B"R1;=X>Q $I-&_$,L2X7J"7LW?K; M]6H_@UN_#JN?'F-0=W^8#.I2);KX%)#9640'L7?4W-P=!E0WHIUUOR?[G VG(D-EW&JZ4MX%H,;Y+OF)*R5E,C%2?%3OFU" M8OG(A.EQ."&W3#@])>?12&B3P#N9!'C.BV26%)\/'SVS5?8&T9=1W5WB,)_, M]GW:ZD;F4$U :\F!S"DDWX>D\33+MW M,AK/&E=G&@&UCD>G7U5/9E3OW1O61N#!Y7?5<\N9Q-G!B9VS/42.K#W, MVH0:YC3O_N!\Q]73.LH&X_MGZTOKMB,3KVC"*9.^$&?.W049[@)B'T^.1SGU M1QHFOB&7=1>?',7.VJ>+#HD"D,["!KJL>[X)4,UNQT>GYU;-.-0-8)'.83O( M]G'_5$6L7]G[BJL0:10^:6$Y5USC*+ 1EA!L+,5^X4:7\W'.6=_E+5BPWB C MS&ZJ<7:S'_[L3NQ?0-PIX&Z.9X_LY1'NP6A^[PW\YZ<6XMQ[C7>^^X]V MGLAIYOWZ/+=?:JEI&N&-?GUVL0/8?381F97S+2SHNI80&_\:UR Z*W$=ACA$ M8 _T[-$H/IM^> YP<]2S)\^Z_5JKUP\]!\-PO]M'D[I8,"N>?\G&+^B^R>#J M<3:73\M$UW%3*CH>PK]A^LV3R^OUI=_&8?X:@XN277H9KY-+KUWU6B+6.;W\ M\E6OO?H:T[P,=K4&*V[TVM]JSFVX%P0DRVB]N6Y615V?)/H,5Z0VM*?OF]UJ MYFZE1]_RS<_GY/JB0#6R=-?6N[FN9K86V 7QL!E 79SB4UF-.?5P;D5NRRBG MMTYP>3PX>@;W5K4'5.4Y/E^I15O@R-YFSD]GX5Y,S9QZ\3I5/X[O0O8>W3H5 M!KLG!KL&RISUG_>'X(\&-!FP]S&F=-4BY).V'V8)YH)3^*K@U$)INV[>E[+% M1<[ U0HLS?_^NEV/GC/7W_Z3/,];\PSYW#G:W_]#[\\5YL;X6TW<7?_MQ[.=Y^B[]M?_^; M;&^]^QB-,T$J@C1-$@%C2*0QDR@Y8W2B)%J9FWKH#A6\P_EEG:/N363RU25% MYRK]=1UR7]2!!?D*\IU#/D>"H-QP*U7DRD07I+;:,Z>3-%CB@GPM1;[O%Y%/ M2>(I*"P4>03D,O()F%1(E'N5 M,-A^U!JO"%5&8\.,9K9&OKDV7 7Y'ASYR)S-YS'F*404'07DHT$@)XU%&(#/ M"R93HA:0SW0P5QVB64&^@GQ/&?F"\C:Q)+PRDJM(M&"&",,-DU@)H0ORM13Y MV$7DWEPJ#[>6RZ089EZZA)WGCE$=C>/:>2>M\H29CY*L ME8Y4K6W<5#I2E8Y4R_WS(\<1/T1GJ2NY0]Q_?>("(Z@E)8=T>VK3?/KOP?8? M;PZV__F;O(=W;^^!#?+]P\%[N@W/_'VR^P^,XU/X]/[3NV\72PYW_GGY]<,? M+[]]V/KOP>X_K[_M_/$*K))7G]Y_/^A^V'HM/GSR)SL4OG?O5=K.G__^2&'] MP"2)"./D$&<.(R>"0=YQ',$;(P*]C%KZ MBQ6'I\F^-Y-DW^:DUC!C7;L_K7-O"L7A"X[L&&Y%1\/!>-+>NCLX.G>Z\&D= M>[/CI3GV)9^P-=T1-SIVHV[HVKJIV;G38,X4C$XV#<^&,MV/5E>PS[["G32; M;IK-;'&I;2M7L\T](L];?Q##<2^70_NZE'RT ZLY^G, S+'9#PN Z4GCTOY' M9[A@VH(K@Z-%''./M%$&&1VLIY9);] ONYK<>%\NE.->GZ48M! M/MJIWEV3:ZJ;W9^CIA'?1!I/Y3FW0O:]XU%^;K)9\\+CPQBZXZII\=!L2NW' M\86OGQ5OS]HDY=ONM9#;CB9G6(WF:[@OD>!)T7/V7!L*KDP!->7K2JE5J:HJ:NR-6V*<2^-D,2Z%C<8V(+89M:)B*V3!8HL[^5JPAF_D N!EE+ M?(;8=;>UZGPU;BEE7JZ4^=2&W3QGA+XXM6%?3FW8%]F&?=48@-G]J>2OK5[N M%<.N'3#R%S/S*D%6]8M8A%G7Z+6IQ0\>3+R:$\J=/WKG$]B6\.($]+\'A]>! M:NCF ^(!T ZZHQNIA64+/99YQS(IW)6 L,7K3S%3/\W06C2$'S:TZ,T-K5(1 M5"J";E<1Y#EVG$:J#/95 #M''SXXP/\N_W]_:_\Y@#%^^G#XGE^L M 'I/7WW^_6/G\,.G@[1] M@O%@Q'AM4?2"(VXI039JA1BG/#&N751T;4-T&%<=0\BJ% 5H"M =^-Y M__(3D>ZRVL>9L_IJ,'Q1YTO^!.R;.*VO^U.7-7NLM<-:4/$.49%>1$6+C6(V M&,0#5WD7H$: C J@43B1G#/"@(TE>$?B^7TP"Z"S"-E0I(9U&)X_KJFEAN+2 M,:14_[-*,:2]DY%UP^X/18PNS/:'(D:W7+&?&12Z[Z ,NTU0YJ:TH,O18J$R M7F6M1#7V*1+!@V%<4FRH8_#3!9-TY*X$(UJA8W9>S D= O8"QS9-G M2+.0?Z5@4W#X5X$4D8X2IL.INJV.60Q,]VIA%QG^.3)\/VYVZGZ+ 7V/PT$1 M]>5$?<[#-CYQDHU(RA5&G.* C$P11>*Q (>"8"W6-NJ>XO1Y$?0BZ,6%7#69 MGW,AO0_*"L$1TUG' WF1\10^44^Q(HXY)]NIWI] I<'K0S<\_@*#>>C*@I:6 MFUU6'T 5HIC=I!GRCZ_:54IBP:H]0B4AB9%@_DOGN;%!0^/M_8]L/;<[[M=:?H_I>5^VI!_T"22YYIXT'#2$Q=90RG*11 MVE ?B"W^7"OPOKL@0X>C8I@*,.JT!KP7#AG'#)+)DJBL)=0U>"]RC^A;EPN7 MP'U[_;G;"G'QYUHH\/.5L-XFD;Q%*?*\/T!%Y(*GR 'E+7AW$K,L\"#N1/!; M^'-%TA^MMB[^7&O%?3Y%9W F,$8\.OC!@D?:DX@(./7.!J"Q26L;<%.'RY*@ M^[EEG,-XF$Y*>F[)[;NDI.?N6T$HP@SWW(']KW(/<4=X([*[N; 2]4LYJ(RQ65'T%MKLI*):&_.\;8B7'*.+13W^;V! MF$2IC40QYJ@43V"X@I^"O.'6$&\$ ?IND(XQ\VTF2L:QK7+> C$O7NJ#"_N< MEQH3ME31@*+.NETY!VJ=!Z0YIT9CKQT-6;?SCF"W[BI3,H[+2.SN^" .2[YQ MN?+1[(9R7/*-][G!@%";C, P1P_J05H*E@#16@1++8^X.'*M /L%VP&]<\0Z MKY!Q+I\W+04R3!,D#!#/:2^=L&L;O*,I[S!3M@.NF POM1WPED)<7+D6"OR< M*X<-U5K3A"R7$7&),7*2!$0T%\H&S+BNZ\4)P1U!RH; U9'U%HAZ<><>7.#G MW#GC?+1:DMRXS2">+'AR,3F4A/">47#O,+ASK*,(Z^C'N"&P_FZUKD1;?+O% M9S/M#<:VUY;\XWV\X[KG)IUE)Z>OSC>77=5FUHO)??-FUG>^/"W18HO790DM M)BTC(A'LB4_<2FJMQ]MX9V^3?/0R M<4\"0T$&C;AF%AF=*&)6&D&,MH)HL$)E!W/=(6+>[[R7HH*;V5D_%N&\,_%] MX)1(0?&"XM>ORS)QA]O">(D[M!+RNQ<@WS!A#<$)!25"+G@&R$^*(!R4#3KH M9)6M>TTRU>'L-H&'IXFX3QQ15QTQ6P"8)7KS\+"Y>]%2YD9%IQQ#J3[XR@6* MK)*Y](8YHQU-B>8._+S#".XH,A^_655+^2>?,$/)TIGO!DY-6_!T,0W^C*/1 ML^K,(>SVW"'LOI;PJ@\<5F^'0\&A_&_GBS M'TYOR'#?'\4W$99SE/&\@/U=@?W+>;!7QB6-#0?SF,(/2AW2,7#$DO2)82Y9 M"FL;E*N.YG>0FFLATEX1PF\/TEX1P*]2(WKP:3@XL;WQ264!6L>C3M6/X_L( M[Y> 3 G(M,J]N"2LOA/'17O,I- 6A."))<$4^QM M4+AV%;"D':U*4/V.%-QOX\S?TYV"9[9B3KX!99!\QN04.;O] &;6,T1T#>1W MNMKZNM6FM4%*?KT76M_DVY^?6Q6]+NM5V#H>VLR#HVIT,/C:KX;Q:!A'L$S5 MX'A8Q=$8( +@!)1I-4C5^"!6_G@XS-?AS@%0J+]?!;@C7_UZ$/N5G>G?K]U> MKQH=N]'8]L>@F'LG5>R'#MS6]0?5H3T!% ,C-U0 BQY&FXE=C8>U"H^CXU[6 MW<.XG^WDP1#4^='1/\0!P>UG\Z/(S#6O\'L)E[@Z-L4L.% MTRG "(_@ PP]?COJ-M.NQP[^U^F8NGW?.PYQ]ER8/I2_")Z$SZ.\7K]6X,4- M&ZDVH_#O:']NC@9+W:@_M@Z8#D+E;]0;9-8.'! M*QC!FMIFL9MUZ\*?ZI6K!QF;18V3X,_Z^;QG9&@04LE,E^-,A_S=P'SAJ,'G1K'DR5=S;7# [, ME$4E\^#LUOW8ATEYD(KQ$'AD!6G+6D?;OUZ_VJNL_[]CD)T 8#2C\ R6@!C@ M$4SH!/28' J\7OT3JP.; S5'1[UN?KB?\6J&;KF#6AVZ.3H>'@U&S?GUPQ\OOWW8^N_! M[C^OO^W\\>K3SN&K3^^_'W0_;+T6'S[YDQUP&';V7H&1_^[[]M\?A8TJN9"/ MYI,)<642,C9RA(%>T43+>=YK3]8OVYSA@(?@MY44;M$VX08#JH9M;X?#DXRW M8 D>QVQEU6&>&EH;I0U"[B*P=:S%_HJH^WH%HIC1>E UX?>ZZ1=Y?B9F/PO> MUDH^O^\OL$&[V0"LWS?)SF4;GJIR@J^H,796&@\/JU2PP-34\-NO 5/V" M/-7,,G"UVV]D,;/,',C^&SZX7GHCHYZ]N19MU^3K'[H^:$=[G?[4T]P06^7^ON:R\^_=L/X M(#N>Z[@)CDQ"E)-OGEQ>KR]=<$6;:Y2O&\HNO8S7R0]>8YK_T)-7#9;P=8)_ M[+4/,%BUSJ5:E<'J=<97:&49E3=Z[36%]TL4B3_0K43,W=NRW9L-B#$F>5^I(M7N*7LWC*5 U.0T\_K5'9HH']<*,R MJH9M=8P"T@^[H1FKA/KOJ+).J7 D(N[0MK%K-CK#T-AUAKV&4^ZV';)L, MWKQ&9^GIMZ0&Y]8-&J17G#-LJ N.TVALD(9KD4BDGKBHZK \(921LK5U017. MI\]X!_ZV<_B>[GS_?)*K<. =W0][[^F'3Z'[_I]ML;OGO[W_])Y6RL@B5PI%:V3>_.F1QAHC*85GP/E 6WIUM3DH=-]!&5:.Z;E_K62X8E9K; 7CG'!N-6D MGI41]!;(>7$A'US:YUU(3[31(.V*$Y!V$RG2+G)$'*.::<:LC+5ZIZ;#13FK MYZ?*[.M#-SS^ H-YZ,J"EI:;77I>C\K'QM*';D'TJ)6$!V/ >BV4-2''H710 MQ(C G9<&>R+1]<*R%]P7H\#5!?1$B22Y(@'AI$S4B$ 9FF("1A4?X9\SG1' M,=RB;OY%AN_8H[NM$!>/KH4"/^?1*4P<58DA8[E%7$N-K,4),<<(\P([^ EJ MD\F.5O/5).6TGK9*>@L$O;AT#R[N>HOM=5>^I!OR2UPP93'ZWB M1"83@C!4Z.BDXLZ3XL^U N^[B\J%*97>2(050#W7FB!0 99IKS%6&)LFN,8 M,>Y@>>LJD!*X;Z\_=ULA+OY<"P5^SI\S'.L$9AQR0I$(25Y2GPSFUGLM6>(> MEMXG&Y)VQ9UK!=POV/V)(WAO40GD?0"X]Y(@0[G*6T"5QBXJ1\W:!GAY';D@ M6E^24]%(H(Y%XN;V@9-MKM@7Z!-+@0<#5)!4\0Y"\AH&I&3B0N79&"8KVTHJCI* MM2DJ622X71)OBS+56 MW.=SCII20[1!$7N)N&(.Z>0YT@0+[[B+5).U#=916G7 R6N1?K^CK&/]W6I= MB;9X=HN/9MH;C&VO+>G'^WC'=<]-&LM.#F"=[RV[JKVL%Y/[YKVL[WQY6J+% M%J_+$EI,.!\EC>"@*,NY(-99T&@ 0#9)Z5GI0=,*G;2]MSG>>8&_U7II;QOO M[&V2CSQZ[91@*'DBLE*RR&@?D$I),DTH-E'4708Q!:]SP2$G]U)3<#,[Z\?B MFW.X;=UT)>]4#*XW*GKM]G_/UV6JUUP?D6&\0SOM@,GXY' MX\/8'V_VP^D-&?'[H_@FPG*.,J07O+\KO'\YC_>,>(NY(RC%G)US/"+MI$56 M8!H-QQ1',),9P1V-YVNOVG?0X?)@>T44OU5@>T48OTJ-],&GX>#$]L8GE05T M'8\Z53^.[R/(?V_.T-/Q(&Z[-BW1/P_N7EP25M^)XZ(Z[DYUO%[@*GCNB94& M7(6D$5SA3P8@A8_.AH.O@#@=6K,S()S MG!^(P\/Z3X>'<5BK_0#6"].'\A?!D_!YE-?KUPK\MT$N":\2#&4PA#6"N>17?+$P7'=2['9RL5WMP'RP=D-S%ZO]G[TV;VDBRL-&_HG"\SRC-T@565E99[E.2?/TNUE2 (+ M#_; -;45HM=K5L;/BHK5R89JT6-8\_/ZN7$V"=!\G392/[#F#[;@\9)[)_$ M3$8O&F?1]J_RP*"QW6]_MFEHISNP@(3RMI_T\J>9^L!,@]F#8LV3:>2LYD+@ M0$R953(-3B\]B%UX*0]<,>P#C3S!O65+M[?O-E]O-ZS_WPAX)X PFN[P5"S! M9H A,-XGV(]Q0^#5QJ?8.+3917-RTFGGF[M97DVE6ZZ>5IPV)Z/^26]0W6R] M[\\^7;>__ MOW@VYLY!WN1Q50G8F+(?.X"Z85,_#HO 'PM7^"Z725AIN-&L#![K+H#=@[$ MM@<'H(HR)5Q(Z1,+B&;8:XQ@N/]E"OL_CY_3IV]S-+T" H0/AR"X#@Y@:;L' M:\> WH:O>_V-JIE70B?_]<+;W*9PXRF7KTP8@^HVO>^O_ M'FY]VOS:>O,:+(771[OGA^V]]4VQ=^3/6A2>N_TZ-8]V1.MTWS'I5'0GJ+/%LO$VX* 01M9_Q7QAN?S&4Q,CF;:^3#N48YG6ND?N^X\7KJCIK@CK7BCBH#Y%?- M% /?MKL5*\Y3S)BZ6J/CC!:JW[,L:7='MK(=9VAJO)*"PU+/UU\Y;8?AX<0M M,7/7V(K#%[=8!Q;;:'C]+8]>ZH;@.]%J;H5[:;5F_CWL7[#:042N'^UG9/-) MZW/;.;5G@V=_77HG@&B3P16%IR_/N\]YELJ[?]C:77N[O=MX]]^U#\VUQKNW MKZZ5-MMYOK:]OPR^O-UEKK MU>;:V\;';?B@N=':_KCT+_;'3FMM9WT3YO_GW%SO/*.U;/U^SSPJ#0(*O%=I M^NO_&23#D%S"3%,//2)>P\SRUWHW%< M.^^D59XPLR_YLYO)+9_8M=/93Z(W"4;#)<5P&5]R%2*-PB*:QP%-L(2 M@HVEV.^O [ZDF.!<$1I^D Q?=2)?'$-.==AF=S#LC[)G91N>]'>GYS__9&S8 M>C7!AH +UP_.F_3#4?/H7\!Q'S[O?6H=;FV'SM[QZ\/=XQW6>O/AJ%6>S =2>3E]%KAKFG[>'AV&Z% MG4$3EVMQN,)B]M*U8ST*;K]8IS+B\_80R,#?8>4>I_[@';>M5RT@D&'(013Y ML+=;CB&*5]?93MG#P6',6Y#Y:NSZ'93;4B]O+ MS1.+@V:&1;-A"&R9OYCPS8D]*T<%%^P+M[@\0/:I%$H9^W!/^KVCL1.XWPLC M/W$B9C$P&7@Y&:V$ MU0Q1YQE6.+^X1J9JYX)B;M(8MSSL>O?5O63>XT+5Q>%U<;#5711KO9W__:T! M[,&^@X5VV.$14C-I[&LQ50+JTX.Q"5Y>(@,;$OP9T79R ME0(_NYV;%V"YNX*XE0H^#/*HTY/RNX3]KLRGT;"L;5\DQ1]EQKT1+% 8 M_'D]_)B1^826K1@OQ,2]5V(Q8$LZ]F00GT]^>!':@Y../7O>[I:%+3>]& \V M]@DN*-5<]K[Z^L)%MHHK-]DXWG#\Y/'7J^6K*Z$EU7=*KF)#K_T:KY)KO[MI M6$I6%=9W&O:66@?WR,M?TN)LB\/2UB9L;H4T5S7G\#\QA[WCWZ)_#YIOWYUOK[\^;;S8YS/5H[ZC5:1UYUOI4G05? MC>;.]=O-XXW1OOM%;0X6G:S"^C-YO"?8>_QT.2U>0J_9"WL^TC;;[(6[Y.J5?G2-[OO M*H_LOSG08+KIV[V9G*W);H^SM&JA_&!"^6Q>*#MG O->(6H801QKA@RS%&FP M8CWV\(V@SUX*D>O6S&?B_I36VP^$GI^(8 3TO*R"\7>H*_E3Y.)TSQ?*Q4G: MZE:J)>0#2\AI5:\9"B1EY P;SZ7WI2;[BJ+S"4A+ M6VNR!J=WEQ>O)@?%Q963G?DS00)7O([YG'DF.>/W0)H_5J .X'7AIZN&_C1V M ZSZMSW;K6SZL8P,M9!\,"'97F#;&YP480Q1PG-A%Q>09B$@PF&%G3%4B_#L MI:0K1IBZO*VO0$GUV[;GRG:%W@(>%#.&^P0 M"3@A[@$)6RHILC@:K*T+6N/LMC5:K%#]/3Z"!^2GIPB:'V#P.G7_^W.B-B?A MBO?)._S&PRJQ3 6NY-,4D-\1LK-!FN_W,2!7&J-!@.88%TB1K,$YX M"K:4IUK5UR#7XRHC\5)LY)UB5)YB#N/2U1W8K**/!NVOC6,8X'"0T\MA%RZA MW95RS87A/DXKGR\6>&H',]&%,SMJB]G93J ZNL-I(8)QZ%.5-CF.-MJVY\!V M[<_7.5N_)P_QW@'1=TS*4;-).3\G\T8]>N;-9G=HNP?M+%:+TWN]/?"P[:/^ M\D0MGEVD9(.8@L\!N1WY?.T98#]XYC^?]]8W3W>W=_G>\:;(48?S*=FO/^^> MPQSH'CP[S^L?P'[_'#>//WQN'OU]V#HZ!!SY&?!=R"*0M=;VE9/)$Q*18,$C MGC!&CD>,3 #\3Q-\:?'5M!L> F$>5%P6D@DS9Q,S7. 0+'7"AJM1CA>+?R51 M9@4(:'AKMLP]4V)NG]WEMS$D>,VL!@W-N##&:)R"5 +XA +&C<\>.]3VHS^, M8=2)6PE00'L8W^88^:L$NUP1MC^#5M_O"Z\2"2Z'U'H#Y@BU2#,MD)&&2Q6Q MIL+>&F%[*=WJQ;5"=0F";@>-P>@X:Z/S.$Z[&0Q7BK'.7WI_*)H MSH*$?M!,N0Q'^X('KP2K5[&REU1F&6M![-[]8V>O>/3#2M8*M:7?_U MMT;3$K8JB/FF86_^CFE>3Y;>;=@[QBD_ <_EVCP3WZ$PZY.*KGX%XN\>[_3K M!9=?R/VU&;G_&R\)@,?&JXFV*]$3]PFU_\&GX,M\?'1-^-&[=VCSWTD!L-\E M:G_Q6OSZ4?O??;JOC;9&HOLWBN^E-=>[;Q?1U8KH2?W1B!]HLKMX=?GU]% M^SU@S&OM]?@A2G!1HI?!7B9G.2*,>,1SB7KG;$)6>M"(7$BCXH,!_@=GIJ?1 MTKN6JK5472*I6CM6'E_.SCE6?(@6>RH1%F!B\)@<,E029 S1DF+NC;&UG*WE M;"UG?QDY6_MN'DRFW\^-]=;G?E*$CEQ>J_3.FI^;;[9.6N]><^;VY]Q\^BSV(7_ M;JW_^WGW^#V\Q[\+PPH#5M%S+!#!-("E(@+28'$BIP,G+ IMZ<,YV.N(FEKD MU2*O]G[_9"$XY_V6DFACG,L'C+G9K MARVIN*LC"^O(PCJRL#Z;?7P%^(!-D&K'QP]1@8LB"ZW"@N0LRN@51;"7&%DK M"N,4H@9C;.#F2 ;5$ D M>!ZB@!VUX<%\*[65L+6=_MIRMW3,6<5R1W,1M$(\AH T#Q9% M9Z7%280<%_HP[INED:@+@@NOUB>]L23I,C9T7U WLYVUP:OCN*55? &1(8;WU[T(!=*(6O@4%C MOU/BH*IPG;P-PZJ]X,#F"J4Y0O#*!L%'7VR_W1L-&IVVS[7HXV"U\7$$&]X? M/QD>$6V_"Z.4.8R' MC<[Y=G38MPCREH)^N T/@XA$D,"JEMC/J]D_BB<=@[ MS87N5X!@050TNKUA12#Y+NO:G=R-'5XDM ?VX* ?#V H)N9J90)3.?9<'8 M#QH3X$'L'?3MR>'9I+SWS'I4;EQT/(S7$@8_ M@R_[G^,P]F%%7H^;Q"]@CRNLVK]FPZ[R+,PF/QCF 01E.ZN-S2[0;3N,;&?F M%>-7'V.6DPV"_]. 20!_ES*Q=WR,]1XD=]Z/7$+]6D@ HL#%_E540".V3 BI M".5>:4-LM-8PH%C/A->E6C+!O*J63*XF'M"KZ.!5KYOC!_MEY3^T!Y_?Q7[^ MP!Y$,E7_B#Y-_?\=Y9+71//]/H^2N, =(E@PQ&&9D;'>(! "W!AE2$SIV4LS MK[O_,T,-@]O(X7HA/TO%9 F)41(MN;0<+$3-'67."6%DY%R1Y&2*M[2CJXGQ M;L1X#D!U?><<@"J'OU];I_N6>*Y4HLB+' RF+- DU4"GD06!@T\J9P$:MH P ML^R_WRXK2V($3=S;ITD/LC@SW9.5N=!XB->W0? MF,&$8UPF. "WD]Z@G<=Z7CJ(P(,N$H8R:)NY:VSFX(M;K .+9C2\_I:YP/F? MA#V)OH*T9_Z]>^\1A9]-;CKL7^0*'$3D^M%^1C;!&SZWG5-[-GCVU^4:\^WN M9$:*PI279\$6MSCYL+6[]G9[M_'NOVL?FFN-=V]?W6Q@+,&46UO;&Q\;VUN- M[?]N-%YMM=8W6A\WUO-/'[?>;JZO;<,OKS=;:ZU7FVMO&Q^WX8/F1FO[X]*_ MV!\[K;6=]4V8_Y_7L/L=9K26(?;WS*-R3("FZ56ZY'EE7;1SF$7C:?ZYA_"\ MB3@NF^,_FCKTHS]L)F]TNLNK@M7T\BUIRT93MN'>ZMA\^[ M=(-O;1^>" M60PP78NK77Q GVBB#;4A8=@B::FSV#B&??!,,W.U+TRKUT4 Y8H#L4I^2ZG= M:6<'PZT-B;[)@[3067/[K"^_)1AR\'G*5R0>M-46,^Q(E!J0+;9D@>[[R9XJ M0H&E/L7**Q,+X0-FF])\QF\^]H<6_@N_MXO_SPX;MM$! -@!;&>'$S=*=J&< MMH>'E[JQM;NI,XH R5<;\)2Q.5B,P>+FF7V4'4PF<%Q8[]*7<,/%]X/H1_UJ M+GFDT\,V#'4Z>8E.Y0#+L#/9=G_29^Y^\@ M*==.VO_ 6CP,?RP9W9877!\5?^3=O'2GF?R ?K+GV_>.X5*8+LCP8GS8J4/C MQ.;3A_9))07*B41EXXQ7L]#QC3166A+.$'K5WND22XW':KCH[6@0&^UA]KD6 MWTH_IDYE &4S*[MNVIA-2<]BL>SGP%4WHXL&F#01VE1 M>0<664Q!&W,"Y9'G=^-L,B5>):G*LWT3=2[_*F^5DZ*Q1^!G+O#XX "4=L@. MSBP(9B"&LYW2#'9P&.-P4=^UU4:KE\_;1MW)$5R8N$ G[+/PKL>1P,NI=+)L M>!L/K#]K?'S[KK&9[<@X^(65T&8W4U$W5L[. H RC6U\]8>V>Q ;6RD!\6_W MX1&5 VUP61?91O9XM8O;_;B^JN!KUJ+7#)E5SGW:;9OD<&+PG*0X MUYXY$P-8!!R0LQ:*Q!)8@G-LR>)VV[<884^B7_8/-\Q:Z^_/]BVV02<1D-&! M(?_;@T$AD<$AX("".+*^S^?[ M[="V_;/5QMJ@0*C!J#,LU)V!S7&\GK;O1,X5T%A QY4ID@]XP>0 >)-'RN@# M5&:&'2" 3V*_T$D6YZ$]&/;;;E0H]\2>5;"I6"ZGO5$G5&:#BS%_VPZ3 0\B MS -F/IGQ6!/?S( %2TY[6.?^XKY2U;D!*!A&L,*VGT^QVX,JJF+^RG8Q<^#! MB^=1JH6I%X4QP?XMS)=W,=]1\,!T1<9#WV7>*Z4S*5QYJ6/I^,XR6UC%+,WDE\U MF[HK\]W(KUG"^/5D;%WTILW,>U]@)D-06W>9>UE*4(V@7ORP<];HG6;B W9' MA5AZP.3 S+.:90NXX,.[S<="*LN@IKY'S,I55*B8P^*; 7FR50VYN8,42O"@6F! M?.@/V#[!S>_>AH'OTSL3Y"G[5ZV+CJ= M'#@S.JD0<[X,Y@-OGP/VQ@K@XM#OXB6J^U<;+/IG:-W-;6/#V M?0"*,MQBPX-6SO'L%5;)"VNXX/!:UC2&K?< MSZ&,M]8W17/=GS:/_'GS8-]23ZW'"NFH#>( &9%-4B'!)*-8*R((H!A^*X;) MA'4?LB!2T( 5!4(@'&MCL3!4,!6 "&24Z99HDYHL'H\LSIJG^T3&$(7&B' 9 M$7T!ZTKJ8LC[1E6.25F=#TJY1!:7 PQ6EM-=LC$OK"]$^"4L%>/@9[I3 MOD6>DX>6YPP[QQ)56@7).0V:Y YP7B2J'9 (O25FL6;&(662,2(B%R%;VDR0+C4K%Z7=;7MPITIEB,D3@JO> D:@U6,.7:*Z.U MS=$M-P>6U73Q>'3!MM;V61#1RN"19@$$.O<*&2L%2@PS%A+S*A5OQ:K^W23Z MZD]UD7\JPCGFA*Z&MX/#2^Z36ZR&GXW$W_5[.5SY!OYC?G5-K+KX#%_/6P3X7GF*A!8K: UK7+"'+;$!8!)$4X#)&='DLXY"#P#0%=QIY&2R2-NJ$=64(WWF8( MW4_>7^S([T+U'VEP9 MC]48]@YBB2 JP1475U1':E=OG.SI--CAQKC2203>AW>;K[?O?Y0X/IA;1%,/ M<-AA&YW>8+#PO&KN+XSC:$:WS-;JU[5GSZ#UKGNX;8YAWT:(<1HXX=@&Y9#D87%*;A#%-AF7 M<5V)CV\%'#IWV:4T4,94AJB5@95')S!TLK)H^'IL^6J?[H.6HXL&C M:!)'G,5W-P7P-@/I3HED2/B $4CCB'1D$0"X;E9/[@!.'"GVM84]ROE\5N#XZ.>F4H#/;*0]?[X\.&FOP87NBL\#F?)?@V1=QJW_W M!J-..ZW.&'(EZA&,[%) HD3#%7]LH[0BO@C9+0JP&FVV$%0.'BUS@DF4'.UB M8?H>2 P@Y]Y)%7!Z $JX2DK*1F0U2A5,V>OF&,F3V+^(/YB96H[4JW)&.IUQ MC'_.R\J.XBQ61]W3'&D)JGX:Y#VH-'3U-K;;'95HWO%+33-( M)E.:]4QVW)"B*)H$)R%[$VG(CDI!!@^06E[NU"O)_;L);J"_V$ M1Y\)6'D8:Q$CR[Y!!^)J[ZD3X#FBO>%8J*R.:/WA1!Y]:^6=^]5I_ 8?\>]7D\=<7Y.G+J^S=%.NR^O4Y77N]^>[ MR^LL _A?7 CEUL(F5PJA)!*83=@0Q2A/P;C$%$ 1QY,.U#%9TF:;]BS;%GIE M?/I2F*+$!.>2!=T+S+XR*?&1L\J.*S4&=N _H\Y945Y%B^4OTZA?I9K/7@3J MKJBZ84Z*\B!9!Q6B3Z,*N%<)W;GZZ[U\)$(Z393@C <>P=[& :<@E >D10'. ME3S7&W!5_Z3_]7E)C'_5.SYN%S2U.9X>6%_EOS6*6GRT/JUEF!TBIZWW^XX' MZYTD2.%D$1<.(\-P0!Y'(R584Q*G9R^I6A5S *HQ]8%4-#;,C<7B/?UEWTD+ M$XQ]A1SJ[;]F^[/O2U!'7!0FHV:%.%<.61IH]I)*XF0(SJCL^\*WGHR5(]SC M46?8/NG$QEFT_XF-8 WO([L5N]'8E7Y_E3;X_ M9]A>9-?ZWJ JROWN, NF"I&S1D[[+#EUPZQH2TZO#5]*/O.[;4Q5/E7HC0X. M8<"#3L_E@BZ3.V:G=-+/);*/I_E\)3WW>)PD;0?#PV,[E^T]+?2^DET\4_?% M8.1]' Q0Y7F9K0T#$ZYJP9_T903RJLLT*S,2IIH>S#-MQ]GCT[R.+WM]TM] M]$N)R#,YS2>=T6!<2SW3Z[A64B6/!B7/_VIYD[+_4W_AN&< 69E&5-PSS@U[ MQ:)@04O/%9$:$T$B)\%R+4"F7R]*KYPX%/UZS0'#SOC=+D1M[;"X1M;N\.;I M?BX";Y5E*!"N$3>@62UW 05!L$F41YX;C3#QX%&/+@2K0M1!4?2:J1_B(.:F,>L7 MX&.MFUGJ9 1&W<=>&I[:?ER^$JJM]H2'FN=;;UX?PW6T^6;G:PN> ^.(UOH_ MARW:/-\[?MUIY8+L1W\?S_'0>9/O?MJ%.>V>[FUOL-:;39CS9]PLSVD=[W[: MP4V8>_/-7FIN;Y#6VKX3D2FM+!+.Z'Q\ZY F@B(3G03\*JQF]JI-+1RG";,L M T'D6@NF-\C @(WQ'/0DNUI"=;(EC?_''I^\:,SLS#3:\D/Y:GT:*OEZ;!)O M?#W)]=$:MY9:?3)H#*MKT=CMZWIY'X))41.2=+0^)Z([*CPS2=%$E&1"P,I7 MRSKU,,3Q]F Z,./ MY:D13<]?KY@%]QY\6N=F4F1E(OSGWZTZZSWHS9E*Q?C*@\NHJ \K.YM08--_7!OKU#)[;6:8Z]>X= M=$LGL^NH]IXGW@:0J<=:\J@!KQIEP>R23*F@DHDXIGLGF$Y$*JBV&7$ZEI9+ M@PM_O$Y;$UO;.U^;V[MG6]OO*5@,WDH?"),(1VI!OTF%K T$>9%XX@%3BV'3 M\8)S6Z=[CM%I?4^HBB(1%Q)C6RD##&'@=$MM0"?P2# M9$$JYW2[TZ5V:]^:QOG H1[SQ26(4C../'>:I%2#L:P@NF8[+T3-FN:N@-- M,3 RJEZ=#7N? 54/V_Z2V6>GC=5*C. MKC+S[%L"3A[4'T;PHSO$UJ,;+I^[:^OCI.]@ZWCOS8;86E_CS3? %.OO^=9Z MYW!O?0.(_Y].Z_S@%+3RU];Q^SF7<9/N?=[=_LR;ZP?PO V<>PIN?7K]N;E] M>+A[O,-@S*_-]0VZMYZ3%C9(\V"?)\I%D!A9PA0@1$J1,5Z -L6&$V>M<(1XIC7W5]U=?_?Z_=YIS@OX#J_5XN.Z6V=R>>9, M1@^@0N==+30-['HKV/_C"&42=NI4R%F]T!K%#1,;\U M&:[M&V)SM4B/%!69#"U!QFN/?+*66T>S\^\J62V;EP6S_U3'PVY*[XN:3BP^ ME9UX('/J1'7TFWJ=3AFE\4>I*]$;P;S"X,_G#^:B>OE_AS;G=4P#>/LA]E%. MI[ G@_A\\L.+T!Z<=.S9\W:WO&^YZ07 JX-V%XVC?N%9+[[$?.IM.V-E5693 M?7T1!+N*JT#881_^ALF3QU^OEJ_^&H;Y[YA:Y49>^S5>)=_X'4B$;[KSILGJ M56E$/=<'GRN!R;*G0@1YLIS>:=B_"C=4' %,E[GT_WT&6G<:=QZR.?*VCQ9VY#;X6OM\].BB=GJO&G,F>\!C>\'LXO]^Q.ERY8 MB2IN>YG68GU"F:=IB;>)W]QDNP(#SKMU^-.1!T:45ND8K. M^L\'_=ZH&]!XTM['F-*+,8P9]DZ>PSHT2A.Q1GZC%TLI2.=A9%Z@C[';[O4; M.]W2_PY 8:LWC(/G=R"9:]?E'K3T'6O[/:/7,WR2,[PWHZ;RYYO9<<;B&0^! M\O7/Y<,;?7=CUOOXA@.+,E$:H]&:,TD=)0QCBX7 @81H%T?1;K9>+_)B7?@/ M7EL?UTJVS-W

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̍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end

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